{"PMC7128285": [["IntroductionDelayed detection and reporting in recent epidemics such as Zika and Ebola have brought renewed attention to outbreak surveillance.", [["Ebola", "DISEASE", 81, 86], ["Ebola", "ORGANISM", 81, 86], ["Delayed detection", "TEST", 12, 29], ["Zika", "PROBLEM", 72, 76], ["outbreak surveillance", "TEST", 121, 142]]], ["In particular, the use of digital technologies to crowd-source and interpret volumes of public information from the Internet for signs of outbreaks\u2014so-called event-based Internet surveillance (EBIS)\u2014has received great interest because of its potential for early detection.", [["digital technologies", "TREATMENT", 26, 46], ["early detection", "PROBLEM", 256, 271]]], ["The National Academy of Medicine suggests that new information technology, which has increased surveillance capacity even in low-resource settings, be fully exploited.1 The United Nations recommends that the World Health Organization (WHO) create an open platform to manage and analyze public data on unusual health events globally.2 Developing the capacity for event-based surveillance is also required under the 2005 International Health Regulations (2005 IHR),3 an international law that binds 196 states worldwide.IntroductionThe growing significance of EBIS in global health raises questions concerning its efficacy, accessibility, and impact.", [["surveillance capacity", "TEST", 95, 116], ["an open platform", "TREATMENT", 247, 263], ["capacity", "OBSERVATION_MODIFIER", 349, 357], ["growing", "OBSERVATION_MODIFIER", 534, 541]]], ["Technical challenges, unreliable funding, institutional exclusivity, and legal shortcomings combine to generate uneven effects across the globe.A Patchwork of ToolsEmerging in the 1990s with the proliferation of the Internet, EBIS has since become a patchwork of overlapping tools created by a multiplicity of actors and institutions principally in the developed world.", [["institutional exclusivity", "TREATMENT", 42, 67], ["legal shortcomings", "TREATMENT", 73, 91], ["uneven effects across the globe", "PROBLEM", 112, 143], ["globe", "ANATOMY", 138, 143], ["Patchwork", "OBSERVATION_MODIFIER", 146, 155]]], ["They are processed through machine translation and automated textual analysis that discards irrelevant documents and extracts key data about potentially relevant events.", [["automated textual analysis", "TEST", 51, 77]]], ["Human analysis may then be employed to determine which events warrant further investigation.A Patchwork of ToolsThe most widely used EBIS tools today are Canada's Global Public Health Information Network (GPHIN), the International Society for Infectious Diseases' Program for Monitoring Emerging Diseases (ProMED-mail), the European Commission's Medical Information System (MedISys), and Harvard University's HealthMap.", [["Infectious Diseases", "DISEASE", 243, 262], ["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human analysis", "TEST", 0, 14], ["further investigation", "TEST", 70, 91]]], ["Each has unique strengths and weaknesses as a result of different information acquisition protocol, subject matter scope, geographic and linguistic coverage, funding base, and access rules (Table 1).A Patchwork of ToolsGPHIN is only accessible to organizations with a public health mandate, whereas the others are freely available to the public.", [["acquisition protocol", "TREATMENT", 78, 98], ["geographic and linguistic coverage", "TREATMENT", 122, 156], ["funding base", "TREATMENT", 158, 170]]], ["GPHIN and ProMED-mail are the most human-driven systems, with expert analysts that moderate content.", [["human", "ORGANISM", 35, 40], ["ProMED", "PROTEIN", 10, 16], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["ProMED", "TREATMENT", 10, 16], ["moderate", "OBSERVATION_MODIFIER", 83, 91], ["content", "OBSERVATION", 92, 99]]], ["HealthMap has some human input, whereas MedISys is fully automated.", [["HealthMap", "CHEMICAL", 0, 9], ["human", "ORGANISM", 19, 24], ["MedISys", "PROTEIN", 40, 47], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["Many more systems exist,4 and the landscape remains volatile with substantial turnover.Technical Strengths and WeaknessesBy looking at data from outside the public health system, EBIS can detect illness before or in the absence of medical treatment, monitor for unknown contagions that may elude traditional surveillance, and overcome transparency problems when outbreaks are covered up by governments.", [["illness", "DISEASE", 195, 202], ["medical treatment", "TREATMENT", 231, 248], ["traditional surveillance", "TEST", 296, 320], ["transparency problems", "PROBLEM", 335, 356], ["outbreaks", "PROBLEM", 362, 371]]], ["Severe acute respiratory syndrome, for example, was first detected in November 2002 when GPHIN picked up rumors of an outbreak affecting large numbers of schoolchildren in mainland China.5 A 2011 WHO report noted that 35% of outbreak events were first reported through open sources.6", [["acute respiratory syndrome", "DISEASE", 7, 33], ["schoolchildren", "SPECIES", 154, 168], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["outbreak events", "PROBLEM", 225, 240], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["large", "OBSERVATION_MODIFIER", 137, 142], ["numbers", "OBSERVATION_MODIFIER", 143, 150]]]], "3695704554777889f8232a9ea086df70bf17ff58": [["IntroductionHuman malaria caused by Plasmodium falciparum has an estimated annual global disease burden of 300 million clinical episodes, leading to one million deaths [1] [2] [3] [4] .", [["malaria", "DISEASE", 18, 25], ["Plasmodium falciparum", "DISEASE", 36, 57], ["deaths", "DISEASE", 161, 167], ["Plasmodium falciparum", "ORGANISM", 36, 57], ["Plasmodium falciparum", "SPECIES", 36, 57], ["Plasmodium falciparum", "SPECIES", 36, 57], ["IntroductionHuman malaria", "PROBLEM", 0, 25], ["Plasmodium falciparum", "PROBLEM", 36, 57], ["an estimated annual global disease burden", "PROBLEM", 62, 103], ["Plasmodium falciparum", "OBSERVATION", 36, 57], ["global", "OBSERVATION_MODIFIER", 82, 88], ["disease", "OBSERVATION", 89, 96]]], ["Eighty-five per cent of the cases and 90% of the mortality occurs in sub-Saharan Africa, mostly amongst children [5, 6] .", [["children", "ORGANISM", 104, 112], ["children", "SPECIES", 104, 112]]], ["Recent reports point to a reduction of malaria cases in parts of Africa [7] .", [["malaria", "DISEASE", 39, 46], ["malaria cases", "PROBLEM", 39, 52], ["malaria", "OBSERVATION", 39, 46]]], ["However, Nigeria, the most populous country of Africa, accounts for a quarter of the global cases and a third of the malaria-attributable childhood deaths [2, 8, 9] .IntroductionCerebral malaria (CM) and severe malarial anemia (SMA) are the major severe disease syndromes in African children with a high level of mortality in the under-five age group.", [["Cerebral", "ANATOMY", 178, 186], ["CM", "ANATOMY", 196, 198], ["malaria", "DISEASE", 117, 124], ["deaths", "DISEASE", 148, 154], ["Cerebral malaria", "DISEASE", 178, 194], ["CM", "DISEASE", 196, 198], ["malarial anemia", "DISEASE", 211, 226], ["SMA", "DISEASE", 228, 231], ["children", "ORGANISM", 283, 291], ["children", "SPECIES", 283, 291], ["the malaria", "PROBLEM", 113, 124], ["Cerebral malaria (CM)", "PROBLEM", 178, 199], ["severe malarial anemia", "PROBLEM", 204, 226], ["the major severe disease syndromes", "PROBLEM", 237, 271], ["malaria", "OBSERVATION", 117, 124], ["Cerebral", "ANATOMY", 178, 186], ["malaria", "OBSERVATION", 187, 194], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["malarial", "OBSERVATION_MODIFIER", 211, 219], ["anemia", "OBSERVATION", 220, 226], ["SMA", "ANATOMY", 228, 231], ["major", "OBSERVATION_MODIFIER", 241, 246], ["severe", "OBSERVATION_MODIFIER", 247, 253], ["disease", "OBSERVATION", 254, 261]]], ["The current WHO case definitions for severe malaria combine P. falciparum blood stage parasitemia with coma, severe anemia or respiratory distress [10] , and it is well documented that there is significant overlap across these syndromes [11] .", [["blood", "ANATOMY", 74, 79], ["respiratory", "ANATOMY", 126, 137], ["malaria", "DISEASE", 44, 51], ["P. falciparum blood stage parasitemia", "DISEASE", 60, 97], ["coma", "DISEASE", 103, 107], ["anemia", "DISEASE", 116, 122], ["respiratory distress", "DISEASE", 126, 146], ["P.", "ORGANISM", 60, 62], ["falciparum", "ORGANISM", 63, 73], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["P. falciparum", "SPECIES", 60, 73], ["P. falciparum", "SPECIES", 60, 73], ["severe malaria", "PROBLEM", 37, 51], ["falciparum blood stage parasitemia", "PROBLEM", 63, 97], ["coma", "PROBLEM", 103, 107], ["severe anemia", "PROBLEM", 109, 122], ["respiratory distress", "PROBLEM", 126, 146], ["significant overlap across these syndromes", "PROBLEM", 194, 236], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["anemia", "OBSERVATION", 116, 122], ["respiratory distress", "OBSERVATION", 126, 146], ["significant", "OBSERVATION_MODIFIER", 194, 205], ["overlap", "OBSERVATION", 206, 213]]], ["Despite the fact that these WHO case definitions are sensitive and useful for clinical diagnosis, the pathogenesis of severe disease is not well understood.", [["severe disease", "PROBLEM", 118, 132], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["disease", "OBSERVATION", 125, 132]]], ["One disadvantage of the WHO clinical definitions is that they lack the specificity required to carry out studies aimed at understanding the pathogenesis of clinically different forms of childhood malaria.IntroductionPrevious studies have attempted to define malaria syndromes by studying plasma correlates of severity using reductionist approaches with variable success [12] [13] [14] .", [["plasma", "ANATOMY", 288, 294], ["malaria", "DISEASE", 196, 203], ["malaria syndromes", "DISEASE", 258, 275], ["plasma", "ORGANISM_SUBSTANCE", 288, 294], ["childhood malaria", "PROBLEM", 186, 203], ["IntroductionPrevious studies", "TEST", 204, 232], ["malaria syndromes", "PROBLEM", 258, 275], ["reductionist approaches", "TREATMENT", 324, 347], ["childhood", "OBSERVATION_MODIFIER", 186, 195], ["malaria", "OBSERVATION", 196, 203]]], ["Small sample sizes, a lack of validation cohorts and a focus on a small selection of host plasma proteins have limited these studies.", [["plasma", "ANATOMY", 90, 96], ["plasma", "ORGANISM_SUBSTANCE", 90, 96], ["host plasma proteins", "PROTEIN", 85, 105], ["Small sample sizes", "PROBLEM", 0, 18], ["host plasma proteins", "TEST", 85, 105], ["these studies", "TEST", 119, 132], ["sample", "OBSERVATION_MODIFIER", 6, 12], ["sizes", "OBSERVATION_MODIFIER", 13, 18]]], ["To overcome such limitations we use a systems approach to define the plasma proteome profile during malaria infection and identify distinctive patterns that are characteristic of different disease states.", [["plasma", "ANATOMY", 69, 75], ["malaria infection", "DISEASE", 100, 117], ["plasma", "ORGANISM_SUBSTANCE", 69, 75], ["a systems approach", "TREATMENT", 36, 54], ["the plasma proteome profile", "TEST", 65, 92], ["malaria infection", "PROBLEM", 100, 117], ["different disease states", "PROBLEM", 179, 203], ["different", "OBSERVATION_MODIFIER", 179, 188], ["disease", "OBSERVATION", 189, 196]]], ["Contrary to other proteomic approaches, high-throughput plasma proteome profiling enables simultaneous analysis of a large number of samples.", [["plasma", "ANATOMY", 56, 62], ["samples", "ANATOMY", 133, 140], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["samples", "CANCER", 133, 140], ["other proteomic approaches", "TEST", 12, 38], ["plasma proteome profiling", "TEST", 56, 81], ["simultaneous analysis", "TEST", 90, 111], ["large", "OBSERVATION_MODIFIER", 117, 122]]], ["Therefore plasma proteome profiling allows the use of statistical pattern-recognition methods to discover and validate proteome-patterns that discriminate disease states.IntroductionWe hypothesized that the plasma proteome during malaria infection reflects the molecules that are modulated as the severe status is established.", [["plasma", "ANATOMY", 10, 16], ["plasma", "ANATOMY", 207, 213], ["malaria infection", "DISEASE", 230, 247], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["plasma", "ORGANISM_SUBSTANCE", 207, 213], ["plasma proteome profiling", "TEST", 10, 35], ["discriminate disease states", "PROBLEM", 142, 169], ["the plasma proteome", "PROBLEM", 203, 222], ["malaria infection", "PROBLEM", 230, 247], ["the severe status", "PROBLEM", 293, 310], ["malaria", "OBSERVATION_MODIFIER", 230, 237], ["infection", "OBSERVATION", 238, 247], ["severe", "OBSERVATION_MODIFIER", 297, 303]]], ["In the present study we show that distinctive plasma proteome-patterns distinguish the different severe presentations of P. falciparum childhood malaria from the uncomplicated cases and also from well or unwell children without malaria.Ethics StatementParents or guardians of study participants gave informed written consent.", [["plasma", "ANATOMY", 46, 52], ["P. falciparum", "DISEASE", 121, 134], ["malaria", "DISEASE", 145, 152], ["malaria", "DISEASE", 228, 235], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["P. falciparum", "ORGANISM", 121, 134], ["children", "ORGANISM", 211, 219], ["participants", "ORGANISM", 282, 294], ["P. falciparum", "SPECIES", 121, 134], ["children", "SPECIES", 211, 219], ["participants", "SPECIES", 282, 294], ["P. falciparum", "SPECIES", 121, 134], ["the present study", "TEST", 3, 20], ["distinctive plasma proteome", "TEST", 34, 61], ["P. falciparum childhood malaria", "PROBLEM", 121, 152], ["malaria", "PROBLEM", 228, 235], ["different", "OBSERVATION_MODIFIER", 87, 96], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["P. falciparum", "OBSERVATION", 121, 134]]], ["This research was approved by the joint ethics committee of the College of Medicine of the University of Ibadan and the University College Hospital Ibadan.Study SiteAll study participants were recruited under the auspices of the Childhood Malaria Research Group (CMRG) at the 600-bed tertiary hospital University College Hospital (UCH) in the city of Ibadan, Nigeria in west sub-Saharan Africa.", [["Malaria", "DISEASE", 239, 246], ["participants", "ORGANISM", 175, 187], ["participants", "SPECIES", 175, 187], ["All study", "TEST", 165, 174], ["joint", "ANATOMY", 34, 39]]], ["Ibadan is a densely populated urban setting with a population of 2.5 million inhabitants.", [["densely", "OBSERVATION_MODIFIER", 12, 19]]], ["Ibadan has a lengthy 8 months rainy season from March to October with malaria transmission and severe disease present all year round (holoendemic).Study SiteThe study site is located in the UCH Ibadan Department of Paediatrics.", [["Ibadan", "CHEMICAL", 0, 6], ["malaria", "DISEASE", 70, 77], ["malaria transmission", "PROBLEM", 70, 90], ["severe disease", "PROBLEM", 95, 109], ["The study", "TEST", 157, 166], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["disease", "OBSERVATION", 102, 109]]], ["We screen about 12,000 children attending the hospital (ill and well) for malaria parasites per year.", [["malaria parasites", "DISEASE", 74, 91], ["children", "ORGANISM", 23, 31], ["children", "SPECIES", 23, 31], ["malaria parasites", "PROBLEM", 74, 91]]], ["Our studies report 11.3% SMA and 19.7% CM admissions in the parasitized children under five years of age [9] .Study Design and Case DefinitionsThe participants in this study were recruited during 2006 to 2009 as part of a larger prospective case-control study of childhood severe malaria currently ongoing under the auspices of the CMRG.", [["CM", "DISEASE", 39, 41], ["malaria", "DISEASE", 280, 287], ["SMA", "MULTI-TISSUE_STRUCTURE", 25, 28], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 72, 80], ["participants", "SPECIES", 147, 159], ["Our studies", "TEST", 0, 11], ["SMA", "TEST", 25, 28], ["childhood severe malaria", "PROBLEM", 263, 287], ["SMA", "ANATOMY", 25, 28], ["severe", "OBSERVATION_MODIFIER", 273, 279], ["malaria", "OBSERVATION", 280, 287]]], ["This case-control study was divided into a Discovery Cohort consisting of those patients recruited during 2006 to 2008 and a Validation Cohort made up of those recruited in the 2008 to 2009 period.Study Design and Case DefinitionsMalaria parasites were detected and counted by microscopy following Giemsa staining of thick and thin blood films [15] .", [["blood", "ANATOMY", 332, 337], ["patients", "ORGANISM", 80, 88], ["Giemsa", "SIMPLE_CHEMICAL", 298, 304], ["blood", "ORGANISM_SUBSTANCE", 332, 337], ["patients", "SPECIES", 80, 88], ["Malaria parasites", "PROBLEM", 230, 247], ["Giemsa staining", "TEST", 298, 313], ["thick and thin blood films", "TEST", 317, 343]]], ["Children with severe malaria were recruited on admission from the Otunba Tunwase Children's Emergency Ward (OTCHEW).", [["malaria", "DISEASE", 21, 28], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["Children", "SPECIES", 81, 89], ["severe malaria", "PROBLEM", 14, 28], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["malaria", "OBSERVATION", 21, 28]]], ["Children with uncomplicated malaria were recruited as part of a daily routine malaria parasite screening at the Children's Outpatient Clinics (CHOP).", [["uncomplicated malaria", "DISEASE", 14, 35], ["malaria parasite", "DISEASE", 78, 94], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["Children", "SPECIES", 112, 120], ["uncomplicated malaria", "PROBLEM", 14, 35], ["a daily routine malaria parasite screening", "TREATMENT", 62, 104], ["uncomplicated", "OBSERVATION_MODIFIER", 14, 27], ["malaria", "OBSERVATION", 28, 35]]], ["Malaria-negative ill children were recruited either at admission from OTCHEW or from the Department of Paediatrics In-patient wards.", [["Malaria-negative ill", "DISEASE", 0, 20], ["children", "ORGANISM", 21, 29], ["patient", "ORGANISM", 118, 125], ["children", "SPECIES", 21, 29], ["patient", "SPECIES", 118, 125], ["Malaria", "PROBLEM", 0, 7]]], ["Malaria-negative healthy community control children were recruited from local vaccination clinics as well as during school visits across several Ibadan districts.Study Design and Case DefinitionsWe recruited children aged from 6 months to 13 years using five participant definitions.", [["Malaria", "DISEASE", 0, 7], ["children", "ORGANISM", 43, 51], ["children", "ORGANISM", 208, 216], ["children", "SPECIES", 43, 51], ["children", "SPECIES", 208, 216], ["Malaria", "PROBLEM", 0, 7], ["negative", "OBSERVATION_MODIFIER", 8, 16], ["healthy community", "OBSERVATION_MODIFIER", 17, 34]]], ["The malaria-positive children, the cases, are Uncomplicated Malaria (UM), Severe Malarial Anemia (SMA) and Cerebral Malaria (CM).", [["malaria-positive", "DISEASE", 4, 20], ["Malaria", "DISEASE", 60, 67], ["UM", "DISEASE", 69, 71], ["Malarial Anemia", "DISEASE", 81, 96], ["SMA", "DISEASE", 98, 101], ["Cerebral Malaria", "DISEASE", 107, 123], ["CM", "DISEASE", 125, 127], ["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["Uncomplicated Malaria (UM)", "PROBLEM", 46, 72], ["Severe Malarial Anemia (SMA)", "PROBLEM", 74, 102], ["Cerebral Malaria (CM)", "PROBLEM", 107, 128], ["malaria", "OBSERVATION", 4, 11], ["positive children", "OBSERVATION_MODIFIER", 12, 29], ["Uncomplicated", "OBSERVATION_MODIFIER", 46, 59], ["Malaria", "OBSERVATION", 60, 67], ["Severe", "OBSERVATION_MODIFIER", 74, 80], ["Malarial", "OBSERVATION_MODIFIER", 81, 89], ["Anemia", "OBSERVATION", 90, 96], ["SMA", "ANATOMY", 98, 101], ["Cerebral", "ANATOMY", 107, 115], ["Malaria", "OBSERVATION", 116, 123]]], ["The malaria-negative children, the controls, are Disease Control (DC) and Community Controls (CC).", [["DC", "ANATOMY", 66, 68], ["malaria", "DISEASE", 4, 11], ["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["Disease Control (DC)", "TREATMENT", 49, 69], ["Community Controls (CC)", "TREATMENT", 74, 97], ["malaria", "OBSERVATION", 4, 11], ["negative children", "OBSERVATION_MODIFIER", 12, 29]]], ["We followed the WHO criteria for severe P. falciparum malaria [10] .", [["P. falciparum malaria", "DISEASE", 40, 61], ["P. falciparum", "ORGANISM", 40, 53], ["P. falciparum", "SPECIES", 40, 53], ["P. falciparum", "SPECIES", 40, 53], ["severe P. falciparum malaria", "PROBLEM", 33, 61]]], ["Cerebral malaria cases were defined as children in unrousable coma for at least one hour in the presence of asexual P. falciparum parasitemia with normal cerebrospinal fluid.", [["Cerebral", "ANATOMY", 0, 8], ["cerebrospinal fluid", "ANATOMY", 154, 173], ["Cerebral malaria", "DISEASE", 0, 16], ["coma", "DISEASE", 62, 66], ["P. falciparum parasitemia", "DISEASE", 116, 141], ["children", "ORGANISM", 39, 47], ["P. falciparum", "ORGANISM", 116, 129], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 154, 173], ["children", "SPECIES", 39, 47], ["P. falciparum", "SPECIES", 116, 129], ["P. falciparum", "SPECIES", 116, 129], ["Cerebral malaria cases", "PROBLEM", 0, 22], ["asexual P. falciparum parasitemia", "PROBLEM", 108, 141], ["malaria", "OBSERVATION", 9, 16], ["falciparum parasitemia", "OBSERVATION", 119, 141], ["cerebrospinal fluid", "OBSERVATION", 154, 173]]], ["A Blantyre coma score less than 2 was used to assess coma status.", [["coma", "DISEASE", 11, 15], ["coma", "DISEASE", 53, 57], ["A Blantyre coma score", "TEST", 0, 21]]], ["Children with hypoglycemia were excluded from the study.", [["hypoglycemia", "DISEASE", 14, 26], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["hypoglycemia", "PROBLEM", 14, 26], ["the study", "TEST", 46, 55], ["hypoglycemia", "OBSERVATION", 14, 26]]], ["Characteristics of discovery and validation study groups. strict clinical and laboratory definitions of CM, our study patients recover consciousness after effective antimalarial therapy.", [["CM", "DISEASE", 104, 106], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["validation study groups", "TEST", 33, 56], ["our study", "TEST", 108, 117], ["consciousness", "PROBLEM", 135, 148], ["effective antimalarial therapy", "TREATMENT", 155, 185]]], ["We excluded from this study those CM patients who died.", [["CM", "DISEASE", 34, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["this study", "TEST", 17, 27]]], ["Our overall mortality rate for CM is of the order of 10%.", [["CM", "DISEASE", 31, 33]]], ["Severe malarial anemia cases were defined as conscious children with Packed Cell Volume (PCV) less than 16% in the presence of P. falciparum parasitemia.", [["Cell", "ANATOMY", 76, 80], ["malarial anemia", "DISEASE", 7, 22], ["P. falciparum parasitemia", "DISEASE", 127, 152], ["children", "ORGANISM", 55, 63], ["P. falciparum", "ORGANISM", 127, 140], ["children", "SPECIES", 55, 63], ["P. falciparum", "SPECIES", 127, 140], ["P. falciparum", "SPECIES", 127, 140], ["Severe malarial anemia cases", "PROBLEM", 0, 28], ["Packed Cell Volume (PCV)", "TREATMENT", 69, 93], ["P. falciparum parasitemia", "PROBLEM", 127, 152], ["malarial", "OBSERVATION_MODIFIER", 7, 15], ["anemia", "OBSERVATION", 16, 22], ["falciparum parasitemia", "OBSERVATION", 130, 152]]], ["We excluded from this study those SMA patients who died.", [["SMA", "DISEASE", 34, 37], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["this study", "TEST", 17, 27], ["SMA", "ANATOMY", 34, 37]]], ["Our overall mortality rate for SMA is less than 1%.", [["SMA", "DISEASE", 31, 34], ["Our overall mortality rate", "TEST", 0, 26], ["SMA", "ANATOMY", 31, 34]]], ["Uncomplicated malaria cases were defined as febrile children with P. falciparum parasitemia who did not require hospital admission.", [["malaria", "DISEASE", 14, 21], ["P. falciparum parasitemia", "DISEASE", 66, 91], ["children", "ORGANISM", 52, 60], ["P. falciparum", "ORGANISM", 66, 79], ["children", "SPECIES", 52, 60], ["P. falciparum", "SPECIES", 66, 79], ["P. falciparum", "SPECIES", 66, 79], ["Uncomplicated malaria cases", "PROBLEM", 0, 27], ["P. falciparum parasitemia", "PROBLEM", 66, 91], ["malaria", "OBSERVATION", 14, 21]]], ["Our study was designed to discover and validate plasma proteome changes in dichotomous cases for which we only included those children with CM and UM with PCV greater than 20% (Table 1) .", [["plasma", "ANATOMY", 48, 54], ["CM", "DISEASE", 140, 142], ["plasma", "ORGANISM_SUBSTANCE", 48, 54], ["children", "ORGANISM", 126, 134], ["children", "SPECIES", 126, 134], ["Our study", "TEST", 0, 9], ["plasma proteome changes", "PROBLEM", 48, 71], ["PCV", "TREATMENT", 155, 158]]], ["We excluded from the study blood culture positive cases.", [["blood", "ANATOMY", 27, 32], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["the study", "TEST", 17, 26], ["blood culture", "TEST", 27, 40]]], ["Although we did not carry out blood cultures in all severe malaria patients, the cases recruited into this study are those in whom septicemia was not suspected and who were successfully treated with antimalarial alone.", [["blood cultures", "ANATOMY", 30, 44], ["malaria", "DISEASE", 59, 66], ["septicemia", "DISEASE", 131, 141], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["blood cultures", "TEST", 30, 44], ["all severe malaria", "PROBLEM", 48, 66], ["this study", "TEST", 102, 112], ["septicemia", "PROBLEM", 131, 141], ["antimalarial alone", "TREATMENT", 199, 217], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["malaria", "OBSERVATION", 59, 66]]], ["The DC group consists of malaria-negative children with infectious diseases such as meningitis, otitis media, diarrhea and upper respiratory tract infections.", [["DC", "ANATOMY", 4, 6], ["upper respiratory tract", "ANATOMY", 123, 146], ["malaria", "DISEASE", 25, 32], ["infectious diseases", "DISEASE", 56, 75], ["meningitis", "DISEASE", 84, 94], ["otitis media", "DISEASE", 96, 108], ["diarrhea", "DISEASE", 110, 118], ["respiratory tract infections", "DISEASE", 129, 157], ["children", "ORGANISM", 42, 50], ["upper", "ORGANISM_SUBDIVISION", 123, 128], ["respiratory tract", "ORGANISM_SUBDIVISION", 129, 146], ["children", "SPECIES", 42, 50], ["malaria", "PROBLEM", 25, 32], ["infectious diseases", "PROBLEM", 56, 75], ["meningitis", "PROBLEM", 84, 94], ["otitis media", "PROBLEM", 96, 108], ["diarrhea", "PROBLEM", 110, 118], ["upper respiratory tract infections", "PROBLEM", 123, 157], ["malaria", "OBSERVATION", 25, 32], ["meningitis", "OBSERVATION", 84, 94], ["upper", "ANATOMY_MODIFIER", 123, 128], ["respiratory tract", "ANATOMY", 129, 146], ["infections", "OBSERVATION", 147, 157]]], ["It also includes mild to moderately anemic children and children admitted for surgery.Clinical Data and Sample CollectionParticipants's clinical data were collected using a malariatailored questionnaire designed by the CMRG.", [["anemic", "DISEASE", 36, 42], ["children", "ORGANISM", 43, 51], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 43, 51], ["children", "SPECIES", 56, 64], ["mild to moderately anemic children", "PROBLEM", 17, 51], ["surgery", "TREATMENT", 78, 85], ["Clinical Data", "TEST", 86, 99], ["mild", "OBSERVATION_MODIFIER", 17, 21], ["moderately", "OBSERVATION_MODIFIER", 25, 35], ["anemic", "OBSERVATION", 36, 42]]], ["A 2.5 ml blood sample was obtained from each participant in an EDTA blood collection tube for subsequent plasma separation.", [["blood sample", "ANATOMY", 9, 21], ["blood", "ANATOMY", 68, 73], ["plasma", "ANATOMY", 105, 111], ["EDTA", "CHEMICAL", 63, 67], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["A 2.5 ml blood sample", "TEST", 0, 21], ["an EDTA blood collection tube", "TREATMENT", 60, 89], ["subsequent plasma separation", "TREATMENT", 94, 122], ["collection tube", "OBSERVATION", 74, 89], ["plasma separation", "OBSERVATION", 105, 122]]], ["Blood samples were kept on ice and transferred to the central malaria laboratory.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13], ["ice", "TREATMENT", 27, 30], ["central", "ANATOMY_MODIFIER", 54, 61]]], ["Plasma for this study was harvested by centrifugation (1000 g, 10Clinical Laboratory AnalysisPacked cell volume (PCV) was measured using the microhaematocrit method [15] .", [["cell", "ANATOMY", 100, 104], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["this study", "TEST", 11, 21], ["PCV", "TEST", 113, 116], ["the microhaematocrit method", "TEST", 137, 164]]], ["Briefly, Blood was obtained in capillary tubes.", [["Blood", "ANATOMY", 9, 14], ["capillary tubes", "ANATOMY", 31, 46], ["Blood", "ORGANISM_SUBSTANCE", 9, 14], ["capillary tubes", "TISSUE", 31, 46], ["capillary tubes", "TREATMENT", 31, 46], ["capillary tubes", "OBSERVATION", 31, 46]]], ["Tubes were centrifuged at 12,000 g for 5 minutes.", [["Tubes", "ORGANISM_SUBSTANCE", 0, 5], ["Tubes", "TREATMENT", 0, 5]]], ["The percentage cell volume compared to the whole tube volume was calculated (i.e. PCV).", [["cell", "ANATOMY", 15, 19], ["whole tube", "ANATOMY", 43, 53], ["cell", "CELL", 15, 19], ["tube", "TISSUE", 49, 53], ["The percentage cell volume", "TEST", 0, 26], ["the whole tube volume", "TEST", 39, 60], ["percentage cell volume", "OBSERVATION", 4, 26]]], ["Mean (6 standard deviation, sd), minimum and maximum PCV for each clinical group are tabulated in Table 1 .", [["Mean", "TEST", 0, 4], ["maximum PCV", "TEST", 45, 56]]], ["For discovery and validation cohort, these data were compared using a one-way multiple ANOVA test (p,0.05).Clinical Laboratory AnalysisMalaria parasites were detected and counted by microscopy following Giemsa staining of thick and thin blood films [15] .", [["blood", "ANATOMY", 237, 242], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["these data", "TEST", 37, 47], ["Clinical Laboratory AnalysisMalaria parasites", "TEST", 107, 152], ["Giemsa staining", "TEST", 203, 218], ["thick and thin blood films", "TEST", 222, 248]]], ["Malaria Parasite (MP) densities were calculated as follows MP/ Table 1) .", [["Malaria Parasite (MP) densities", "PROBLEM", 0, 31], ["MP/ Table", "TEST", 59, 68]]], ["The microscopic criterion for declaring a participant to be free of malaria was the absence of parasites in 100 high-power (1000X) fields.", [["malaria", "DISEASE", 68, 75], ["The microscopic criterion", "TEST", 0, 25], ["malaria", "PROBLEM", 68, 75], ["parasites", "PROBLEM", 95, 104], ["malaria", "OBSERVATION", 68, 75]]], ["One in 10 thick blood films were randomly selected and independently reviewed by local experienced microscopists not part of the research team.Solid-phase High-throughput Plasma Fractionation and Proteomic ProfilingCrude plasma was profiled using Surface Enhanced Laser Desorption/Ionization-Time Of Flight (SELDI-TOF) mass spectrometry.", [["blood", "ANATOMY", 16, 21], ["plasma", "ANATOMY", 221, 227], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["plasma", "ORGANISM_SUBSTANCE", 221, 227], ["thick blood films", "TEST", 10, 27], ["Solid-phase", "TEST", 143, 154], ["Plasma Fractionation", "TEST", 171, 191], ["Proteomic Profiling", "TEST", 196, 215], ["Crude plasma", "TEST", 215, 227], ["Surface Enhanced Laser Desorption/Ionization", "TREATMENT", 247, 291], ["Flight", "TEST", 300, 306], ["mass spectrometry", "PROBLEM", 319, 336]]], ["All plasma samples underwent two freeze-thaw cycles prior to analysis.", [["plasma samples", "ANATOMY", 4, 18], ["plasma samples", "ORGANISM_SUBSTANCE", 4, 18], ["All plasma samples", "TEST", 0, 18], ["two freeze-thaw cycles", "TREATMENT", 29, 51], ["analysis", "TEST", 61, 69]]], ["Plasma samples were coded, blinded and randomized before application onto the following solid-phase fractionation surfaces (ProteinChipH arrays Bio-Rad): weak-cation exchange (CM10), strong-anion exchange (Q10) and reverse phase (H50) as previously described [16] .", [["Plasma samples", "ANATOMY", 0, 14], ["Plasma samples", "ORGANISM_SUBSTANCE", 0, 14], ["cation", "SIMPLE_CHEMICAL", 159, 165], ["Plasma samples", "TEST", 0, 14]]], ["Each ProteinChipH 96 well BioprocessorH included 1 quality control plasma standard derived from a single healthy individual, placed at random.", [["plasma", "ANATOMY", 67, 73], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["Each ProteinChipH", "TEST", 0, 17]]], ["Mass spectra were generated on a System 4000 Bio-Rad ProteinChipH mass spectrometer.", [["Mass spectra", "PROBLEM", 0, 12], ["a System", "TEST", 31, 39], ["mass", "OBSERVATION", 66, 70]]], ["Spectral peaks corresponding to mass/charge (m/z) clusters were detected and clustered using ProteinChipH Datamanager Client 4.1 software (BioRad).", [["Spectral peaks", "PROBLEM", 0, 14], ["mass/charge (m/z) clusters", "PROBLEM", 32, 58], ["mass", "OBSERVATION", 32, 36]]], ["Mass spectrometer calibration was performed using Allin-1 Peptide and Protein calibrants (Bio-Rad).", [["Allin-1 Peptide", "GENE_OR_GENE_PRODUCT", 50, 65], ["Mass spectrometer calibration", "TREATMENT", 0, 29], ["Allin-1 Peptide", "TREATMENT", 50, 65], ["Protein calibrants", "TREATMENT", 70, 88]]], ["Overall interchip CV for the quality control sample was 20%, consistent with similar studies.Liquid-phase High-throughput Anionic Exchange Plasma FractionationLiquid-phase anion-exchange fractionation of plasma samples was carried out using the ProteinChipH Fractionation Kit (Bio-Rad) according to the manufacturer's instructions with a Biomek 3000 Laboratory Automation Workstation.", [["plasma samples", "ANATOMY", 204, 218], ["anion", "CHEMICAL", 172, 177], ["anion", "SIMPLE_CHEMICAL", 172, 177], ["plasma samples", "ORGANISM_SUBSTANCE", 204, 218], ["the quality control sample", "TEST", 25, 51], ["Liquid-phase", "TEST", 93, 105], ["Anionic Exchange Plasma FractionationLiquid-phase anion-exchange fractionation", "TREATMENT", 122, 200], ["plasma samples", "TEST", 204, 218], ["the ProteinChipH Fractionation Kit (Bio-Rad)", "TREATMENT", 241, 285]]], ["Six fractions were obtained from each sample eluting at pH 9.0 (f1), pH 7.0 (f2), pH 5.0 (f3), pH 4.0 (f4), pH 3.0 (f5) and organic phase (f6).Data AnalysisWe selected subsets of the most relevant mass clusters in the discovery cohort groups using the weighted Kernel-based Iterative Estimation of Relevance Algorithm [17] (wKIERA) that combines a stochastic-search estimation of distribution algorithm with a kernel pattern-recognition method.", [["sample", "ANATOMY", 38, 44], ["Six fractions", "TEST", 0, 13], ["pH", "TEST", 56, 58], ["pH", "TEST", 69, 71], ["pH", "TEST", 82, 84], ["pH", "TEST", 95, 97], ["pH", "TEST", 108, 110], ["organic phase", "TEST", 124, 137], ["the weighted Kernel", "TREATMENT", 248, 267], ["mass", "OBSERVATION", 197, 201]]], ["We then used discovered relevant subsets of mass clusters to build discriminatory predictive models.", [["mass clusters", "PROBLEM", 44, 57], ["mass", "OBSERVATION", 44, 48]]], ["We adopted a supervised learning approach to derive a classification rule using the Support Vector Machine (SVM) method [18] .", [["the Support Vector Machine", "TREATMENT", 80, 106]]], ["Briefly, we used 10-fold cross validation to select parameters for the SVM.", [["10-fold cross validation", "TREATMENT", 17, 41], ["the SVM", "TREATMENT", 67, 74]]], ["To obtain robust accuracy estimates for the classifier on the discovery data, we took 100 random re-samplings of the data, using 80% for training and 20% for testing.", [["testing", "TEST", 158, 165]]], ["We selected as a final classifier the one that produced the highest accuracy and was then tested on the validation cohort data.", [["the validation cohort data", "TEST", 100, 126]]], ["Results were expressed as sensitivity, specificity and accuracy (proportion of correct classifications) and plotted on Receiver Operator Characteristic (ROC) space plots.Data AnalysisOur multivariate statistical tests included testing against age or sex to ascertain that significant pattern changes in the proteome were not dependent on those variables in the population studied.Data AnalysisTo visualize the covariance within the mass spectral profiles we used Principal Component Analysis (PCA).", [["accuracy", "TEST", 55, 63], ["space plots", "TEST", 158, 169], ["multivariate statistical tests", "TEST", 187, 217], ["testing", "TEST", 227, 234], ["significant pattern changes in the proteome", "PROBLEM", 272, 315], ["significant", "OBSERVATION_MODIFIER", 272, 283], ["pattern", "OBSERVATION", 284, 291]]], ["PCA encapsulates the covariance within a set of variables by extracting a ranked set of independent factors or principal components.", [["PCA", "TREATMENT", 0, 3]]], ["The first 3 components encompass a high proportion (,95%) of the informational content of a multivariate dataset.", [["high", "OBSERVATION_MODIFIER", 35, 39], ["proportion", "OBSERVATION_MODIFIER", 40, 50]]], ["We plotted each patient with respect to the first 3 components, in 3-dimensional space, color-coding according to patient group.Study ParticipantsA total of 946 children participated in this study as part of the discovery and validation case-controlled cohorts.", [["patient", "ORGANISM", 16, 23], ["patient", "ORGANISM", 114, 121], ["children", "ORGANISM", 161, 169], ["patient", "SPECIES", 16, 23], ["patient", "SPECIES", 114, 121], ["children", "SPECIES", 161, 169], ["this study", "TEST", 186, 196]]], ["The discovery cohort comprised of 367 malaria-positive children with either Cerebral Malaria (CM), Severe Malarial Anemia (SMA) or Uncomplicated Malaria (UM), and 289 malaria-negative children who were either Disease Controls (DC) or Community Controls (CC) ( Table 1 ).", [["Cerebral", "ANATOMY", 76, 84], ["DC", "ANATOMY", 227, 229], ["malaria", "DISEASE", 38, 45], ["Cerebral Malaria", "DISEASE", 76, 92], ["CM", "DISEASE", 94, 96], ["Malarial Anemia", "DISEASE", 106, 121], ["SMA", "DISEASE", 123, 126], ["Malaria", "DISEASE", 145, 152], ["malaria", "DISEASE", 167, 174], ["children", "ORGANISM", 55, 63], ["children", "ORGANISM", 184, 192], ["children", "SPECIES", 55, 63], ["children", "SPECIES", 184, 192], ["Cerebral Malaria (CM)", "PROBLEM", 76, 97], ["Severe Malarial Anemia (SMA)", "PROBLEM", 99, 127], ["Uncomplicated Malaria (UM)", "PROBLEM", 131, 157], ["Disease Controls (DC)", "TREATMENT", 209, 230], ["Community Controls (CC)", "TREATMENT", 234, 257], ["Cerebral", "ANATOMY", 76, 84], ["Malaria", "OBSERVATION", 85, 92], ["Severe", "OBSERVATION_MODIFIER", 99, 105], ["Malarial", "OBSERVATION_MODIFIER", 106, 114], ["Anemia", "OBSERVATION", 115, 121], ["SMA", "ANATOMY", 123, 126], ["Uncomplicated", "OBSERVATION_MODIFIER", 131, 144], ["Malaria", "OBSERVATION", 145, 152]]], ["The validation cohort was prospectively recruited after the discovery cohort and comprised 160 malaria-positive children with either CM, SMA or UM, and 130 malaria-negative DC or CC children (Table 1) .", [["CM", "ANATOMY", 133, 135], ["DC", "ANATOMY", 173, 175], ["malaria", "DISEASE", 95, 102], ["CM", "DISEASE", 133, 135], ["malaria", "DISEASE", 156, 163], ["CC", "CHEMICAL", 179, 181], ["children", "ORGANISM", 112, 120], ["children", "ORGANISM", 182, 190], ["DC", "CELL_TYPE", 173, 175], ["children", "SPECIES", 112, 120], ["children", "SPECIES", 182, 190], ["SMA", "ANATOMY", 137, 140]]], ["PCV and malaria parasite (MP) densities are presented in Table 1 .", [["malaria", "DISEASE", 8, 15], ["PCV", "TREATMENT", 0, 3], ["malaria parasite (MP) densities", "PROBLEM", 8, 39], ["malaria parasite", "OBSERVATION", 8, 24]]], ["Consistent with the recruitment criteria, both discovery and validation SMA groups had PCVs below 16% (Table 1 ).", [["PCVs", "TEST", 87, 91], ["recruitment", "OBSERVATION", 20, 31], ["SMA", "ANATOMY", 72, 75]]], ["There was mild anemia across CM, UM and DC groups in both cohorts, whereas CC had normal mean hematocrit (Table 1) .", [["CM", "ANATOMY", 29, 31], ["DC", "ANATOMY", 40, 42], ["anemia", "DISEASE", 15, 21], ["CM", "DISEASE", 29, 31], ["CC", "CHEMICAL", 75, 77], ["mild anemia across CM", "PROBLEM", 10, 31], ["UM", "PROBLEM", 33, 35], ["mild", "OBSERVATION_MODIFIER", 10, 14], ["anemia", "OBSERVATION", 15, 21], ["across CM", "OBSERVATION_MODIFIER", 22, 31], ["mean hematocrit", "OBSERVATION", 89, 104]]], ["Parasite densities across all the infected groups were similar (Table 1) .Plasma Proteome-patterns Define the Major childhood Malaria SyndromesTo compare the proteome-patterns of the study groups, we fractionated plasma samples by three different chromatography procedures on solid-phase surfaces (weak-cationic and stronganionic ion-exchange, and reverse-phase) followed by Time-Of-Flight mass spectrometry.", [["plasma samples", "ANATOMY", 213, 227], ["Malaria Syndromes", "DISEASE", 126, 143], ["Plasma", "ORGANISM_SUBSTANCE", 74, 80], ["plasma samples", "ORGANISM_SUBSTANCE", 213, 227], ["stronganionic", "SIMPLE_CHEMICAL", 316, 329], ["Parasite densities", "PROBLEM", 0, 18], ["Plasma Proteome", "TEST", 74, 89], ["the Major childhood Malaria Syndromes", "PROBLEM", 106, 143], ["the study groups", "TEST", 179, 195], ["fractionated plasma samples", "TEST", 200, 227], ["three different chromatography procedures", "TEST", 231, 272], ["solid-phase surfaces", "TEST", 276, 296], ["stronganionic ion-exchange", "TREATMENT", 316, 342], ["densities", "OBSERVATION", 9, 18], ["infected", "OBSERVATION", 34, 42], ["Major", "OBSERVATION_MODIFIER", 110, 115], ["childhood", "OBSERVATION_MODIFIER", 116, 125], ["Malaria", "OBSERVATION", 126, 133]]], ["The resulting mass spectra from each of the surfaces contained a series of mass/charge ratio (m/z) peak clusters, each representing a protein of a particular mass.", [["The resulting mass spectra", "PROBLEM", 0, 26], ["mass/charge ratio", "TEST", 75, 92], ["peak clusters", "PROBLEM", 99, 112], ["a particular mass", "PROBLEM", 145, 162], ["resulting", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["surfaces", "OBSERVATION_MODIFIER", 44, 52], ["mass", "OBSERVATION", 75, 79], ["protein", "OBSERVATION", 134, 141], ["particular", "OBSERVATION_MODIFIER", 147, 157], ["mass", "OBSERVATION", 158, 162]]], ["A set of proteins that are present, absent or at a different level in the samples defines a proteome-pattern that may discriminate between two or more of the study groups.", [["samples", "ANATOMY", 74, 81], ["A set of proteins", "TEST", 0, 17], ["proteins", "OBSERVATION", 9, 17]]], ["We built predictive models with the selected proteome-pattern for each study group comparison using a non-parametric supervised learning statistical framework.", [["each study", "TEST", 66, 76]]], ["To determine differences for malaria-positive children from healthy malaria-negative children we compared individually the plasma proteome of CM, SMA and UM groups with that of the CC group.Plasma Proteome-patterns Define the Major childhood Malaria SyndromesOverall, 22 to 33 proteins composed the discriminatory patterns with accuracies above 90% across the three comparisons (Figure 1a, blue bars) .", [["plasma", "ANATOMY", 123, 129], ["CM", "ANATOMY", 142, 144], ["malaria", "DISEASE", 29, 36], ["malaria", "DISEASE", 68, 75], ["CM", "DISEASE", 142, 144], ["CC", "CHEMICAL", 181, 183], ["Malaria", "DISEASE", 242, 249], ["children", "ORGANISM", 46, 54], ["children", "ORGANISM", 85, 93], ["plasma", "ORGANISM_SUBSTANCE", 123, 129], ["CM", "CELL", 142, 144], ["Plasma", "ORGANISM_SUBSTANCE", 190, 196], ["children", "SPECIES", 46, 54], ["children", "SPECIES", 85, 93], ["malaria", "PROBLEM", 29, 36], ["Plasma Proteome", "TEST", 190, 205], ["the Major childhood Malaria SyndromesOverall", "PROBLEM", 222, 266], ["accuracies", "TEST", 328, 338], ["SMA", "ANATOMY", 146, 149], ["Major", "OBSERVATION_MODIFIER", 226, 231], ["childhood", "OBSERVATION_MODIFIER", 232, 241], ["Malaria", "OBSERVATION", 242, 249]]], ["Twenty-six proteins discriminated healthy from ill (hospital admitted) malaria-negative children (CC vs. DC) with similar accuracy (Figure 1a, green bar) .", [["DC", "ANATOMY", 105, 107], ["malaria", "DISEASE", 71, 78], ["CC", "CHEMICAL", 98, 100], ["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["malaria", "PROBLEM", 71, 78]]], ["To examine proteins that are specific to malaria infection we compared each of the malaria-positive groups (CM, SMA, UM) to the DC group, obtaining discrimination accuracies above 80% (Figure 1a . orange bars).", [["DC", "ANATOMY", 128, 130], ["malaria infection", "DISEASE", 41, 58], ["malaria", "DISEASE", 83, 90], ["CM", "DISEASE", 108, 110], ["malaria infection", "PROBLEM", 41, 58], ["the malaria", "TEST", 79, 90], ["discrimination accuracies", "TEST", 148, 173], ["SMA", "ANATOMY", 112, 115]]], ["Finally, to assess differences between defined malaria syndromes we compared the malaria-positive groups (Figure 1a . yellow bars).", [["malaria syndromes", "DISEASE", 47, 64], ["malaria", "DISEASE", 81, 88], ["defined malaria syndromes", "PROBLEM", 39, 64], ["the malaria", "TEST", 77, 88]]], ["In the comparison between CM and SMA, the two major severe syndromes, the accuracy was 70% (24 proteins).", [["CM", "DISEASE", 26, 28], ["SMA", "MULTI-TISSUE_STRUCTURE", 33, 36], ["the two major severe syndromes", "PROBLEM", 38, 68], ["the accuracy", "TEST", 70, 82], ["SMA", "ANATOMY", 33, 36], ["major", "OBSERVATION_MODIFIER", 46, 51], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["syndromes", "OBSERVATION", 59, 68]]], ["Higher accuracies between 70 to 80% were observed when samples from either CM or SMA groups were compared to UM children, using 36 and 54 proteins, respectively.Plasma Proteome-patterns Define the Major childhood Malaria SyndromesTo validate the accuracy of the discrimination for the discovered plasma proteome-patterns, we tested the predictive models on the validation cohort groups (Figure 1b) .", [["samples", "ANATOMY", 55, 62], ["plasma", "ANATOMY", 296, 302], ["CM", "DISEASE", 75, 77], ["children", "ORGANISM", 112, 120], ["Plasma", "ORGANISM_SUBSTANCE", 161, 167], ["plasma", "ORGANISM_SUBSTANCE", 296, 302], ["children", "SPECIES", 112, 120], ["Higher accuracies", "TEST", 0, 17], ["Plasma Proteome", "TEST", 161, 176], ["plasma proteome", "TEST", 296, 311], ["SMA", "ANATOMY", 81, 84]]], ["We compared the sensitivity and specificity of the predictive models for both discovery and validation cohort groups in ROC space and found them to be similar ( Figure 2) .Plasma Proteome-patterns Define the Major childhood Malaria SyndromesWe then used Principal Component Analysis (PCA) on the selected proteins to visualize the separation of patient groups.", [["Malaria", "DISEASE", 224, 231], ["Plasma", "ORGANISM_SUBSTANCE", 172, 178], ["patient", "ORGANISM", 345, 352], ["patient", "SPECIES", 345, 352], ["the sensitivity", "TEST", 12, 27], ["ROC space", "TEST", 120, 129], ["Plasma Proteome", "TEST", 172, 187], ["the Major childhood Malaria SyndromesWe", "PROBLEM", 204, 243], ["Principal Component Analysis (PCA", "TREATMENT", 254, 287]]], ["The CC group clustered tightly together (Figure 3 , green spheres).", [["CC", "CHEMICAL", 4, 6]]], ["Individual malaria-positive groups showed good separation from the malaria-negative CC group (Figure 3a-c) indicating that regardless of disease severity there are significant differences in the proteomes of the groups.", [["malaria", "DISEASE", 11, 18], ["malaria", "DISEASE", 67, 74], ["CC", "CHEMICAL", 84, 86], ["Individual malaria", "TEST", 0, 18], ["the malaria", "TEST", 63, 74], ["disease severity", "PROBLEM", 137, 153], ["malaria", "OBSERVATION", 11, 18], ["good", "OBSERVATION_MODIFIER", 42, 46], ["separation", "OBSERVATION_MODIFIER", 47, 57], ["malaria", "OBSERVATION", 67, 74], ["disease", "OBSERVATION", 137, 144], ["significant", "OBSERVATION_MODIFIER", 164, 175], ["differences", "OBSERVATION_MODIFIER", 176, 187]]], ["The heterogeneous DC group had a more dispersed cluster pattern with little overlap with the CC group (Figure 3d ).", [["DC", "ANATOMY", 18, 20], ["CC", "CHEMICAL", 93, 95], ["DC", "CELL_TYPE", 18, 20], ["heterogeneous", "OBSERVATION_MODIFIER", 4, 17], ["little", "OBSERVATION_MODIFIER", 69, 75], ["overlap", "OBSERVATION_MODIFIER", 76, 83]]], ["The DC group, despite being distinct, showed different degrees of overlap with the malaria-positive groups (Figure 4a-c) .", [["DC", "ANATOMY", 4, 6], ["malaria", "DISEASE", 83, 90], ["DC", "CELL_TYPE", 4, 6], ["the malaria", "PROBLEM", 79, 90], ["different degrees", "OBSERVATION_MODIFIER", 45, 62], ["malaria", "OBSERVATION", 83, 90]]], ["Of these comparisons, the CM vs. DC patient groups showed the greatest level of cluster dispersion (Figure 4a ) indicating greater covariance in the proteins that define these groups.", [["DC", "ANATOMY", 33, 35], ["CM", "DISEASE", 26, 28], ["patient", "ORGANISM", 36, 43], ["DC", "CELL_TYPE", 33, 35], ["patient", "SPECIES", 36, 43], ["these comparisons", "TEST", 3, 20], ["the CM vs", "TEST", 22, 31], ["greater covariance in the proteins", "PROBLEM", 123, 157], ["cluster dispersion", "OBSERVATION", 80, 98]]], ["We then compared the malaria-positive patient groups among themselves (Figure 4d-f ).", [["malaria", "DISEASE", 21, 28], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["the malaria", "TEST", 17, 28]]], ["CM and SMA groups showed overlap at the cluster interface and clearer segregation at the periphery; in the comparison of both severe forms (CM and SMA) with UM we observed that the severe patient groups had compact center clusters surrounded by a more disperse cluster of the UM patient group.Reduction of Plasma Proteome Complexity Provides Further Discriminatory Proteins for Severe Childhood MalariaWe simplified further the complexity of the plasma proteome by high-throughput liquid-phase anion-exchange fractionation followed by solid-phase weak-cation exchange fractionation prior to protein mass determination in the spectrometer on a subset of the samples.", [["plasma", "ANATOMY", 446, 452], ["samples", "ANATOMY", 657, 664], ["CM", "DISEASE", 0, 2], ["CM", "DISEASE", 140, 142], ["anion", "CHEMICAL", 494, 499], ["patient", "ORGANISM", 188, 195], ["patient", "ORGANISM", 279, 286], ["plasma", "ORGANISM_SUBSTANCE", 446, 452], ["anion", "SIMPLE_CHEMICAL", 494, 499], ["cation", "SIMPLE_CHEMICAL", 552, 558], ["patient", "SPECIES", 188, 195], ["patient", "SPECIES", 279, 286], ["overlap at the cluster interface", "PROBLEM", 25, 57], ["clearer segregation at the periphery", "PROBLEM", 62, 98], ["the severe patient groups", "PROBLEM", 177, 202], ["Severe Childhood MalariaWe", "PROBLEM", 378, 404], ["the plasma proteome", "TEST", 442, 461], ["anion-exchange fractionation", "TREATMENT", 494, 522], ["cation exchange fractionation", "TREATMENT", 552, 581], ["protein mass determination", "PROBLEM", 591, 617], ["SMA", "ANATOMY", 7, 10], ["overlap", "OBSERVATION", 25, 32], ["cluster interface", "OBSERVATION", 40, 57], ["clearer", "OBSERVATION_MODIFIER", 62, 69], ["segregation", "OBSERVATION_MODIFIER", 70, 81], ["periphery", "OBSERVATION_MODIFIER", 89, 98], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["SMA", "ANATOMY", 147, 150], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["mass", "OBSERVATION", 599, 603]]], ["We assessed the discriminatory accuracy of relevant proteins obtained from each of the six anion-exchange fractions ( Figure 5 , f1 to f6) (Data S2).", [["f6", "PROTEIN", 135, 137], ["relevant proteins", "PROBLEM", 43, 60], ["the six anion-exchange fractions", "TREATMENT", 83, 115]]], ["The reduction in the complexity of each fraction of the plasma samples resulted in a larger subset of proteins that improved discrimination between the malaria syndromes.", [["plasma samples", "ANATOMY", 56, 70], ["malaria syndromes", "DISEASE", 152, 169], ["plasma samples", "ORGANISM_SUBSTANCE", 56, 70], ["The reduction", "TREATMENT", 0, 13], ["the plasma samples", "TEST", 52, 70], ["a larger subset of proteins", "PROBLEM", 83, 110], ["the malaria syndromes", "PROBLEM", 148, 169], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["complexity", "OBSERVATION_MODIFIER", 21, 31], ["larger", "OBSERVATION_MODIFIER", 85, 91], ["improved", "OBSERVATION_MODIFIER", 116, 124], ["malaria syndromes", "OBSERVATION", 152, 169]]], ["Sets of proteins that distinguish between SMA and CM groups (Figure 5a , f1 to f6 in brackets) slightly outperformed the proteome-pattern from non-fractionated plasma.", [["plasma", "ANATOMY", 160, 166], ["CM", "DISEASE", 50, 52], ["SMA", "MULTI-TISSUE_STRUCTURE", 42, 45], ["plasma", "ORGANISM_SUBSTANCE", 160, 166], ["SMA", "PROTEIN", 42, 45], ["f6", "PROTEIN", 79, 81], ["SMA", "ANATOMY", 42, 45]]], ["Sets of proteins differentiated the CM and UM groups with accuracies ranging from 70 to 80% (Figure 5b , f1 to f6 in brackets) and distinguished between SMA and UM with comparable accuracy (Figure 5c, f1 to f6 in brackets) .Reduction of Plasma Proteome Complexity Provides Further Discriminatory Proteins for Severe Childhood MalariaWe carried out an overall analysis of plasma proteome pattern overlap by comparing the discovered sets of proteins that discriminate UM, CM, SMA (malaria-positive) and DC (malaria-negative) ill children from the malaria-negative well children CC (Figure 6 , f1 to f6).", [["CM", "ANATOMY", 36, 38], ["plasma", "ANATOMY", 371, 377], ["CM", "ANATOMY", 470, 472], ["DC", "ANATOMY", 501, 503], ["CM", "DISEASE", 36, 38], ["CM", "DISEASE", 470, 472], ["malaria", "DISEASE", 479, 486], ["malaria-negative) ill", "DISEASE", 505, 526], ["malaria", "DISEASE", 545, 552], ["CC", "CHEMICAL", 576, 578], ["CM", "CELL", 36, 38], ["SMA", "MULTI-TISSUE_STRUCTURE", 153, 156], ["plasma", "ORGANISM_SUBSTANCE", 371, 377], ["SMA", "GENE_OR_GENE_PRODUCT", 474, 477], ["children", "ORGANISM", 527, 535], ["children", "ORGANISM", 567, 575], ["DC", "CELL_TYPE", 501, 503], ["children", "SPECIES", 527, 535], ["children", "SPECIES", 567, 575], ["UM groups", "TEST", 43, 52], ["accuracies", "TEST", 58, 68], ["Severe Childhood MalariaWe", "PROBLEM", 309, 335], ["an overall analysis", "TEST", 348, 367], ["plasma proteome pattern overlap", "PROBLEM", 371, 402], ["CM", "TEST", 470, 472], ["SMA (malaria-positive)", "PROBLEM", 474, 496], ["DC (malaria", "PROBLEM", 501, 512], ["the malaria", "PROBLEM", 541, 552], ["differentiated", "OBSERVATION_MODIFIER", 17, 31], ["SMA", "ANATOMY", 153, 156], ["SMA", "ANATOMY", 474, 477]]], ["We show that each plasma fraction (f1 to f6) contains a set of proteins that clearly define both the malariapositive and malaria-negative ill children to those malaria-negative well children in the community.", [["plasma", "ANATOMY", 18, 24], ["malaria-negative ill", "DISEASE", 121, 141], ["malaria", "DISEASE", 160, 167], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["children", "ORGANISM", 142, 150], ["children", "ORGANISM", 182, 190], ["children", "SPECIES", 142, 150], ["children", "SPECIES", 182, 190], ["each plasma fraction", "TEST", 13, 33], ["malaria", "PROBLEM", 121, 128], ["malaria", "OBSERVATION", 121, 128]]], ["Furthermore, we also show that the set of proteins that discriminate SMA and CM from UM have very little overlap across the six plasma fractions (Figure 6 , f1 to f6).DiscussionIn the present study we carried out a large case-control study of severe childhood malaria, using a discovery cohort to define discriminatory plasma proteome-patterns and a second cohort to validate our findings, at the main tertiary hospital of the city of Ibadan, Nigeria.DiscussionWe show that proteome-patterns from both crude and prefractionated plasma samples accurately define childhood malaria syndromes in the discovery cohort.", [["plasma fractions", "ANATOMY", 128, 144], ["plasma", "ANATOMY", 319, 325], ["plasma samples", "ANATOMY", 528, 542], ["CM", "DISEASE", 77, 79], ["malaria", "DISEASE", 260, 267], ["malaria syndromes", "DISEASE", 571, 588], ["SMA", "GENE_OR_GENE_PRODUCT", 69, 72], ["plasma", "ORGANISM_SUBSTANCE", 128, 134], ["plasma", "ORGANISM_SUBSTANCE", 319, 325], ["plasma samples", "ORGANISM_SUBSTANCE", 528, 542], ["SMA", "PROTEIN", 69, 72], ["severe childhood malaria", "PROBLEM", 243, 267], ["discriminatory plasma proteome", "TEST", 304, 334], ["plasma samples", "TEST", 528, 542], ["childhood malaria syndromes", "PROBLEM", 561, 588], ["SMA", "ANATOMY", 69, 72], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["malaria", "OBSERVATION", 260, 267]]], ["We confirmed these findings using a prospectively collected validation cohort.", [["a prospectively collected validation cohort", "TREATMENT", 34, 77]]], ["Malaria infection introduces distinguishable changes in the plasma proteome of children as seen by the striking differences between the malarianegative CC and the malaria-positive children groups.", [["plasma", "ANATOMY", 60, 66], ["Malaria infection", "DISEASE", 0, 17], ["CC", "CHEMICAL", 152, 154], ["malaria", "DISEASE", 163, 170], ["plasma", "ORGANISM_SUBSTANCE", 60, 66], ["children", "ORGANISM", 79, 87], ["CC", "CANCER", 152, 154], ["children", "ORGANISM", 180, 188], ["children", "SPECIES", 79, 87], ["children", "SPECIES", 180, 188], ["Malaria infection", "PROBLEM", 0, 17], ["infection", "OBSERVATION", 8, 17]]], ["The plasma proteome differences are specific for the malaria disease process and not surrogate markers of acute illness, as we are able to accurately distinguish between malaria-negative ill children and malaria-positive groups independently of their disease severity.", [["plasma", "ANATOMY", 4, 10], ["malaria disease", "DISEASE", 53, 68], ["acute illness", "DISEASE", 106, 119], ["malaria-negative ill", "DISEASE", 170, 190], ["malaria", "DISEASE", 204, 211], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["children", "ORGANISM", 191, 199], ["children", "SPECIES", 191, 199], ["The plasma proteome differences", "TEST", 0, 31], ["the malaria disease process", "PROBLEM", 49, 76], ["acute illness", "PROBLEM", 106, 119], ["malaria", "PROBLEM", 170, 177], ["malaria", "PROBLEM", 204, 211], ["their disease severity", "PROBLEM", 245, 267], ["malaria", "OBSERVATION", 53, 60], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["illness", "OBSERVATION", 112, 119], ["disease", "OBSERVATION", 251, 258]]], ["We have also discovered plasma proteome differences that are specific to each of the childhood malaria syndromes assessed in the present study.", [["plasma", "ANATOMY", 24, 30], ["malaria syndromes", "DISEASE", 95, 112], ["plasma", "ORGANISM_SUBSTANCE", 24, 30], ["plasma proteome differences", "PROBLEM", 24, 51], ["the childhood malaria syndromes", "PROBLEM", 81, 112], ["the present study", "TEST", 125, 142], ["plasma proteome", "OBSERVATION_MODIFIER", 24, 39], ["malaria", "OBSERVATION", 95, 102]]], ["Our findings provide a starting point to refine the current WHO definitions of these syndromes, which lack the necessary specificity to further study severe malaria pathogenesis.DiscussionWe show that assessing the plasma proteome of the major malaria syndromes provides an unbiased discovery of combination of proteins that could be used to deepen our understanding of the pathogenesis of childhood malaria.", [["plasma", "ANATOMY", 215, 221], ["malaria", "DISEASE", 157, 164], ["malaria syndromes", "DISEASE", 244, 261], ["malaria", "DISEASE", 400, 407], ["plasma", "ORGANISM_SUBSTANCE", 215, 221], ["these syndromes", "PROBLEM", 79, 94], ["further study", "TEST", 136, 149], ["severe malaria pathogenesis", "PROBLEM", 150, 177], ["the major malaria syndromes", "PROBLEM", 234, 261], ["proteins", "TREATMENT", 311, 319], ["childhood malaria", "PROBLEM", 390, 407], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["malaria", "OBSERVATION", 157, 164], ["major", "OBSERVATION_MODIFIER", 238, 243], ["malaria", "OBSERVATION", 244, 251], ["childhood", "OBSERVATION_MODIFIER", 390, 399], ["malaria", "OBSERVATION", 400, 407]]], ["This is supported by the finding that we can discriminate children with uncomplicated malaria from those with severe malarial anemia or cerebral malaria in both discovery and validation cohorts.", [["cerebral", "ANATOMY", 136, 144], ["malaria", "DISEASE", 86, 93], ["malarial anemia", "DISEASE", 117, 132], ["cerebral malaria", "DISEASE", 136, 152], ["children", "ORGANISM", 58, 66], ["cerebral", "ORGAN", 136, 144], ["children", "SPECIES", 58, 66], ["uncomplicated malaria", "PROBLEM", 72, 93], ["severe malarial anemia", "PROBLEM", 110, 132], ["cerebral malaria", "PROBLEM", 136, 152], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["malarial", "OBSERVATION_MODIFIER", 117, 125], ["anemia", "OBSERVATION", 126, 132], ["cerebral", "ANATOMY", 136, 144], ["malaria", "OBSERVATION", 145, 152]]], ["These proteomepatterns encapsulate what changes differentiate uncomplicated malaria from the severe cases.DiscussionOverall, accuracy of discrimination between the CM and SMA was lower than that in the comparison of each of these syndromes with the UM group.", [["malaria", "DISEASE", 76, 83], ["CM", "DISEASE", 164, 166], ["uncomplicated malaria", "PROBLEM", 62, 83], ["the severe cases", "PROBLEM", 89, 105], ["these syndromes", "PROBLEM", 224, 239], ["uncomplicated", "OBSERVATION_MODIFIER", 62, 75], ["malaria", "OBSERVATION", 76, 83], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["SMA", "ANATOMY", 171, 174], ["lower", "OBSERVATION_MODIFIER", 179, 184]]], ["The degree of overlap between CM and SMA goes beyond that expected from strict application of the WHO case definitions used in this study.", [["CM", "DISEASE", 30, 32], ["overlap between CM and SMA", "PROBLEM", 14, 40], ["this study", "TEST", 127, 137], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["overlap", "OBSERVATION", 14, 21], ["SMA", "ANATOMY", 37, 40]]], ["Nevertheless, the plasma proteome-pattern discriminated with over 70% accuracy between the severe groups.", [["plasma", "ANATOMY", 18, 24], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["the plasma proteome", "TEST", 14, 33], ["severe", "OBSERVATION_MODIFIER", 91, 97]]], ["This suggests that beyond common underlying mechanisms, such as acute inflammation, there are significant differences in the pathogenesis of the severe syndromes studied.DiscussionOur large cohorts allowed us to statistically validate the patternbased proteome definitions of the major childhood malaria syndromes.", [["inflammation", "DISEASE", 70, 82], ["malaria syndromes", "DISEASE", 296, 313], ["acute inflammation", "PROBLEM", 64, 82], ["the severe syndromes", "PROBLEM", 141, 161], ["the major childhood malaria syndromes", "PROBLEM", 276, 313], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["inflammation", "OBSERVATION", 70, 82], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["differences", "OBSERVATION_MODIFIER", 106, 117], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["syndromes", "OBSERVATION", 152, 161], ["major", "OBSERVATION_MODIFIER", 280, 285], ["childhood", "OBSERVATION_MODIFIER", 286, 295], ["malaria", "OBSERVATION", 296, 303]]], ["Although the mass spectrometry platform used in our study does not provide direct molecular identification, the chromatographic chemistry used and the mass-to-charge (m/z) ratio can be exploited to guide the identification of the set of proteins relevant for discrimination between syndromes.", [["the mass spectrometry platform", "TEST", 9, 39], ["our study", "TEST", 48, 57], ["direct molecular identification", "TEST", 75, 106], ["the chromatographic chemistry", "TEST", 108, 137], ["the mass", "TEST", 147, 155], ["discrimination between syndromes", "PROBLEM", 259, 291], ["mass", "OBSERVATION", 13, 17], ["mass", "OBSERVATION", 151, 155]]], ["Plasma proteome profiling has been used to define a variety of disease states [16, [19] [20] [21] [22] [23] [24] as there is growing recognition of the advantages of using 'omics'-based methods to achieve sufficient levels of accuracy [24] .", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["[19] [20] [21] [22] [23", "SIMPLE_CHEMICAL", 83, 106], ["Plasma proteome profiling", "TEST", 0, 25], ["a variety of disease states", "PROBLEM", 50, 77], ["'omics'-based methods", "TREATMENT", 172, 193]]], ["Our study showed that complex plasma protein patterns were necessary to discriminate between the different malaria syndromes.", [["plasma", "ANATOMY", 30, 36], ["malaria syndromes", "DISEASE", 107, 124], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["Our study", "TEST", 0, 9], ["complex plasma protein patterns", "PROBLEM", 22, 53], ["the different malaria syndromes", "PROBLEM", 93, 124], ["different", "OBSERVATION_MODIFIER", 97, 106], ["malaria syndromes", "OBSERVATION", 107, 124]]], ["This further underlines the advantage of using unbiased high-throughput pattern recognition based methods.DiscussionIn many infectious diseases, there are clinically important distinctions to be made between different manifestations associated with the same underlying pathogen and malaria clinical syndromes are a clear case in point.", [["infectious diseases", "DISEASE", 124, 143], ["malaria", "DISEASE", 282, 289], ["different manifestations", "PROBLEM", 208, 232], ["the same underlying pathogen", "PROBLEM", 249, 277], ["malaria clinical syndromes", "PROBLEM", 282, 308], ["infectious", "OBSERVATION_MODIFIER", 124, 134], ["pathogen", "OBSERVATION", 269, 277]]], ["The pathogenesis of malaria due to its erythrocytic cycle occurs in the cardiovascular system and it is plausible that proteome changes in organs such as brain, spleen, kidney and bone marrow can be reflected in the plasma proteome.", [["cardiovascular system", "ANATOMY", 72, 93], ["organs", "ANATOMY", 139, 145], ["brain", "ANATOMY", 154, 159], ["spleen", "ANATOMY", 161, 167], ["kidney", "ANATOMY", 169, 175], ["bone marrow", "ANATOMY", 180, 191], ["plasma", "ANATOMY", 216, 222], ["malaria", "DISEASE", 20, 27], ["cardiovascular", "ANATOMICAL_SYSTEM", 72, 86], ["system", "ANATOMICAL_SYSTEM", 87, 93], ["organs", "ORGAN", 139, 145], ["brain", "ORGAN", 154, 159], ["spleen", "ORGAN", 161, 167], ["kidney", "ORGAN", 169, 175], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 180, 191], ["plasma", "ORGANISM_SUBSTANCE", 216, 222], ["malaria", "PROBLEM", 20, 27], ["its erythrocytic cycle", "PROBLEM", 35, 57], ["proteome changes in organs such as brain, spleen, kidney and bone marrow", "PROBLEM", 119, 191], ["the plasma proteome", "TEST", 212, 231], ["malaria", "OBSERVATION", 20, 27], ["erythrocytic cycle", "OBSERVATION", 39, 57], ["cardiovascular system", "ANATOMY", 72, 93], ["brain", "ANATOMY", 154, 159], ["spleen", "ANATOMY", 161, 167], ["kidney", "ANATOMY", 169, 175], ["bone", "ANATOMY", 180, 184], ["marrow", "OBSERVATION", 185, 191]]], ["Our study confirms that there are proteome changes characteristic of the clinical malarial syndromes with different level of accuracy.", [["malarial syndromes", "DISEASE", 82, 100], ["Our study", "TEST", 0, 9], ["proteome changes", "PROBLEM", 34, 50], ["the clinical malarial syndromes", "PROBLEM", 69, 100], ["accuracy", "TEST", 125, 133], ["proteome", "OBSERVATION", 34, 42], ["malarial syndromes", "OBSERVATION", 82, 100]]], ["Furthermore, host modulation by the pathogen is likely to generate changing patterns of protein expression associated with the progression of severe malaria syndromes and our current studies are designed to address such changes.DiscussionThe lack of specific childhood malaria definitions has limited the progress on understanding the pathology of the major severe syndromes.", [["malaria syndromes", "DISEASE", 149, 166], ["malaria", "DISEASE", 269, 276], ["the pathogen", "PROBLEM", 32, 44], ["protein expression", "PROBLEM", 88, 106], ["severe malaria syndromes", "PROBLEM", 142, 166], ["our current studies", "TEST", 171, 190], ["specific childhood malaria definitions", "PROBLEM", 250, 288], ["the major severe syndromes", "PROBLEM", 348, 374], ["host modulation", "OBSERVATION_MODIFIER", 13, 28], ["protein expression", "OBSERVATION", 88, 106], ["progression", "OBSERVATION_MODIFIER", 127, 138], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["malaria", "OBSERVATION", 149, 156], ["severe", "OBSERVATION_MODIFIER", 358, 364], ["syndromes", "OBSERVATION", 365, 374]]], ["To the best of our knowledge this study is the first to show that a panel of proteins, defined as a proteome-pattern, dissects clinical malaria syndromes.", [["malaria syndromes", "DISEASE", 136, 153], ["this study", "TEST", 29, 39], ["a panel of proteins", "TEST", 66, 85], ["a proteome", "TEST", 98, 108], ["clinical malaria syndromes", "PROBLEM", 127, 153], ["malaria syndromes", "OBSERVATION", 136, 153]]], ["Further identification of the proteins that comprise the proteome-patterns will provide hints to the underlying pathogenesis on each of the syndromes.", [["the proteins", "PROBLEM", 26, 38], ["the underlying pathogenesis", "PROBLEM", 97, 124], ["the syndromes", "PROBLEM", 136, 149]]], ["Furthermore, these proteome-patterns provide a reference point to facilitate the identification of other complex and overlapping severe childhood malaria syndromes.Supporting InformationData S1 Solid-phase fractionation data.", [["malaria syndromes", "DISEASE", 146, 163], ["other complex and overlapping severe childhood malaria syndromes", "PROBLEM", 99, 163], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["childhood", "OBSERVATION_MODIFIER", 136, 145], ["malaria", "OBSERVATION", 146, 153]]]], "725b175750813a29f16faee9a389ed706eba5ae4": [["IntroductionMacrophage (MO) apoptosis during Mycobacterium tuberculosis (Mtb) infection has focused much attention on its possible role in disease pathogenesis.", [["Mycobacterium tuberculosis", "DISEASE", 45, 71], ["infection", "DISEASE", 78, 87], ["Mycobacterium tuberculosis", "GENE_OR_GENE_PRODUCT", 45, 71], ["Mycobacterium tuberculosis", "SPECIES", 45, 71], ["Mycobacterium tuberculosis", "SPECIES", 45, 71], ["IntroductionMacrophage (MO) apoptosis", "TREATMENT", 0, 37], ["Mycobacterium tuberculosis (Mtb) infection", "PROBLEM", 45, 87], ["disease pathogenesis", "PROBLEM", 139, 159], ["Mycobacterium tuberculosis", "OBSERVATION", 45, 71], ["disease", "OBSERVATION", 139, 146]]], ["A number of findings support this view; it has been shown that virulent mycobacterial strains are less apoptogenic than their attenuated counterparts [1] and MO proapoptotic genes are downregulated by virulent strains while the opposite occurs with avirulent mycobacteria [2] .", [["strains", "ANATOMY", 86, 93], ["mycobacterial strains", "ORGANISM", 72, 93], ["MO", "GENE_OR_GENE_PRODUCT", 158, 160], ["MO proapoptotic genes", "DNA", 158, 179], ["this view", "TEST", 29, 38], ["virulent mycobacterial strains", "PROBLEM", 63, 93], ["MO proapoptotic genes", "PROBLEM", 158, 179], ["virulent strains", "PROBLEM", 201, 217], ["avirulent mycobacteria", "PROBLEM", 249, 271], ["virulent", "OBSERVATION_MODIFIER", 63, 71], ["mycobacterial strains", "OBSERVATION", 72, 93], ["mycobacteria", "OBSERVATION", 259, 271]]], ["In contrast with latent infection, in active TB patients the expression of genes that promote apoptosis is diminished [3] .", [["latent infection", "DISEASE", 17, 33], ["TB", "DISEASE", 45, 47], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["latent infection", "PROBLEM", 17, 33], ["latent", "OBSERVATION_MODIFIER", 17, 23], ["infection", "OBSERVATION", 24, 33], ["active", "OBSERVATION_MODIFIER", 38, 44], ["TB", "OBSERVATION", 45, 47], ["apoptosis", "OBSERVATION", 94, 103], ["diminished", "OBSERVATION_MODIFIER", 107, 117]]], ["These data and the identification of genes that inhibit MO apoptosis in some Mtb mutants [4] have added further support to the view that the ability of Mtb to prevent the apoptotic death of host cells is a virulence trait aimed to preserve its cellular niche.", [["cells", "ANATOMY", 195, 200], ["cellular niche", "ANATOMY", 244, 258], ["death", "DISEASE", 181, 186], ["MO", "GENE_OR_GENE_PRODUCT", 56, 58], ["Mtb", "GENE_OR_GENE_PRODUCT", 77, 80], ["Mtb", "GENE_OR_GENE_PRODUCT", 152, 155], ["host cells", "CELL", 190, 200], ["cellular", "CELL", 244, 252], ["host cells", "CELL_TYPE", 190, 200], ["These data", "TEST", 0, 10], ["MO apoptosis", "PROBLEM", 56, 68], ["further support", "TREATMENT", 104, 119], ["Mtb", "TREATMENT", 152, 155], ["the apoptotic death of host cells", "PROBLEM", 167, 200], ["a virulence trait", "PROBLEM", 204, 221], ["cellular niche", "OBSERVATION", 244, 258]]], ["On the other hand, that MO apoptosis represents an innate immune response of the host is suggested by decreased viability of bacilli in apoptotic MO [5] [6] [7] .", [["MO", "GENE_OR_GENE_PRODUCT", 24, 26]]], ["There is also evidence that dendritic cells that have ingested apoptotic MO infected by Mtb can activate T cells through a process known as crosspriming which results in the activation of CD8+ T cells [7, 8] .", [["dendritic cells", "ANATOMY", 28, 43], ["T cells", "ANATOMY", 105, 112], ["CD8+ T cells", "ANATOMY", 188, 200], ["dendritic cells", "CELL", 28, 43], ["MO", "GENE_OR_GENE_PRODUCT", 73, 75], ["Mtb", "GENE_OR_GENE_PRODUCT", 88, 91], ["T cells", "CELL", 105, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 188, 191], ["dendritic cells", "CELL_TYPE", 28, 43], ["T cells", "CELL_TYPE", 105, 112], ["CD8", "PROTEIN", 188, 191], ["T cells", "CELL_TYPE", 193, 200], ["dendritic cells", "PROBLEM", 28, 43], ["dendritic cells", "OBSERVATION", 28, 43], ["infected", "OBSERVATION_MODIFIER", 76, 84]]], ["It is also of interest the identification of Mtb proapoptotic mutants that induce higher T cell immunity which favors the control of infection [9] .IntroductionKnowledge about the mechanisms involved in the death of mycobacteria-infected MOs has greatly increased during the last decade.", [["T cell", "ANATOMY", 89, 95], ["infection", "DISEASE", 133, 142], ["death", "DISEASE", 207, 212], ["mycobacteria-infected", "DISEASE", 216, 237], ["Mtb", "GENE_OR_GENE_PRODUCT", 45, 48], ["T cell", "CELL", 89, 95], ["MOs", "CELL", 238, 241], ["Mtb proapoptotic mutants", "PROTEIN", 45, 69], ["Mtb proapoptotic mutants", "PROBLEM", 45, 69], ["higher T cell immunity", "PROBLEM", 82, 104], ["infection", "PROBLEM", 133, 142], ["mycobacteria", "PROBLEM", 216, 228], ["infected MOs", "PROBLEM", 229, 241], ["infection", "OBSERVATION", 133, 142], ["mycobacteria", "OBSERVATION", 216, 228], ["infected", "OBSERVATION", 229, 237], ["greatly", "OBSERVATION_MODIFIER", 246, 253], ["increased", "OBSERVATION_MODIFIER", 254, 263]]], ["Initially, it was characterized as extrinsic type, caspase-dependent apoptosis with TNF-\u03b1 activation [10, 11] .", [["caspase", "GENE_OR_GENE_PRODUCT", 51, 58], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["caspase", "PROTEIN", 51, 58], ["TNF", "PROTEIN", 84, 87], ["extrinsic type, caspase-dependent apoptosis", "PROBLEM", 35, 78], ["TNF", "TEST", 84, 87], ["dependent", "OBSERVATION_MODIFIER", 59, 68], ["apoptosis", "OBSERVATION_MODIFIER", 69, 78]]], ["More recent studies have come to show that MO apoptosis in mycobacterial infection is a complex and variegated process.", [["mycobacterial infection", "DISEASE", 59, 82], ["MO", "GENE_OR_GENE_PRODUCT", 43, 45], ["recent studies", "TEST", 5, 19], ["MO apoptosis", "PROBLEM", 43, 55], ["mycobacterial infection", "PROBLEM", 59, 82], ["a complex and variegated process", "PROBLEM", 86, 118], ["mycobacterial", "OBSERVATION_MODIFIER", 59, 72], ["infection", "OBSERVATION", 73, 82]]], ["Some reports document the participation of the intrinsic or mitochondrial pathway.", [["mitochondrial", "ANATOMY", 60, 73], ["mitochondrial", "CELLULAR_COMPONENT", 60, 73]]], ["Infection with attenuated Mtb strains results in mitochondrial outer membrane permeability with release of cytochrome c and activation of caspase 9 [12, 13] .", [["mitochondrial", "ANATOMY", 49, 62], ["membrane", "ANATOMY", 69, 77], ["mitochondrial", "CELLULAR_COMPONENT", 49, 62], ["outer membrane", "CELLULAR_COMPONENT", 63, 77], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 107, 119], ["caspase 9", "GENE_OR_GENE_PRODUCT", 138, 147], ["cytochrome c", "PROTEIN", 107, 119], ["caspase 9", "PROTEIN", 138, 147], ["Infection", "PROBLEM", 0, 9], ["attenuated Mtb strains", "PROBLEM", 15, 37], ["mitochondrial outer membrane permeability", "PROBLEM", 49, 90], ["cytochrome c", "PROBLEM", 107, 119], ["activation of caspase", "TREATMENT", 124, 145], ["attenuated", "OBSERVATION_MODIFIER", 15, 25], ["Mtb strains", "OBSERVATION", 26, 37], ["outer membrane permeability", "OBSERVATION", 63, 90]]], ["Recently, the endoplasmic reticulum stress and lysosome pathways have been implicated in macrophage apoptosis provoked by mycobacteria [14] .", [["endoplasmic reticulum", "ANATOMY", 14, 35], ["lysosome", "ANATOMY", 47, 55], ["macrophage", "ANATOMY", 89, 99], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 14, 35], ["lysosome", "CELLULAR_COMPONENT", 47, 55], ["macrophage", "CELL", 89, 99], ["the endoplasmic reticulum stress", "PROBLEM", 10, 42], ["macrophage apoptosis", "PROBLEM", 89, 109], ["mycobacteria", "PROBLEM", 122, 134], ["endoplasmic", "OBSERVATION", 14, 25], ["reticulum stress", "OBSERVATION", 26, 42], ["lysosome pathways", "OBSERVATION", 47, 64], ["macrophage apoptosis", "OBSERVATION", 89, 109], ["mycobacteria", "OBSERVATION", 122, 134]]], ["It has been also reported that host cell death might show features of necrosis particularly with increased bacillary loads [15] .", [["cell", "ANATOMY", 36, 40], ["death", "DISEASE", 41, 46], ["necrosis", "DISEASE", 70, 78], ["cell", "CELL", 36, 40], ["host cell death", "PROBLEM", 31, 46], ["necrosis", "PROBLEM", 70, 78], ["increased bacillary loads", "PROBLEM", 97, 122], ["necrosis", "OBSERVATION", 70, 78], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["bacillary loads", "OBSERVATION", 107, 122]]], ["These observations could suggest that mycobacteria instead of apoptosis favor necrosis as a mechanism of dissemination and survival.IntroductionA few mycobacterial molecules involved in macrophage apoptosis have been identified; among these are LpqH [16, 17] , ESAT 6 [11] , PE PGRS33 [18] , and PstS-1 [19] .", [["macrophage", "ANATOMY", 186, 196], ["necrosis", "DISEASE", 78, 86], ["macrophage", "CELL", 186, 196], ["LpqH", "GENE_OR_GENE_PRODUCT", 245, 249], ["ESAT 6", "GENE_OR_GENE_PRODUCT", 261, 267], ["PstS-1", "GENE_OR_GENE_PRODUCT", 296, 302], ["mycobacterial molecules", "PROTEIN", 150, 173], ["mycobacteria", "PROBLEM", 38, 50], ["apoptosis", "PROBLEM", 62, 71], ["necrosis", "PROBLEM", 78, 86], ["IntroductionA few mycobacterial molecules", "PROBLEM", 132, 173], ["macrophage apoptosis", "PROBLEM", 186, 206], ["LpqH", "TEST", 245, 249], ["ESAT", "TEST", 261, 265], ["PE PGRS33", "TEST", 275, 284], ["PstS", "TEST", 296, 300], ["mycobacteria", "OBSERVATION", 38, 50], ["necrosis", "OBSERVATION", 78, 86], ["mycobacterial molecules", "OBSERVATION", 150, 173], ["macrophage apoptosis", "OBSERVATION", 186, 206], ["PE", "OBSERVATION", 275, 277]]], ["We undertook this study with the aim of knowing better the biochemical pathways used by LpqH to induce MO apoptosis, specially to know if mitochondrial factors were involved.", [["mitochondrial", "ANATOMY", 138, 151], ["LpqH", "CHEMICAL", 88, 92], ["LpqH", "SIMPLE_CHEMICAL", 88, 92], ["MO", "GENE_OR_GENE_PRODUCT", 103, 105], ["mitochondrial", "CELLULAR_COMPONENT", 138, 151], ["LpqH", "PROTEIN", 88, 92], ["mitochondrial factors", "PROTEIN", 138, 159], ["this study", "TEST", 13, 23], ["mitochondrial factors", "PROBLEM", 138, 159]]], ["LpqH is interesting for several reasons; it is one of the few mycobacterial proteins, which in addition to acyl groups possess mannose residues [20] .", [["LpqH", "CHEMICAL", 0, 4], ["acyl", "CHEMICAL", 107, 111], ["acyl", "CHEMICAL", 107, 111], ["mannose", "CHEMICAL", 127, 134], ["LpqH", "SIMPLE_CHEMICAL", 0, 4], ["mannose", "SIMPLE_CHEMICAL", 127, 134], ["LpqH", "PROTEIN", 0, 4], ["mycobacterial proteins", "PROTEIN", 62, 84], ["the few mycobacterial proteins", "PROBLEM", 54, 84], ["acyl groups", "TREATMENT", 107, 118], ["mannose residues", "PROBLEM", 127, 143]]], ["Recently, we demonstrated that LpqH behaves as an adhesin that interacts with the mannose receptor to promote phagocytosis of mycobacteria [21] .", [["LpqH", "CHEMICAL", 31, 35], ["mannose", "CHEMICAL", 82, 89], ["LpqH", "GENE_OR_GENE_PRODUCT", 31, 35], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 82, 98], ["LpqH", "PROTEIN", 31, 35], ["adhesin", "PROTEIN", 50, 57], ["mannose receptor", "PROTEIN", 82, 98], ["the mannose receptor", "TREATMENT", 78, 98], ["mycobacteria", "PROBLEM", 126, 138]]], ["LpqH induces T cell-mediated immunity, although it might also behave as a TLR2 agonist that downregulates antigen presentation to T cells [22] .IntroductionFrom the above data, it is clear that the death of mycobacteria-infected MOs is a relevant, mechanistically complex phenomenon.", [["T cell", "ANATOMY", 13, 19], ["T cells", "ANATOMY", 130, 137], ["LpqH", "CHEMICAL", 0, 4], ["death", "DISEASE", 198, 203], ["mycobacteria-infected", "DISEASE", 207, 228], ["LpqH", "SIMPLE_CHEMICAL", 0, 4], ["T cell", "CELL", 13, 19], ["TLR2", "GENE_OR_GENE_PRODUCT", 74, 78], ["T cells", "CELL", 130, 137], ["MOs", "CELL", 229, 232], ["LpqH", "PROTEIN", 0, 4], ["TLR2", "PROTEIN", 74, 78], ["T cells", "CELL_TYPE", 130, 137], ["LpqH", "TEST", 0, 4], ["a TLR2 agonist", "TREATMENT", 72, 86], ["the above data", "TEST", 161, 175], ["mycobacteria", "PROBLEM", 207, 219], ["infected MOs", "PROBLEM", 220, 232], ["mechanistically complex phenomenon", "PROBLEM", 248, 282], ["mycobacteria", "OBSERVATION", 207, 219], ["complex phenomenon", "OBSERVATION", 264, 282]]], ["We show that in addition to TLR2 dependent, death receptor-mediated apoptosis, LpqH triggers an intrinsic or mitochondrial pathway, with the participation of cytochrome c and the apoptosis-inducing mitochondrial factor (AIF), a previously unrecognized mechanism of MO cell death induced by Mtb.Materials.Murine monoclonal antibodies (mAbs) to human TNF-\u03b1 (clone 28401) and human TNFR1 and human TNFR2 (clone 22221) were purchased from R&D Systems (Minneapolis, MN, USA); mAbs to human Fas (clone ZB4) and FasL (clone B-R17), caspase 8, caspase 9, and caspase 3 were purchased from Upstate Cell Signaling (Lake Placid, NY, USA); mAb to human TLR2 (clone TL2.1) were from eBioscience (San Diego, CA, USA) and TLR4 (clone HTA-125) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).", [["mitochondrial", "ANATOMY", 109, 122], ["mitochondrial", "ANATOMY", 198, 211], ["cell", "ANATOMY", 268, 272], ["Cell", "ANATOMY", 589, 593], ["death", "DISEASE", 44, 49], ["death", "DISEASE", 273, 278], ["clone HTA-125", "CHEMICAL", 713, 726], ["TLR2", "GENE_OR_GENE_PRODUCT", 28, 32], ["LpqH", "GENE_OR_GENE_PRODUCT", 79, 83], ["mitochondrial", "CELLULAR_COMPONENT", 109, 122], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 158, 170], ["mitochondrial factor", "GENE_OR_GENE_PRODUCT", 198, 218], ["AIF", "GENE_OR_GENE_PRODUCT", 220, 223], ["MO cell", "CELL", 265, 272], ["Mtb", "GENE_OR_GENE_PRODUCT", 290, 293], ["Murine", "ORGANISM", 304, 310], ["human", "ORGANISM", 343, 348], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 349, 354], ["clone 28401", "CELL", 356, 367], ["human", "ORGANISM", 373, 378], ["TNFR1", "GENE_OR_GENE_PRODUCT", 379, 384], ["human", "ORGANISM", 389, 394], ["TNFR2", "GENE_OR_GENE_PRODUCT", 395, 400], ["clone 22221", "CELL", 402, 413], ["human", "ORGANISM", 479, 484], ["Fas", "GENE_OR_GENE_PRODUCT", 485, 488], ["clone ZB4", "GENE_OR_GENE_PRODUCT", 490, 499], ["FasL", "GENE_OR_GENE_PRODUCT", 505, 509], ["clone B-R17", "GENE_OR_GENE_PRODUCT", 511, 522], ["caspase 8", "GENE_OR_GENE_PRODUCT", 525, 534], ["caspase 9", "GENE_OR_GENE_PRODUCT", 536, 545], ["caspase 3", "GENE_OR_GENE_PRODUCT", 551, 560], ["Cell", "CELL", 589, 593], ["mAb", "GENE_OR_GENE_PRODUCT", 628, 631], ["human", "ORGANISM", 635, 640], ["TLR2", "GENE_OR_GENE_PRODUCT", 641, 645], ["TLR4", "GENE_OR_GENE_PRODUCT", 707, 711], ["TLR2", "PROTEIN", 28, 32], ["death receptor", "PROTEIN", 44, 58], ["LpqH", "PROTEIN", 79, 83], ["cytochrome c", "PROTEIN", 158, 170], ["mitochondrial factor", "PROTEIN", 198, 218], ["AIF", "PROTEIN", 220, 223], ["Murine monoclonal antibodies", "PROTEIN", 304, 332], ["mAbs", "PROTEIN", 334, 338], ["human TNF-\u03b1", "PROTEIN", 343, 354], ["clone 28401", "PROTEIN", 356, 367], ["human TNFR1", "PROTEIN", 373, 384], ["human TNFR2", "PROTEIN", 389, 400], ["clone 22221", "PROTEIN", 402, 413], ["mAbs", "PROTEIN", 471, 475], ["human Fas", "PROTEIN", 479, 488], ["clone ZB4", "PROTEIN", 490, 499], ["FasL", "PROTEIN", 505, 509], ["clone B", "PROTEIN", 511, 518], ["R17", "PROTEIN", 519, 522], ["caspase 8", "PROTEIN", 525, 534], ["caspase 9", "PROTEIN", 536, 545], ["caspase 3", "PROTEIN", 551, 560], ["mAb", "PROTEIN", 628, 631], ["human TLR2", "PROTEIN", 635, 645], ["clone TL2", "PROTEIN", 647, 656], ["TLR4", "PROTEIN", 707, 711], ["Santa Cruz Biotechnology", "PROTEIN", 746, 770], ["Murine", "SPECIES", 304, 310], ["human", "SPECIES", 343, 348], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 389, 394], ["human", "SPECIES", 479, 484], ["human", "SPECIES", 635, 640], ["Murine", "SPECIES", 304, 310], ["human", "SPECIES", 343, 348], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 389, 394], ["human", "SPECIES", 479, 484], ["human", "SPECIES", 635, 640], ["TLR2 dependent", "PROBLEM", 28, 42], ["mediated apoptosis", "PROBLEM", 59, 77], ["cytochrome c", "PROBLEM", 158, 170], ["the apoptosis", "PROBLEM", 175, 188], ["mitochondrial factor (AIF", "PROBLEM", 198, 223], ["MO cell death", "PROBLEM", 265, 278], ["Mtb", "PROBLEM", 290, 293], ["Murine monoclonal antibodies", "TEST", 304, 332], ["human TNF", "TEST", 343, 352], ["clone", "TEST", 356, 361], ["human TNFR1", "TEST", 373, 384], ["human TNFR2", "TEST", 389, 400], ["mAbs to human Fas (clone ZB4)", "TREATMENT", 471, 500], ["FasL (clone B-R17)", "TREATMENT", 505, 523], ["caspase", "TREATMENT", 525, 532], ["caspase", "TREATMENT", 536, 543], ["caspase", "TREATMENT", 551, 558], ["mAb to human TLR2 (clone TL2", "TREATMENT", 628, 656], ["TLR4 (clone HTA", "TEST", 707, 722], ["TLR2 dependent", "OBSERVATION_MODIFIER", 28, 42], ["MO cell death", "OBSERVATION", 265, 278]]], ["A mouse monoclonal antibody to the human-apoptosis inducing factor (AIF) was obtained from Santa Cruz Biotechnology (clone E20).", [["mouse", "ORGANISM", 2, 7], ["human", "ORGANISM", 35, 40], ["-apoptosis inducing factor", "GENE_OR_GENE_PRODUCT", 40, 66], ["AIF", "GENE_OR_GENE_PRODUCT", 68, 71], ["mouse monoclonal antibody", "PROTEIN", 2, 27], ["human-apoptosis inducing factor", "PROTEIN", 35, 66], ["AIF", "PROTEIN", 68, 71], ["Santa Cruz Biotechnology", "PROTEIN", 91, 115], ["mouse", "SPECIES", 2, 7], ["human", "SPECIES", 35, 40], ["mouse", "SPECIES", 2, 7], ["human", "SPECIES", 35, 40], ["A mouse monoclonal antibody", "TEST", 0, 27], ["monoclonal antibody", "OBSERVATION", 8, 27]]], ["A goat polyclonal antibody to human cytochrome c was purchased from Santa Cruz Biotechnology (clone C-20).", [["goat", "ORGANISM", 2, 6], ["human", "ORGANISM", 30, 35], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 36, 48], ["goat polyclonal antibody", "PROTEIN", 2, 26], ["human cytochrome c", "PROTEIN", 30, 48], ["Santa Cruz Biotechnology", "PROTEIN", 68, 92], ["goat", "SPECIES", 2, 6], ["human", "SPECIES", 30, 35], ["goat", "SPECIES", 2, 6], ["human", "SPECIES", 30, 35], ["A goat polyclonal antibody", "TREATMENT", 0, 26], ["clone C", "TEST", 94, 101]]], ["Horseradish peroxidase-conjugated control isotype antibodies to goat IgG and to mouse IgG were from Dako (Carpinteria, CA, USA).", [["peroxidase", "GENE_OR_GENE_PRODUCT", 12, 22], ["goat", "ORGANISM", 64, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["mouse", "ORGANISM", 80, 85], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["Horseradish peroxidase", "PROTEIN", 0, 22], ["isotype antibodies", "PROTEIN", 42, 60], ["goat IgG", "PROTEIN", 64, 72], ["mouse IgG", "PROTEIN", 80, 89], ["Horseradish", "SPECIES", 0, 11], ["goat", "SPECIES", 64, 68], ["mouse", "SPECIES", 80, 85], ["goat", "SPECIES", 64, 68], ["mouse", "SPECIES", 80, 85], ["Horseradish peroxidase", "TREATMENT", 0, 22], ["conjugated control isotype antibodies", "TREATMENT", 23, 60], ["goat IgG", "TEST", 64, 72], ["mouse IgG", "TEST", 80, 89]]], ["A cell-death detection enzyme-linked immunosorbent assay (ELISA) Plus was obtained from Roche Diagnostics (Penzberg, Germany).", [["cell", "ANATOMY", 2, 6], ["cell", "CELL", 2, 6], ["A cell-death detection enzyme", "TEST", 0, 29], ["immunosorbent assay", "TEST", 37, 56]]], ["A specific cell-permeable pancaspase inhibitor Z-VAD-FMK was obtained from BD Pharmingen (San Diego, CA, USA).", [["cell", "ANATOMY", 11, 15], ["Z-VAD-FMK", "CHEMICAL", 47, 56], ["Z-VAD-FMK", "CHEMICAL", 47, 56], ["cell", "CELL", 11, 15], ["pancaspase", "GENE_OR_GENE_PRODUCT", 26, 36], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 47, 56], ["BD Pharmingen", "PROTEIN", 75, 88], ["A specific cell", "TEST", 0, 15]]], ["Ficoll-Hypaque was from Amersham Biosciences (Piscataway, NJ, USA); polymyxin B, Ponceau red, and dimethyl sulfoxide (DMSO) were from Sigma-Aldrich (St. Louis, MO, USA).", [["polymyxin B", "CHEMICAL", 68, 79], ["Ponceau red", "CHEMICAL", 81, 92], ["dimethyl sulfoxide", "CHEMICAL", 98, 116], ["DMSO", "CHEMICAL", 118, 122], ["polymyxin B", "CHEMICAL", 68, 79], ["Ponceau red", "CHEMICAL", 81, 92], ["dimethyl sulfoxide", "CHEMICAL", 98, 116], ["DMSO", "CHEMICAL", 118, 122], ["polymyxin B", "SIMPLE_CHEMICAL", 68, 79], ["Ponceau red", "SIMPLE_CHEMICAL", 81, 92], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 98, 116], ["DMSO", "SIMPLE_CHEMICAL", 118, 122], ["Sigma-Aldrich", "ORGANISM", 134, 147], ["St. Louis", "ORGANISM", 149, 158], ["MO, USA", "ORGANISM", 160, 167], ["Ponceau red", "SPECIES", 81, 92], ["polymyxin B", "TREATMENT", 68, 79], ["Ponceau red", "TREATMENT", 81, 92], ["dimethyl sulfoxide (DMSO", "TREATMENT", 98, 122]]], ["A subcellular protein fractionation kit fractionation was obtained from Thermo Scientific (Rockford, IL, USA).", [["subcellular", "ANATOMY", 2, 13], ["A subcellular protein fractionation kit fractionation", "TEST", 0, 53], ["protein fractionation", "OBSERVATION", 14, 35]]], ["The fluorescent lipophilic dye 3,3 dihexyloxacarbocyanine iodide (DiOC6) was purchased from Molecular Probes (Eugene, OR, USA).Mycobacteria and Isolation of LpqH.A native Mycobacterium smegmatis strain (mc2155) and its counterpart transformed by electroporation with the plasmid p16R1 containing a 1.8 kb SmaI fragment that includes the structural gene encoding the LpqH lipoprotein were kindly donated by Y. Zhang (MRC Tuberculosis and Related Infections Unit, Hammersmith Hospital, London, UK).", [["3,3", "CHEMICAL", 31, 34], ["dihexyloxacarbocyanine iodide", "CHEMICAL", 35, 64], ["DiOC6", "CHEMICAL", 66, 71], ["mc2155", "CHEMICAL", 203, 209], ["Tuberculosis", "DISEASE", 420, 432], ["Infections", "DISEASE", 445, 455], ["3,3 dihexyloxacarbocyanine iodide", "CHEMICAL", 31, 64], ["DiOC6", "CHEMICAL", 66, 71], ["fluorescent lipophilic dye 3,3 dihexyloxacarbocyanine iodide", "SIMPLE_CHEMICAL", 4, 64], ["DiOC6", "SIMPLE_CHEMICAL", 66, 71], ["LpqH", "GENE_OR_GENE_PRODUCT", 157, 161], ["Mycobacterium smegmatis", "ORGANISM", 171, 194], ["mc2155", "CELL", 203, 209], ["SmaI", "GENE_OR_GENE_PRODUCT", 305, 309], ["LpqH lipoprotein", "GENE_OR_GENE_PRODUCT", 366, 382], ["LpqH", "PROTEIN", 157, 161], ["plasmid p16R1", "DNA", 271, 284], ["1.8 kb SmaI fragment", "DNA", 298, 318], ["LpqH lipoprotein", "PROTEIN", 366, 382], ["Mycobacterium smegmatis", "SPECIES", 171, 194], ["Mycobacterium smegmatis", "SPECIES", 171, 194], ["The fluorescent lipophilic dye", "TEST", 0, 30], ["dihexyloxacarbocyanine iodide", "TREATMENT", 35, 64], ["Mycobacteria", "PROBLEM", 127, 139], ["Isolation of LpqH", "TREATMENT", 144, 161], ["A native Mycobacterium smegmatis strain", "PROBLEM", 162, 201], ["the plasmid p16R1", "TREATMENT", 267, 284], ["a 1.8 kb SmaI fragment", "PROBLEM", 296, 318], ["lipophilic dye", "OBSERVATION", 16, 30], ["native", "OBSERVATION_MODIFIER", 164, 170], ["Mycobacterium smegmatis", "OBSERVATION", 171, 194]]], ["M. smegmatis strains were grown for 4-5 days in Middlebrook 7H9 medium (BBL, Becton-Dickinson, Cockeysville, MD, USA) supplemented with 2% glucose and hygromycin B (50 mg/mL).", [["glucose", "CHEMICAL", 139, 146], ["hygromycin B", "CHEMICAL", 151, 163], ["glucose", "CHEMICAL", 139, 146], ["hygromycin B", "CHEMICAL", 151, 163], ["M. smegmatis", "ORGANISM", 0, 12], ["glucose", "SIMPLE_CHEMICAL", 139, 146], ["hygromycin B", "SIMPLE_CHEMICAL", 151, 163], ["M. smegmatis", "SPECIES", 0, 12], ["M. smegmatis", "SPECIES", 0, 12], ["M. smegmatis strains", "PROBLEM", 0, 20], ["2% glucose", "TREATMENT", 136, 146], ["hygromycin B", "TREATMENT", 151, 163], ["smegmatis strains", "OBSERVATION", 3, 20]]], ["Bacteria were harvested by centrifugation and washed with ice-cold sodium phosphate buffer (10 mM/L).", [["Bacteria", "ANATOMY", 0, 8], ["sodium phosphate", "CHEMICAL", 67, 83], ["sodium phosphate", "CHEMICAL", 67, 83], ["Bacteria", "CELL", 0, 8], ["sodium phosphate buffer", "SIMPLE_CHEMICAL", 67, 90], ["Bacteria", "PROBLEM", 0, 8], ["ice-cold sodium phosphate buffer", "TREATMENT", 58, 90]]], ["To isolate LpqH, cellwall fractions were obtained by sonication of bacteria at 20 KHz in iced water (five cycles of 5 min each).", [["cellwall fractions", "ANATOMY", 17, 35], ["LpqH", "SIMPLE_CHEMICAL", 11, 15], ["LpqH", "PROTEIN", 11, 15], ["cellwall fractions", "PROBLEM", 17, 35], ["bacteria", "PROBLEM", 67, 75]]], ["Proteins were resolved by 12% or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose.", [["sodium dodecyl sulfate", "CHEMICAL", 37, 59], ["SDS-PAGE", "CHEMICAL", 96, 104], ["sodium dodecyl sulfate", "CHEMICAL", 37, 59], ["polyacrylamide", "CHEMICAL", 60, 74], ["nitrocellulose", "CHEMICAL", 125, 139], ["sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 37, 74], ["Proteins", "TEST", 0, 8], ["15% sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 33, 94], ["nitrocellulose", "TREATMENT", 125, 139]]], ["The 19 kDa LpqH band was identified by immunoblot with mAb IT-19, which was donated by TB Vaccines Testing and Research Materials Contract, Colorado State University.", [["LpqH", "GENE_OR_GENE_PRODUCT", 11, 15], ["19 kDa LpqH band", "PROTEIN", 4, 20], ["mAb IT-19", "PROTEIN", 55, 64], ["The 19 kDa LpqH band", "TEST", 0, 20], ["immunoblot", "TEST", 39, 49], ["mAb IT", "TEST", 55, 61], ["TB Vaccines", "TREATMENT", 87, 98]]], ["In order to obtain LpqH to induce apoptosis, cell wall fractions were obtained by sonication and 30 \u03bcg protein was mixed with an equal volume of reducing sample buffer (0.05 mM EDTA, 0.1% SDS, 1% glycerol, 10% 2mercaptoethanol, and 0.5 mM/mL Tris-HCl pH 6.8), heated for 5 min at 95 \u2022 C, and loaded into 1 \u03bcL 1.5 mm slot 20 cm long gels.", [["cell wall fractions", "ANATOMY", 45, 64], ["LpqH", "CHEMICAL", 19, 23], ["glycerol", "CHEMICAL", 196, 204], ["2mercaptoethanol", "CHEMICAL", 210, 226], ["Tris-HCl", "CHEMICAL", 242, 250], ["LpqH", "CHEMICAL", 19, 23], ["EDTA", "CHEMICAL", 177, 181], ["glycerol", "CHEMICAL", 196, 204], ["2mercaptoethanol", "CHEMICAL", 210, 226], ["Tris-HCl", "CHEMICAL", 242, 250], ["LpqH", "SIMPLE_CHEMICAL", 19, 23], ["cell", "ORGANISM_SUBSTANCE", 45, 49], ["EDTA", "SIMPLE_CHEMICAL", 177, 181], ["glycerol", "SIMPLE_CHEMICAL", 196, 204], ["2mercaptoethanol", "SIMPLE_CHEMICAL", 210, 226], ["LpqH", "PROTEIN", 19, 23], ["LpqH", "TREATMENT", 19, 23], ["apoptosis", "PROBLEM", 34, 43], ["cell wall fractions", "TEST", 45, 64], ["reducing sample buffer", "TREATMENT", 145, 167], ["EDTA", "TEST", 177, 181], ["glycerol", "TREATMENT", 196, 204], ["HCl pH", "TEST", 247, 253]]], ["After electrophoresis, proteins were transferred to nitrocellulose sheets and stained with Ponceau red to identify the 19 kDa band; the identity of this band was confirmed in parallel blots with the IT-19 mAb.", [["nitrocellulose", "CHEMICAL", 52, 66], ["Ponceau red", "CHEMICAL", 91, 102], ["Ponceau red", "PROTEIN", 91, 102], ["19 kDa band", "PROTEIN", 119, 130], ["IT-19 mAb", "PROTEIN", 199, 208], ["Ponceau red", "SPECIES", 91, 102], ["electrophoresis", "TEST", 6, 21], ["the 19 kDa band", "PROBLEM", 115, 130], ["this band", "PROBLEM", 148, 157]]], ["Thereafter, the band was excised, solubilized in DMSO, and precipitated with an equal volume of carbonate/bicarbonate sodium buffer (0.05 M, pH 9.6).", [["DMSO", "CHEMICAL", 49, 53], ["bicarbonate sodium", "CHEMICAL", 106, 124], ["DMSO", "CHEMICAL", 49, 53], ["carbonate", "CHEMICAL", 96, 105], ["bicarbonate sodium", "CHEMICAL", 106, 124], ["DMSO", "SIMPLE_CHEMICAL", 49, 53], ["carbonate", "SIMPLE_CHEMICAL", 96, 105], ["bicarbonate sodium buffer", "SIMPLE_CHEMICAL", 106, 131], ["DMSO", "TREATMENT", 49, 53], ["an equal volume of carbonate/bicarbonate sodium buffer", "TREATMENT", 77, 131], ["pH", "TEST", 141, 143]]], ["The pellet was rinsed three times with ice-cold PBS and aliquots were stored at 20 \u2022 C. Protein concentration was determined with the Lowry method using BSA as standard.", [["pellet", "ANATOMY", 4, 10], ["BSA", "SIMPLE_CHEMICAL", 153, 156], ["The pellet", "TREATMENT", 0, 10], ["ice-cold PBS and aliquots", "TREATMENT", 39, 64], ["Protein concentration", "TEST", 88, 109], ["pellet", "OBSERVATION", 4, 10]]], ["Native M. smegmatis cell wall fractions were electron-transferred to nitrocellulose membranes and a 19-kDa strip was excised and processed as above to be used in apoptosis assays as a control.", [["cell wall fractions", "ANATOMY", 20, 39], ["membranes", "ANATOMY", 84, 93], ["nitrocellulose", "CHEMICAL", 69, 83], ["electron", "SIMPLE_CHEMICAL", 45, 53], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["M. smegmatis", "SPECIES", 7, 19], ["M. smegmatis", "SPECIES", 7, 19], ["Native M. smegmatis cell wall fractions", "PROBLEM", 0, 39], ["nitrocellulose membranes", "TREATMENT", 69, 93], ["a 19-kDa strip", "TREATMENT", 98, 112], ["apoptosis assays", "TEST", 162, 178], ["smegmatis cell", "OBSERVATION", 10, 24], ["wall", "ANATOMY_MODIFIER", 25, 29]]], ["Western blots with the IT-19 mAb failed to demonstrate LpqH in cell walls of native M. smegmatis bacilli (not shown).Apoptosis Assays to Determine Capacity of LpqH toKill Human Monocyte-Derived Macrophages.", [["cell walls", "ANATOMY", 63, 73], ["Macrophages", "ANATOMY", 194, 205], ["LpqH", "GENE_OR_GENE_PRODUCT", 55, 59], ["cell", "CELL", 63, 67], ["M. smegmatis", "ORGANISM", 84, 96], ["Human", "ORGANISM", 171, 176], ["Monocyte-Derived Macrophages", "CELL", 177, 205], ["IT-19 mAb", "PROTEIN", 23, 32], ["LpqH", "PROTEIN", 55, 59], ["LpqH toKill Human Monocyte-Derived Macrophages", "CELL_LINE", 159, 205], ["M. smegmatis", "SPECIES", 84, 96], ["Human", "SPECIES", 171, 176], ["M. smegmatis", "SPECIES", 84, 96], ["the IT", "TEST", 19, 25], ["native M. smegmatis bacilli", "PROBLEM", 77, 104], ["Apoptosis Assays", "TEST", 117, 133], ["Capacity", "TEST", 147, 155], ["LpqH", "TEST", 159, 163], ["smegmatis bacilli", "OBSERVATION", 87, 104], ["Macrophages", "OBSERVATION", 194, 205]]], ["Blood samples were obtained from healthy donors and mononuclear cells were separated by the Ficoll-Hypaque gradient centrifugation.", [["Blood samples", "ANATOMY", 0, 13], ["mononuclear cells", "ANATOMY", 52, 69], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["donors", "ORGANISM", 41, 47], ["mononuclear cells", "CELL", 52, 69], ["mononuclear cells", "CELL_TYPE", 52, 69], ["Blood samples", "TEST", 0, 13], ["the Ficoll-Hypaque gradient centrifugation", "TREATMENT", 88, 130], ["mononuclear cells", "OBSERVATION", 52, 69], ["gradient centrifugation", "OBSERVATION", 107, 130]]], ["Cells were cultured in Petri dishes (Corning Inc., Corning, NY, USA), in RPMI-1640 supplemented with 20% fetal bovine serum, 5 mM/L L-glutamine, and 5 \u03bcg/mL penicillin-streptomycin, at 37 \u2022 C in a humidified 5% CO 2 atmosphere.", [["Cells", "ANATOMY", 0, 5], ["fetal bovine serum", "ANATOMY", 105, 123], ["RPMI-1640", "CHEMICAL", 73, 82], ["L-glutamine", "CHEMICAL", 132, 143], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 168, 180], ["L-glutamine", "CHEMICAL", 132, 143], ["penicillin", "CHEMICAL", 157, 167], ["streptomycin", "CHEMICAL", 168, 180], ["CO", "CHEMICAL", 211, 213], ["Cells", "CELL", 0, 5], ["RPMI-1640", "CELL", 73, 82], ["bovine", "ORGANISM", 111, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["L-glutamine", "SIMPLE_CHEMICAL", 132, 143], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 157, 180], ["bovine", "SPECIES", 111, 117], ["bovine", "SPECIES", 111, 117], ["RPMI", "TEST", 73, 77], ["20% fetal bovine serum", "TREATMENT", 101, 123], ["L L-glutamine", "TREATMENT", 130, 143], ["penicillin", "TREATMENT", 157, 167], ["streptomycin", "TREATMENT", 168, 180], ["a humidified", "TREATMENT", 195, 207]]], ["After overnight incubation at 37 \u2022 C, adherent cells were cultured with 10% fetal bovine serum.", [["cells", "ANATOMY", 47, 52], ["fetal bovine serum", "ANATOMY", 76, 94], ["cells", "CELL", 47, 52], ["bovine", "ORGANISM", 82, 88], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["adherent cells", "CELL_TYPE", 38, 52], ["bovine", "SPECIES", 82, 88], ["bovine", "SPECIES", 82, 88], ["overnight incubation", "TEST", 6, 26], ["adherent cells", "TEST", 38, 52], ["% fetal bovine serum", "TEST", 74, 94]]], ["This step is considered necessary to get rid of nonadherent cells, death cells, and nonmacrophagic cells.", [["cells", "ANATOMY", 60, 65], ["cells", "ANATOMY", 73, 78], ["nonmacrophagic cells", "ANATOMY", 84, 104], ["death", "DISEASE", 67, 72], ["cells", "CELL", 60, 65], ["cells", "CELL", 73, 78], ["nonmacrophagic cells", "CELL", 84, 104], ["nonadherent cells", "CELL_TYPE", 48, 65], ["death cells", "CELL_TYPE", 67, 78], ["nonmacrophagic cells", "CELL_TYPE", 84, 104], ["nonadherent cells", "PROBLEM", 48, 65], ["death cells", "PROBLEM", 67, 78], ["nonmacrophagic cells", "PROBLEM", 84, 104], ["nonadherent cells", "OBSERVATION", 48, 65], ["nonmacrophagic cells", "OBSERVATION", 84, 104]]], ["At 7 days of culture and after treatment with RPMI-1640 containing EDTA (5 mM/L), at 3 4 \u2022 C for 10 min, activated macrophages were gently detached with a cell scraper.", [["macrophages", "ANATOMY", 115, 126], ["cell", "ANATOMY", 155, 159], ["RPMI-1640", "CHEMICAL", 46, 55], ["EDTA", "CHEMICAL", 67, 71], ["EDTA", "CHEMICAL", 67, 71], ["EDTA", "SIMPLE_CHEMICAL", 67, 71], ["macrophages", "CELL", 115, 126], ["cell", "CELL", 155, 159], ["activated macrophages", "CELL_TYPE", 105, 126], ["culture", "TEST", 13, 20], ["treatment", "TREATMENT", 31, 40], ["RPMI", "TEST", 46, 50], ["EDTA", "TEST", 67, 71], ["activated macrophages", "TREATMENT", 105, 126], ["a cell scraper", "TREATMENT", 153, 167]]], ["After rinsing, cells (5 \u00d7 10 5 ) were placed in 12-well flat-bottom plates (Corning Inc., Corning, NY, USA); at this time, trypan blue exclusion showed >95% cell viability.", [["cells", "ANATOMY", 15, 20], ["cell", "ANATOMY", 157, 161], ["trypan blue", "CHEMICAL", 123, 134], ["trypan blue", "CHEMICAL", 123, 134], ["cells", "CELL", 15, 20], ["trypan blue", "SIMPLE_CHEMICAL", 123, 134], ["cell", "CELL", 157, 161], ["rinsing, cells", "TREATMENT", 6, 20], ["trypan blue exclusion", "TEST", 123, 144], ["% cell viability", "OBSERVATION", 155, 171]]], ["Thereafter, cells were incubated with 0.5, 5, or 50 \u03bcg of LpqH for 1 or 24 h at 37 \u2022 C. For control, cells were incubated with 100 \u03bcg protein present in 19 kDa region of native M. smegmatis cell wall.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 101, 106], ["cell wall", "ANATOMY", 190, 199], ["LpqH", "CHEMICAL", 58, 62], ["cells", "CELL", 12, 17], ["LpqH", "SIMPLE_CHEMICAL", 58, 62], ["cells", "CELL", 101, 106], ["cell wall", "TISSUE", 190, 199], ["19 kDa region", "PROTEIN", 153, 166], ["M. smegmatis", "SPECIES", 177, 189], ["M. smegmatis", "SPECIES", 177, 189], ["LpqH", "TREATMENT", 58, 62], ["19 kDa", "OBSERVATION_MODIFIER", 153, 159], ["native", "OBSERVATION_MODIFIER", 170, 176], ["M. smegmatis", "OBSERVATION", 177, 189], ["cell", "OBSERVATION", 190, 194], ["wall", "ANATOMY_MODIFIER", 195, 199]]], ["Apoptosis was measured by ELISA with a cell-death detection kit according to the manufacturer's instructions.", [["cell", "ANATOMY", 39, 43], ["cell", "CELL", 39, 43], ["Apoptosis", "PROBLEM", 0, 9]]], ["Plates were analyzed with an ELISA reader (Bio-Tek Instruments, Winooski, VT, USA).Detection of Caspase Activation by Immunoblot andInhibition Assays with a Pancaspase Inhibitor.", [["Caspase", "GENE_OR_GENE_PRODUCT", 96, 103], ["Pancaspase Inhibitor", "GENE_OR_GENE_PRODUCT", 157, 177], ["Caspase", "PROTEIN", 96, 103], ["an ELISA", "TEST", 26, 34], ["Bio-Tek Instruments", "TREATMENT", 43, 62], ["Caspase Activation", "TREATMENT", 96, 114], ["Immunoblot", "TEST", 118, 128], ["Inhibition Assays", "TREATMENT", 132, 149], ["a Pancaspase Inhibitor", "TREATMENT", 155, 177], ["Caspase Activation", "OBSERVATION", 96, 114]]], ["Macrophages (2 \u00d7 10 6 ) were incubated with 5 \u03bcg LpqH for 1 h.", [["Macrophages", "ANATOMY", 0, 11], ["LpqH", "CHEMICAL", 49, 53], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "TEST", 0, 11]]], ["Thereafter, whole cell extracts were obtained after cells were lysed and vortexed with 100 \u03bcL radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.0, 50 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) and let stand for 20 min at 4 \u2022 C. Cell lysates were centrifuged (34025.6 g for 15 min at 4 \u2022 C) and the supernatant was obtained; 35 \u03bcg protein were resolved by 17.5% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes; after blocking with 5% nonfat milk in PBS, membranes were incubated with mAbs to caspase 8, 9, and 3 (dilution 1/1000), overnight, at 4 \u2022 C. After rinsing, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (dilution 1/1000), for 1 h, at room temperature.", [["cell extracts", "ANATOMY", 18, 31], ["cells", "ANATOMY", 52, 57], ["Cell lysates", "ANATOMY", 253, 265], ["supernatant", "ANATOMY", 323, 334], ["membranes", "ANATOMY", 447, 456], ["milk", "ANATOMY", 488, 492], ["membranes", "ANATOMY", 501, 510], ["membranes", "ANATOMY", 614, 623], ["Tris-HCl", "CHEMICAL", 139, 147], ["NaCl", "CHEMICAL", 163, 167], ["sodium deoxycholate", "CHEMICAL", 183, 202], ["Tris-HCl", "CHEMICAL", 139, 147], ["NaCl", "CHEMICAL", 163, 167], ["NP40", "CHEMICAL", 172, 176], ["sodium deoxycholate", "CHEMICAL", 183, 202], ["polyvinylidene difluoride", "CHEMICAL", 414, 439], ["PVDF", "CHEMICAL", 441, 445], ["cell extracts", "ORGANISM_SUBSTANCE", 18, 31], ["cells", "CELL", 52, 57], ["Tris-HCl", "SIMPLE_CHEMICAL", 139, 147], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 183, 202], ["Cell lysates", "CELL", 253, 265], ["milk", "ORGANISM_SUBSTANCE", 488, 492], ["PBS", "SIMPLE_CHEMICAL", 496, 499], ["membranes", "CELLULAR_COMPONENT", 501, 510], ["caspase 8", "GENE_OR_GENE_PRODUCT", 539, 548], ["membranes", "CELLULAR_COMPONENT", 614, 623], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 644, 666], ["mAbs", "PROTEIN", 531, 535], ["horseradish peroxidase", "PROTEIN", 644, 666], ["conjugated secondary antibodies", "PROTEIN", 667, 698], ["horseradish", "SPECIES", 644, 655], ["whole cell extracts", "TEST", 12, 31], ["Tris", "TEST", 139, 143], ["pH", "TEST", 149, 151], ["NaCl", "TEST", 163, 167], ["NP40", "TEST", 172, 176], ["sodium deoxycholate", "TREATMENT", 183, 202], ["Cell lysates", "TEST", 253, 265], ["polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 414, 456], ["blocking", "TREATMENT", 464, 472], ["5% nonfat milk in PBS", "TREATMENT", 478, 499], ["caspase", "TEST", 539, 546], ["membranes", "TREATMENT", 614, 623], ["horseradish peroxidase", "TREATMENT", 644, 666]]], ["Reactive bands were visualized by chemiluminescence with SuperSignal West Dura kit (Pierce, Rockford, IL, USA).", [["Reactive bands", "PROBLEM", 0, 14], ["chemiluminescence", "TEST", 34, 51]]], ["Inhibition of caspase activity was measured as follows.", [["caspase", "GENE_OR_GENE_PRODUCT", 14, 21], ["caspase", "PROTEIN", 14, 21], ["Inhibition of caspase activity", "TREATMENT", 0, 30], ["caspase activity", "OBSERVATION", 14, 30]]], ["Monocyte-derived macrophages (1 \u00d7 10 6 ) were preincubated for 30 min at 37 \u2022 C with 20 \u03bcM of the pancaspase inhibitor Z-VAD-FMK.", [["Monocyte", "ANATOMY", 0, 8], ["macrophages", "ANATOMY", 17, 28], ["Z-VAD-FMK", "CHEMICAL", 119, 128], ["Z-VAD-FMK", "CHEMICAL", 119, 128], ["Monocyte", "CELL", 0, 8], ["macrophages", "CELL", 17, 28], ["pancaspase", "GENE_OR_GENE_PRODUCT", 98, 108], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 119, 128], ["Monocyte-derived macrophages", "CELL_TYPE", 0, 28], ["Monocyte", "TEST", 0, 8], ["macrophages", "TEST", 17, 28], ["the pancaspase inhibitor", "TREATMENT", 94, 118], ["macrophages", "OBSERVATION", 17, 28]]], ["After rinsing, cells were incubated with 5 \u03bcg LpqH for 1 or 24 h at 37 \u2022 C. Apoptosis was measured by ELISA as described before.Quantitation of Death Receptors TNFR1, TNFR2, and Fas and Their Ligands TNF-\u03b1 and Fas.To quantitate TNF\u03b1 production, 5 \u00d7 10 5 cells were incubated for 1 h with 5 \u03bcg LpqH or with 100 \u03bcg protein present in native M. smegmatis 19 kDa strips.", [["cells", "ANATOMY", 15, 20], ["cells", "ANATOMY", 254, 259], ["LpqH", "CHEMICAL", 46, 50], ["LpqH", "CHEMICAL", 293, 297], ["cells", "CELL", 15, 20], ["TNFR1", "GENE_OR_GENE_PRODUCT", 160, 165], ["TNFR2", "GENE_OR_GENE_PRODUCT", 167, 172], ["Fas", "GENE_OR_GENE_PRODUCT", 178, 181], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 200, 205], ["Fas", "GENE_OR_GENE_PRODUCT", 210, 213], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 228, 232], ["cells", "CELL", 254, 259], ["LpqH", "SIMPLE_CHEMICAL", 293, 297], ["Death Receptors", "PROTEIN", 144, 159], ["TNFR1", "PROTEIN", 160, 165], ["TNFR2", "PROTEIN", 167, 172], ["Fas", "PROTEIN", 178, 181], ["TNF", "PROTEIN", 200, 203], ["\u03b1", "PROTEIN", 204, 205], ["Fas", "PROTEIN", 210, 213], ["TNF\u03b1", "PROTEIN", 228, 232], ["M. smegmatis", "SPECIES", 339, 351], ["M. smegmatis", "SPECIES", 339, 351], ["Apoptosis", "PROBLEM", 76, 85], ["TNFR1", "TEST", 160, 165], ["TNFR2", "TEST", 167, 172], ["Fas", "TEST", 178, 181], ["Their Ligands TNF", "TEST", 186, 203], ["Fas", "TEST", 210, 213], ["5 \u03bcg LpqH", "TREATMENT", 288, 297], ["Apoptosis", "OBSERVATION", 76, 85]]], ["Supernatants were collected by centrifugation at 390.6 g for 5 min and TNF-\u03b1 was measured after 0, 5, 15, 30, 45, and 60 min treatment, with an ELISA kit according to the manufacturer's instructions (Assay Designs, Inc, Ann Arbor, MI, USA).", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "CELL", 0, 12], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 71, 76], ["TNF", "PROTEIN", 71, 74], ["TNF", "TEST", 71, 74], ["an ELISA kit", "TREATMENT", 141, 153]]], ["Duplicate samples were analyzed with an ELISA reader and compared with a standard curve.", [["samples", "ANATOMY", 10, 17], ["Duplicate samples", "TEST", 0, 17], ["an ELISA", "TEST", 37, 45], ["a standard curve", "TEST", 71, 87]]], ["The expression of death receptors and their ligands was determined by a cell-surface ELISA method.", [["cell", "ANATOMY", 72, 76], ["surface", "ANATOMY", 77, 84], ["death", "DISEASE", 18, 23], ["cell", "CELL", 72, 76], ["death receptors", "PROTEIN", 18, 33], ["death receptors", "PROBLEM", 18, 33]]], ["After induction of apoptosis by incubation of cells (5 \u00d7 10 5 ) with 5 \u03bcg LpqH for 1 h at 37 \u2022 C, cells were rinsed with PBS containing 1% fetal bovine serum and 0.1% NaN 3 .", [["cells", "ANATOMY", 46, 51], ["cells", "ANATOMY", 98, 103], ["fetal bovine serum", "ANATOMY", 139, 157], ["LpqH", "CHEMICAL", 74, 78], ["cells", "CELL", 46, 51], ["cells", "CELL", 98, 103], ["bovine", "ORGANISM", 145, 151], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["bovine", "SPECIES", 145, 151], ["bovine", "SPECIES", 145, 151], ["apoptosis", "PROBLEM", 19, 28], ["cells", "TEST", 46, 51], ["PBS", "TEST", 121, 124], ["fetal bovine serum", "TEST", 139, 157]]], ["The mouse mAb used were: to human TNFR1 (1 \u03bcg/mL, dilution 1/100), human TNFR2 (2 \u03bcg/mL, dilution 1/100), human Fas (1 \u03bcg/mL, dilution 1 : 100), and human FasL (0.5 \u03bcg/mL, dilution 1/100).", [["mouse", "ORGANISM", 4, 9], ["mAb", "GENE_OR_GENE_PRODUCT", 10, 13], ["human", "ORGANISM", 28, 33], ["TNFR1", "GENE_OR_GENE_PRODUCT", 34, 39], ["human", "ORGANISM", 67, 72], ["TNFR2", "GENE_OR_GENE_PRODUCT", 73, 78], ["human", "ORGANISM", 106, 111], ["Fas", "GENE_OR_GENE_PRODUCT", 112, 115], ["human", "ORGANISM", 149, 154], ["FasL", "GENE_OR_GENE_PRODUCT", 155, 159], ["mouse mAb", "PROTEIN", 4, 13], ["human TNFR1", "PROTEIN", 28, 39], ["human TNFR2", "PROTEIN", 67, 78], ["human Fas", "PROTEIN", 106, 115], ["human FasL", "PROTEIN", 149, 159], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 149, 154], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 149, 154], ["The mouse mAb", "TREATMENT", 0, 13], ["human TNFR1", "TREATMENT", 28, 39], ["human TNFR2", "TREATMENT", 67, 78], ["dilution", "TREATMENT", 89, 97], ["human Fas", "TREATMENT", 106, 115], ["human FasL (", "TREATMENT", 149, 161]]], ["After apoptosis induction, cells were extensively rinsed and incubated for 1 h with each of the above antibodies.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["antibodies", "PROTEIN", 102, 112], ["apoptosis induction", "TREATMENT", 6, 25], ["cells", "PROBLEM", 27, 32]]], ["For control, irrelevant isotype antibodies were used.", [["isotype antibodies", "PROTEIN", 24, 42], ["irrelevant isotype antibodies", "TREATMENT", 13, 42], ["isotype antibodies", "OBSERVATION", 24, 42]]], ["Thereafter, cells were rinsed with PBS and incubated for 1 h with peroxidaselabeled goat or mouse anti-IgG antibodies diluted 1/1000.", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["goat", "ORGANISM", 84, 88], ["mouse", "ORGANISM", 92, 97], ["peroxidaselabeled goat", "PROTEIN", 66, 88], ["mouse anti-IgG antibodies", "PROTEIN", 92, 117], ["goat", "SPECIES", 84, 88], ["mouse", "SPECIES", 92, 97], ["goat", "SPECIES", 84, 88], ["mouse", "SPECIES", 92, 97], ["PBS", "TREATMENT", 35, 38], ["peroxidaselabeled goat", "TREATMENT", 66, 88], ["mouse anti-IgG antibodies", "TREATMENT", 92, 117]]], ["Finally, 100 \u03bcLof ABTS solution were added to the cells.", [["cells", "ANATOMY", 50, 55], ["Lof ABTS", "CHEMICAL", 14, 22], ["ABTS", "CHEMICAL", 18, 22], ["cells", "CELL", 50, 55], ["100 \u03bcLof ABTS solution", "TREATMENT", 9, 31]]], ["Optical densities at 405 nm was read by an ELISA reader (Asys Expert Plus, HyTech, Austria).Inhibition Assays to Assess the Role of TLR2 and TLR4 and of Death Receptors and Their Ligands in LpqH-InducedMacrophage Apoptosis.", [["Macrophage", "ANATOMY", 202, 212], ["TLR2", "GENE_OR_GENE_PRODUCT", 132, 136], ["TLR4", "GENE_OR_GENE_PRODUCT", 141, 145], ["LpqH-", "SIMPLE_CHEMICAL", 190, 195], ["Macrophage", "CELL", 202, 212], ["TLR2", "PROTEIN", 132, 136], ["TLR4", "PROTEIN", 141, 145], ["Death Receptors", "PROTEIN", 153, 168], ["Optical densities", "PROBLEM", 0, 17], ["Inhibition Assays", "TEST", 92, 109], ["Death Receptors", "TREATMENT", 153, 168], ["Macrophage Apoptosis", "PROBLEM", 202, 222], ["densities", "OBSERVATION", 8, 17], ["Macrophage Apoptosis", "OBSERVATION", 202, 222]]], ["Cells were preincubated for 30 min at 37 \u2022 C with blocking mAb to human TNF-\u03b1 (1 \u03bcg/mL), human TNFR1 (5 \u03bcg/mL), or human TNFR2 (1.5 \u03bcg/mL).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["human", "ORGANISM", 66, 71], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["human", "ORGANISM", 89, 94], ["TNFR1", "GENE_OR_GENE_PRODUCT", 95, 100], ["human", "ORGANISM", 115, 120], ["TNFR2", "GENE_OR_GENE_PRODUCT", 121, 126], ["mAb", "PROTEIN", 59, 62], ["human TNF-\u03b1", "PROTEIN", 66, 77], ["human TNFR1", "PROTEIN", 89, 100], ["human TNFR2", "PROTEIN", 115, 126], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 115, 120], ["blocking mAb", "TREATMENT", 50, 62], ["human TNF", "TEST", 66, 75], ["human TNFR1", "TREATMENT", 89, 100], ["human TNFR2", "TREATMENT", 115, 126]]], ["Inhibition assays were also performed with blocking mAbs to human Fas (500 ng/mL) and to human FasL (32 ng/mL).Inhibition Assays to Assess the Role of TLR2 and TLR4 and of Death Receptors and Their Ligands in LpqH-InducedTo study the role of Toll-like receptors in the induction of apoptosis, cells were preincubated with blocking mAbs (20 \u03bcg/mL) to TLR2 and to TLR4.", [["cells", "ANATOMY", 293, 298], ["LpqH", "CHEMICAL", 209, 213], ["human", "ORGANISM", 60, 65], ["Fas", "GENE_OR_GENE_PRODUCT", 66, 69], ["human", "ORGANISM", 89, 94], ["FasL", "GENE_OR_GENE_PRODUCT", 95, 99], ["TLR2", "GENE_OR_GENE_PRODUCT", 151, 155], ["TLR4", "GENE_OR_GENE_PRODUCT", 160, 164], ["LpqH", "SIMPLE_CHEMICAL", 209, 213], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 242, 261], ["cells", "CELL", 293, 298], ["TLR2", "GENE_OR_GENE_PRODUCT", 350, 354], ["TLR4", "GENE_OR_GENE_PRODUCT", 362, 366], ["mAbs", "PROTEIN", 52, 56], ["human Fas", "PROTEIN", 60, 69], ["human FasL", "PROTEIN", 89, 99], ["TLR2", "PROTEIN", 151, 155], ["TLR4", "PROTEIN", 160, 164], ["Death Receptors", "PROTEIN", 172, 187], ["LpqH", "PROTEIN", 209, 213], ["Toll-like receptors", "PROTEIN", 242, 261], ["mAbs", "PROTEIN", 331, 335], ["TLR2", "PROTEIN", 350, 354], ["TLR4", "PROTEIN", 362, 366], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 89, 94], ["Inhibition assays", "TEST", 0, 17], ["blocking mAbs", "TREATMENT", 43, 56], ["Inhibition Assays", "TEST", 111, 128], ["Death Receptors", "TREATMENT", 172, 187], ["LpqH", "TEST", 209, 213], ["Toll-like receptors", "TREATMENT", 242, 261], ["apoptosis", "PROBLEM", 282, 291], ["blocking mAbs", "TREATMENT", 322, 335]]], ["Control isotype antibodies were used.", [["isotype antibodies", "PROTEIN", 8, 26], ["Control isotype antibodies", "TREATMENT", 0, 26], ["isotype antibodies", "OBSERVATION", 8, 26]]], ["After preincubation with antibodies, without rinsing, 5 \u03bcg of LpqH was added to the cells to induce apoptosis which was analyzed by ELISA as above.Evaluation of Mitochondrial Membrane Potential by FlowCytometry with DiOC6.", [["cells", "ANATOMY", 84, 89], ["Mitochondrial Membrane", "ANATOMY", 161, 183], ["LpqH", "CHEMICAL", 62, 66], ["LpqH", "CHEMICAL", 62, 66], ["LpqH", "SIMPLE_CHEMICAL", 62, 66], ["cells", "CELL", 84, 89], ["antibodies", "PROTEIN", 25, 35], ["LpqH", "PROTEIN", 62, 66], ["DiOC6", "PROTEIN", 216, 221], ["antibodies", "TREATMENT", 25, 35], ["rinsing", "TREATMENT", 45, 52], ["LpqH", "TREATMENT", 62, 66], ["apoptosis", "PROBLEM", 100, 109], ["Evaluation", "TEST", 147, 157], ["Mitochondrial Membrane", "OBSERVATION", 161, 183]]], ["In order to analyze the participation of the mitochondria, we analyze the mitochondrial membrane potential by flow cytometry using the cationic lipophilic fluorochrome 3,3 -dihexyloxacarbocyanine iodide (DiOC6).", [["mitochondria", "ANATOMY", 45, 57], ["mitochondrial membrane", "ANATOMY", 74, 96], ["3,3 -dihexyloxacarbocyanine iodide", "CHEMICAL", 168, 202], ["DiOC6", "CHEMICAL", 204, 209], ["3,3 -dihexyloxacarbocyanine iodide", "CHEMICAL", 168, 202], ["DiOC6", "CHEMICAL", 204, 209], ["mitochondria", "CELLULAR_COMPONENT", 45, 57], ["mitochondrial membrane", "CELLULAR_COMPONENT", 74, 96], ["fluorochrome 3,3 -dihexyloxacarbocyanine iodide", "SIMPLE_CHEMICAL", 155, 202], ["DiOC6", "SIMPLE_CHEMICAL", 204, 209], ["flow cytometry", "TEST", 110, 124], ["the cationic lipophilic fluorochrome", "TREATMENT", 131, 167], ["dihexyloxacarbocyanine iodide", "TREATMENT", 173, 202]]], ["Loss in DiOC6 staining indicates disruption of the mitochondrial inner transmembrane potential (\u0394\u03a8m) which is often associated with apoptosis [23] .", [["mitochondrial inner transmembrane", "ANATOMY", 51, 84], ["DiOC6", "GENE_OR_GENE_PRODUCT", 8, 13], ["mitochondrial", "CELLULAR_COMPONENT", 51, 64], ["inner transmembrane", "CELLULAR_COMPONENT", 65, 84], ["DiOC6", "PROTEIN", 8, 13], ["Loss in DiOC6 staining", "PROBLEM", 0, 22], ["the mitochondrial inner transmembrane potential", "PROBLEM", 47, 94], ["apoptosis", "PROBLEM", 132, 141], ["disruption", "OBSERVATION", 33, 43], ["mitochondrial", "ANATOMY_MODIFIER", 51, 64], ["inner", "ANATOMY_MODIFIER", 65, 70], ["transmembrane", "ANATOMY_MODIFIER", 71, 84]]], ["Cells (1 \u00d7 10 6 /mL) were incubated with 5 \u03bcg LpqH for 1 and 24 h and washed three times with PBS, and 40 nM DIOC6 was added to pellet for 30 min at 37 \u2022 C in the dark.", [["Cells", "ANATOMY", 0, 5], ["LpqH", "CHEMICAL", 46, 50], ["DIOC6", "CHEMICAL", 109, 114], ["LpqH", "CHEMICAL", 46, 50], ["DIOC6", "CHEMICAL", 109, 114], ["Cells", "CELL", 0, 5], ["DIOC6", "SIMPLE_CHEMICAL", 109, 114], ["Cells", "TEST", 0, 5], ["PBS", "TEST", 94, 97], ["40 nM DIOC6", "TREATMENT", 103, 114]]], ["DiOC6 was prepared from a 40 mM stock solution in DMSO which was diluted with PBS, pH 7.4, to a 400 nM working solution.", [["DiOC6", "CHEMICAL", 0, 5], ["DMSO", "CHEMICAL", 50, 54], ["DiOC6", "CHEMICAL", 0, 5], ["DMSO", "CHEMICAL", 50, 54], ["DiOC6", "SIMPLE_CHEMICAL", 0, 5], ["DMSO", "SIMPLE_CHEMICAL", 50, 54], ["a 40 mM stock solution in DMSO", "TREATMENT", 24, 54], ["PBS", "TREATMENT", 78, 81], ["pH", "TEST", 83, 85], ["a 400 nM working solution", "TREATMENT", 94, 119]]], ["Cells were diluted with PBS to a final volume of 1 mL and analyzed by flow cytometry.Subcellular Fractionation and Immunoblot to DetermineMitochondrial Release of Cytochrome c and AIF.", [["Cells", "ANATOMY", 0, 5], ["Subcellular", "ANATOMY", 85, 96], ["Cells", "CELL", 0, 5], ["Cytochrome c", "GENE_OR_GENE_PRODUCT", 163, 175], ["AIF", "GENE_OR_GENE_PRODUCT", 180, 183], ["Cytochrome c", "PROTEIN", 163, 175], ["AIF", "PROTEIN", 180, 183], ["PBS", "TREATMENT", 24, 27], ["flow cytometry", "TEST", 70, 84], ["Subcellular Fractionation", "TREATMENT", 85, 110], ["Immunoblot", "TREATMENT", 115, 125], ["Cytochrome c and AIF", "PROBLEM", 163, 183], ["flow cytometry", "OBSERVATION", 70, 84], ["Fractionation", "OBSERVATION", 97, 110]]], ["MOs treated with 5 \u03bcg LpqH for 1 and 24 h were subjected to a subcellular fractionation procedure.", [["subcellular", "ANATOMY", 62, 73], ["LpqH", "CHEMICAL", 22, 26], ["LpqH", "CHEMICAL", 22, 26], ["5 \u03bcg LpqH", "TREATMENT", 17, 26], ["a subcellular fractionation procedure", "TREATMENT", 60, 97]]], ["Cytosolic and nuclear proteins were extracted using a subcellular protein fractionation kit, following protocols from the manufacturer (Thermo-Scientific).", [["Cytosolic", "ANATOMY", 0, 9], ["nuclear", "ANATOMY", 14, 21], ["subcellular", "ANATOMY", 54, 65], ["Cytosolic", "ORGANISM_SUBSTANCE", 0, 9], ["nuclear", "CELLULAR_COMPONENT", 14, 21], ["Cytosolic and nuclear proteins", "PROTEIN", 0, 30], ["Cytosolic and nuclear proteins", "PROBLEM", 0, 30], ["a subcellular protein fractionation kit", "TREATMENT", 52, 91]]], ["Protein concentrations were measured with the Bio-Rad DC protein assay (Hercules, CA, USA).", [["Protein concentrations", "TEST", 0, 22], ["the Bio", "TEST", 42, 49]]], ["Proteins (50 \u03bcg) were separated by SDS-PAGE in 7.5% polyacrylamide gels and transferred to nitrocellulose membranes.", [["membranes", "ANATOMY", 106, 115], ["polyacrylamide", "CHEMICAL", 52, 66], ["nitrocellulose", "CHEMICAL", 91, 105], ["membranes", "CELLULAR_COMPONENT", 106, 115], ["Proteins", "TEST", 0, 8], ["SDS", "TEST", 35, 38], ["7.5% polyacrylamide gels", "TREATMENT", 47, 71], ["nitrocellulose membranes", "TREATMENT", 91, 115]]], ["After blocking in 5% non-fat dried milk at room temperature for 1 h, membranes were incubated overnight with a mouse mAb to human AIF diluted 1/200 in TBS with BSA 5% and 0.01% Tween 20; a secondary anti-mouse IgG peroxidaselabeled antibody was used.", [["fat", "ANATOMY", 25, 28], ["milk", "ANATOMY", 35, 39], ["membranes", "ANATOMY", 69, 78], ["BSA", "CHEMICAL", 160, 163], ["Tween 20", "CHEMICAL", 177, 185], ["fat", "TISSUE", 25, 28], ["milk", "ORGANISM_SUBSTANCE", 35, 39], ["membranes", "CELLULAR_COMPONENT", 69, 78], ["mouse", "ORGANISM", 111, 116], ["human", "ORGANISM", 124, 129], ["AIF", "GENE_OR_GENE_PRODUCT", 130, 133], ["TBS", "SIMPLE_CHEMICAL", 151, 154], ["BSA", "SIMPLE_CHEMICAL", 160, 163], ["mouse mAb", "PROTEIN", 111, 120], ["human AIF", "PROTEIN", 124, 133], ["anti-mouse IgG peroxidaselabeled antibody", "PROTEIN", 199, 240], ["mouse", "SPECIES", 111, 116], ["human", "SPECIES", 124, 129], ["anti-mouse", "SPECIES", 199, 209], ["mouse", "SPECIES", 111, 116], ["human", "SPECIES", 124, 129], ["anti-mouse", "SPECIES", 199, 209], ["blocking in 5% non-fat dried milk", "TREATMENT", 6, 39], ["a mouse mAb", "TREATMENT", 109, 120], ["BSA", "TEST", 160, 163], ["a secondary anti-mouse IgG peroxidaselabeled antibody", "TEST", 187, 240]]], ["Different strips were incubated with a polyclonal goat antibody to human cytochrome c, diluted 1/200 in PBS Tween 20, 0.01%, overnight.", [["Tween 20", "CHEMICAL", 108, 116], ["human", "ORGANISM", 67, 72], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 73, 85], ["polyclonal goat antibody", "PROTEIN", 39, 63], ["human cytochrome c", "PROTEIN", 67, 85], ["goat", "SPECIES", 50, 54], ["human", "SPECIES", 67, 72], ["goat", "SPECIES", 50, 54], ["human", "SPECIES", 67, 72], ["Different strips", "TREATMENT", 0, 16], ["a polyclonal goat antibody", "TREATMENT", 37, 63], ["human cytochrome c", "TREATMENT", 67, 85], ["PBS Tween", "TREATMENT", 104, 113]]], ["A secondary antibody to goat IgG labeled with peroxidase was used diluted 1/1000.", [["goat", "ORGANISM", 24, 28], ["IgG", "GENE_OR_GENE_PRODUCT", 29, 32], ["peroxidase", "GENE_OR_GENE_PRODUCT", 46, 56], ["secondary antibody", "PROTEIN", 2, 20], ["goat IgG", "PROTEIN", 24, 32], ["peroxidase", "PROTEIN", 46, 56], ["goat", "SPECIES", 24, 28], ["goat", "SPECIES", 24, 28], ["A secondary antibody to goat IgG", "TREATMENT", 0, 32], ["peroxidase", "TREATMENT", 46, 56]]], ["The SuperSignal West Femto Maximum Sensitivity Substrate chemiluminescence kit was used to reveal reactive bands.Immunofluorescence to Detect AIF in Nuclei of Macrophages Treated with LpqH.Translocation of AIF from mitochondria to the nucleus during apoptosis was analyzed by immunofluorescence of untreated cells or cells treated with LpqH for 1 and 24 h.", [["Nuclei", "ANATOMY", 149, 155], ["Macrophages", "ANATOMY", 159, 170], ["mitochondria", "ANATOMY", 215, 227], ["nucleus", "ANATOMY", 235, 242], ["cells", "ANATOMY", 308, 313], ["cells", "ANATOMY", 317, 322], ["LpqH", "CHEMICAL", 336, 340], ["LpqH", "CHEMICAL", 336, 340], ["AIF", "GENE_OR_GENE_PRODUCT", 142, 145], ["Nuclei", "ORGANISM_SUBSTANCE", 149, 155], ["Macrophages", "CELL", 159, 170], ["AIF", "GENE_OR_GENE_PRODUCT", 206, 209], ["mitochondria", "CELLULAR_COMPONENT", 215, 227], ["nucleus", "CELLULAR_COMPONENT", 235, 242], ["cells", "CELL", 308, 313], ["cells", "CELL", 317, 322], ["LpqH", "SIMPLE_CHEMICAL", 336, 340], ["AIF", "PROTEIN", 142, 145], ["Macrophages", "CELL_TYPE", 159, 170], ["LpqH", "PROTEIN", 184, 188], ["AIF", "PROTEIN", 206, 209], ["untreated cells", "CELL_TYPE", 298, 313], ["Substrate chemiluminescence kit", "TEST", 47, 78], ["reactive bands", "PROBLEM", 98, 112], ["Immunofluorescence", "TEST", 113, 131], ["LpqH", "TREATMENT", 184, 188], ["apoptosis", "PROBLEM", 250, 259], ["untreated cells", "PROBLEM", 298, 313], ["LpqH", "TREATMENT", 336, 340], ["reactive bands", "OBSERVATION", 98, 112], ["Nuclei", "ANATOMY", 149, 155], ["Macrophages", "OBSERVATION", 159, 170], ["nucleus", "ANATOMY", 235, 242], ["untreated cells", "OBSERVATION", 298, 313]]], ["Cells were rinsed with PBS and fixed in a solution of 1% paraformaldehyde in PBS.", [["Cells", "ANATOMY", 0, 5], ["paraformaldehyde", "CHEMICAL", 57, 73], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 57, 73], ["PBS", "TREATMENT", 23, 26], ["a solution of 1% paraformaldehyde in PBS", "TREATMENT", 40, 80]]], ["Cell suspensions were placed by cytospin onto glass slides previously treated with poly-L-lysine.", [["Cell", "ANATOMY", 0, 4], ["poly-L-lysine", "CHEMICAL", 83, 96], ["poly-L-lysine", "CHEMICAL", 83, 96], ["Cell", "CELL", 0, 4], ["poly-L-lysine", "SIMPLE_CHEMICAL", 83, 96], ["Cell suspensions", "TREATMENT", 0, 16], ["poly-L-lysine", "TREATMENT", 83, 96]]], ["Slides were washed once with PBS and a drop a 0.05% saponin solution in PBS was added for 5 min, rinsed with PBS, and incubated for 1 h with the anti-AIF mAb, diluted 1/200, at room temperature in a humidified chamber; slides were rinsed with PBS and incubated for 45 min with a 1/500 dilution of an anti-mouse IgG antibody labeled with CY5.", [["saponin", "CHEMICAL", 52, 59], ["saponin", "CHEMICAL", 52, 59], ["saponin", "SIMPLE_CHEMICAL", 52, 59], ["PBS", "SIMPLE_CHEMICAL", 72, 75], ["CY5", "SIMPLE_CHEMICAL", 337, 340], ["anti-AIF mAb", "PROTEIN", 145, 157], ["anti-mouse IgG antibody", "PROTEIN", 300, 323], ["CY5", "PROTEIN", 337, 340], ["PBS", "TREATMENT", 29, 32], ["a 0.05% saponin solution in PBS", "TREATMENT", 44, 75], ["PBS", "TREATMENT", 109, 112], ["the anti-AIF mAb", "TREATMENT", 141, 157], ["a humidified chamber", "TREATMENT", 197, 217], ["PBS", "TREATMENT", 243, 246], ["a 1/500 dilution", "TREATMENT", 277, 293], ["an anti-mouse IgG antibody", "TEST", 297, 323]]], ["Slides were mounted with ProLong Gold antifade with DAPI (Molecular Probes).", [["DAPI", "CHEMICAL", 52, 56], ["DAPI", "SIMPLE_CHEMICAL", 52, 56], ["DAPI (Molecular Probes", "TREATMENT", 52, 74]]], ["Cells were examined with an Olympus BX51 microscope and with a laser scanning confocal microscope LSM 5 Pascal Zeiss with Software 2.8.Statistical AnalysisTo compare individual experiments, optical density (OD) of cells that were not exposed to the apoptogenic protein was set to 1.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 214, 219], ["Cells", "CELL", 0, 5], ["cells", "CELL", 214, 219], ["apoptogenic protein", "PROTEIN", 249, 268], ["a laser scanning", "TEST", 61, 77], ["Software", "TEST", 122, 130], ["optical density (OD) of cells", "PROBLEM", 190, 219], ["the apoptogenic protein", "TEST", 245, 268]]], ["All other OD values within an experiment were divided by the OD of untreated control cells to provide a relative apoptosis value in arbitrary units.", [["cells", "ANATOMY", 85, 90], ["cells", "CELL", 85, 90], ["All other OD values", "TEST", 0, 19], ["untreated control cells", "TREATMENT", 67, 90]]], ["Data obtained from independent experiments are presented as the mean \u00b1 SE, and the differences between conditions were analyzed using Student's t-test and Student's paired t-test.", [["Student's t-test", "TEST", 134, 150], ["Student's paired t-test", "TEST", 155, 178]]], ["Differences at P < 0.05 and P < 0.01 were considered significant.In the Apoptotic Death of Human Macrophages ParticipateCaspase-Dependent Mechanisms.", [["Macrophages", "ANATOMY", 97, 108], ["Human", "ORGANISM", 91, 96], ["Macrophages", "CELL", 97, 108], ["Human", "SPECIES", 91, 96], ["P", "TEST", 15, 16], ["P", "TEST", 28, 29], ["Human Macrophages ParticipateCaspase", "TREATMENT", 91, 127], ["Apoptotic Death", "OBSERVATION", 72, 87], ["Human Macrophages", "OBSERVATION", 91, 108]]], ["Studies in our laboratory with whole bacilli or cell walls showed that a transformed M. smegmatis strain that overexpresses the LpqH lipoprotein induces high levels of apoptosis in the human monocytic THP-1 cell line (data not shown).", [["cell walls", "ANATOMY", 48, 58], ["monocytic THP-1 cell line", "ANATOMY", 191, 216], ["cell", "CELL", 48, 52], ["M. smegmatis", "ORGANISM", 85, 97], ["strain", "ORGANISM", 98, 104], ["LpqH lipoprotein", "GENE_OR_GENE_PRODUCT", 128, 144], ["human", "ORGANISM", 185, 190], ["monocytic THP-1 cell line", "CELL", 191, 216], ["LpqH lipoprotein", "PROTEIN", 128, 144], ["human monocytic THP-1 cell line", "CELL_LINE", 185, 216], ["M. smegmatis", "SPECIES", 85, 97], ["human", "SPECIES", 185, 190], ["M. smegmatis", "SPECIES", 85, 97], ["human", "SPECIES", 185, 190], ["whole bacilli or cell walls", "TEST", 31, 58], ["a transformed M. smegmatis strain", "PROBLEM", 71, 104], ["the LpqH lipoprotein", "TEST", 124, 144], ["high levels of apoptosis", "PROBLEM", 153, 177], ["the human monocytic THP", "TEST", 181, 204], ["M. smegmatis", "OBSERVATION", 85, 97], ["cell line", "OBSERVATION", 207, 216]]], ["To investigate whether the transfected LpqH was responsible, we incubated human MO obtained from peripheral blood from healthy individuals with 0.5, 5, or 50 \u03bcg isolated LpqH.", [["peripheral blood", "ANATOMY", 97, 113], ["LpqH", "GENE_OR_GENE_PRODUCT", 39, 43], ["human", "ORGANISM", 74, 79], ["MO", "GENE_OR_GENE_PRODUCT", 80, 82], ["peripheral blood", "ORGANISM_SUBSTANCE", 97, 113], ["LpqH", "PROTEIN", 39, 43], ["human MO", "PROTEIN", 74, 82], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["the transfected LpqH", "PROBLEM", 23, 43], ["peripheral", "ANATOMY_MODIFIER", 97, 107], ["blood", "ANATOMY", 108, 113]]], ["As a control, MOs were incubated with 100 \u03bcg protein present in 19-kDa nitrocellulose strips of native M. smegmatis which does not contain LpqH as shown by immunoblot (not shown).", [["nitrocellulose", "CHEMICAL", 71, 85], ["MOs", "CELL", 14, 17], ["M. smegmatis", "ORGANISM", 103, 115], ["LpqH", "GENE_OR_GENE_PRODUCT", 139, 143], ["MOs", "CELL_TYPE", 14, 17], ["LpqH", "PROTEIN", 139, 143], ["M. smegmatis", "SPECIES", 103, 115], ["M. smegmatis", "SPECIES", 103, 115], ["19-kDa nitrocellulose strips", "TREATMENT", 64, 92], ["native M. smegmatis", "PROBLEM", 96, 115], ["immunoblot", "TEST", 156, 166], ["M. smegmatis", "OBSERVATION", 103, 115]]], ["A nucleosome ELISA method revealed that LpqH induces apoptosis at high rates, significantly higher than those induced by native M. smegmatis proteins (Figure 1(a) ; P < 0.05).", [["LpqH", "CHEMICAL", 40, 44], ["LpqH", "SIMPLE_CHEMICAL", 40, 44], ["M. smegmatis", "GENE_OR_GENE_PRODUCT", 128, 140], ["LpqH", "PROTEIN", 40, 44], ["M. smegmatis", "SPECIES", 128, 140], ["M. smegmatis", "SPECIES", 128, 140], ["A nucleosome ELISA method", "TEST", 0, 25], ["LpqH", "PROBLEM", 40, 44], ["apoptosis at high rates", "PROBLEM", 53, 76], ["M. smegmatis", "OBSERVATION", 128, 140]]], ["Assays using polymyxin B ruled out LPS participation (data not shown).", [["polymyxin B", "CHEMICAL", 13, 24], ["LPS", "CHEMICAL", 35, 38], ["polymyxin B", "CHEMICAL", 13, 24], ["polymyxin B", "SIMPLE_CHEMICAL", 13, 24], ["LPS", "SIMPLE_CHEMICAL", 35, 38], ["Assays", "TEST", 0, 6], ["polymyxin B", "TREATMENT", 13, 24]]], ["To investigate the caspase dependence of apoptosis, protein extracts from apoptotic cells were separated by SDS-PAGE, transferred to PVDF sheets, and incubated with mAb to detect activated forms of caspases.", [["extracts", "ANATOMY", 60, 68], ["cells", "ANATOMY", 84, 89], ["PVDF", "CHEMICAL", 133, 137], ["caspase", "GENE_OR_GENE_PRODUCT", 19, 26], ["extracts", "ORGANISM_SUBSTANCE", 60, 68], ["cells", "CELL", 84, 89], ["caspases", "GENE_OR_GENE_PRODUCT", 198, 206], ["apoptotic cells", "CELL_TYPE", 74, 89], ["mAb", "PROTEIN", 165, 168], ["caspases", "PROTEIN", 198, 206], ["the caspase dependence", "PROBLEM", 15, 37], ["apoptosis", "PROBLEM", 41, 50], ["protein extracts", "PROBLEM", 52, 68], ["apoptotic cells", "PROBLEM", 74, 89], ["mAb", "TREATMENT", 165, 168], ["caspases", "PROBLEM", 198, 206], ["apoptotic cells", "OBSERVATION", 74, 89]]], ["Results revealed procaspases as well as bands corresponding to the activated isoforms of caspases 8, 3, and 9 (Figure 1(b) ).Mycobacterium tuberculosis LpqH Activates a ProapoptoticRole in TLR2.", [["Mycobacterium tuberculosis", "DISEASE", 125, 151], ["procaspases", "GENE_OR_GENE_PRODUCT", 17, 28], ["caspases 8", "GENE_OR_GENE_PRODUCT", 89, 99], ["3", "GENE_OR_GENE_PRODUCT", 101, 102], ["Figure 1", "GENE_OR_GENE_PRODUCT", 111, 119], ["b", "GENE_OR_GENE_PRODUCT", 120, 121], ["Mycobacterium tuberculosis", "ORGANISM", 125, 151], ["TLR2", "GENE_OR_GENE_PRODUCT", 189, 193], ["procaspases", "PROTEIN", 17, 28], ["caspases 8, 3, and 9", "PROTEIN", 89, 109], ["Figure 1(b)", "PROTEIN", 111, 122], ["LpqH", "PROTEIN", 152, 156], ["ProapoptoticRole", "PROTEIN", 169, 185], ["TLR2", "PROTEIN", 189, 193], ["Mycobacterium tuberculosis", "SPECIES", 125, 151], ["Mycobacterium tuberculosis", "SPECIES", 125, 151], ["procaspases", "PROBLEM", 17, 28], ["bands", "PROBLEM", 40, 45], ["caspases", "TEST", 89, 97], ["Mycobacterium tuberculosis LpqH", "PROBLEM", 125, 156], ["a ProapoptoticRole in TLR2", "TREATMENT", 167, 193], ["procaspases", "OBSERVATION", 17, 28], ["TLR2", "ANATOMY", 189, 193]]], ["It is well established that TLR2 and TLR4 may behave as cell death receptors and that activation of TLR2 by bacterial lipoproteins may induce apoptosis [24, 25] .", [["cell", "ANATOMY", 56, 60], ["death", "DISEASE", 61, 66], ["TLR2", "GENE_OR_GENE_PRODUCT", 28, 32], ["TLR4", "GENE_OR_GENE_PRODUCT", 37, 41], ["cell", "CELL", 56, 60], ["TLR2", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR2", "PROTEIN", 28, 32], ["TLR4", "PROTEIN", 37, 41], ["cell death receptors", "PROTEIN", 56, 76], ["TLR2", "PROTEIN", 100, 104], ["bacterial lipoproteins", "PROTEIN", 108, 130], ["TLR2 and TLR4", "TREATMENT", 28, 41], ["cell death receptors", "PROBLEM", 56, 76], ["bacterial lipoproteins", "TEST", 108, 130], ["apoptosis", "PROBLEM", 142, 151]]], ["To investigate if this occurred in LpqH-treated MO, we carried out inhibition assays with blocking antibodies to these receptors.", [["LpqH", "CHEMICAL", 35, 39], ["LpqH", "CHEMICAL", 35, 39], ["LpqH", "SIMPLE_CHEMICAL", 35, 39], ["LpqH", "PROTEIN", 35, 39], ["antibodies", "PROTEIN", 99, 109], ["inhibition assays", "TEST", 67, 84], ["blocking antibodies", "TREATMENT", 90, 109]]], ["In cells preincubated with a mAb to human TLR2 and then exposed to 5 \u03bcg LpqH, there was a significant reduction in apoptosis levels ( Figure 2 ; P < 0.01).", [["cells", "ANATOMY", 3, 8], ["LpqH", "CHEMICAL", 72, 76], ["cells", "CELL", 3, 8], ["human", "ORGANISM", 36, 41], ["TLR2", "GENE_OR_GENE_PRODUCT", 42, 46], ["mAb", "PROTEIN", 29, 32], ["human TLR2", "PROTEIN", 36, 46], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["a mAb to human TLR2", "TREATMENT", 27, 46], ["a significant reduction in apoptosis levels", "PROBLEM", 88, 131], ["Figure", "TEST", 134, 140], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["reduction", "OBSERVATION_MODIFIER", 102, 111], ["apoptosis levels", "OBSERVATION", 115, 131]]], ["This finding indicates that apoptosis is induced by the interaction of TLR2 with motifs present in the mycobacterial lipoprotein.", [["TLR2", "GENE_OR_GENE_PRODUCT", 71, 75], ["lipoprotein", "GENE_OR_GENE_PRODUCT", 117, 128], ["TLR2", "PROTEIN", 71, 75], ["mycobacterial lipoprotein", "PROTEIN", 103, 128], ["apoptosis", "PROBLEM", 28, 37], ["the mycobacterial lipoprotein", "TEST", 99, 128], ["apoptosis", "OBSERVATION", 28, 37], ["mycobacterial lipoprotein", "OBSERVATION", 103, 128]]], ["Apoptosis of cells that were preincubated with a mAb to human TLR4 was not modified, a finding in keeping with the fact that this receptor is activated preferentially by LPS motifs and not by lipoproteins [25] .", [["cells", "ANATOMY", 13, 18], ["cells", "CELL", 13, 18], ["human", "ORGANISM", 56, 61], ["TLR4", "GENE_OR_GENE_PRODUCT", 62, 66], ["LPS", "SIMPLE_CHEMICAL", 170, 173], ["mAb", "PROTEIN", 49, 52], ["human TLR4", "PROTEIN", 56, 66], ["lipoproteins", "PROTEIN", 192, 204], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["Apoptosis of cells", "PROBLEM", 0, 18], ["a mAb to human TLR4", "TREATMENT", 47, 66]]], ["These findings suggest that TLR2 activation acts upstream in the signaling cascade leading to LpqH-induced MO apoptotic death.Fas and FasL Participate in Macrophage ApoptosisTriggered by LpqH.", [["LpqH", "CHEMICAL", 94, 98], ["death", "DISEASE", 120, 125], ["LpqH", "CHEMICAL", 94, 98], ["TLR2", "GENE_OR_GENE_PRODUCT", 28, 32], ["LpqH", "GENE_OR_GENE_PRODUCT", 94, 98], ["Fas", "GENE_OR_GENE_PRODUCT", 126, 129], ["FasL", "GENE_OR_GENE_PRODUCT", 134, 138], ["Macrophage", "CELL", 154, 164], ["LpqH", "GENE_OR_GENE_PRODUCT", 187, 191], ["TLR2", "PROTEIN", 28, 32], ["LpqH", "PROTEIN", 94, 98], ["Fas", "PROTEIN", 126, 129], ["FasL", "PROTEIN", 134, 138], ["LpqH", "PROTEIN", 187, 191], ["TLR2 activation acts upstream", "PROBLEM", 28, 57], ["the signaling cascade", "PROBLEM", 61, 82], ["LpqH", "PROBLEM", 94, 98], ["apoptotic death", "PROBLEM", 110, 125], ["TLR2 activation", "OBSERVATION", 28, 43], ["apoptotic death", "OBSERVATION", 110, 125], ["FasL", "OBSERVATION", 134, 138], ["Macrophage", "OBSERVATION_MODIFIER", 154, 164]]], ["Information on the role of FasL in macrophage apoptosis induced by mycobacteria is scanty [5] ; therefore, we examined the role of FasL and its receptor in LpqH-induced apoptosis.", [["macrophage", "ANATOMY", 35, 45], ["LpqH", "CHEMICAL", 156, 160], ["FasL", "GENE_OR_GENE_PRODUCT", 27, 31], ["macrophage", "CELL", 35, 45], ["FasL", "GENE_OR_GENE_PRODUCT", 131, 135], ["LpqH", "SIMPLE_CHEMICAL", 156, 160], ["FasL", "PROTEIN", 27, 31], ["FasL", "PROTEIN", 131, 135], ["LpqH", "PROTEIN", 156, 160], ["mycobacteria", "PROBLEM", 67, 79], ["apoptosis", "PROBLEM", 169, 178], ["mycobacteria", "OBSERVATION", 67, 79], ["apoptosis", "OBSERVATION", 169, 178]]], ["A cell surface ELISA analysis showed that in cells incubated with LpqH, Fas expression was similar to that of untreated cells.", [["cell surface", "ANATOMY", 2, 14], ["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 120, 125], ["cell", "CELL", 2, 6], ["cells", "CELL", 45, 50], ["LpqH", "GENE_OR_GENE_PRODUCT", 66, 70], ["Fas", "GENE_OR_GENE_PRODUCT", 72, 75], ["cells", "CELL", 120, 125], ["LpqH", "PROTEIN", 66, 70], ["Fas", "PROTEIN", 72, 75], ["untreated cells", "CELL_TYPE", 110, 125], ["A cell surface ELISA analysis", "TEST", 0, 29], ["LpqH", "TEST", 66, 70], ["Fas expression", "TEST", 72, 86], ["untreated cells", "PROBLEM", 110, 125], ["untreated cells", "OBSERVATION", 110, 125]]], ["In contrast, membrane-bound FasL was significantly increased (P < 0.01; Figure 3(a) ).", [["membrane", "ANATOMY", 13, 21], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["FasL", "GENE_OR_GENE_PRODUCT", 28, 32], ["FasL", "PROTEIN", 28, 32], ["membrane-bound FasL", "TEST", 13, 32], ["significantly increased", "PROBLEM", 37, 60]]], ["This finding is of note because usually FasL is released efficiently from the cell-surface by metalloproteinases [26] .", [["cell-surface", "ANATOMY", 78, 90], ["FasL", "GENE_OR_GENE_PRODUCT", 40, 44], ["cell-surface", "CELLULAR_COMPONENT", 78, 90], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 94, 112], ["FasL", "PROTEIN", 40, 44], ["metalloproteinases", "PROTEIN", 94, 112]]], ["To know if Fas or FasL had a role in apoptosis, inhibition assays were carried out.", [["Fas", "GENE_OR_GENE_PRODUCT", 11, 14], ["FasL", "GENE_OR_GENE_PRODUCT", 18, 22], ["Fas", "PROTEIN", 11, 14], ["FasL", "PROTEIN", 18, 22], ["apoptosis", "PROBLEM", 37, 46], ["inhibition assays", "TEST", 48, 65]]], ["When MOs were preincubated with blocking mAb against Fas and FasL, the apoptosis levels were significantly decreased (Figure 3 (b); P < 0.01; P < 0.05).Involvement of TNF-\u03b1 and Its Receptors in MacrophageApoptosis.", [["MOs", "CELL", 5, 8], ["Fas", "GENE_OR_GENE_PRODUCT", 53, 56], ["FasL", "GENE_OR_GENE_PRODUCT", 61, 65], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 167, 172], ["Its Receptors", "GENE_OR_GENE_PRODUCT", 177, 190], ["MOs", "CELL_TYPE", 5, 8], ["mAb", "PROTEIN", 41, 44], ["Fas", "PROTEIN", 53, 56], ["FasL", "PROTEIN", 61, 65], ["TNF", "PROTEIN", 167, 170], ["\u03b1", "PROTEIN", 171, 172], ["blocking mAb", "TREATMENT", 32, 44], ["Fas", "TEST", 53, 56], ["the apoptosis levels", "TEST", 67, 87], ["Figure", "TEST", 118, 124], ["P", "TEST", 132, 133], ["P", "TEST", 142, 143], ["TNF", "TEST", 167, 170], ["MacrophageApoptosis", "PROBLEM", 194, 213], ["TNF", "ANATOMY", 167, 170], ["MacrophageApoptosis", "OBSERVATION", 194, 213]]], ["TNF-\u03b1 production during LpqH-induced MO apoptosis was measured by an ELISA method in the cultured medium of cells incubated with 5 \u03bcg LpqH for 15, 30, 45, and 60 min.", [["cells", "ANATOMY", 108, 113], ["LpqH", "CHEMICAL", 24, 28], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["LpqH", "SIMPLE_CHEMICAL", 24, 28], ["MO", "ORGANISM", 37, 39], ["cells", "CELL", 108, 113], ["TNF", "PROTEIN", 0, 3], ["TNF", "TEST", 0, 3], ["LpqH", "TEST", 24, 28], ["MO apoptosis", "PROBLEM", 37, 49], ["an ELISA method", "TEST", 66, 81]]], ["Increased time-dependent TNF-\u03b1 values were observed, which were maximal at 60 min (Figure 4(a) ).", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["TNF", "PROTEIN", 25, 28], ["Increased time-dependent TNF", "PROBLEM", 0, 28]]], ["At this time, cells treated with LpqH released TNF-\u03b1 in amounts significantly higher than those of cells incubated with 100 \u03bcg native M. smegmatis proteins present in the 19-kDa region (Figure 4(b) ; P < 0.05).", [["cells", "ANATOMY", 14, 19], ["cells", "ANATOMY", 99, 104], ["cells", "CELL", 14, 19], ["LpqH", "SIMPLE_CHEMICAL", 33, 37], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["cells", "CELL", 99, 104], ["M. smegmatis", "GENE_OR_GENE_PRODUCT", 134, 146], ["LpqH", "PROTEIN", 33, 37], ["TNF", "PROTEIN", 47, 50], ["\u03b1", "PROTEIN", 51, 52], ["M. smegmatis", "SPECIES", 134, 146], ["M. smegmatis", "SPECIES", 134, 146], ["LpqH", "TREATMENT", 33, 37], ["TNF", "TEST", 47, 50], ["smegmatis proteins", "TEST", 137, 155], ["Figure", "TEST", 186, 192]]], ["In view of the importance of TNFR1 and TNFR2 in the cytotoxic capacity of TNF-\u03b1 [27] , their expression was analyzed by a cell surface ELISA procedure.", [["cell surface", "ANATOMY", 122, 134], ["TNFR1", "GENE_OR_GENE_PRODUCT", 29, 34], ["TNFR2", "GENE_OR_GENE_PRODUCT", 39, 44], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["cell", "CELL", 122, 126], ["TNFR1", "PROTEIN", 29, 34], ["TNFR2", "PROTEIN", 39, 44], ["TNF", "PROTEIN", 74, 77], ["TNFR1", "TEST", 29, 34], ["TNFR2", "TREATMENT", 39, 44], ["the cytotoxic capacity", "TEST", 48, 70], ["TNF", "TEST", 74, 77], ["a cell surface ELISA procedure", "TREATMENT", 120, 150]]], ["Both receptors were overexpressed after treatment with 5 \u03bcg LpqH (Figure 4 (c); P < 0.01).", [["treatment", "TREATMENT", 40, 49], ["5 \u03bcg LpqH", "TREATMENT", 55, 64]]], ["To know whether TNF-\u03b1 and death receptors upregulation was related to the induction of apoptosis, inhibition assays with blocking antibodies were carried out.", [["death", "DISEASE", 26, 31], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["TNF", "PROTEIN", 16, 19], ["death receptors", "PROTEIN", 26, 41], ["TNF", "TEST", 16, 19], ["death receptors upregulation", "PROBLEM", 26, 54], ["apoptosis", "PROBLEM", 87, 96], ["inhibition assays", "TEST", 98, 115], ["blocking antibodies", "TEST", 121, 140]]], ["It was observed that mAbs to TNF-\u03b1 (P < 0.05), TNFR1 (P < 0.01), and TNFR2 (P < 0.01) decreased apoptosis significantly (Figure 4(d) ).", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 29, 34], ["TNFR1", "GENE_OR_GENE_PRODUCT", 47, 52], ["TNFR2", "GENE_OR_GENE_PRODUCT", 69, 74], ["mAbs", "PROTEIN", 21, 25], ["TNF", "PROTEIN", 29, 32], ["TNFR1", "PROTEIN", 47, 52], ["TNFR2", "PROTEIN", 69, 74], ["mAbs", "TEST", 21, 25], ["TNF", "TEST", 29, 32], ["TNFR1", "TEST", 47, 52], ["TNFR2", "TEST", 69, 74], ["decreased apoptosis", "PROBLEM", 86, 105]]], ["The latter observation is interesting because TNFR2 is a receptor devoid of celldeath domains [27, 28] .", [["TNFR2", "GENE_OR_GENE_PRODUCT", 46, 51], ["TNFR2", "PROTEIN", 46, 51], ["celldeath domains", "PROTEIN", 76, 93], ["celldeath domains", "PROBLEM", 76, 93]]], ["By cell surface ELISA no differences were found in TNF-\u03b1 membrane expression between LpqHtreated and untreated cells (not shown).", [["cell surface", "ANATOMY", 3, 15], ["membrane", "ANATOMY", 57, 65], ["cells", "ANATOMY", 111, 116], ["cell", "CELL", 3, 7], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["cells", "CELL", 111, 116], ["TNF", "PROTEIN", 51, 54], ["LpqHtreated and untreated cells", "CELL_LINE", 85, 116], ["cell surface ELISA", "TEST", 3, 21], ["TNF", "TEST", 51, 54], ["LpqHtreated and untreated cells", "PROBLEM", 85, 116]]], ["No effect was observed with an isotype control.Participation of Mitochondrial Factors in LpqH-InducedApoptosis.", [["Mitochondrial", "ANATOMY", 64, 77], ["Mitochondrial", "CELLULAR_COMPONENT", 64, 77], ["Mitochondrial Factors", "PROTEIN", 64, 85], ["an isotype control", "TREATMENT", 28, 46], ["Mitochondrial Factors in LpqH-InducedApoptosis", "PROBLEM", 64, 110], ["effect", "OBSERVATION_MODIFIER", 3, 9], ["Mitochondrial Factors", "OBSERVATION", 64, 85]]], ["Immunoblot analysis of cells driven apoptotic by Clinical and Developmental ImmunologyMedium IsotypeAnti-TLR2 Anti-TLR4 * * Figure 2 : LpqH triggers a TLR2 cell death program.", [["cells", "ANATOMY", 23, 28], ["cell", "ANATOMY", 156, 160], ["death", "DISEASE", 161, 166], ["cells", "CELL", 23, 28], ["LpqH", "SIMPLE_CHEMICAL", 135, 139], ["TLR2", "GENE_OR_GENE_PRODUCT", 151, 155], ["LpqH", "PROTEIN", 135, 139], ["TLR2", "PROTEIN", 151, 155], ["Immunoblot analysis", "TEST", 0, 19], ["Developmental ImmunologyMedium IsotypeAnti-TLR2 Anti-TLR4", "TREATMENT", 62, 119], ["a TLR2 cell death program", "TREATMENT", 149, 174]]], ["To determine a possible role of TLR2 in MO apoptosis, inhibition assays were performed using a specific mAb known by its ability to block TLR2 activation; 0.5 \u00d7 10 6 cells were preincubated with 20 \u03bcg antibody for 1 h and then with 5 \u03bcg LpqH to induce apoptosis.", [["cells", "ANATOMY", 166, 171], ["LpqH", "CHEMICAL", 237, 241], ["TLR2", "GENE_OR_GENE_PRODUCT", 32, 36], ["MO", "GENE_OR_GENE_PRODUCT", 40, 42], ["TLR2", "GENE_OR_GENE_PRODUCT", 138, 142], ["cells", "CELL", 166, 171], ["LpqH", "SIMPLE_CHEMICAL", 237, 241], ["TLR2", "PROTEIN", 32, 36], ["specific mAb", "PROTEIN", 95, 107], ["TLR2", "PROTEIN", 138, 142], ["inhibition assays", "TEST", 54, 71], ["a specific mAb", "TREATMENT", 93, 107], ["block TLR2 activation", "TREATMENT", 132, 153], ["5 \u03bcg LpqH", "TREATMENT", 232, 241], ["apoptosis", "PROBLEM", 252, 261], ["apoptosis", "OBSERVATION", 252, 261]]], ["A similar procedure was used to analyze the participation of TLR4.", [["TLR4", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR4", "PROTEIN", 61, 65], ["A similar procedure", "TREATMENT", 0, 19]]], ["Apoptosis was analyzed with a nucleosome ELISA kit.", [["Apoptosis", "TEST", 0, 9], ["a nucleosome ELISA kit", "TEST", 28, 50]]], ["Values are given as the mean \u00b1 SE of four independent experiments.", [["Values", "TEST", 0, 6]]], ["Statistically significant differences are indicated; * * P < 0.01.Medium IsotypeLpqH exposure showed activation of caspase 9 (Figure 1(b) ) which requires the participation of mitochondrial factors [29] .", [["mitochondrial", "ANATOMY", 176, 189], ["IsotypeLpqH", "CHEMICAL", 73, 84], ["caspase 9", "GENE_OR_GENE_PRODUCT", 115, 124], ["Figure 1(b)", "GENE_OR_GENE_PRODUCT", 126, 137], ["mitochondrial", "CELLULAR_COMPONENT", 176, 189], ["IsotypeLpqH", "PROTEIN", 73, 84], ["caspase 9", "PROTEIN", 115, 124], ["Figure 1(b)", "PROTEIN", 126, 137], ["mitochondrial factors", "PROTEIN", 176, 197], ["Medium IsotypeLpqH exposure", "PROBLEM", 66, 93], ["caspase", "TEST", 115, 122], ["mitochondrial factors", "PROBLEM", 176, 197]]], ["Activation of caspase 9 requires apoptosome formation which is promoted by cytochrome c when it is released from the mitochondria [29] .", [["apoptosome", "ANATOMY", 33, 43], ["mitochondria", "ANATOMY", 117, 129], ["caspase 9", "GENE_OR_GENE_PRODUCT", 14, 23], ["apoptosome", "GENE_OR_GENE_PRODUCT", 33, 43], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 75, 87], ["mitochondria", "CELLULAR_COMPONENT", 117, 129], ["caspase 9", "PROTEIN", 14, 23], ["cytochrome c", "PROTEIN", 75, 87], ["Activation of caspase", "TREATMENT", 0, 21], ["apoptosome formation", "TREATMENT", 33, 53]]], ["Hence, we obtained subcellular fractions from MO treated with LpqH for 24 h to perform immunoblot analysis.", [["subcellular fractions", "ANATOMY", 19, 40], ["LpqH", "CHEMICAL", 62, 66], ["LpqH", "CHEMICAL", 62, 66], ["MO", "SIMPLE_CHEMICAL", 46, 48], ["LpqH", "SIMPLE_CHEMICAL", 62, 66], ["LpqH", "TREATMENT", 62, 66], ["immunoblot analysis", "TEST", 87, 106]]], ["In the cytosol, a mAb antibody specific for human cytochrome c revealed the expected presence of a 15 kDa band ( Figure 5(a) ).", [["cytosol", "ANATOMY", 7, 14], ["cytosol", "CELLULAR_COMPONENT", 7, 14], ["human", "ORGANISM", 44, 49], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 50, 62], ["mAb antibody", "PROTEIN", 18, 30], ["human cytochrome c", "PROTEIN", 44, 62], ["15 kDa band", "PROTEIN", 99, 110], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["a mAb antibody", "TEST", 16, 30], ["human cytochrome c", "TEST", 44, 62], ["a 15 kDa band", "PROBLEM", 97, 110]]], ["To further asses the role of mitochondria, we tested whether LpqH caused a loss in mitochondrial transmembrane potential (\u0394\u03a8m) using the cationic lipophilic fluorochrome DiOC6 [30, 31] .", [["mitochondria", "ANATOMY", 29, 41], ["mitochondrial transmembrane", "ANATOMY", 83, 110], ["LpqH", "CHEMICAL", 61, 65], ["DiOC6", "CHEMICAL", 170, 175], ["LpqH", "CHEMICAL", 61, 65], ["DiOC6", "CHEMICAL", 170, 175], ["mitochondria", "CELLULAR_COMPONENT", 29, 41], ["LpqH", "SIMPLE_CHEMICAL", 61, 65], ["mitochondrial", "CELLULAR_COMPONENT", 83, 96], ["LpqH", "PROTEIN", 61, 65], ["a loss in mitochondrial transmembrane potential", "PROBLEM", 73, 120], ["the cationic lipophilic fluorochrome DiOC6", "TREATMENT", 133, 175], ["loss", "OBSERVATION", 75, 79]]], ["In this study, fluorescence microscopy of labeled MO displayed the punctate cytoplasmic pattern characteristic of mitochondria labeling, with no discernible plasma membrane labeling (data not shown).", [["cytoplasmic", "ANATOMY", 76, 87], ["mitochondria", "ANATOMY", 114, 126], ["plasma membrane", "ANATOMY", 157, 172], ["MO", "GENE_OR_GENE_PRODUCT", 50, 52], ["cytoplasmic", "ORGANISM_SUBSTANCE", 76, 87], ["mitochondria", "CELLULAR_COMPONENT", 114, 126], ["plasma membrane", "CELLULAR_COMPONENT", 157, 172], ["this study", "TEST", 3, 13], ["fluorescence microscopy", "TEST", 15, 38], ["the punctate cytoplasmic pattern", "PROBLEM", 63, 95], ["mitochondria labeling", "PROBLEM", 114, 135], ["discernible plasma membrane labeling", "PROBLEM", 145, 181], ["punctate", "OBSERVATION_MODIFIER", 67, 75], ["cytoplasmic pattern", "OBSERVATION", 76, 95], ["mitochondria labeling", "OBSERVATION", 114, 135]]], ["In comparison with control cells, in LpqHtreated cells, there was a 27.51% decrease in DiOC6 labeling ( Figure 5(b) ), indicating disruption of the mitochondrial inner transmembrane potential (\u0394\u03a8m), a change often associated with apoptosis [31] .Caspase-Independent Mechanisms Are Involved in LpqH-Induced Apoptosis: A Role for the Apoptosis-Inducing Factor (AIF).In view of the implication of mitochondrial factors in the induction of caspase-dependent apoptosis, we considered possible that caspase-independent factors could be also involved in LpqH-induced MO death.", [["cells", "ANATOMY", 27, 32], ["LpqHtreated cells", "ANATOMY", 37, 54], ["mitochondrial inner transmembrane", "ANATOMY", 148, 181], ["mitochondrial", "ANATOMY", 394, 407], ["LpqH", "CHEMICAL", 547, 551], ["death", "DISEASE", 563, 568], ["cells", "CELL", 27, 32], ["LpqHtreated cells", "CELL", 37, 54], ["DiOC6", "SIMPLE_CHEMICAL", 87, 92], ["mitochondrial", "CELLULAR_COMPONENT", 148, 161], ["Caspase", "GENE_OR_GENE_PRODUCT", 246, 253], ["LpqH", "SIMPLE_CHEMICAL", 293, 297], ["Apoptosis-Inducing Factor", "GENE_OR_GENE_PRODUCT", 332, 357], ["AIF", "GENE_OR_GENE_PRODUCT", 359, 362], ["mitochondrial", "CELLULAR_COMPONENT", 394, 407], ["caspase", "GENE_OR_GENE_PRODUCT", 436, 443], ["caspase", "GENE_OR_GENE_PRODUCT", 493, 500], ["LpqH", "SIMPLE_CHEMICAL", 547, 551], ["MO", "MULTI-TISSUE_STRUCTURE", 560, 562], ["LpqHtreated cells", "CELL_LINE", 37, 54], ["DiOC6", "PROTEIN", 87, 92], ["Caspase", "PROTEIN", 246, 253], ["Apoptosis-Inducing Factor", "PROTEIN", 332, 357], ["AIF", "PROTEIN", 359, 362], ["mitochondrial factors", "PROTEIN", 394, 415], ["caspase", "PROTEIN", 436, 443], ["caspase", "PROTEIN", 493, 500], ["LpqH", "PROTEIN", 547, 551], ["DiOC6 labeling", "TEST", 87, 101], ["disruption of the mitochondrial inner transmembrane potential", "PROBLEM", 130, 191], ["apoptosis", "PROBLEM", 230, 239], ["Caspase", "TREATMENT", 246, 253], ["the Apoptosis", "PROBLEM", 328, 341], ["mitochondrial factors", "PROBLEM", 394, 415], ["caspase", "TREATMENT", 436, 443], ["dependent apoptosis", "PROBLEM", 444, 463], ["decrease", "OBSERVATION_MODIFIER", 75, 83], ["disruption", "OBSERVATION", 130, 140], ["mitochondrial", "ANATOMY_MODIFIER", 148, 161], ["inner", "ANATOMY_MODIFIER", 162, 167], ["mitochondrial factors", "OBSERVATION", 394, 415]]], ["Therefore, we carried out assays with the pancaspase inhibitor Z-VAD-FMK (Figure 6(a) ).", [["Z-VAD-FMK", "CHEMICAL", 63, 72], ["Z-VAD-FMK", "CHEMICAL", 63, 72], ["pancaspase", "GENE_OR_GENE_PRODUCT", 42, 52], ["assays", "TEST", 26, 32], ["the pancaspase inhibitor Z", "TREATMENT", 38, 64]]], ["In cells treated with LpqH for 1 h, there was 49.08% reduction in apoptosis (P < 0.05), while in cells treated with LpqH for 24 h, apoptosis reduction was of only 19.41% (P < 0.05).", [["cells", "ANATOMY", 3, 8], ["cells", "ANATOMY", 97, 102], ["LpqH", "CHEMICAL", 22, 26], ["LpqH", "CHEMICAL", 116, 120], ["LpqH", "CHEMICAL", 22, 26], ["LpqH", "CHEMICAL", 116, 120], ["cells", "CELL", 3, 8], ["LpqH", "SIMPLE_CHEMICAL", 22, 26], ["cells", "CELL", 97, 102], ["LpqH", "SIMPLE_CHEMICAL", 116, 120], ["LpqH", "TREATMENT", 22, 26], ["apoptosis", "TEST", 66, 75], ["P", "TEST", 77, 78], ["LpqH", "TREATMENT", 116, 120], ["apoptosis reduction", "TEST", 131, 150]]], ["This suggested a role for a caspase-independent mechanism.", [["caspase", "GENE_OR_GENE_PRODUCT", 28, 35], ["caspase", "PROTEIN", 28, 35]]], ["It is well established that after a variety of apoptotic stimuli, AIF is rapidly released from the mitochondria and relocated to the nuclei to induce chromatin condensation and cell death which is unresponsive to caspase inhibitors [32, 33] .", [["mitochondria", "ANATOMY", 99, 111], ["nuclei", "ANATOMY", 133, 139], ["chromatin", "ANATOMY", 150, 159], ["cell", "ANATOMY", 177, 181], ["death", "DISEASE", 182, 187], ["AIF", "GENE_OR_GENE_PRODUCT", 66, 69], ["mitochondria", "CELLULAR_COMPONENT", 99, 111], ["nuclei", "CELLULAR_COMPONENT", 133, 139], ["chromatin", "CELLULAR_COMPONENT", 150, 159], ["cell", "CELL", 177, 181], ["caspase", "GENE_OR_GENE_PRODUCT", 213, 220], ["AIF", "PROTEIN", 66, 69], ["chromatin", "DNA", 150, 159], ["apoptotic stimuli", "TREATMENT", 47, 64], ["AIF", "PROBLEM", 66, 69], ["chromatin condensation", "PROBLEM", 150, 172], ["cell death", "PROBLEM", 177, 187], ["caspase inhibitors", "TREATMENT", 213, 231], ["apoptotic stimuli", "OBSERVATION", 47, 64], ["chromatin condensation", "OBSERVATION", 150, 172], ["cell death", "OBSERVATION", 177, 187]]], ["Therefore, we 6 Clinical and Developmental Immunology investigated by immunoblot the subcellular distribution of AIF in cells treated with LpqH for 24 hr.", [["subcellular", "ANATOMY", 85, 96], ["cells", "ANATOMY", 120, 125], ["LpqH", "CHEMICAL", 139, 143], ["LpqH", "CHEMICAL", 139, 143], ["AIF", "GENE_OR_GENE_PRODUCT", 113, 116], ["cells", "CELL", 120, 125], ["LpqH", "SIMPLE_CHEMICAL", 139, 143], ["AIF", "PROTEIN", 113, 116], ["AIF in cells", "PROBLEM", 113, 125], ["LpqH", "TREATMENT", 139, 143]]], ["In nuclei and cytosol, a doublet band was observed, one of them of 57 kDa, a molecular weight that corresponds to activated or truncated AIF (Figure 6(b) ); the upper band corresponds to uncleaved AIF [32, 33] .", [["nuclei", "ANATOMY", 3, 9], ["cytosol", "ANATOMY", 14, 21], ["nuclei", "CELLULAR_COMPONENT", 3, 9], ["cytosol", "CELLULAR_COMPONENT", 14, 21], ["AIF", "GENE_OR_GENE_PRODUCT", 137, 140], ["AIF", "GENE_OR_GENE_PRODUCT", 197, 200], ["57 kDa", "PROTEIN", 67, 73], ["truncated AIF", "PROTEIN", 127, 140], ["Figure 6(b)", "PROTEIN", 142, 153], ["upper band", "PROTEIN", 161, 171], ["AIF", "PROTEIN", 197, 200], ["cytosol", "TREATMENT", 14, 21], ["a doublet band", "TREATMENT", 23, 37], ["a molecular weight", "TEST", 75, 93], ["activated or truncated AIF", "PROBLEM", 114, 140], ["the upper band", "PROBLEM", 157, 171], ["uncleaved AIF", "PROBLEM", 187, 200], ["upper", "ANATOMY_MODIFIER", 161, 166]]], ["To confirm these findings, we performed immunofluorescence with a CY5-labeled mAb to AIF; many confocal microscopy photographs taken at the central part of the cell were examined.", [["cell", "ANATOMY", 160, 164], ["CY5", "SIMPLE_CHEMICAL", 66, 69], ["mAb", "GENE_OR_GENE_PRODUCT", 78, 81], ["AIF", "GENE_OR_GENE_PRODUCT", 85, 88], ["cell", "CELL", 160, 164], ["CY5-labeled mAb", "PROTEIN", 66, 81], ["AIF", "PROTEIN", 85, 88], ["immunofluorescence", "TEST", 40, 58], ["a CY5-labeled mAb", "TREATMENT", 64, 81], ["many confocal microscopy photographs", "TEST", 90, 126]]], ["In cells treated with LpqH for 1 and 24 h, translocation of AIF was seen in many nuclei as magenta fluorescent spots or massive fluorescence (Figure 6(c) ); magenta fluorescence results from the colocalization of CY5 (red fluorescence) which labels AIF and DAPI nuclear staining (blue fluorescence).", [["cells", "ANATOMY", 3, 8], ["nuclei", "ANATOMY", 81, 87], ["nuclear", "ANATOMY", 262, 269], ["LpqH", "CHEMICAL", 22, 26], ["LpqH", "CHEMICAL", 22, 26], ["DAPI", "CHEMICAL", 257, 261], ["cells", "CELL", 3, 8], ["LpqH", "SIMPLE_CHEMICAL", 22, 26], ["AIF", "GENE_OR_GENE_PRODUCT", 60, 63], ["nuclei", "CELLULAR_COMPONENT", 81, 87], ["CY5", "SIMPLE_CHEMICAL", 213, 216], ["AIF", "GENE_OR_GENE_PRODUCT", 249, 252], ["DAPI", "SIMPLE_CHEMICAL", 257, 261], ["LpqH", "PROTEIN", 22, 26], ["AIF", "PROTEIN", 60, 63], ["CY5", "PROTEIN", 213, 216], ["AIF", "PROTEIN", 249, 252], ["LpqH", "TREATMENT", 22, 26], ["translocation of AIF", "PROBLEM", 43, 63], ["magenta fluorescent spots", "PROBLEM", 91, 116], ["massive fluorescence", "PROBLEM", 120, 140], ["magenta fluorescence", "TEST", 157, 177], ["red fluorescence", "TEST", 218, 234], ["DAPI nuclear staining", "TEST", 257, 278], ["blue fluorescence", "TEST", 280, 297], ["DAPI nuclear staining", "OBSERVATION", 257, 278]]], ["Unaffected or not treated control cells showed AIF emitting CY5 red fluorescence, localized to the cytoplasm, with a punctate pattern characteristic of mitochondrial labeling (Figure 6(c) ).", [["cells", "ANATOMY", 34, 39], ["cytoplasm", "ANATOMY", 99, 108], ["mitochondrial", "ANATOMY", 152, 165], ["CY5 red", "CHEMICAL", 60, 67], ["cells", "CELL", 34, 39], ["AIF", "GENE_OR_GENE_PRODUCT", 47, 50], ["cytoplasm", "ORGANISM_SUBSTANCE", 99, 108], ["mitochondrial", "CELLULAR_COMPONENT", 152, 165], ["AIF", "PROTEIN", 47, 50], ["AIF emitting CY5 red fluorescence", "PROBLEM", 47, 80], ["a punctate pattern", "PROBLEM", 115, 133], ["cytoplasm", "ANATOMY_MODIFIER", 99, 108], ["punctate", "OBSERVATION_MODIFIER", 117, 125], ["mitochondrial labeling", "OBSERVATION", 152, 174]]], ["Epifluorescence was used to quantitate AIF nuclear translocation in 3 independent experiments; photographs were taken in several randomly chosen fields, and for quantitative analysis at least 500 cells per condition were scored as showing or not AIF in nuclei (Figure 6(d) ); similar percentages of cells were positive for AIF at 1 (67.7%) and 24 h (59.5%).DiscussionAlthough the apoptogenic capacity of LpqH has been reported before [16, 17] , this study gives new insight about the mechanisms involved.", [["nuclear", "ANATOMY", 43, 50], ["cells", "ANATOMY", 196, 201], ["nuclei", "ANATOMY", 253, 259], ["cells", "ANATOMY", 299, 304], ["LpqH", "CHEMICAL", 404, 408], ["AIF", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 196, 201], ["AIF", "GENE_OR_GENE_PRODUCT", 246, 249], ["nuclei", "CELLULAR_COMPONENT", 253, 259], ["cells", "CELL", 299, 304], ["AIF", "GENE_OR_GENE_PRODUCT", 323, 326], ["LpqH", "GENE_OR_GENE_PRODUCT", 404, 408], ["AIF", "PROTEIN", 39, 42], ["AIF", "PROTEIN", 246, 249], ["AIF", "PROTEIN", 323, 326], ["LpqH", "PROTEIN", 404, 408], ["Epifluorescence", "TEST", 0, 15], ["photographs", "TEST", 95, 106], ["quantitative analysis", "TEST", 161, 182], ["similar percentages of cells", "PROBLEM", 276, 304], ["AIF", "TEST", 323, 326], ["the apoptogenic capacity of LpqH", "PROBLEM", 376, 408], ["this study", "TEST", 445, 455], ["apoptogenic", "OBSERVATION_MODIFIER", 380, 391], ["capacity", "OBSERVATION_MODIFIER", 392, 400]]], ["It is shown that both extrinsic and intrinsic mechanisms, including AIF relocation, act together to provoke the apoptotic death of human MO challenged with LpqH.", [["death", "DISEASE", 122, 127], ["LpqH", "CHEMICAL", 156, 160], ["AIF", "GENE_OR_GENE_PRODUCT", 68, 71], ["human", "ORGANISM", 131, 136], ["MO", "ORGANISM", 137, 139], ["LpqH", "GENE_OR_GENE_PRODUCT", 156, 160], ["AIF", "PROTEIN", 68, 71], ["LpqH", "PROTEIN", 156, 160], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136]]], ["In the extrinsic or receptor-mediated pathway, a novel observation was the overexpression of membrane-bound FasL, a protein that is cleaved with high efficiency from the cell surface by metalloproteinases [26] .", [["membrane", "ANATOMY", 93, 101], ["cell surface", "ANATOMY", 170, 182], ["membrane", "CELLULAR_COMPONENT", 93, 101], ["FasL", "GENE_OR_GENE_PRODUCT", 108, 112], ["cell surface", "CELLULAR_COMPONENT", 170, 182], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 186, 204], ["FasL", "PROTEIN", 108, 112], ["metalloproteinases", "PROTEIN", 186, 204], ["a protein", "TEST", 114, 123], ["high efficiency", "PROBLEM", 145, 160], ["high efficiency", "OBSERVATION_MODIFIER", 145, 160]]], ["It is interesting that membrane-bound FasL is a considerably more potent inducer of apoptosis than soluble FasL [34] .", [["membrane", "ANATOMY", 23, 31], ["membrane", "CELLULAR_COMPONENT", 23, 31], ["FasL", "GENE_OR_GENE_PRODUCT", 38, 42], ["FasL", "GENE_OR_GENE_PRODUCT", 107, 111], ["FasL", "PROTEIN", 38, 42], ["FasL", "PROTEIN", 107, 111], ["bound FasL", "OBSERVATION", 32, 42]]], ["This property could be relevant in TB since tuberculous granulomas contain numerous macrophages that express surface FasL [35] ; this raises the possibility that these FasL armed cells may kill by direct contact Fas-expressing cells within the granuloma.", [["tuberculous granulomas", "ANATOMY", 44, 66], ["macrophages", "ANATOMY", 84, 95], ["surface", "ANATOMY", 109, 116], ["cells", "ANATOMY", 179, 184], ["cells", "ANATOMY", 227, 232], ["granuloma", "ANATOMY", 244, 253], ["TB", "DISEASE", 35, 37], ["granulomas", "DISEASE", 56, 66], ["granuloma", "DISEASE", 244, 253], ["tuberculous granulomas", "PATHOLOGICAL_FORMATION", 44, 66], ["macrophages", "CELL", 84, 95], ["FasL", "GENE_OR_GENE_PRODUCT", 117, 121], ["FasL", "GENE_OR_GENE_PRODUCT", 168, 172], ["cells", "CELL", 179, 184], ["Fas-expressing cells", "CELL", 212, 232], ["granuloma", "PATHOLOGICAL_FORMATION", 244, 253], ["macrophages", "CELL_TYPE", 84, 95], ["FasL", "PROTEIN", 117, 121], ["FasL", "PROTEIN", 168, 172], ["Fas-expressing cells", "CELL_TYPE", 212, 232], ["TB", "PROBLEM", 35, 37], ["tuberculous granulomas", "PROBLEM", 44, 66], ["numerous macrophages", "PROBLEM", 75, 95], ["these FasL armed cells", "TREATMENT", 162, 184], ["the granuloma", "PROBLEM", 240, 253], ["could be relevant", "UNCERTAINTY", 14, 31], ["tuberculous", "OBSERVATION_MODIFIER", 44, 55], ["granulomas", "OBSERVATION", 56, 66], ["numerous", "OBSERVATION_MODIFIER", 75, 83], ["macrophages", "OBSERVATION", 84, 95], ["raises the possibility", "UNCERTAINTY", 134, 156], ["granuloma", "OBSERVATION", 244, 253]]], ["Another new observation was the upregulation not only of TNF-\u03b1 but also of both TNFR1 and TNFR2 receptors; this increased expression was significant as shown by inhibition assays with blocking mAb which reduced apoptosis levels significantly.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 57, 62], ["TNFR1", "GENE_OR_GENE_PRODUCT", 80, 85], ["TNFR2", "GENE_OR_GENE_PRODUCT", 90, 95], ["TNF", "PROTEIN", 57, 60], ["TNFR1", "PROTEIN", 80, 85], ["TNFR2 receptors", "PROTEIN", 90, 105], ["mAb", "PROTEIN", 193, 196], ["TNF", "TEST", 57, 60], ["TNFR2 receptors", "TREATMENT", 90, 105], ["inhibition assays", "TEST", 161, 178], ["blocking mAb", "TREATMENT", 184, 196], ["reduced apoptosis levels", "PROBLEM", 203, 227], ["new", "OBSERVATION_MODIFIER", 8, 11]]], ["This finding poses the question of how TNFR2 participates in LpqH induced cell death considering that in contrast to TNFR1, TNFR2 lacks a death domain.", [["cell", "ANATOMY", 74, 78], ["LpqH", "CHEMICAL", 61, 65], ["death", "DISEASE", 79, 84], ["death", "DISEASE", 138, 143], ["TNFR2", "GENE_OR_GENE_PRODUCT", 39, 44], ["LpqH", "SIMPLE_CHEMICAL", 61, 65], ["cell", "CELL", 74, 78], ["TNFR1", "GENE_OR_GENE_PRODUCT", 117, 122], ["TNFR2", "GENE_OR_GENE_PRODUCT", 124, 129], ["TNFR2", "PROTEIN", 39, 44], ["LpqH", "PROTEIN", 61, 65], ["TNFR1", "PROTEIN", 117, 122], ["TNFR2", "PROTEIN", 124, 129], ["death domain", "PROTEIN", 138, 150], ["cell death", "PROBLEM", 74, 84], ["a death domain", "PROBLEM", 136, 150]]], ["It has been reported that TNFR2 may participate in apoptosis by inducing endogenous TNF-\u03b1, depleting antiapoptotic signals, or increasing TNFR1 expression [27, 28] .DiscussionIn this study we found that in the MO death induced by LpqH, TLR2 signals as an upstream activator of the apoptosis cascade.", [["death", "DISEASE", 213, 218], ["TNFR2", "GENE_OR_GENE_PRODUCT", 26, 31], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["TNFR1", "GENE_OR_GENE_PRODUCT", 138, 143], ["LpqH", "GENE_OR_GENE_PRODUCT", 230, 234], ["TLR2", "GENE_OR_GENE_PRODUCT", 236, 240], ["TNFR2", "PROTEIN", 26, 31], ["TNF", "PROTEIN", 84, 87], ["TNFR1", "PROTEIN", 138, 143], ["LpqH", "PROTEIN", 230, 234], ["TLR2", "PROTEIN", 236, 240], ["apoptosis", "PROBLEM", 51, 60], ["endogenous TNF", "TEST", 73, 87], ["depleting antiapoptotic signals", "PROBLEM", 91, 122], ["increasing TNFR1 expression", "PROBLEM", 127, 154], ["this study", "TEST", 178, 188], ["the apoptosis cascade", "TREATMENT", 277, 298], ["apoptosis cascade", "OBSERVATION", 281, 298]]], ["This was demonstrated in inhibition assays with blocking antibodies.", [["blocking antibodies", "PROTEIN", 48, 67], ["inhibition assays", "TEST", 25, 42], ["blocking antibodies", "PROBLEM", 48, 67]]], ["Like other bacterial lipoproteins LpqH is a TLR2 agonist that can either activate cells to produce proinflammatory cytokines [22] or trigger the death of host cells [16, 17] .", [["cells", "ANATOMY", 82, 87], ["cells", "ANATOMY", 159, 164], ["death", "DISEASE", 145, 150], ["LpqH", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLR2", "GENE_OR_GENE_PRODUCT", 44, 48], ["cells", "CELL", 82, 87], ["host cells", "CELL", 154, 164], ["bacterial lipoproteins", "PROTEIN", 11, 33], ["LpqH", "PROTEIN", 34, 38], ["TLR2", "PROTEIN", 44, 48], ["proinflammatory cytokines", "PROTEIN", 99, 124], ["host cells", "CELL_TYPE", 154, 164], ["other bacterial lipoproteins", "TEST", 5, 33], ["a TLR2 agonist", "TREATMENT", 42, 56], ["proinflammatory cytokines", "PROBLEM", 99, 124], ["bacterial lipoproteins", "OBSERVATION", 11, 33], ["host cells", "OBSERVATION", 154, 164]]], ["The motifs in LpqH that active TLR2 are unknown; acyl groups in the lipoprotein are likely candidates, as suggested by studies with artificial bacterial lipoprotein motifs [36] .", [["acyl", "CHEMICAL", 49, 53], ["acyl", "CHEMICAL", 49, 53], ["LpqH", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLR2", "GENE_OR_GENE_PRODUCT", 31, 35], ["lipoprotein", "SIMPLE_CHEMICAL", 68, 79], ["LpqH", "PROTEIN", 14, 18], ["TLR2", "PROTEIN", 31, 35], ["The motifs in LpqH", "TEST", 0, 18], ["active TLR2", "PROBLEM", 24, 35], ["artificial bacterial lipoprotein motifs", "TEST", 132, 171], ["active", "OBSERVATION_MODIFIER", 24, 30], ["TLR2", "OBSERVATION", 31, 35]]], ["When TLR2 activated by LpqH will behave as a cell death receptor, as shown in this study, and when it will mediate proinflammatory signals remain as intriguing as yet unanswered questions.DiscussionAn interesting finding of this study was the apparent cooperation found between extrinsic and intrinsic pathways to provoke MO apoptosis.", [["cell", "ANATOMY", 45, 49], ["death", "DISEASE", 50, 55], ["TLR2", "GENE_OR_GENE_PRODUCT", 5, 9], ["LpqH", "GENE_OR_GENE_PRODUCT", 23, 27], ["cell", "CELL", 45, 49], ["MO", "GENE_OR_GENE_PRODUCT", 322, 324], ["TLR2", "PROTEIN", 5, 9], ["LpqH", "PROTEIN", 23, 27], ["cell death receptor", "PROTEIN", 45, 64], ["this study", "TEST", 78, 88], ["this study", "TEST", 224, 234], ["MO apoptosis", "PROBLEM", 322, 334]]], ["Indeed, activation of caspase 9 and cytochrome c released from mitochondria into the cytosol were demonstrated.", [["mitochondria", "ANATOMY", 63, 75], ["cytosol", "ANATOMY", 85, 92], ["caspase 9", "GENE_OR_GENE_PRODUCT", 22, 31], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 36, 48], ["mitochondria", "CELLULAR_COMPONENT", 63, 75], ["cytosol", "CELLULAR_COMPONENT", 85, 92], ["caspase 9", "PROTEIN", 22, 31], ["cytochrome c", "PROTEIN", 36, 48], ["caspase", "TREATMENT", 22, 29], ["cytochrome c", "TREATMENT", 36, 48]]], ["When a given apoptotic stimulus induces outer mitochondrial membrane (OMM) permeability, cytochrome c is released from the mitochondria to the cytosol where it mediates apoptosome formation; this macromolecular complex results from the interaction of APAF-1, ATP, and procaspase 9, which is cleaved into its activated form.", [["outer mitochondrial membrane", "ANATOMY", 40, 68], ["OMM", "ANATOMY", 70, 73], ["mitochondria", "ANATOMY", 123, 135], ["cytosol", "ANATOMY", 143, 150], ["apoptosome", "ANATOMY", 169, 179], ["ATP", "CHEMICAL", 259, 262], ["ATP", "CHEMICAL", 259, 262], ["outer", "CELLULAR_COMPONENT", 40, 45], ["mitochondrial membrane", "CELLULAR_COMPONENT", 46, 68], ["OMM", "CELLULAR_COMPONENT", 70, 73], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 89, 101], ["mitochondria", "CELLULAR_COMPONENT", 123, 135], ["cytosol", "CELLULAR_COMPONENT", 143, 150], ["apoptosome", "GENE_OR_GENE_PRODUCT", 169, 179], ["APAF-1", "GENE_OR_GENE_PRODUCT", 251, 257], ["ATP", "SIMPLE_CHEMICAL", 259, 262], ["procaspase 9", "GENE_OR_GENE_PRODUCT", 268, 280], ["cytochrome c", "PROTEIN", 89, 101], ["macromolecular complex", "PROTEIN", 196, 218], ["APAF", "PROTEIN", 251, 255], ["procaspase 9", "PROTEIN", 268, 280], ["a given apoptotic stimulus", "TREATMENT", 5, 31], ["cytochrome c", "PROBLEM", 89, 101], ["apoptosome formation", "PROBLEM", 169, 189], ["APAF", "TEST", 251, 255], ["ATP", "TEST", 259, 262], ["procaspase", "TREATMENT", 268, 278], ["mitochondrial membrane", "OBSERVATION", 46, 68]]], ["In turn, active caspase 9 cleaves and activates procaspase 3, thereby triggering the executioner phase of caspase-dependent apoptosis [29] .", [["caspase 9", "GENE_OR_GENE_PRODUCT", 16, 25], ["procaspase 3", "GENE_OR_GENE_PRODUCT", 48, 60], ["caspase", "GENE_OR_GENE_PRODUCT", 106, 113], ["caspase 9", "PROTEIN", 16, 25], ["procaspase 3", "PROTEIN", 48, 60], ["caspase", "PROTEIN", 106, 113], ["active caspase", "TREATMENT", 9, 23], ["activates procaspase", "TREATMENT", 38, 58], ["dependent apoptosis", "PROBLEM", 114, 133]]], ["In addition, as shown by flow cytometry using the lipophilic fluorochrome DiOC6 a reduction of the mitochondrial transmembrane potential was found; this change indicates permeabilization of the inner membrane, an apoptosis feature less frequent than OMM permeabilization but frequently associated with cytochrome c release [37] .", [["mitochondrial transmembrane", "ANATOMY", 99, 126], ["inner membrane", "ANATOMY", 194, 208], ["DiOC6", "CHEMICAL", 74, 79], ["DiOC6", "CHEMICAL", 74, 79], ["fluorochrome DiOC6", "SIMPLE_CHEMICAL", 61, 79], ["mitochondrial", "CELLULAR_COMPONENT", 99, 112], ["inner membrane", "CELLULAR_COMPONENT", 194, 208], ["OMM", "CELLULAR_COMPONENT", 250, 253], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 302, 314], ["cytochrome c", "PROTEIN", 302, 314], ["flow cytometry", "TEST", 25, 39], ["the lipophilic fluorochrome DiOC6", "TREATMENT", 46, 79], ["the mitochondrial transmembrane potential", "PROBLEM", 95, 136], ["permeabilization of the inner membrane", "PROBLEM", 170, 208], ["an apoptosis feature", "PROBLEM", 210, 230], ["lipophilic fluorochrome", "OBSERVATION", 50, 73], ["permeabilization", "OBSERVATION", 170, 186], ["inner membrane", "ANATOMY", 194, 208], ["apoptosis", "OBSERVATION", 213, 222]]], ["The mechanism interconnecting the extrinsic pathway with the mitochondrial pathway in apoptosis induction requires further study.", [["mitochondrial", "ANATOMY", 61, 74], ["mitochondrial", "CELLULAR_COMPONENT", 61, 74], ["apoptosis induction", "TREATMENT", 86, 105], ["further study", "TEST", 115, 128], ["apoptosis", "OBSERVATION", 86, 95]]], ["It has been described that caspase 8 might cleave Bid (BH3-interacting domain death agonist), a proapoptotic Bcl2 (B-cell lymphoma 2) family member; then truncated Bid localizes to the OMM where it promotes Bax (Bcl-2-associated X protein) activation, resulting in release into the cytosol of proapoptotic or antiapoptotic molecules from the mitochondria [38] .DiscussionThe above findings featured the participation of the mitochondria in a caspase-dependent mechanism that trigger MO death after LpqH exposure.", [["OMM", "ANATOMY", 185, 188], ["cytosol", "ANATOMY", 282, 289], ["mitochondria", "ANATOMY", 342, 354], ["mitochondria", "ANATOMY", 424, 436], ["death", "DISEASE", 486, 491], ["LpqH", "CHEMICAL", 498, 502], ["LpqH", "CHEMICAL", 498, 502], ["caspase 8", "GENE_OR_GENE_PRODUCT", 27, 36], ["Bid", "GENE_OR_GENE_PRODUCT", 50, 53], ["BH3-interacting domain death agonist", "GENE_OR_GENE_PRODUCT", 55, 91], ["Bcl2", "GENE_OR_GENE_PRODUCT", 109, 113], ["B-cell lymphoma 2", "GENE_OR_GENE_PRODUCT", 115, 132], ["Bid", "GENE_OR_GENE_PRODUCT", 164, 167], ["OMM", "CELLULAR_COMPONENT", 185, 188], ["Bax", "GENE_OR_GENE_PRODUCT", 207, 210], ["Bcl-2-associated X protein", "GENE_OR_GENE_PRODUCT", 212, 238], ["cytosol", "CELLULAR_COMPONENT", 282, 289], ["mitochondria", "CELLULAR_COMPONENT", 342, 354], ["mitochondria", "CELLULAR_COMPONENT", 424, 436], ["caspase", "GENE_OR_GENE_PRODUCT", 442, 449], ["MO", "GENE_OR_GENE_PRODUCT", 483, 485], ["LpqH", "SIMPLE_CHEMICAL", 498, 502], ["caspase 8", "PROTEIN", 27, 36], ["Bid", "PROTEIN", 50, 53], ["BH3", "PROTEIN", 55, 58], ["proapoptotic Bcl2 (B-cell lymphoma 2) family member", "PROTEIN", 96, 147], ["Bid", "PROTEIN", 164, 167], ["Bax", "PROTEIN", 207, 210], ["Bcl-2-associated X protein", "PROTEIN", 212, 238], ["proapoptotic or antiapoptotic molecules", "PROTEIN", 293, 332], ["caspase", "PROTEIN", 442, 449], ["caspase", "TREATMENT", 27, 34], ["a proapoptotic Bcl2 (B-cell lymphoma", "PROBLEM", 94, 130], ["Bcl", "TEST", 212, 215], ["the mitochondria", "PROBLEM", 420, 436], ["LpqH exposure", "PROBLEM", 498, 511], ["proapoptotic Bcl2", "OBSERVATION", 96, 113], ["cell lymphoma", "OBSERVATION", 117, 130]]], ["Since it is well recognized that mitochondria can also release factors involved in caspase-independent cell death [37] , we considered this possible.", [["mitochondria", "ANATOMY", 33, 45], ["cell", "ANATOMY", 103, 107], ["death", "DISEASE", 108, 113], ["mitochondria", "CELLULAR_COMPONENT", 33, 45], ["caspase", "GENE_OR_GENE_PRODUCT", 83, 90], ["cell", "CELL", 103, 107], ["caspase", "PROTEIN", 83, 90], ["independent cell death", "PROBLEM", 91, 113]]], ["This was also entertained by the limited effect of a pancaspase inhibitor to avoid apoptosis in LpqHchallenged cells.", [["cells", "ANATOMY", 111, 116], ["pancaspase", "GENE_OR_GENE_PRODUCT", 53, 63], ["LpqHchallenged cells", "CELL", 96, 116], ["LpqHchallenged cells", "CELL_LINE", 96, 116], ["a pancaspase inhibitor", "TREATMENT", 51, 73], ["apoptosis in LpqHchallenged cells", "PROBLEM", 83, 116], ["LpqHchallenged cells", "OBSERVATION", 96, 116]]], ["Among the proapoptotic molecules released with OMM permeability is AIF, which has been shown to be frequently involved in caspase-independent apoptosis [39] .", [["OMM", "CELLULAR_COMPONENT", 47, 50], ["AIF", "GENE_OR_GENE_PRODUCT", 67, 70], ["caspase", "GENE_OR_GENE_PRODUCT", 122, 129], ["proapoptotic molecules", "PROTEIN", 10, 32], ["AIF", "PROTEIN", 67, 70], ["caspase", "PROTEIN", 122, 129], ["proapoptotic molecules", "OBSERVATION", 10, 32], ["OMM permeability", "OBSERVATION_MODIFIER", 47, 63]]], ["AIF is a mitochondrial flavoprotein with a twofold function, in the mitochondria it participates in oxidative phosphorylation, a life function, and, when out of the mitochondria, it provokes cell death [39] .", [["mitochondrial", "ANATOMY", 9, 22], ["mitochondria", "ANATOMY", 68, 80], ["mitochondria", "ANATOMY", 165, 177], ["cell", "ANATOMY", 191, 195], ["death", "DISEASE", 196, 201], ["AIF", "GENE_OR_GENE_PRODUCT", 0, 3], ["mitochondrial", "CELLULAR_COMPONENT", 9, 22], ["mitochondria", "CELLULAR_COMPONENT", 68, 80], ["mitochondria", "CELLULAR_COMPONENT", 165, 177], ["cell", "CELL", 191, 195], ["AIF", "PROTEIN", 0, 3], ["mitochondrial flavoprotein", "PROTEIN", 9, 35], ["a mitochondrial flavoprotein", "PROBLEM", 7, 35], ["oxidative phosphorylation", "TREATMENT", 100, 125], ["cell death", "PROBLEM", 191, 201], ["oxidative phosphorylation", "OBSERVATION", 100, 125]]], ["After an apoptotic stimulus, AIF can be cleaved by calpains or cathepsins yielding a truncated 57-kDa form which, once released in the cytosol, relocates to the nucleus to promote chromatinolysis and programmed cell death [33] .", [["cytosol", "ANATOMY", 135, 142], ["nucleus", "ANATOMY", 161, 168], ["cell", "ANATOMY", 211, 215], ["death", "DISEASE", 216, 221], ["AIF", "GENE_OR_GENE_PRODUCT", 29, 32], ["calpains", "GENE_OR_GENE_PRODUCT", 51, 59], ["cathepsins", "GENE_OR_GENE_PRODUCT", 63, 73], ["cytosol", "CELLULAR_COMPONENT", 135, 142], ["nucleus", "CELLULAR_COMPONENT", 161, 168], ["cell", "CELL", 211, 215], ["AIF", "PROTEIN", 29, 32], ["calpains", "PROTEIN", 51, 59], ["cathepsins", "PROTEIN", 63, 73], ["truncated 57-kDa form", "PROTEIN", 85, 106], ["an apoptotic stimulus", "TREATMENT", 6, 27], ["AIF", "PROBLEM", 29, 32], ["cathepsins", "TREATMENT", 63, 73], ["programmed cell death", "PROBLEM", 200, 221], ["apoptotic stimulus", "OBSERVATION", 9, 27], ["nucleus", "ANATOMY", 161, 168]]], ["In this study, in cells treated with LpqH, AIF was seen by immunoblot in the nuclei and to a lesser extent in the cytosol.", [["cells", "ANATOMY", 18, 23], ["nuclei", "ANATOMY", 77, 83], ["cytosol", "ANATOMY", 114, 121], ["cells", "CELL", 18, 23], ["LpqH", "SIMPLE_CHEMICAL", 37, 41], ["AIF", "GENE_OR_GENE_PRODUCT", 43, 46], ["nuclei", "CELLULAR_COMPONENT", 77, 83], ["cytosol", "CELLULAR_COMPONENT", 114, 121], ["LpqH", "PROTEIN", 37, 41], ["AIF", "PROTEIN", 43, 46], ["this study", "TEST", 3, 13], ["LpqH", "TREATMENT", 37, 41], ["AIF", "TREATMENT", 43, 46], ["nuclei", "ANATOMY", 77, 83], ["lesser", "OBSERVATION_MODIFIER", 93, 99], ["extent", "OBSERVATION_MODIFIER", 100, 106], ["cytosol", "ANATOMY", 114, 121]]], ["In both locations, two bands were detected, one of 57 kDa, possibly corresponding to truncated AIF.", [["AIF", "GENE_OR_GENE_PRODUCT", 95, 98], ["truncated AIF", "PROTEIN", 85, 98], ["two bands", "PROBLEM", 19, 28], ["truncated AIF", "PROBLEM", 85, 98], ["two", "OBSERVATION_MODIFIER", 19, 22], ["bands", "OBSERVATION_MODIFIER", 23, 28], ["possibly corresponding to", "UNCERTAINTY", 59, 84], ["truncated AIF", "OBSERVATION", 85, 98]]], ["In addition, by epifluorescence and confocal microscopy, translocation of AIF to the nuclei of most cells was seen at 1 and 24 h.", [["nuclei", "ANATOMY", 85, 91], ["cells", "ANATOMY", 100, 105], ["AIF", "GENE_OR_GENE_PRODUCT", 74, 77], ["nuclei", "CELLULAR_COMPONENT", 85, 91], ["cells", "CELL", 100, 105], ["AIF", "PROTEIN", 74, 77], ["epifluorescence", "TEST", 16, 31], ["confocal microscopy", "TEST", 36, 55], ["translocation of AIF", "PROBLEM", 57, 77], ["most cells", "OBSERVATION", 95, 105]]], ["As far as the mechanisms involved in AIF release, it has been shown that overexpression of PARP-1 generates PAR polymers which colocalize with the mitochondria where they induce liberation of AIF to the cytosol with subsequent translocation to cell nuclei [40] .", [["mitochondria", "ANATOMY", 147, 159], ["cytosol", "ANATOMY", 203, 210], ["cell nuclei", "ANATOMY", 244, 255], ["AIF", "GENE_OR_GENE_PRODUCT", 37, 40], ["PARP-1", "GENE_OR_GENE_PRODUCT", 91, 97], ["PAR polymers", "GENE_OR_GENE_PRODUCT", 108, 120], ["mitochondria", "CELLULAR_COMPONENT", 147, 159], ["AIF", "GENE_OR_GENE_PRODUCT", 192, 195], ["cytosol", "CELLULAR_COMPONENT", 203, 210], ["cell", "CELL", 244, 248], ["AIF", "PROTEIN", 37, 40], ["PARP-1", "PROTEIN", 91, 97], ["AIF", "PROTEIN", 192, 195], ["PARP", "TEST", 91, 95], ["PAR polymers", "TREATMENT", 108, 120]]], ["Another factor that may connect caspase-dependent and caspase-independent pathways is caspase 3, which might cleave nuclear PARP-1 [41] .DiscussionAIF has focused much attention not only as a model of cell death, but also for its role in pathological conditions.", [["nuclear", "ANATOMY", 116, 123], ["cell", "ANATOMY", 201, 205], ["death", "DISEASE", 206, 211], ["caspase", "GENE_OR_GENE_PRODUCT", 32, 39], ["caspase", "GENE_OR_GENE_PRODUCT", 54, 61], ["caspase 3", "GENE_OR_GENE_PRODUCT", 86, 95], ["PARP-1", "GENE_OR_GENE_PRODUCT", 124, 130], ["cell", "CELL", 201, 205], ["caspase", "PROTEIN", 32, 39], ["caspase", "PROTEIN", 54, 61], ["caspase 3", "PROTEIN", 86, 95], ["PARP", "PROTEIN", 124, 128], ["caspase", "TREATMENT", 54, 61], ["nuclear PARP", "TEST", 116, 128]]], ["It Clinical and Developmental Immunology Figure 6 : Caspase-independent mechanisms with AIF relocation are involved in LpqH-induced MO. (a) MOs were preincubated with the pancasphae inhibitor Z-VAD-FMK for 30 min and thereafter apoptosis was induced with 5 \u03bcg LpqH for 1 and 24 h; apoptosis was measured by a nucleosome ELISA kit.", [["LpqH", "CHEMICAL", 119, 123], ["Z-VAD-FMK", "CHEMICAL", 192, 201], ["Z-VAD-FMK", "CHEMICAL", 192, 201], ["LpqH", "CHEMICAL", 260, 264], ["Caspase", "GENE_OR_GENE_PRODUCT", 52, 59], ["AIF", "GENE_OR_GENE_PRODUCT", 88, 91], ["LpqH", "SIMPLE_CHEMICAL", 119, 123], ["MOs", "CELL", 140, 143], ["pancasphae", "SIMPLE_CHEMICAL", 171, 181], ["Z-VAD-FMK", "SIMPLE_CHEMICAL", 192, 201], ["Caspase", "PROTEIN", 52, 59], ["AIF", "PROTEIN", 88, 91], ["LpqH", "PROTEIN", 119, 123], ["AIF relocation", "TREATMENT", 88, 102], ["the pancasphae inhibitor", "TREATMENT", 167, 191], ["apoptosis", "PROBLEM", 281, 290]]], ["At 1 h apoptosis (left) inhibition was of 49.08% and at 24 h of 19.41% (right).", [["left", "ANATOMY_MODIFIER", 18, 22], ["right", "ANATOMY_MODIFIER", 72, 77]]], ["Data from four independent experiments are expressed as mean \u00b1 SE of the optical density found; * P < 0.05. (b) Cells, untreated or treated with LpqH for 24 h, were subjected to subcellular fractionation and immunoblot with a mAb to human AIF using cytosolic and nuclear fractions. (c) For immunofluorescence, after 1 and 24 h apoptosis induction, MOs were incubated with a mAb to human AIF labeled with CY5 (red fluorescence); nuclei were labeled with DAPI (blue fluorescence).", [["Cells", "ANATOMY", 112, 117], ["subcellular", "ANATOMY", 178, 189], ["cytosolic", "ANATOMY", 249, 258], ["nuclear fractions", "ANATOMY", 263, 280], ["nuclei", "ANATOMY", 428, 434], ["LpqH", "CHEMICAL", 145, 149], ["LpqH", "CHEMICAL", 145, 149], ["DAPI", "CHEMICAL", 453, 457], ["Cells", "CELL", 112, 117], ["human", "ORGANISM", 233, 238], ["AIF", "GENE_OR_GENE_PRODUCT", 239, 242], ["cytosolic", "CELLULAR_COMPONENT", 249, 258], ["nuclear", "CELLULAR_COMPONENT", 263, 270], ["MOs", "CELL", 348, 351], ["human", "ORGANISM", 381, 386], ["AIF", "GENE_OR_GENE_PRODUCT", 387, 390], ["CY5", "SIMPLE_CHEMICAL", 404, 407], ["nuclei", "CELLULAR_COMPONENT", 428, 434], ["DAPI", "SIMPLE_CHEMICAL", 453, 457], ["mAb", "PROTEIN", 226, 229], ["human AIF", "PROTEIN", 233, 242], ["MOs", "CELL_TYPE", 348, 351], ["mAb", "PROTEIN", 374, 377], ["human AIF", "PROTEIN", 381, 390], ["CY5", "PROTEIN", 404, 407], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 381, 386], ["human", "SPECIES", 233, 238], ["human", "SPECIES", 381, 386], ["LpqH", "TREATMENT", 145, 149], ["subcellular fractionation", "TREATMENT", 178, 203], ["immunoblot", "TEST", 208, 218], ["a mAb", "TREATMENT", 224, 229], ["cytosolic and nuclear fractions", "TREATMENT", 249, 280], ["immunofluorescence", "TEST", 290, 308], ["a mAb", "TREATMENT", 372, 377], ["red fluorescence", "TEST", 409, 425]]], ["By confocal microscopy, photographs were taken at the midsection of at least 100 cells per condition; photographs were analyzed and merged using the National Institutes of Health ImageJ software (Bethesda, MD, USA).", [["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["confocal microscopy", "TEST", 3, 22], ["photographs", "TEST", 24, 35], ["photographs", "TEST", 102, 113]]], ["AIF is seen in nuclei as magenta fluorescence frequently massive resulting from the colocalization of CY5 and DAPI; \u00d740, original magnification. (d) Epifluorescence was used to estimate the percentage of cells showing AIF nuclear translocation at 1 and 24 h; at least 500 cells randomly chosen were photographed and analyzed with ImageJ; * P < 0.05. participates in the death of cancer cells treated with cytotoxic drugs and in various neuropathological processes [42] .", [["nuclei", "ANATOMY", 15, 21], ["cells", "ANATOMY", 204, 209], ["nuclear", "ANATOMY", 222, 229], ["cells", "ANATOMY", 272, 277], ["cancer cells", "ANATOMY", 379, 391], ["death", "DISEASE", 370, 375], ["cancer", "DISEASE", 379, 385], ["DAPI", "CHEMICAL", 110, 114], ["AIF", "GENE_OR_GENE_PRODUCT", 0, 3], ["nuclei", "CELLULAR_COMPONENT", 15, 21], ["CY5", "GENE_OR_GENE_PRODUCT", 102, 105], ["DAPI", "SIMPLE_CHEMICAL", 110, 114], ["cells", "CELL", 204, 209], ["AIF", "GENE_OR_GENE_PRODUCT", 218, 221], ["nuclear", "CELLULAR_COMPONENT", 222, 229], ["cells", "CELL", 272, 277], ["cancer cells", "CELL", 379, 391], ["AIF", "PROTEIN", 0, 3], ["CY5", "PROTEIN", 102, 105], ["AIF", "PROTEIN", 218, 221], ["cancer cells", "CELL_TYPE", 379, 391], ["AIF", "PROBLEM", 0, 3], ["DAPI", "TEST", 110, 114], ["Epifluorescence", "TEST", 149, 164], ["AIF nuclear translocation", "PROBLEM", 218, 243], ["ImageJ", "TEST", 330, 336], ["cancer cells", "PROBLEM", 379, 391], ["cytotoxic drugs", "TREATMENT", 405, 420], ["nuclei", "ANATOMY", 15, 21]]], ["Cell death with the participation of AIF has been reported in infectious processes including viral infections such as HIV, [43] , rabies [44] , and coronavirus [45] .", [["Cell", "ANATOMY", 0, 4], ["death", "DISEASE", 5, 10], ["viral infections", "DISEASE", 93, 109], ["Cell", "CELL", 0, 4], ["AIF", "GENE_OR_GENE_PRODUCT", 37, 40], ["HIV", "ORGANISM", 118, 121], ["rabies", "ORGANISM", 130, 136], ["coronavirus", "ORGANISM", 148, 159], ["AIF", "PROTEIN", 37, 40], ["HIV", "SPECIES", 118, 121], ["HIV", "SPECIES", 118, 121], ["Cell death", "PROBLEM", 0, 10], ["AIF", "PROBLEM", 37, 40], ["viral infections", "PROBLEM", 93, 109], ["HIV", "PROBLEM", 118, 121], ["rabies", "TEST", 130, 136], ["coronavirus", "PROBLEM", 148, 159], ["infectious", "OBSERVATION", 62, 72]]], ["In some bacterial infections, AIF triggers the death of infected cells, including Helicobacter pylori [46] , pneumococcus [47] , and Coxiella burnetii infections [48] .", [["cells", "ANATOMY", 65, 70], ["bacterial infections", "DISEASE", 8, 28], ["death of infected", "DISEASE", 47, 64], ["Helicobacter pylori", "DISEASE", 82, 101], ["Coxiella burnetii infections", "DISEASE", 133, 161], ["AIF", "GENE_OR_GENE_PRODUCT", 30, 33], ["cells", "CELL", 65, 70], ["Helicobacter pylori", "ORGANISM", 82, 101], ["pneumococcus", "ORGANISM", 109, 121], ["Coxiella burnetii", "ORGANISM", 133, 150], ["AIF", "PROTEIN", 30, 33], ["infected cells", "CELL_TYPE", 56, 70], ["Helicobacter pylori", "SPECIES", 82, 101], ["Coxiella burnetii", "SPECIES", 133, 150], ["Helicobacter pylori", "SPECIES", 82, 101], ["Coxiella burnetii", "SPECIES", 133, 150], ["some bacterial infections", "PROBLEM", 3, 28], ["AIF", "PROBLEM", 30, 33], ["infected cells", "PROBLEM", 56, 70], ["Helicobacter pylori", "PROBLEM", 82, 101], ["pneumococcus", "PROBLEM", 109, 121], ["Coxiella burnetii infections", "PROBLEM", 133, 161], ["bacterial", "OBSERVATION_MODIFIER", 8, 17], ["infections", "OBSERVATION", 18, 28], ["infected cells", "OBSERVATION", 56, 70], ["Coxiella", "OBSERVATION_MODIFIER", 133, 141], ["burnetii infections", "OBSERVATION", 142, 161]]], ["Regarding pathogenic mycobacteria, AIF-induced MO death has been reported to occur in THP-1 monocytes and bovine MO infected in vitro with M. bovis [49, 50] .", [["THP-1 monocytes", "ANATOMY", 86, 101], ["AIF", "CHEMICAL", 35, 38], ["death", "DISEASE", 50, 55], ["AIF", "GENE_OR_GENE_PRODUCT", 35, 38], ["MO", "GENE_OR_GENE_PRODUCT", 47, 49], ["THP-1 monocytes", "CELL", 86, 101], ["bovine", "ORGANISM", 106, 112], ["MO", "ORGANISM", 113, 115], ["M. bovis", "ORGANISM", 139, 147], ["AIF", "PROTEIN", 35, 38], ["THP-1 monocytes", "CELL_LINE", 86, 101], ["bovine", "SPECIES", 106, 112], ["M. bovis", "SPECIES", 139, 147], ["bovine", "SPECIES", 106, 112], ["M. bovis", "SPECIES", 139, 147], ["pathogenic mycobacteria", "PROBLEM", 10, 33], ["AIF", "PROBLEM", 35, 38], ["MO death", "PROBLEM", 47, 55], ["THP", "TEST", 86, 89], ["bovine MO", "PROBLEM", 106, 115], ["mycobacteria", "OBSERVATION", 21, 33]]], ["To these observations, it should be added the data herein presented showing that AIF can participate in the death of human MO treated with LpqH, a cell wall, 19 kDa lipoprotein of Mtb.ConclusionOur study documents the high capacity and versatility of a Mtb lipoprotein to assure the death of human monocytederived macrophages.", [["cell wall", "ANATOMY", 147, 156], ["macrophages", "ANATOMY", 314, 325], ["death", "DISEASE", 108, 113], ["LpqH", "CHEMICAL", 139, 143], ["death", "DISEASE", 283, 288], ["AIF", "GENE_OR_GENE_PRODUCT", 81, 84], ["human", "ORGANISM", 117, 122], ["MO", "ORGANISM", 123, 125], ["LpqH", "GENE_OR_GENE_PRODUCT", 139, 143], ["cell wall", "CELLULAR_COMPONENT", 147, 156], ["lipoprotein", "GENE_OR_GENE_PRODUCT", 165, 176], ["Mtb", "GENE_OR_GENE_PRODUCT", 180, 183], ["Mtb lipoprotein", "GENE_OR_GENE_PRODUCT", 253, 268], ["human", "ORGANISM", 292, 297], ["monocytederived macrophages", "CELL", 298, 325], ["AIF", "PROTEIN", 81, 84], ["LpqH", "PROTEIN", 139, 143], ["19 kDa lipoprotein", "PROTEIN", 158, 176], ["Mtb", "PROTEIN", 180, 183], ["Mtb lipoprotein", "PROTEIN", 253, 268], ["human monocytederived macrophages", "CELL_TYPE", 292, 325], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 292, 297], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 292, 297], ["LpqH", "TREATMENT", 139, 143], ["a cell wall", "TREATMENT", 145, 156], ["Mtb", "PROBLEM", 180, 183], ["ConclusionOur study", "TEST", 184, 203], ["the high capacity", "PROBLEM", 214, 231], ["a Mtb lipoprotein", "TEST", 251, 268], ["high capacity", "OBSERVATION_MODIFIER", 218, 231]]], ["It also shows the high complexity of the cell death process and how extrinsic and intrinsic pathways of apoptosis cooperate.", [["cell", "ANATOMY", 41, 45], ["death", "DISEASE", 46, 51], ["cell", "CELL", 41, 45], ["the cell death process", "PROBLEM", 37, 59], ["high complexity", "OBSERVATION_MODIFIER", 18, 33], ["cell death", "OBSERVATION", 41, 51], ["apoptosis", "OBSERVATION", 104, 113]]], ["The most interesting and previously unreported observation was the participation of the mitochondrial apoptosis factor (AIF) in the macrophage death triggered by a Mtb lipoprotein.", [["mitochondrial", "ANATOMY", 88, 101], ["macrophage", "ANATOMY", 132, 142], ["death", "DISEASE", 143, 148], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["AIF", "GENE_OR_GENE_PRODUCT", 120, 123], ["macrophage", "CELL", 132, 142], ["Mtb lipoprotein", "GENE_OR_GENE_PRODUCT", 164, 179], ["mitochondrial apoptosis factor", "PROTEIN", 88, 118], ["AIF", "PROTEIN", 120, 123], ["Mtb lipoprotein", "PROTEIN", 164, 179], ["the mitochondrial apoptosis factor", "PROBLEM", 84, 118], ["the macrophage death", "PROBLEM", 128, 148], ["a Mtb lipoprotein", "TEST", 162, 179], ["mitochondrial apoptosis", "OBSERVATION", 88, 111], ["macrophage death", "OBSERVATION", 132, 148]]], ["It follows to study the molecular mechanisms and the significance of the cooperation between death-receptor and mitochondrial mediated apoptosis.", [["mitochondrial", "ANATOMY", 112, 125], ["death", "DISEASE", 93, 98], ["death-receptor", "GENE_OR_GENE_PRODUCT", 93, 107], ["mitochondrial", "CELLULAR_COMPONENT", 112, 125], ["death-receptor", "PROTEIN", 93, 107], ["death", "PROBLEM", 93, 98], ["mitochondrial mediated apoptosis", "PROBLEM", 112, 144], ["apoptosis", "OBSERVATION", 135, 144]]]], "PMC7191060": [["IntroductionSince its outbreak in December 2019, Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) has spread worldwide and is considered a pandemic.", [["Acute Respiratory Syndrome CoronaVirus", "DISEASE", 56, 94], ["SARS-CoV-2)", "CHEMICAL", 98, 109], ["SARS-CoV-2", "ORGANISM", 98, 108], ["Severe Acute Respiratory Syndrome CoronaVirus 2", "SPECIES", 49, 96], ["SARS-CoV-2", "SPECIES", 98, 108], ["Severe Acute Respiratory Syndrome CoronaVirus", "PROBLEM", 49, 94], ["SARS", "TEST", 98, 102], ["CoV", "TEST", 103, 106], ["a pandemic", "PROBLEM", 149, 159], ["Severe", "OBSERVATION_MODIFIER", 49, 55], ["Acute", "OBSERVATION_MODIFIER", 56, 61], ["Respiratory Syndrome", "OBSERVATION", 62, 82], ["pandemic", "OBSERVATION", 151, 159]]], ["Coronavirus disease (COVID-19) can lead to acute respiratory distress syndrome (ARDS) or death.", [["respiratory", "ANATOMY", 49, 60], ["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 21, 29], ["acute respiratory distress syndrome", "DISEASE", 43, 78], ["ARDS", "DISEASE", 80, 84], ["death", "DISEASE", 89, 94], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 21, 26], ["acute respiratory distress syndrome", "PROBLEM", 43, 78], ["ARDS", "PROBLEM", 80, 84], ["death", "PROBLEM", 89, 94], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory", "ANATOMY", 49, 60], ["distress", "OBSERVATION", 61, 69]]], ["Many efforts have been made to identify risk factors predisposing to a severe issue.", [["a severe issue", "PROBLEM", 69, 83], ["severe", "OBSERVATION_MODIFIER", 71, 77]]], ["In the first SARS-CoV epidemic in 2002, hypertension was noted in 9/19 patients who died from SARS-CoV in Toronto (1).", [["SARS-CoV epidemic", "DISEASE", 13, 30], ["hypertension", "DISEASE", 40, 52], ["SARS", "DISEASE", 94, 98], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 94, 102], ["hypertension", "PROBLEM", 40, 52], ["SARS", "PROBLEM", 94, 98], ["hypertension", "OBSERVATION", 40, 52]]], ["In the two largest cohorts of SARS-CoV-2 published, hypertension is the most common comorbidity in patients with severe disease or in those who died or were ventilated (2, 3).", [["SARS", "DISEASE", 30, 34], ["hypertension", "DISEASE", 52, 64], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["hypertension", "PROBLEM", 52, 64], ["severe disease", "PROBLEM", 113, 127], ["largest", "OBSERVATION_MODIFIER", 11, 18], ["SARS", "OBSERVATION", 30, 34], ["hypertension", "OBSERVATION", 52, 64], ["most common", "OBSERVATION_MODIFIER", 72, 83], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["disease", "OBSERVATION", 120, 127]]], ["Nevertheless, these data are not adjusted for age, although age appears to be a strong predictor of adverse outcome (4) and hypertension is a very common finding in older patients.", [["hypertension", "DISEASE", 124, 136], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["hypertension", "PROBLEM", 124, 136], ["hypertension", "OBSERVATION", 124, 136]]], ["Finally, cohort studies only show correlation, not causality.", [["cohort studies", "TEST", 9, 23]]], ["In this paper, we hypothesize that the reductions in Angiotensin-Converting Enzyme 2 (ACE-2) observed in hypertension and obesity can explain many abnormalities observed in SARS-CoV-2 and question the role of treatments interfering with ACE2.ACE2 in the Cardiovascular SystemLike SARS-CoV, SARS-CoV-2 fuses with human cells after the receptor-binding domain of its S (Spike) protein binds with Angiotensin-Converting Enzyme 2 (ACE-2), an enzyme located on membrane of lung alveolar epithelial cells, renal tubular epithelial cells, enterocytes of the small intestine, and arterial and venous endothelial cells of the kidney (5\u201310).", [["Cardiovascular", "ANATOMY", 254, 268], ["cells", "ANATOMY", 318, 323], ["membrane", "ANATOMY", 456, 464], ["lung alveolar epithelial cells", "ANATOMY", 468, 498], ["renal tubular epithelial cells", "ANATOMY", 500, 530], ["enterocytes", "ANATOMY", 532, 543], ["small intestine", "ANATOMY", 551, 566], ["arterial", "ANATOMY", 572, 580], ["venous endothelial cells", "ANATOMY", 585, 609], ["kidney", "ANATOMY", 617, 623], ["Angiotensin", "CHEMICAL", 53, 64], ["hypertension", "DISEASE", 105, 117], ["obesity", "DISEASE", 122, 129], ["SARS", "DISEASE", 173, 177], ["SARS", "DISEASE", 290, 294], ["Angiotensin", "CHEMICAL", 394, 405], ["Angiotensin-Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 53, 84], ["ACE-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["SARS-CoV-2", "ORGANISM", 173, 183], ["ACE2", "GENE_OR_GENE_PRODUCT", 237, 241], ["ACE2", "GENE_OR_GENE_PRODUCT", 242, 246], ["SARS-CoV-2", "ORGANISM", 290, 300], ["human", "ORGANISM", 312, 317], ["cells", "CELL", 318, 323], ["Spike", "GENE_OR_GENE_PRODUCT", 368, 373], ["Angiotensin-Converting Enzyme 2", "GENE_OR_GENE_PRODUCT", 394, 425], ["ACE-2", "GENE_OR_GENE_PRODUCT", 427, 432], ["membrane", "CELLULAR_COMPONENT", 456, 464], ["lung alveolar epithelial cells", "CELL", 468, 498], ["renal tubular epithelial cells", "CELL", 500, 530], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 532, 543], ["small intestine", "ORGAN", 551, 566], ["arterial", "MULTI-TISSUE_STRUCTURE", 572, 580], ["venous endothelial cells", "CELL", 585, 609], ["kidney", "ORGAN", 617, 623], ["Angiotensin", "PROTEIN", 53, 64], ["ACE", "PROTEIN", 86, 89], ["ACE2", "PROTEIN", 237, 241], ["ACE2", "PROTEIN", 242, 246], ["human cells", "CELL_TYPE", 312, 323], ["receptor-binding domain", "PROTEIN", 334, 357], ["S (Spike) protein", "PROTEIN", 365, 382], ["Angiotensin-Converting Enzyme 2 (ACE-2", "PROTEIN", 394, 432], ["lung alveolar epithelial cells", "CELL_TYPE", 468, 498], ["renal tubular epithelial cells", "CELL_TYPE", 500, 530], ["enterocytes", "CELL_TYPE", 532, 543], ["arterial and venous endothelial cells", "CELL_TYPE", 572, 609], ["human", "SPECIES", 312, 317], ["SARS-CoV", "SPECIES", 173, 181], ["SARS-CoV", "SPECIES", 280, 288], ["human", "SPECIES", 312, 317], ["Angiotensin", "TEST", 53, 64], ["Converting Enzyme", "TEST", 65, 82], ["ACE", "TEST", 86, 89], ["hypertension", "PROBLEM", 105, 117], ["obesity", "PROBLEM", 122, 129], ["many abnormalities", "PROBLEM", 142, 160], ["ACE2", "TREATMENT", 237, 241], ["ACE2", "TEST", 242, 246], ["CoV", "TEST", 285, 288], ["SARS", "TEST", 290, 294], ["CoV", "TEST", 295, 298], ["human cells", "TREATMENT", 312, 323], ["protein binds", "TEST", 375, 388], ["Angiotensin", "TEST", 394, 405], ["Converting Enzyme", "TEST", 406, 423], ["ACE", "TEST", 427, 430], ["an enzyme", "TEST", 435, 444], ["lung alveolar epithelial cells", "TEST", 468, 498], ["renal tubular epithelial cells", "PROBLEM", 500, 530], ["enterocytes of the small intestine, and arterial and venous endothelial cells of the kidney", "PROBLEM", 532, 623], ["hypertension", "OBSERVATION", 105, 117], ["obesity", "OBSERVATION", 122, 129], ["Cardiovascular", "ANATOMY", 254, 268], ["membrane", "ANATOMY_MODIFIER", 456, 464], ["lung", "ANATOMY", 468, 472], ["alveolar", "ANATOMY_MODIFIER", 473, 481], ["epithelial cells", "OBSERVATION", 482, 498], ["renal", "ANATOMY", 500, 505], ["tubular", "ANATOMY_MODIFIER", 506, 513], ["epithelial cells", "OBSERVATION", 514, 530], ["enterocytes", "ANATOMY_MODIFIER", 532, 543], ["small intestine", "ANATOMY", 551, 566], ["arterial", "ANATOMY_MODIFIER", 572, 580], ["venous endothelial", "ANATOMY", 585, 603], ["cells", "ANATOMY_MODIFIER", 604, 609], ["kidney", "ANATOMY", 617, 623]]], ["Cardiomyocytes, fibroblasts, endothelial cells, and pericytes account for the vast majority of cells expressing ACE2 in the heart (10).ACE2 in the Cardiovascular SystemACE-2 is a monocarboxypeptidase homologous to Angiotensin-Converting Enzyme (ACE) whose active site is exposed at the extracellular surface (8, 11).", [["Cardiomyocytes", "ANATOMY", 0, 14], ["fibroblasts", "ANATOMY", 16, 27], ["endothelial cells", "ANATOMY", 29, 46], ["pericytes", "ANATOMY", 52, 61], ["cells", "ANATOMY", 95, 100], ["heart", "ANATOMY", 124, 129], ["Cardiovascular", "ANATOMY", 147, 161], ["extracellular surface", "ANATOMY", 286, 307], ["Angiotensin", "CHEMICAL", 214, 225], ["Cardiomyocytes", "CELL", 0, 14], ["fibroblasts", "CELL", 16, 27], ["endothelial cells", "CELL", 29, 46], ["pericytes", "CELL", 52, 61], ["cells", "CELL", 95, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["heart", "ORGAN", 124, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 135, 139], ["SystemACE-2", "GENE_OR_GENE_PRODUCT", 162, 173], ["monocarboxypeptidase", "GENE_OR_GENE_PRODUCT", 179, 199], ["Angiotensin-Converting Enzyme", "GENE_OR_GENE_PRODUCT", 214, 243], ["ACE", "GENE_OR_GENE_PRODUCT", 245, 248], ["extracellular surface", "CELLULAR_COMPONENT", 286, 307], ["Cardiomyocytes", "CELL_TYPE", 0, 14], ["fibroblasts", "CELL_TYPE", 16, 27], ["endothelial cells", "CELL_TYPE", 29, 46], ["pericytes", "CELL_TYPE", 52, 61], ["ACE2", "PROTEIN", 112, 116], ["ACE2", "PROTEIN", 135, 139], ["Cardiovascular SystemACE-2", "DNA", 147, 173], ["Angiotensin-Converting Enzyme", "PROTEIN", 214, 243], ["ACE", "PROTEIN", 245, 248], ["Cardiomyocytes", "PROBLEM", 0, 14], ["fibroblasts", "PROBLEM", 16, 27], ["endothelial cells", "PROBLEM", 29, 46], ["pericytes", "PROBLEM", 52, 61], ["ACE2", "TREATMENT", 135, 139], ["a monocarboxypeptidase homologous", "TREATMENT", 177, 210], ["Angiotensin", "TREATMENT", 214, 225], ["Converting Enzyme (ACE)", "TREATMENT", 226, 249], ["active site", "PROBLEM", 256, 267], ["fibroblasts", "OBSERVATION", 16, 27], ["endothelial cells", "OBSERVATION", 29, 46], ["heart", "ANATOMY", 124, 129], ["active", "OBSERVATION_MODIFIER", 256, 262], ["extracellular", "ANATOMY_MODIFIER", 286, 299], ["surface", "ANATOMY_MODIFIER", 300, 307]]], ["ACE cleaves angiotensin I (ANGI) to generate angiotensin II (ANGII), which binds to and activates Angiotensin Type 1 Receptor (AT1R) to constrict blood vessels and increase salt and fluid retention, thereby elevating blood pressure.", [["blood vessels", "ANATOMY", 146, 159], ["fluid", "ANATOMY", 182, 187], ["blood", "ANATOMY", 217, 222], ["angiotensin I", "CHEMICAL", 12, 25], ["angiotensin II", "CHEMICAL", 45, 59], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 12, 25], ["ANGI", "GENE_OR_GENE_PRODUCT", 27, 31], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 45, 59], ["ANGII", "GENE_OR_GENE_PRODUCT", 61, 66], ["Angiotensin Type 1 Receptor", "GENE_OR_GENE_PRODUCT", 98, 125], ["AT1R", "GENE_OR_GENE_PRODUCT", 127, 131], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 146, 159], ["salt", "SIMPLE_CHEMICAL", 173, 177], ["fluid", "ORGANISM_SUBSTANCE", 182, 187], ["blood", "ORGANISM_SUBSTANCE", 217, 222], ["ACE", "PROTEIN", 0, 3], ["angiotensin I", "PROTEIN", 12, 25], ["ANGI", "PROTEIN", 27, 31], ["angiotensin II", "PROTEIN", 45, 59], ["ANGII", "PROTEIN", 61, 66], ["Angiotensin Type 1 Receptor", "PROTEIN", 98, 125], ["AT1R", "PROTEIN", 127, 131], ["ACE cleaves angiotensin I (ANGI)", "TREATMENT", 0, 32], ["angiotensin II (ANGII)", "TREATMENT", 45, 67], ["Angiotensin Type 1 Receptor (AT1R)", "TREATMENT", 98, 132], ["constrict blood vessels", "PROBLEM", 136, 159], ["increase salt and fluid retention", "PROBLEM", 164, 197], ["blood pressure", "TEST", 217, 231], ["blood vessels", "ANATOMY", 146, 159], ["fluid retention", "OBSERVATION", 182, 197]]], ["ACE2 inactivates ANGII by converting it to angiotensin-(1\u20137), which has a vasodilator effect when binding to Mas receptor (12) (Figure 1A).", [["angiotensin-(1\u20137)", "CHEMICAL", 43, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ANGII", "GENE_OR_GENE_PRODUCT", 17, 22], ["angiotensin-(1\u20137)", "SIMPLE_CHEMICAL", 43, 60], ["Mas receptor (12) (Figure 1A", "GENE_OR_GENE_PRODUCT", 109, 137], ["ACE2", "PROTEIN", 0, 4], ["ANGII", "PROTEIN", 17, 22], ["Mas receptor", "PROTEIN", 109, 121], ["ACE2 inactivates ANGII", "TREATMENT", 0, 22], ["angiotensin", "TEST", 43, 54], ["a vasodilator effect", "TREATMENT", 72, 92]]], ["Moreover, ACE2 cleaves ANGI into angiotensin-(1\u20139) (albeit with lower affinity than for ANGII), which is further converted into angiotensin-(1\u20137) by ACE (12).", [["angiotensin-(1\u20139)", "CHEMICAL", 33, 50], ["angiotensin-(1\u20137)", "CHEMICAL", 128, 145], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ANGI", "GENE_OR_GENE_PRODUCT", 23, 27], ["angiotensin-(1\u20139)", "GENE_OR_GENE_PRODUCT", 33, 50], ["ANGII", "GENE_OR_GENE_PRODUCT", 88, 93], ["angiotensin-(1\u20137)", "SIMPLE_CHEMICAL", 128, 145], ["ACE (12)", "GENE_OR_GENE_PRODUCT", 149, 157], ["ACE2", "PROTEIN", 10, 14], ["ANGI", "PROTEIN", 23, 27], ["ANGII", "PROTEIN", 88, 93], ["ACE2", "TEST", 10, 14], ["angiotensin", "TEST", 33, 44], ["angiotensin", "TEST", 128, 139]]], ["Thus, ACE2 negatively regulates the renin-angiotensin system and modulates the vasoconstriction, fibrosis, and hypertrophy induced by that system (8, 11).", [["angiotensin", "CHEMICAL", 42, 53], ["fibrosis", "DISEASE", 97, 105], ["hypertrophy", "DISEASE", 111, 122], ["ACE2", "GENE_OR_GENE_PRODUCT", 6, 10], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 36, 53], ["ACE2", "PROTEIN", 6, 10], ["renin", "PROTEIN", 36, 41], ["ACE2", "TEST", 6, 10], ["the vasoconstriction", "PROBLEM", 75, 95], ["fibrosis", "PROBLEM", 97, 105], ["hypertrophy", "PROBLEM", 111, 122], ["angiotensin system", "OBSERVATION", 42, 60], ["vasoconstriction", "OBSERVATION_MODIFIER", 79, 95], ["fibrosis", "OBSERVATION", 97, 105], ["hypertrophy", "OBSERVATION", 111, 122]]], ["In rats, ACE2 deficiency worsens hypertension when ANGII is in excess (8, 13).", [["hypertension", "DISEASE", 33, 45], ["ANGII", "CHEMICAL", 51, 56], ["rats", "ORGANISM", 3, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["ACE2", "PROTEIN", 9, 13], ["rats", "SPECIES", 3, 7], ["ACE2 deficiency", "PROBLEM", 9, 24], ["hypertension", "PROBLEM", 33, 45], ["ACE2 deficiency", "OBSERVATION", 9, 24], ["worsens", "OBSERVATION_MODIFIER", 25, 32], ["hypertension", "OBSERVATION", 33, 45]]], ["In human, gene expression and/or ACE2 activity is lower in hypertensive patients than in normotensive ones (13).ACE2 in the Cardiovascular SystemConversely, ANGII negatively regulates ACE2.", [["Cardiovascular", "ANATOMY", 124, 138], ["hypertensive", "DISEASE", 59, 71], ["human", "ORGANISM", 3, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["patients", "ORGANISM", 72, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["ACE2", "PROTEIN", 33, 37], ["ACE2", "PROTEIN", 112, 116], ["ACE2", "PROTEIN", 184, 188], ["human", "SPECIES", 3, 8], ["patients", "SPECIES", 72, 80], ["human", "SPECIES", 3, 8], ["Cardiovascular", "ANATOMY", 124, 138]]], ["AT1R and ACE2 physically interact to form complexes on the cell membrane in the absence of excess Ang II (11).", [["cell membrane", "ANATOMY", 59, 72], ["Ang II", "CHEMICAL", 98, 104], ["AT1R", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["cell membrane", "CELLULAR_COMPONENT", 59, 72], ["Ang II", "GENE_OR_GENE_PRODUCT", 98, 104], ["AT1R", "PROTEIN", 0, 4], ["ACE2", "PROTEIN", 9, 13], ["Ang II", "PROTEIN", 98, 104], ["cell membrane", "OBSERVATION", 59, 72]]], ["ANGII increase separates AT1R and ACE2 on the cell surface and leads to ACE2 internalization and lysosomal degradation through an AT1R-dependent mechanism (11, 13).", [["cell surface", "ANATOMY", 46, 58], ["lysosomal", "ANATOMY", 97, 106], ["AT1R", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["cell surface", "CELLULAR_COMPONENT", 46, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["lysosomal", "CELLULAR_COMPONENT", 97, 106], ["AT1R", "GENE_OR_GENE_PRODUCT", 130, 134], ["ANGII", "PROTEIN", 0, 5], ["AT1R", "PROTEIN", 25, 29], ["ACE2", "PROTEIN", 34, 38], ["ACE2", "PROTEIN", 72, 76], ["AT1R", "PROTEIN", 130, 134], ["ANGII", "PROBLEM", 0, 5], ["ACE2 internalization", "TREATMENT", 72, 92], ["lysosomal degradation", "PROBLEM", 97, 118], ["increase", "OBSERVATION_MODIFIER", 6, 14], ["lysosomal degradation", "OBSERVATION", 97, 118]]], ["Moreover, cellular ACE2 can be cleaved and released (shedding) by the metalloproteinase ADAM17, which is upregulated by ANGII (14).", [["cellular", "ANATOMY", 10, 18], ["cellular", "CELL", 10, 18], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["ADAM17", "GENE_OR_GENE_PRODUCT", 88, 94], ["ACE2", "PROTEIN", 19, 23], ["metalloproteinase", "PROTEIN", 70, 87], ["ADAM17", "PROTEIN", 88, 94], ["cellular ACE2", "TEST", 10, 23], ["the metalloproteinase ADAM17", "TEST", 66, 94]]], ["The soluble form of ACE2 circulates in small amounts in the blood, but its physiological role remains elusive, and shedding could be only a mechanism to regulate ACE2 activity on the cell surface (15).ACE2 in the Cardiovascular SystemNotably, it has been shown that infection with SARS-CoV can be blocked with soluble ACE2 molecules (6), and some have hypothesized that a soluble recombinant form can be used to overwhelm SARS-CoV-2 to prevent its binding to cellular ACE2 (16).", [["blood", "ANATOMY", 60, 65], ["cell surface", "ANATOMY", 183, 195], ["Cardiovascular", "ANATOMY", 213, 227], ["cellular", "ANATOMY", 459, 467], ["infection", "DISEASE", 266, 275], ["SARS", "DISEASE", 281, 285], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["cell surface", "CELLULAR_COMPONENT", 183, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 201, 205], ["SARS-CoV", "ORGANISM", 281, 289], ["ACE2", "GENE_OR_GENE_PRODUCT", 318, 322], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 422, 432], ["cellular", "CELL", 459, 467], ["ACE2", "GENE_OR_GENE_PRODUCT", 468, 472], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 162, 166], ["ACE2", "PROTEIN", 201, 205], ["ACE2 molecules", "PROTEIN", 318, 332], ["ACE2", "PROTEIN", 468, 472], ["SARS-CoV", "SPECIES", 281, 289], ["ACE2 circulates in small amounts in the blood", "PROBLEM", 20, 65], ["infection", "PROBLEM", 266, 275], ["SARS", "PROBLEM", 281, 285], ["CoV", "PROBLEM", 286, 289], ["soluble ACE2 molecules", "TREATMENT", 310, 332], ["a soluble recombinant form", "TREATMENT", 370, 396], ["small", "OBSERVATION_MODIFIER", 39, 44], ["amounts", "OBSERVATION_MODIFIER", 45, 52], ["blood", "ANATOMY", 60, 65], ["infection", "OBSERVATION", 266, 275]]], ["Recombinant human ACE2 has been tested in a phase 2\u20133 trial in ARDS with interesting results (17), and a pilot trial has recently been launched in COVID-19 (NCT04287686).ACE2 in the Cardiovascular SystemACE inhibitors (ACEi) and AT1R blockers (ARB) are two classes of drugs that are widely used in medicine to treat hypertension or heart failure.", [["Cardiovascular", "ANATOMY", 182, 196], ["heart", "ANATOMY", 332, 337], ["ARDS", "DISEASE", 63, 67], ["ACEi", "CHEMICAL", 219, 223], ["ARB", "CHEMICAL", 244, 247], ["hypertension", "DISEASE", 316, 328], ["heart failure", "DISEASE", 332, 345], ["COVID-19", "CHEMICAL", 147, 155], ["human", "ORGANISM", 12, 17], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 170, 174], ["ACEi", "SIMPLE_CHEMICAL", 219, 223], ["AT1R blockers", "SIMPLE_CHEMICAL", 229, 242], ["ARB", "SIMPLE_CHEMICAL", 244, 247], ["heart", "ORGAN", 332, 337], ["Recombinant human ACE2", "PROTEIN", 0, 22], ["ACE2", "PROTEIN", 170, 174], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["ARDS", "PROBLEM", 63, 67], ["a pilot trial", "TREATMENT", 103, 116], ["ACE2", "TREATMENT", 170, 174], ["the Cardiovascular SystemACE inhibitors", "TREATMENT", 178, 217], ["ACEi", "TREATMENT", 219, 223], ["AT1R blockers", "TREATMENT", 229, 242], ["ARB", "TREATMENT", 244, 247], ["drugs", "TREATMENT", 268, 273], ["hypertension", "PROBLEM", 316, 328], ["heart failure", "PROBLEM", 332, 345], ["hypertension", "OBSERVATION", 316, 328], ["heart", "ANATOMY", 332, 337], ["failure", "OBSERVATION", 338, 345]]], ["ACEi and ARB upregulate ACE2 expression on the cell surface, and ACE2 activity is not prevented by ACEi (8, 11, 18).", [["cell surface", "ANATOMY", 47, 59], ["ACEi", "CHEMICAL", 0, 4], ["ARB", "CHEMICAL", 9, 12], ["ACEi", "CHEMICAL", 99, 103], ["ACEi", "CHEMICAL", 99, 103], ["ACEi", "SIMPLE_CHEMICAL", 0, 4], ["ARB", "SIMPLE_CHEMICAL", 9, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["cell surface", "CELLULAR_COMPONENT", 47, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACEi", "SIMPLE_CHEMICAL", 99, 103], ["ACE2", "PROTEIN", 24, 28], ["ACE2", "PROTEIN", 65, 69], ["ACEi", "TREATMENT", 0, 4], ["ARB", "TREATMENT", 9, 12], ["the cell surface", "TEST", 43, 59], ["ACE2 activity", "TEST", 65, 78], ["ACEi", "TEST", 99, 103]]], ["Accordingly, patients treated with ACEi/ARB could have a higher level of membrane-bound ACE2, providing a more potent binding site to COVID-19 S protein.", [["membrane", "ANATOMY", 73, 81], ["ACEi", "CHEMICAL", 35, 39], ["ARB", "CHEMICAL", 40, 43], ["patients", "ORGANISM", 13, 21], ["ACEi", "SIMPLE_CHEMICAL", 35, 39], ["ARB", "SIMPLE_CHEMICAL", 40, 43], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["COVID-19 S", "GENE_OR_GENE_PRODUCT", 134, 144], ["ACE2", "PROTEIN", 88, 92], ["COVID-19 S protein", "PROTEIN", 134, 152], ["patients", "SPECIES", 13, 21], ["ACEi", "TREATMENT", 35, 39], ["ARB", "TREATMENT", 40, 43], ["COVID", "TEST", 134, 139]]], ["Nevertheless, in the absence of excess ANGII (either by reduction of ANGII synthesis by ACEi or by AT1R blockade thanks to ARB), AT1R is thought to interact with ACE2 (11).", [["ACEi", "CHEMICAL", 88, 92], ["ARB", "CHEMICAL", 123, 126], ["ANGII", "GENE_OR_GENE_PRODUCT", 39, 44], ["ANGII", "GENE_OR_GENE_PRODUCT", 69, 74], ["ACEi", "SIMPLE_CHEMICAL", 88, 92], ["AT1R", "GENE_OR_GENE_PRODUCT", 99, 103], ["ARB", "GENE_OR_GENE_PRODUCT", 123, 126], ["AT1R", "GENE_OR_GENE_PRODUCT", 129, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["ANGII", "PROTEIN", 39, 44], ["ANGII", "PROTEIN", 69, 74], ["AT1R", "PROTEIN", 99, 103], ["AT1R", "PROTEIN", 129, 133], ["ACE2", "PROTEIN", 162, 166], ["excess ANGII", "PROBLEM", 32, 44], ["ANGII synthesis", "TREATMENT", 69, 84], ["ACEi", "TREATMENT", 88, 92], ["AT1R blockade", "TREATMENT", 99, 112], ["ACE2", "TEST", 162, 166], ["ANGII", "OBSERVATION", 39, 44]]], ["This interaction could reduce the affinity of COVID S protein to ACE2 and then reduce COVID-19 viral entry (11).ACE2 in the Cardiovascular SystemIn the heart, ACE and ACE2 balance Ang II levels and ACE2 is known to be cardioprotective (8).", [["Cardiovascular", "ANATOMY", 124, 138], ["heart", "ANATOMY", 152, 157], ["Ang II", "CHEMICAL", 180, 186], ["COVID S protein", "GENE_OR_GENE_PRODUCT", 46, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["heart", "ORGAN", 152, 157], ["ACE", "GENE_OR_GENE_PRODUCT", 159, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["Ang II", "GENE_OR_GENE_PRODUCT", 180, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 198, 202], ["COVID S protein", "PROTEIN", 46, 61], ["ACE2", "PROTEIN", 65, 69], ["COVID", "PROTEIN", 86, 91], ["ACE2", "PROTEIN", 112, 116], ["ACE2", "PROTEIN", 167, 171], ["Ang II", "PROTEIN", 180, 186], ["ACE2", "PROTEIN", 198, 202], ["COVID S protein", "TREATMENT", 46, 61], ["ACE2", "TEST", 65, 69], ["COVID", "TEST", 86, 91], ["ACE2", "TREATMENT", 112, 116], ["ACE", "TREATMENT", 159, 162], ["ACE2 balance", "TEST", 167, 179], ["Ang II levels", "TEST", 180, 193], ["ACE2", "TEST", 198, 202], ["heart", "ANATOMY", 152, 157], ["ACE", "OBSERVATION", 159, 162]]], ["ACE2 loss leads to a decrease in myocardial function in rodents, likely mediated by ANGII-induced oxidative stress and inflammation through AT1R, but it is unknown whether excess ANGII has a role in an acute setting (8, 19).", [["myocardial", "ANATOMY", 33, 43], ["inflammation", "DISEASE", 119, 131], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["myocardial", "MULTI-TISSUE_STRUCTURE", 33, 43], ["ANGII", "GENE_OR_GENE_PRODUCT", 84, 89], ["AT1R", "GENE_OR_GENE_PRODUCT", 140, 144], ["ANGII", "GENE_OR_GENE_PRODUCT", 179, 184], ["ACE2", "PROTEIN", 0, 4], ["AT1R", "PROTEIN", 140, 144], ["ANGII", "PROTEIN", 179, 184], ["ACE2 loss", "PROBLEM", 0, 9], ["a decrease in myocardial function", "PROBLEM", 19, 52], ["induced oxidative stress", "PROBLEM", 90, 114], ["inflammation through AT1R", "PROBLEM", 119, 144], ["loss", "OBSERVATION", 5, 9], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["myocardial", "ANATOMY", 33, 43], ["function", "OBSERVATION", 44, 52], ["likely mediated", "UNCERTAINTY", 65, 80], ["ANGII", "OBSERVATION", 84, 89], ["oxidative stress", "OBSERVATION", 98, 114], ["inflammation", "OBSERVATION", 119, 131], ["ANGII", "OBSERVATION", 179, 184], ["acute", "OBSERVATION_MODIFIER", 202, 207]]], ["This decrease is corrected by ARB or ACEi, and these drugs rapidly increase ACE2 activity and mRNA expression in the heart of rats (8, 20).", [["heart", "ANATOMY", 117, 122], ["ARB", "CHEMICAL", 30, 33], ["ACEi", "CHEMICAL", 37, 41], ["ARB", "SIMPLE_CHEMICAL", 30, 33], ["ACEi", "SIMPLE_CHEMICAL", 37, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["heart", "ORGAN", 117, 122], ["rats", "ORGANISM", 126, 130], ["ACE2", "PROTEIN", 76, 80], ["rats", "SPECIES", 126, 130], ["ARB", "TREATMENT", 30, 33], ["ACEi", "TREATMENT", 37, 41], ["these drugs", "TREATMENT", 47, 58], ["ACE2 activity", "TREATMENT", 76, 89], ["mRNA expression", "TEST", 94, 109], ["heart", "ANATOMY", 117, 122]]], ["Evidence for such an increase in humans is lacking, but studies checked for variation in the circulating level rather than the tissular level of ACE2 (21).", [["tissular", "ANATOMY", 127, 135], ["humans", "ORGANISM", 33, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["ACE2", "PROTEIN", 145, 149], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["an increase in humans", "PROBLEM", 18, 39], ["studies", "TEST", 56, 63], ["variation in the circulating level", "PROBLEM", 76, 110], ["ACE2", "TEST", 145, 149], ["increase", "OBSERVATION_MODIFIER", 21, 29]]], ["In human failing heart, ACE2 expression is increased, correlating with disease severity, and is thought to be a compensatory mechanism (8, 10).Role of ACE2 in SARS-COV-2 InfectionSARS-CoV-2 has a 10\u201320-fold higher affinity for ACE2 than does the 2002 SARS-CoV (22).", [["heart", "ANATOMY", 17, 22], ["SARS", "DISEASE", 159, 163], ["human", "ORGANISM", 3, 8], ["heart", "ORGAN", 17, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 24, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["CoV-2", "GENE_OR_GENE_PRODUCT", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 227, 231], ["ACE2", "PROTEIN", 24, 28], ["ACE2", "PROTEIN", 151, 155], ["ACE2", "PROTEIN", 227, 231], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["SARS-CoV", "SPECIES", 251, 259], ["disease severity", "PROBLEM", 71, 87], ["ACE2", "TEST", 151, 155], ["SARS", "TEST", 159, 163], ["COV", "TEST", 164, 167], ["InfectionSARS", "TEST", 170, 183], ["CoV", "TEST", 184, 187], ["ACE2", "TEST", 227, 231], ["CoV", "TEST", 256, 259], ["heart", "ANATOMY", 17, 22], ["ACE2 expression", "OBSERVATION", 24, 39], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["thought to be", "UNCERTAINTY", 96, 109], ["compensatory", "OBSERVATION", 112, 124]]], ["An increased abundance of cellular ACE2 is associated with a higher susceptibility to SARS-CoV infection in mice (23).", [["cellular", "ANATOMY", 26, 34], ["SARS-CoV infection", "DISEASE", 86, 104], ["cellular", "CELL", 26, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["mice", "ORGANISM", 108, 112], ["cellular ACE2", "PROTEIN", 26, 39], ["mice", "SPECIES", 108, 112], ["SARS-CoV", "SPECIES", 86, 94], ["mice", "SPECIES", 108, 112], ["cellular ACE2", "PROBLEM", 26, 39], ["a higher susceptibility to SARS", "PROBLEM", 59, 90], ["CoV infection", "PROBLEM", 91, 104], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["abundance", "OBSERVATION_MODIFIER", 13, 22], ["cellular ACE2", "OBSERVATION", 26, 39], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["susceptibility", "OBSERVATION_MODIFIER", 68, 82], ["CoV", "OBSERVATION_MODIFIER", 91, 94], ["infection", "OBSERVATION", 95, 104]]], ["However, in both heart and lung, binding of the SARS-CoV to ACE2 leads to the loss of ACE2 by ACE2 internalization with the virus and ACE2 shedding (7, 9, 14).", [["heart", "ANATOMY", 17, 22], ["lung", "ANATOMY", 27, 31], ["SARS", "DISEASE", 48, 52], ["heart", "ORGAN", 17, 22], ["lung", "ORGAN", 27, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 48, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 134, 138], ["ACE2", "PROTEIN", 60, 64], ["ACE2", "PROTEIN", 86, 90], ["ACE2", "PROTEIN", 94, 98], ["ACE2", "PROTEIN", 134, 138], ["SARS-CoV", "SPECIES", 48, 56], ["the SARS", "PROBLEM", 44, 52], ["ACE2", "TEST", 60, 64], ["the loss of ACE2", "PROBLEM", 74, 90], ["the virus", "PROBLEM", 120, 129], ["ACE2 shedding", "TEST", 134, 147], ["both", "ANATOMY_MODIFIER", 12, 16], ["heart", "ANATOMY", 17, 22], ["lung", "ANATOMY", 27, 31], ["SARS", "OBSERVATION", 48, 52], ["virus", "OBSERVATION", 124, 129]]], ["Lower availability of ACE2 results in a lower rate of ANGII degradation.", [["ACE2", "GENE_OR_GENE_PRODUCT", 22, 26], ["ANGII", "GENE_OR_GENE_PRODUCT", 54, 59], ["ACE2", "PROTEIN", 22, 26], ["ACE2 results", "TEST", 22, 34], ["ANGII degradation", "PROBLEM", 54, 71], ["ANGII degradation", "OBSERVATION", 54, 71]]], ["In rodent lungs, excess ANGII binding to AT1R increases pulmonary vascular permeability and neutrophil accumulation and enhances lung injury (7, 24) (Figure 1B).", [["lungs", "ANATOMY", 10, 15], ["pulmonary vascular", "ANATOMY", 56, 74], ["neutrophil", "ANATOMY", 92, 102], ["lung", "ANATOMY", 129, 133], ["lung injury", "DISEASE", 129, 140], ["lungs", "ORGAN", 10, 15], ["ANGII", "GENE_OR_GENE_PRODUCT", 24, 29], ["AT1R", "GENE_OR_GENE_PRODUCT", 41, 45], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 56, 74], ["neutrophil", "CELL", 92, 102], ["lung", "ORGAN", 129, 133], ["ANGII", "PROTEIN", 24, 29], ["AT1R", "PROTEIN", 41, 45], ["rodent", "SPECIES", 3, 9], ["excess ANGII binding", "PROBLEM", 17, 37], ["pulmonary vascular permeability", "PROBLEM", 56, 87], ["neutrophil accumulation", "PROBLEM", 92, 115], ["enhances lung injury", "PROBLEM", 120, 140], ["lungs", "ANATOMY", 10, 15], ["excess", "OBSERVATION_MODIFIER", 17, 23], ["ANGII", "OBSERVATION", 24, 29], ["pulmonary", "ANATOMY_MODIFIER", 56, 65], ["vascular", "ANATOMY", 66, 74], ["permeability", "OBSERVATION", 75, 87], ["neutrophil accumulation", "OBSERVATION", 92, 115], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["Thus, decreased ACE2 expression promotes increased lung injury and ARB prevents it by limiting ANGII binding to AT1R (7, 8, 24, 25) (Figure 1C).", [["lung", "ANATOMY", 51, 55], ["lung injury", "DISEASE", 51, 62], ["ARB", "CHEMICAL", 67, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["lung", "ORGAN", 51, 55], ["ARB", "SIMPLE_CHEMICAL", 67, 70], ["ANGII", "GENE_OR_GENE_PRODUCT", 95, 100], ["AT1R", "GENE_OR_GENE_PRODUCT", 112, 116], ["ACE2", "PROTEIN", 16, 20], ["ANGII", "PROTEIN", 95, 100], ["AT1R", "PROTEIN", 112, 116], ["decreased ACE2 expression", "PROBLEM", 6, 31], ["increased lung injury", "PROBLEM", 41, 62], ["ARB", "TREATMENT", 67, 70], ["AT1R", "TEST", 112, 116], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["lung", "ANATOMY", 51, 55], ["injury", "OBSERVATION", 56, 62]]], ["This hypothesis is supported in vivo by the increased frequency of severe ARDS in patients infected with SARS-CoV with higher levels of ACE determined by genetic predisposition, leading to higher levels of ANGII (26), and by the correlation between viral load, ANGII plasma level, and disease severity in influenza H7N5 (27) and respiratory syncytial virus infection (25).", [["plasma", "ANATOMY", 267, 273], ["ARDS", "DISEASE", 74, 78], ["SARS", "DISEASE", 105, 109], ["influenza H7N5", "DISEASE", 305, 319], ["respiratory syncytial virus infection", "DISEASE", 329, 366], ["patients", "ORGANISM", 82, 90], ["SARS-CoV", "ORGANISM", 105, 113], ["ACE", "GENE_OR_GENE_PRODUCT", 136, 139], ["plasma", "ORGANISM_SUBSTANCE", 267, 273], ["influenza H7N5", "ORGANISM", 305, 319], ["respiratory syncytial virus", "ORGANISM", 329, 356], ["ACE", "PROTEIN", 136, 139], ["patients", "SPECIES", 82, 90], ["respiratory syncytial virus", "SPECIES", 329, 356], ["SARS-CoV", "SPECIES", 105, 113], ["influenza H7N5", "SPECIES", 305, 319], ["respiratory syncytial virus", "SPECIES", 329, 356], ["severe ARDS", "PROBLEM", 67, 78], ["SARS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["ACE", "TREATMENT", 136, 139], ["viral load", "TEST", 249, 259], ["ANGII plasma level", "TEST", 261, 279], ["disease severity in influenza H7N5", "PROBLEM", 285, 319], ["respiratory syncytial virus infection", "PROBLEM", 329, 366], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["ARDS", "OBSERVATION", 74, 78], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["respiratory", "ANATOMY", 329, 340], ["syncytial virus", "OBSERVATION", 341, 356]]], ["More notably, in a small cohort of patients infected with SARS-CoV-2, viral load was correlated with plasma ANGII level (28).", [["plasma", "ANATOMY", 101, 107], ["SARS", "DISEASE", 58, 62], ["patients", "ORGANISM", 35, 43], ["SARS-CoV-2", "ORGANISM", 58, 68], ["viral", "ORGANISM", 70, 75], ["plasma", "ORGANISM_SUBSTANCE", 101, 107], ["ANGII", "GENE_OR_GENE_PRODUCT", 108, 113], ["ANGII", "PROTEIN", 108, 113], ["patients", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "TEST", 58, 66], ["viral load", "TEST", 70, 80], ["plasma ANGII level", "TEST", 101, 119], ["small", "OBSERVATION_MODIFIER", 19, 24], ["infected", "OBSERVATION", 44, 52]]], ["Unfortunately, baseline treatments are unknown in this cohort, and correlation between ARDS severity and plasma ANGII level failed to reach statistical significance, maybe because of the low number of patients.Role of ACE2 in SARS-COV-2 InfectionMoreover, some have suggested that viral replication by itself can reduce cellular ACE2 expression (29).", [["plasma", "ANATOMY", 105, 111], ["cellular", "ANATOMY", 320, 328], ["ARDS", "DISEASE", 87, 91], ["SARS", "DISEASE", 226, 230], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["ANGII", "GENE_OR_GENE_PRODUCT", 112, 117], ["patients", "ORGANISM", 201, 209], ["ACE2", "GENE_OR_GENE_PRODUCT", 218, 222], ["cellular", "CELL", 320, 328], ["ACE2", "GENE_OR_GENE_PRODUCT", 329, 333], ["ANGII", "PROTEIN", 112, 117], ["ACE2", "PROTEIN", 218, 222], ["ACE2", "PROTEIN", 329, 333], ["patients", "SPECIES", 201, 209], ["baseline treatments", "TREATMENT", 15, 34], ["ARDS severity", "PROBLEM", 87, 100], ["plasma ANGII level", "TEST", 105, 123], ["SARS", "PROBLEM", 226, 230], ["viral replication", "TREATMENT", 281, 298], ["cellular ACE2 expression", "TEST", 320, 344]]], ["This point is of importance because limitation of ANGII formation by ACEi and binding to AT1R by ARB may yet become the best ways to limit lung injuries if ACE2 is less or not synthetized following viral infection.Role of ACE2 in SARS-COV-2 InfectionSARS-CoV- and SARS-CoV-2-associated cardiac injury contributes significantly to morbidity and mortality and could hit as much as a third of patients with a severe form of the disease (9, 28, 30, 31).", [["lung", "ANATOMY", 139, 143], ["cardiac", "ANATOMY", 286, 293], ["ACEi", "CHEMICAL", 69, 73], ["ARB", "CHEMICAL", 97, 100], ["lung injuries", "DISEASE", 139, 152], ["viral infection", "DISEASE", 198, 213], ["SARS", "DISEASE", 230, 234], ["SARS", "DISEASE", 264, 268], ["cardiac injury", "DISEASE", 286, 300], ["ANGII", "SIMPLE_CHEMICAL", 50, 55], ["ACEi", "SIMPLE_CHEMICAL", 69, 73], ["AT1R", "GENE_OR_GENE_PRODUCT", 89, 93], ["ARB", "SIMPLE_CHEMICAL", 97, 100], ["lung", "ORGAN", 139, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["ACE2", "GENE_OR_GENE_PRODUCT", 222, 226], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 230, 240], ["InfectionSARS-CoV", "ORGANISM", 241, 258], ["SARS-CoV-2", "ORGANISM", 264, 274], ["cardiac", "ORGAN", 286, 293], ["patients", "ORGANISM", 390, 398], ["AT1R", "PROTEIN", 89, 93], ["ACE2", "PROTEIN", 156, 160], ["ACE2", "PROTEIN", 222, 226], ["patients", "SPECIES", 390, 398], ["SARS-CoV", "SPECIES", 264, 272], ["ANGII formation", "TREATMENT", 50, 65], ["ACEi", "TREATMENT", 69, 73], ["ARB", "TREATMENT", 97, 100], ["lung injuries", "PROBLEM", 139, 152], ["ACE2", "PROBLEM", 156, 160], ["viral infection", "PROBLEM", 198, 213], ["ACE2", "TEST", 222, 226], ["SARS", "TEST", 230, 234], ["COV", "TEST", 235, 238], ["InfectionSARS", "TEST", 241, 254], ["CoV", "TEST", 255, 258], ["SARS", "PROBLEM", 264, 268], ["CoV", "TEST", 269, 272], ["cardiac injury", "PROBLEM", 286, 300], ["the disease", "PROBLEM", 421, 432], ["lung", "ANATOMY", 139, 143], ["injuries", "OBSERVATION", 144, 152], ["infection", "OBSERVATION", 204, 213], ["cardiac", "ANATOMY", 286, 293], ["injury", "OBSERVATION", 294, 300], ["severe", "OBSERVATION_MODIFIER", 406, 412], ["disease", "OBSERVATION", 425, 432]]], ["SARS-CoV was found in the heart of a third of human autopsy hearts, with a concomitant marked reduction in cellular ACE2 (9).", [["heart", "ANATOMY", 26, 31], ["hearts", "ANATOMY", 60, 66], ["cellular", "ANATOMY", 107, 115], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["heart", "ORGAN", 26, 31], ["human", "ORGANISM", 46, 51], ["hearts", "ORGAN", 60, 66], ["cellular", "CELL", 107, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["ACE2", "PROTEIN", 116, 120], ["human", "SPECIES", 46, 51], ["SARS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 46, 51], ["SARS", "PROBLEM", 0, 4], ["CoV", "PROBLEM", 5, 8], ["a concomitant marked reduction in cellular ACE2", "PROBLEM", 73, 120], ["CoV", "OBSERVATION", 5, 8], ["heart", "ANATOMY", 26, 31], ["autopsy", "OBSERVATION", 52, 59], ["hearts", "ANATOMY", 60, 66], ["concomitant", "OBSERVATION_MODIFIER", 75, 86], ["marked", "OBSERVATION_MODIFIER", 87, 93], ["reduction", "OBSERVATION_MODIFIER", 94, 103], ["cellular ACE2", "OBSERVATION", 107, 120]]], ["As in lungs, ANGII probably contributes to the deleterious effect of SARS-CoV on the heart and to SARS-associated cardiomyopathy, even if myocardial dysfunction can also be influenced by the strong immune response observed in those patients (9).", [["lungs", "ANATOMY", 6, 11], ["heart", "ANATOMY", 85, 90], ["myocardial", "ANATOMY", 138, 148], ["SARS", "DISEASE", 69, 73], ["SARS", "DISEASE", 98, 102], ["cardiomyopathy", "DISEASE", 114, 128], ["myocardial dysfunction", "DISEASE", 138, 160], ["lungs", "ORGAN", 6, 11], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 69, 77], ["heart", "ORGAN", 85, 90], ["myocardial", "MULTI-TISSUE_STRUCTURE", 138, 148], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73], ["CoV on the heart", "PROBLEM", 74, 90], ["SARS", "PROBLEM", 98, 102], ["cardiomyopathy", "PROBLEM", 114, 128], ["myocardial dysfunction", "PROBLEM", 138, 160], ["lungs", "ANATOMY", 6, 11], ["ANGII", "OBSERVATION", 13, 18], ["heart", "ANATOMY", 85, 90], ["cardiomyopathy", "OBSERVATION", 114, 128]]], ["Inflammatory signals are likely to suppress ACE2 transcription and down-regulate cell-surface expression of ACE2 (8).", [["cell", "ANATOMY", 81, 85], ["surface", "ANATOMY", 86, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 44, 48], ["cell", "CELL", 81, 85], ["ACE2 (8)", "GENE_OR_GENE_PRODUCT", 108, 116], ["ACE2", "PROTEIN", 44, 48], ["ACE2", "PROTEIN", 108, 112], ["Inflammatory signals", "PROBLEM", 0, 20], ["ACE2 transcription", "TEST", 44, 62], ["ACE2", "TEST", 108, 112]]], ["Thus, inflammatory signals could decrease the cellular susceptibility to SARS-CoV infection but increase the ANGII-mediated tissular injury.", [["cellular", "ANATOMY", 46, 54], ["tissular", "ANATOMY", 124, 132], ["SARS-CoV infection", "DISEASE", 73, 91], ["tissular injury", "DISEASE", 124, 139], ["cellular", "CELL", 46, 54], ["SARS-CoV", "ORGANISM", 73, 81], ["ANGII", "GENE_OR_GENE_PRODUCT", 109, 114], ["tissular", "MULTI-TISSUE_STRUCTURE", 124, 132], ["SARS-CoV", "SPECIES", 73, 81], ["inflammatory signals", "PROBLEM", 6, 26], ["the cellular susceptibility", "PROBLEM", 42, 69], ["SARS", "PROBLEM", 73, 77], ["CoV infection", "PROBLEM", 78, 91], ["the ANGII-mediated tissular injury", "PROBLEM", 105, 139], ["inflammatory", "OBSERVATION", 6, 18], ["cellular", "OBSERVATION_MODIFIER", 46, 54], ["susceptibility", "OBSERVATION_MODIFIER", 55, 69], ["CoV", "OBSERVATION_MODIFIER", 78, 81], ["infection", "OBSERVATION", 82, 91], ["increase", "OBSERVATION_MODIFIER", 96, 104], ["ANGII", "OBSERVATION", 109, 114], ["tissular", "ANATOMY", 124, 132], ["injury", "OBSERVATION", 133, 139]]], ["Moreover, because pericytes are supposed to play a role in myocardial microcirculation, SARS-CoV-2-induced microcirculation disorder could explain the frequent cardiac marker increase observed in hospitalized patients (2), exacerbated by the reduced oxygen supply caused by lung failure (10).Role of ACE2 in SARS-COV-2 InfectionIn summary, a decrease in cellular ACE2 may reduce the susceptibility of cells to SARS CoV-2 but leads to greater activation of AT1R and more severe tissue damage.", [["pericytes", "ANATOMY", 18, 27], ["myocardial", "ANATOMY", 59, 69], ["cardiac", "ANATOMY", 160, 167], ["lung", "ANATOMY", 274, 278], ["cellular", "ANATOMY", 354, 362], ["cells", "ANATOMY", 401, 406], ["tissue", "ANATOMY", 477, 483], ["microcirculation disorder", "DISEASE", 107, 132], ["oxygen", "CHEMICAL", 250, 256], ["lung failure", "DISEASE", 274, 286], ["tissue damage", "DISEASE", 477, 490], ["oxygen", "CHEMICAL", 250, 256], ["pericytes", "CELL", 18, 27], ["myocardial", "MULTI-TISSUE_STRUCTURE", 59, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["cardiac", "ORGAN", 160, 167], ["patients", "ORGANISM", 209, 217], ["oxygen", "SIMPLE_CHEMICAL", 250, 256], ["lung", "ORGAN", 274, 278], ["ACE2", "GENE_OR_GENE_PRODUCT", 300, 304], ["cellular", "CELL", 354, 362], ["ACE2", "GENE_OR_GENE_PRODUCT", 363, 367], ["cells", "CELL", 401, 406], ["CoV-2", "GENE_OR_GENE_PRODUCT", 415, 420], ["AT1R", "GENE_OR_GENE_PRODUCT", 456, 460], ["tissue", "TISSUE", 477, 483], ["pericytes", "CELL_TYPE", 18, 27], ["ACE2", "PROTEIN", 300, 304], ["ACE2", "PROTEIN", 363, 367], ["AT1R", "PROTEIN", 456, 460], ["patients", "SPECIES", 209, 217], ["SARS CoV", "SPECIES", 410, 418], ["pericytes", "PROBLEM", 18, 27], ["myocardial microcirculation", "TEST", 59, 86], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["microcirculation disorder", "PROBLEM", 107, 132], ["the frequent cardiac marker increase", "PROBLEM", 147, 183], ["the reduced oxygen supply", "TREATMENT", 238, 263], ["lung failure", "PROBLEM", 274, 286], ["ACE2", "TEST", 300, 304], ["Infection", "PROBLEM", 319, 328], ["a decrease in cellular ACE2", "PROBLEM", 340, 367], ["the susceptibility of cells", "PROBLEM", 379, 406], ["SARS CoV", "TEST", 410, 418], ["AT1R", "PROBLEM", 456, 460], ["more severe tissue damage", "PROBLEM", 465, 490], ["myocardial microcirculation", "ANATOMY", 59, 86], ["increase", "OBSERVATION_MODIFIER", 175, 183], ["reduced", "OBSERVATION_MODIFIER", 242, 249], ["oxygen supply", "OBSERVATION", 250, 263], ["lung", "ANATOMY", 274, 278], ["failure", "OBSERVATION", 279, 286], ["Infection", "OBSERVATION", 319, 328], ["decrease", "OBSERVATION_MODIFIER", 342, 350], ["more severe", "OBSERVATION_MODIFIER", 465, 476], ["tissue", "OBSERVATION_MODIFIER", 477, 483], ["damage", "OBSERVATION", 484, 490]]], ["In contrast, the higher the abundance of ACE2 on the cell membrane, the greater the susceptibility to viral particles but the less the damage, due to less AT1R activation occurring.", [["cell membrane", "ANATOMY", 53, 66], ["ACE2", "GENE_OR_GENE_PRODUCT", 41, 45], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["AT1R", "GENE_OR_GENE_PRODUCT", 155, 159], ["ACE2", "PROTEIN", 41, 45], ["AT1R", "PROTEIN", 155, 159], ["the cell membrane", "TREATMENT", 49, 66], ["viral particles", "PROBLEM", 102, 117], ["the damage", "PROBLEM", 131, 141], ["less AT1R activation", "PROBLEM", 150, 170], ["higher", "OBSERVATION_MODIFIER", 17, 23], ["abundance", "OBSERVATION_MODIFIER", 28, 37], ["cell membrane", "OBSERVATION", 53, 66], ["greater", "OBSERVATION_MODIFIER", 72, 79], ["viral particles", "OBSERVATION_MODIFIER", 102, 117]]], ["This latter condition is the one provoked by ACEi/ARB treatment.", [["ACEi", "CHEMICAL", 45, 49], ["ARB", "CHEMICAL", 50, 53], ["ACEi", "SIMPLE_CHEMICAL", 45, 49], ["ARB", "SIMPLE_CHEMICAL", 50, 53], ["ACEi", "TREATMENT", 45, 49], ["ARB treatment", "TREATMENT", 50, 63]]], ["On the one hand, ACE2 increase under ARB/ACEi treatment could be protective during COVID-19 because some ACE2 remains free to degrade ANGII, but on the other hand, this ACE2 increase could be deleterious by favoring cellular infection by COVID-19, leading to potent myocarditis (Figure 1C).", [["cellular", "ANATOMY", 216, 224], ["ARB", "CHEMICAL", 37, 40], ["ACEi", "CHEMICAL", 41, 45], ["infection", "DISEASE", 225, 234], ["COVID-19", "CHEMICAL", 238, 246], ["myocarditis", "DISEASE", 266, 277], ["COVID-19", "CHEMICAL", 83, 91], ["COVID-19", "CHEMICAL", 238, 246], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["ARB", "SIMPLE_CHEMICAL", 37, 40], ["ACEi", "SIMPLE_CHEMICAL", 41, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["ANGII", "GENE_OR_GENE_PRODUCT", 134, 139], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["cellular", "CELL", 216, 224], ["ACE2", "PROTEIN", 17, 21], ["ACE2", "PROTEIN", 105, 109], ["ANGII", "PROTEIN", 134, 139], ["ACE2", "PROTEIN", 169, 173], ["ARB", "TREATMENT", 37, 40], ["ACEi treatment", "TREATMENT", 41, 55], ["COVID", "TEST", 83, 88], ["some ACE2", "PROBLEM", 100, 109], ["this ACE2 increase", "PROBLEM", 164, 182], ["cellular infection", "PROBLEM", 216, 234], ["COVID", "TEST", 238, 243], ["potent myocarditis", "PROBLEM", 259, 277], ["ANGII", "OBSERVATION", 134, 139], ["cellular", "OBSERVATION_MODIFIER", 216, 224], ["infection", "OBSERVATION", 225, 234], ["potent", "OBSERVATION_MODIFIER", 259, 265], ["myocarditis", "OBSERVATION", 266, 277]]], ["The protective or deleterious role of ACEi/ARB in COVID-19 is harder to modelize, as ACE2 is not the only protein required for SARS-COV-2 penetration (5).Are ACEI and ARB Deleterious in SARS-COV-2 Infection?It has been shown that both ACEi and ARB upregulates ACE2, and a hypothesis was proposed by several authors of a potential deleterious effect of treatment with ARB and ACEi in the course of SARS-CoV-2 infection (32, 33).", [["ACEi", "CHEMICAL", 38, 42], ["ARB", "CHEMICAL", 43, 46], ["COVID-19", "CHEMICAL", 50, 58], ["ACEI", "CHEMICAL", 158, 162], ["ARB", "CHEMICAL", 167, 170], ["ACEi", "CHEMICAL", 235, 239], ["ARB", "CHEMICAL", 244, 247], ["ARB", "CHEMICAL", 367, 370], ["ACEi", "CHEMICAL", 375, 379], ["SARS-CoV-2 infection", "DISEASE", 397, 417], ["ACEi", "SIMPLE_CHEMICAL", 38, 42], ["ARB", "SIMPLE_CHEMICAL", 43, 46], ["COVID-19", "GENE_OR_GENE_PRODUCT", 50, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["COV-2", "GENE_OR_GENE_PRODUCT", 132, 137], ["ARB", "SIMPLE_CHEMICAL", 167, 170], ["ACEi", "SIMPLE_CHEMICAL", 235, 239], ["ARB", "SIMPLE_CHEMICAL", 244, 247], ["ACE2", "GENE_OR_GENE_PRODUCT", 260, 264], ["ARB", "SIMPLE_CHEMICAL", 367, 370], ["ACEi", "SIMPLE_CHEMICAL", 375, 379], ["SARS-CoV-2", "ORGANISM", 397, 407], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 260, 264], ["SARS-CoV-2", "SPECIES", 397, 407], ["ACEi", "TREATMENT", 38, 42], ["ARB in COVID", "TREATMENT", 43, 55], ["ACE2", "TEST", 85, 89], ["SARS", "PROBLEM", 127, 131], ["ACEI", "TREATMENT", 158, 162], ["ARB", "TREATMENT", 167, 170], ["Infection", "PROBLEM", 197, 206], ["both ACEi", "TREATMENT", 230, 239], ["ARB upregulates ACE2", "TREATMENT", 244, 264], ["treatment", "TREATMENT", 352, 361], ["ARB", "TREATMENT", 367, 370], ["ACEi", "TREATMENT", 375, 379], ["SARS", "PROBLEM", 397, 401], ["CoV-2 infection", "PROBLEM", 402, 417], ["Infection", "OBSERVATION", 197, 206], ["infection", "OBSERVATION", 408, 417]]], ["Since these molecules are widely used to treat hypertension or heart failure, such a fact could be a huge matter of concern.Are ACEI and ARB Deleterious in SARS-COV-2 Infection?Obesity seems to be a major determinant of adverse outcome in COVID-19 (34).", [["heart", "ANATOMY", 63, 68], ["hypertension", "DISEASE", 47, 59], ["heart failure", "DISEASE", 63, 76], ["ACEI", "CHEMICAL", 128, 132], ["ARB", "CHEMICAL", 137, 140], ["SARS", "DISEASE", 156, 160], ["Obesity", "DISEASE", 177, 184], ["heart", "ORGAN", 63, 68], ["ARB", "SIMPLE_CHEMICAL", 137, 140], ["hypertension", "PROBLEM", 47, 59], ["heart failure", "PROBLEM", 63, 76], ["ACEI", "TREATMENT", 128, 132], ["ARB", "TREATMENT", 137, 140], ["SARS", "PROBLEM", 156, 160], ["COV", "PROBLEM", 161, 164], ["Infection", "PROBLEM", 167, 176], ["Obesity", "PROBLEM", 177, 184], ["COVID", "TEST", 239, 244], ["molecules", "OBSERVATION", 12, 21], ["hypertension", "OBSERVATION", 47, 59], ["heart", "ANATOMY", 63, 68], ["failure", "OBSERVATION", 69, 76], ["huge", "OBSERVATION_MODIFIER", 101, 105], ["matter", "OBSERVATION", 106, 112], ["Infection", "OBSERVATION", 167, 176]]], ["Besides the altered pulmonary function associated with obesity, it must be noted that obesity is associated with a decrease in membranous ACE2 (35, 36).", [["pulmonary", "ANATOMY", 20, 29], ["membranous", "ANATOMY", 127, 137], ["obesity", "DISEASE", 55, 62], ["obesity", "DISEASE", 86, 93], ["pulmonary", "ORGAN", 20, 29], ["ACE2", "GENE_OR_GENE_PRODUCT", 138, 142], ["ACE2", "PROTEIN", 138, 142], ["the altered pulmonary function", "PROBLEM", 8, 38], ["obesity", "PROBLEM", 55, 62], ["obesity", "PROBLEM", 86, 93], ["a decrease in membranous ACE2", "PROBLEM", 113, 142], ["altered", "OBSERVATION_MODIFIER", 12, 19], ["pulmonary", "ANATOMY", 20, 29], ["obesity", "OBSERVATION", 55, 62], ["obesity", "OBSERVATION", 86, 93], ["decrease", "OBSERVATION_MODIFIER", 115, 123], ["membranous ACE2", "OBSERVATION", 127, 142]]], ["Moreover, empirical observations are suggestive of an abnormally high prevalence of pulmonary embolism in patients with COVID-19 (37), and prophylactic curative anticoagulation is recommended in severe patients (38).", [["pulmonary", "ANATOMY", 84, 93], ["pulmonary embolism", "DISEASE", 84, 102], ["pulmonary", "ORGAN", 84, 93], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 202, 210], ["empirical observations", "TEST", 10, 32], ["pulmonary embolism", "PROBLEM", 84, 102], ["COVID", "TEST", 120, 125], ["prophylactic curative anticoagulation", "TREATMENT", 139, 176], ["suggestive of", "UNCERTAINTY", 37, 50], ["abnormally", "OBSERVATION_MODIFIER", 54, 64], ["high", "OBSERVATION_MODIFIER", 65, 69], ["pulmonary", "ANATOMY", 84, 93], ["embolism", "OBSERVATION", 94, 102]]], ["Severe infections are a known precipitant factor for acute venous thrombo-embolism because of epithelial damage and platelet and endothelial cell dysfunction, but does it by itself explain the observed high prevalence of pulmonary embolism in these patients?", [["venous", "ANATOMY", 59, 65], ["epithelial", "ANATOMY", 94, 104], ["platelet", "ANATOMY", 116, 124], ["endothelial cell", "ANATOMY", 129, 145], ["pulmonary", "ANATOMY", 221, 230], ["infections", "DISEASE", 7, 17], ["acute venous thrombo-embolism", "DISEASE", 53, 82], ["pulmonary embolism", "DISEASE", 221, 239], ["epithelial", "TISSUE", 94, 104], ["platelet", "CELL", 116, 124], ["endothelial cell", "CELL", 129, 145], ["pulmonary", "ORGAN", 221, 230], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["Severe infections", "PROBLEM", 0, 17], ["acute venous thrombo-embolism", "PROBLEM", 53, 82], ["epithelial damage", "PROBLEM", 94, 111], ["platelet and endothelial cell dysfunction", "PROBLEM", 116, 157], ["pulmonary embolism", "PROBLEM", 221, 239], ["infections", "OBSERVATION", 7, 17], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["venous", "ANATOMY", 59, 65], ["thrombo-embolism", "OBSERVATION", 66, 82], ["epithelial", "ANATOMY_MODIFIER", 94, 104], ["damage", "OBSERVATION", 105, 111], ["platelet", "OBSERVATION_MODIFIER", 116, 124], ["endothelial cell dysfunction", "OBSERVATION", 129, 157], ["pulmonary", "ANATOMY", 221, 230], ["embolism", "OBSERVATION", 231, 239]]], ["When ANGII is increased, it can be metabolized to angiotensin IV (ANGIV) by aminopeptidase A and binds to Angiotensin Type 4 Receptor (AT4R) (39).", [["angiotensin IV", "CHEMICAL", 50, 64], ["Angiotensin", "CHEMICAL", 106, 117], ["angiotensin IV", "GENE_OR_GENE_PRODUCT", 50, 64], ["ANGIV", "GENE_OR_GENE_PRODUCT", 66, 71], ["aminopeptidase A", "GENE_OR_GENE_PRODUCT", 76, 92], ["Angiotensin Type 4 Receptor", "GENE_OR_GENE_PRODUCT", 106, 133], ["AT4R", "GENE_OR_GENE_PRODUCT", 135, 139], ["ANGII", "PROTEIN", 5, 10], ["angiotensin IV", "PROTEIN", 50, 64], ["ANGIV", "PROTEIN", 66, 71], ["aminopeptidase A", "PROTEIN", 76, 92], ["Angiotensin Type 4 Receptor", "PROTEIN", 106, 133], ["AT4R", "PROTEIN", 135, 139], ["angiotensin IV (ANGIV)", "TREATMENT", 50, 72], ["aminopeptidase A and binds to Angiotensin Type 4 Receptor (AT4R)", "TREATMENT", 76, 140], ["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["Multiple datasets underline the enhancement of thrombosis development by ANGII and ANGIV (40, 41), and it can be hypothesized that a reduction in ACE2 can increase thrombotic risk.Are ACEI and ARB Deleterious in SARS-COV-2 Infection?Despite the many potential cofounders, reduction in membranous ACE2 expression could be an explanation for numerous abnormalities observed in SARS-CoV-2 infection.", [["membranous", "ANATOMY", 285, 295], ["thrombosis", "DISEASE", 47, 57], ["thrombotic", "DISEASE", 164, 174], ["ACEI", "CHEMICAL", 184, 188], ["ARB", "CHEMICAL", 193, 196], ["SARS", "DISEASE", 212, 216], ["SARS-CoV-2 infection", "DISEASE", 375, 395], ["ACE2", "GENE_OR_GENE_PRODUCT", 146, 150], ["ARB", "SIMPLE_CHEMICAL", 193, 196], ["ACE2", "GENE_OR_GENE_PRODUCT", 296, 300], ["SARS-CoV-2", "ORGANISM", 375, 385], ["ACE2", "PROTEIN", 146, 150], ["ACE2", "PROTEIN", 296, 300], ["SARS-CoV", "SPECIES", 375, 383], ["thrombosis development", "PROBLEM", 47, 69], ["ANGII", "TEST", 73, 78], ["ANGIV", "TEST", 83, 88], ["a reduction in ACE2", "PROBLEM", 131, 150], ["thrombotic risk", "PROBLEM", 164, 179], ["ACEI", "TREATMENT", 184, 188], ["ARB", "TREATMENT", 193, 196], ["SARS", "PROBLEM", 212, 216], ["COV", "PROBLEM", 217, 220], ["Infection", "PROBLEM", 223, 232], ["membranous ACE2 expression", "PROBLEM", 285, 311], ["numerous abnormalities", "PROBLEM", 340, 362], ["SARS", "PROBLEM", 375, 379], ["CoV-2 infection", "PROBLEM", 380, 395], ["enhancement", "OBSERVATION_MODIFIER", 32, 43], ["thrombosis", "OBSERVATION", 47, 57], ["ANGII", "OBSERVATION_MODIFIER", 73, 78], ["reduction", "OBSERVATION_MODIFIER", 133, 142], ["Infection", "OBSERVATION", 223, 232], ["reduction", "OBSERVATION_MODIFIER", 272, 281], ["membranous ACE2 expression", "OBSERVATION", 285, 311], ["infection", "OBSERVATION", 386, 395]]], ["Thus, even if both ARB and ACEi increase the level of ACE2, more ACE2 could be better rather than worse: more ACE2 remains on the cell surface after virus binding, maintaining ANGII degradation and less stimulation of AT1R.", [["cell surface", "ANATOMY", 130, 142], ["ARB", "CHEMICAL", 19, 22], ["ACEi", "CHEMICAL", 27, 31], ["ARB", "SIMPLE_CHEMICAL", 19, 22], ["ACEi", "SIMPLE_CHEMICAL", 27, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["cell surface", "CELLULAR_COMPONENT", 130, 142], ["ANGII", "GENE_OR_GENE_PRODUCT", 176, 181], ["AT1R", "GENE_OR_GENE_PRODUCT", 218, 222], ["ACE2", "PROTEIN", 54, 58], ["ACE2", "PROTEIN", 65, 69], ["ACE2", "PROTEIN", 110, 114], ["ANGII", "PROTEIN", 176, 181], ["AT1R", "PROTEIN", 218, 222], ["ARB", "TREATMENT", 19, 22], ["ACEi", "TREATMENT", 27, 31], ["ACE2", "TEST", 54, 58], ["the cell surface", "TREATMENT", 126, 142], ["virus binding", "PROBLEM", 149, 162], ["ANGII degradation", "TREATMENT", 176, 193], ["less stimulation of AT1R", "TREATMENT", 198, 222], ["ANGII degradation", "OBSERVATION", 176, 193]]], ["Furthermore, treatment with ARB inhibits AT1R and limits the damage induced by its overstimulation.", [["ARB", "CHEMICAL", 28, 31], ["ARB", "CHEMICAL", 28, 31], ["ARB", "SIMPLE_CHEMICAL", 28, 31], ["AT1R", "GENE_OR_GENE_PRODUCT", 41, 45], ["AT1R", "PROTEIN", 41, 45], ["treatment", "TREATMENT", 13, 22], ["ARB", "TREATMENT", 28, 31], ["AT1R", "TREATMENT", 41, 45], ["the damage", "PROBLEM", 57, 67], ["its overstimulation", "PROBLEM", 79, 98]]], ["It is not clear whether continuation or discontinuation of ARB or ACEi is a good option in COVID-19 infection, as there is a lack of clinical data to support an increased risk of contracting a severe form of COVID-19.", [["ARB", "CHEMICAL", 59, 62], ["ACEi", "CHEMICAL", 66, 70], ["infection", "DISEASE", 100, 109], ["COVID-19", "CHEMICAL", 208, 216], ["ARB", "SIMPLE_CHEMICAL", 59, 62], ["ACEi", "SIMPLE_CHEMICAL", 66, 70], ["COVID-19", "ORGANISM", 91, 99], ["COVID-19", "SPECIES", 91, 99], ["ARB", "TREATMENT", 59, 62], ["ACEi", "TREATMENT", 66, 70], ["COVID-19 infection", "PROBLEM", 91, 109], ["clinical data", "TEST", 133, 146], ["COVID", "TEST", 208, 213], ["infection", "OBSERVATION", 100, 109]]], ["In addition, we do not even know whether renin angiotensin system inhibitor therapy is beneficial or harmful for virally mediated lesions, and switching to other drugs may worsen the patient's condition, especially for heart failure patients with reduced ejection fraction (42).", [["lesions", "ANATOMY", 130, 137], ["heart", "ANATOMY", 219, 224], ["angiotensin", "CHEMICAL", 47, 58], ["heart failure", "DISEASE", 219, 232], ["renin angiotensin", "GENE_OR_GENE_PRODUCT", 41, 58], ["lesions", "PATHOLOGICAL_FORMATION", 130, 137], ["patient", "ORGANISM", 183, 190], ["heart", "ORGAN", 219, 224], ["patients", "ORGANISM", 233, 241], ["patient", "SPECIES", 183, 190], ["patients", "SPECIES", 233, 241], ["renin angiotensin system inhibitor therapy", "TREATMENT", 41, 83], ["virally mediated lesions", "PROBLEM", 113, 137], ["other drugs", "TREATMENT", 156, 167], ["the patient's condition", "PROBLEM", 179, 202], ["heart failure", "PROBLEM", 219, 232], ["reduced ejection fraction", "PROBLEM", 247, 272], ["lesions", "OBSERVATION", 130, 137], ["heart", "ANATOMY", 219, 224], ["failure", "OBSERVATION", 225, 232]]], ["Clinical trials are ongoing to analyze the beneficial effect of LOSARTAN in COVID-19 (NCT04311177 and NCT04312009), and a trial will start soon to analyze the consequences of discontinuation or continuation of ACEi/ARB (NCT04338009).Are ACEI and ARB Deleterious in SARS-COV-2 Infection?ACEi and ARB are not the only treatments for hypertension or heart failure, but other classes only have a limited impact on ACE2.", [["heart", "ANATOMY", 347, 352], ["ACEi", "CHEMICAL", 210, 214], ["ARB", "CHEMICAL", 215, 218], ["ACEI", "CHEMICAL", 237, 241], ["ARB", "CHEMICAL", 246, 249], ["SARS", "DISEASE", 265, 269], ["ACEi", "CHEMICAL", 286, 290], ["ARB", "CHEMICAL", 295, 298], ["hypertension", "DISEASE", 331, 343], ["heart failure", "DISEASE", 347, 360], ["COVID-19", "CHEMICAL", 76, 84], ["ACEi", "SIMPLE_CHEMICAL", 210, 214], ["ARB", "SIMPLE_CHEMICAL", 215, 218], ["ARB", "SIMPLE_CHEMICAL", 246, 249], ["ACEi", "SIMPLE_CHEMICAL", 286, 290], ["ARB", "SIMPLE_CHEMICAL", 295, 298], ["heart", "ORGAN", 347, 352], ["ACE2", "GENE_OR_GENE_PRODUCT", 410, 414], ["ACE2", "PROTEIN", 410, 414], ["LOSARTAN", "TREATMENT", 64, 72], ["discontinuation", "TREATMENT", 175, 190], ["ACEi", "TREATMENT", 210, 214], ["ARB", "TREATMENT", 215, 218], ["ACEI", "TREATMENT", 237, 241], ["ARB", "TREATMENT", 246, 249], ["SARS", "PROBLEM", 265, 269], ["COV", "PROBLEM", 270, 273], ["Infection", "PROBLEM", 276, 285], ["ACEi", "TREATMENT", 286, 290], ["ARB", "TREATMENT", 295, 298], ["hypertension", "PROBLEM", 331, 343], ["heart failure", "PROBLEM", 347, 360], ["Infection", "OBSERVATION", 276, 285], ["hypertension", "OBSERVATION", 331, 343], ["heart", "ANATOMY", 347, 352], ["failure", "OBSERVATION", 353, 360]]], ["Beta blockers suppress plasma angiotensin II levels by inhibiting prorenin processing to renin and probably do not interfere with ACE or ACE2 (43).", [["plasma", "ANATOMY", 23, 29], ["angiotensin II", "CHEMICAL", 30, 44], ["Beta blockers", "GENE_OR_GENE_PRODUCT", 0, 13], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 30, 44], ["prorenin", "GENE_OR_GENE_PRODUCT", 66, 74], ["renin", "GENE_OR_GENE_PRODUCT", 89, 94], ["ACE", "GENE_OR_GENE_PRODUCT", 130, 133], ["ACE2", "GENE_OR_GENE_PRODUCT", 137, 141], ["plasma angiotensin II", "PROTEIN", 23, 44], ["prorenin", "PROTEIN", 66, 74], ["renin", "PROTEIN", 89, 94], ["ACE", "PROTEIN", 130, 133], ["ACE2", "PROTEIN", 137, 141], ["Beta blockers", "TREATMENT", 0, 13], ["plasma angiotensin II levels", "TREATMENT", 23, 51], ["renin", "TEST", 89, 94], ["ACE or ACE2", "TREATMENT", 130, 141]]], ["Calcium channel blockers seem to reduce ANGII-induced downregulation of ACE2, but data are limited to those presented in one paper on the effect of nifedipine on fractionated cell extracts (44).", [["cell extracts", "ANATOMY", 175, 188], ["Calcium", "CHEMICAL", 0, 7], ["ANGII", "CHEMICAL", 40, 45], ["nifedipine", "CHEMICAL", 148, 158], ["Calcium", "CHEMICAL", 0, 7], ["nifedipine", "CHEMICAL", 148, 158], ["Calcium channel blockers", "SIMPLE_CHEMICAL", 0, 24], ["ANGII", "SIMPLE_CHEMICAL", 40, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["nifedipine", "SIMPLE_CHEMICAL", 148, 158], ["cell extracts", "ORGANISM_SUBSTANCE", 175, 188], ["ANGII", "PROTEIN", 40, 45], ["ACE2", "PROTEIN", 72, 76], ["Calcium channel blockers", "TREATMENT", 0, 24], ["ANGII", "TEST", 40, 45], ["downregulation of ACE2", "PROBLEM", 54, 76], ["nifedipine", "TREATMENT", 148, 158], ["fractionated cell extracts", "TREATMENT", 162, 188]]], ["In hypertensive rats, neither thiazides nor mineralocorticoid-receptor antagonists (MRAs) improve the spontaneous low ACE2 activity (18, 45), but MRA could decrease ACE expression (18).", [["hypertensive", "DISEASE", 3, 15], ["thiazides", "CHEMICAL", 30, 39], ["thiazides", "CHEMICAL", 30, 39], ["rats", "ORGANISM", 16, 20], ["thiazides", "SIMPLE_CHEMICAL", 30, 39], ["mineralocorticoid-receptor antagonists", "GENE_OR_GENE_PRODUCT", 44, 82], ["MRAs", "SIMPLE_CHEMICAL", 84, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 118, 122], ["ACE", "GENE_OR_GENE_PRODUCT", 165, 168], ["ACE2", "PROTEIN", 118, 122], ["ACE", "PROTEIN", 165, 168], ["rats", "SPECIES", 16, 20], ["hypertensive rats", "PROBLEM", 3, 20], ["thiazides", "TREATMENT", 30, 39], ["mineralocorticoid-receptor antagonists", "TREATMENT", 44, 82], ["MRAs", "TEST", 84, 88], ["the spontaneous low ACE2 activity", "PROBLEM", 98, 131], ["MRA", "TEST", 146, 149], ["ACE expression", "TEST", 165, 179]]], ["Conversely, MRAs increase membranous ACE2 activity in patients (46) with heart failure.", [["membranous", "ANATOMY", 26, 36], ["heart", "ANATOMY", 73, 78], ["heart failure", "DISEASE", 73, 86], ["MRAs", "SIMPLE_CHEMICAL", 12, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["patients", "ORGANISM", 54, 62], ["heart", "ORGAN", 73, 78], ["MRAs", "PROTEIN", 12, 16], ["ACE2", "PROTEIN", 37, 41], ["patients", "SPECIES", 54, 62], ["MRAs", "TEST", 12, 16], ["membranous ACE2 activity", "PROBLEM", 26, 50], ["heart failure", "PROBLEM", 73, 86], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["membranous", "OBSERVATION_MODIFIER", 26, 36], ["ACE2 activity", "OBSERVATION", 37, 50], ["heart", "ANATOMY", 73, 78], ["failure", "OBSERVATION", 79, 86]]], ["If the reduction of membranous ACE2 observed in hypertension and obesity plays an important role in the pathophysiology of severe COVID-19, can it be hypothesized that non-ACEi/BRA drugs (beta-blockers, calcium channel blockers, diuretics) are more likely to increase the risk of deleterious outcomes than ACEi/BRA drugs that increase ACE2 and provide theoretical protection?", [["hypertension", "DISEASE", 48, 60], ["obesity", "DISEASE", 65, 72], ["COVID", "DISEASE", 130, 135], ["calcium", "CHEMICAL", 203, 210], ["ACEi", "CHEMICAL", 306, 310], ["COVID-19", "CHEMICAL", 130, 138], ["calcium", "CHEMICAL", 203, 210], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["non-ACEi", "SIMPLE_CHEMICAL", 168, 176], ["BRA drugs", "SIMPLE_CHEMICAL", 177, 186], ["beta-blockers", "SIMPLE_CHEMICAL", 188, 201], ["calcium channel blockers", "SIMPLE_CHEMICAL", 203, 227], ["diuretics", "SIMPLE_CHEMICAL", 229, 238], ["ACEi", "SIMPLE_CHEMICAL", 306, 310], ["BRA", "SIMPLE_CHEMICAL", 311, 314], ["ACE2", "GENE_OR_GENE_PRODUCT", 335, 339], ["membranous ACE2", "PROTEIN", 20, 35], ["ACE2", "PROTEIN", 335, 339], ["membranous ACE2", "PROBLEM", 20, 35], ["hypertension", "PROBLEM", 48, 60], ["obesity", "PROBLEM", 65, 72], ["severe COVID", "PROBLEM", 123, 135], ["non-ACEi/BRA drugs", "TREATMENT", 168, 186], ["beta-blockers", "TREATMENT", 188, 201], ["calcium channel blockers", "TREATMENT", 203, 227], ["diuretics", "TREATMENT", 229, 238], ["deleterious outcomes", "PROBLEM", 280, 300], ["ACEi/BRA drugs", "TREATMENT", 306, 320], ["ACE2", "TREATMENT", 335, 339], ["theoretical protection", "TREATMENT", 352, 374], ["reduction", "OBSERVATION_MODIFIER", 7, 16], ["membranous ACE2", "OBSERVATION", 20, 35], ["hypertension", "OBSERVATION", 48, 60], ["obesity", "OBSERVATION", 65, 72]]], ["Data on baseline treatments are urgently needed but are lacking to date in published cohorts.ConclusionThe downregulation of ACE2 induced by viral binding, resulting in increased stimulation of AT1R, may be an important element in explaining severe COVID-19.", [["COVID-19", "CHEMICAL", 249, 257], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["AT1R", "GENE_OR_GENE_PRODUCT", 194, 198], ["ACE2", "PROTEIN", 125, 129], ["AT1R", "PROTEIN", 194, 198], ["baseline treatments", "TREATMENT", 8, 27], ["ACE2", "PROBLEM", 125, 129], ["viral binding", "PROBLEM", 141, 154], ["increased stimulation of AT1R", "PROBLEM", 169, 198], ["severe COVID", "PROBLEM", 242, 254], ["viral binding", "OBSERVATION", 141, 154], ["increased", "OBSERVATION_MODIFIER", 169, 178]]], ["Overall, the ACEi/ARB-mediated increase in ACE2 is not obviously deleterious and may even be protective.", [["ACEi", "CHEMICAL", 13, 17], ["ARB", "CHEMICAL", 18, 21], ["ACEi", "SIMPLE_CHEMICAL", 13, 17], ["ARB", "SIMPLE_CHEMICAL", 18, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["ACE2", "PROTEIN", 43, 47], ["the ACEi", "TEST", 9, 17], ["ARB", "TREATMENT", 18, 21], ["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["To date, stopping this treatment solely on the basis of presumed considerations does not seem to be a good option.Author ContributionsMR and FZ wrote the manuscript, conceptualized the idea, and made the figure.", [["MR", "PROTEIN", 134, 136], ["this treatment", "TREATMENT", 18, 32]]]], "daff6ac7ece180dfb53e12fbaf8a1902f1a31d83": [["Nosocomial infections is among the most important causes of morbidity, prolonged hospital stay, increased hospital costs, and mortality in neonates, particularly those born preterm.", [["Nosocomial infections", "DISEASE", 0, 21], ["neonates", "ORGANISM", 139, 147], ["Nosocomial infections", "PROBLEM", 0, 21], ["infections", "OBSERVATION", 11, 21], ["morbidity", "OBSERVATION", 60, 69]]], ["Infants admitted to neonatal intensive care units (NICUs) are at particularly high risk for exposure to infection during their hospital stay because of their vulnerable condition and the presence of pathogens resistant to common antibiotics in NICUs.", [["infection", "DISEASE", 104, 113], ["Infants", "SPECIES", 0, 7], ["infection", "PROBLEM", 104, 113], ["their vulnerable condition", "PROBLEM", 152, 178], ["pathogens", "PROBLEM", 199, 208], ["common antibiotics", "TREATMENT", 222, 240], ["infection", "OBSERVATION", 104, 113]]]], "c1ee5df27248e018720541fbc745ccb373db171e": [["SARS-CoV-2 antibodies.", [["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 0, 21], ["SARS-CoV-2 antibodies", "PROTEIN", 0, 21], ["SARS-CoV", "TEST", 0, 8]]], ["This study was performed with: (i) a positive panel constituted of 88 SARS-CoV-2 specimens collected from patients with a positive SARS-CoV-2 RT-PCR, , in particular patients presenting strong COVID-19 suspicions with negative PCR.", [["specimens", "ANATOMY", 81, 90], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 166, 174], ["This study", "TEST", 0, 10], ["a positive panel", "TEST", 35, 51], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["specimens", "TEST", 81, 90], ["a positive SARS", "PROBLEM", 120, 135], ["CoV", "TEST", 136, 139], ["RT-PCR", "TEST", 142, 148]]], ["Serological tests also make it possible to catch up later with undiagnosed people at time of active infection, since antibodies have been found in almost all people who have been in contact with SARS-CoV-2 within a variable period depending on the severity of the infection [1, 2] .", [["infection", "DISEASE", 100, 109], ["SARS", "DISEASE", 195, 199], ["infection", "DISEASE", 264, 273], ["people", "ORGANISM", 75, 81], ["people", "ORGANISM", 158, 164], ["SARS-CoV-2", "ORGANISM", 195, 205], ["antibodies", "PROTEIN", 117, 127], ["people", "SPECIES", 75, 81], ["people", "SPECIES", 158, 164], ["SARS-CoV", "SPECIES", 195, 203], ["Serological tests", "TEST", 0, 17], ["active infection", "PROBLEM", 93, 109], ["the infection", "PROBLEM", 260, 273], ["active", "OBSERVATION_MODIFIER", 93, 99], ["infection", "OBSERVATION", 100, 109], ["infection", "OBSERVATION", 264, 273]]], ["Furthermore, studies showed that the kinetics of appearance of IgM and IgG were relatively close [3] .", [["IgM", "GENE_OR_GENE_PRODUCT", 63, 66], ["IgG", "GENE_OR_GENE_PRODUCT", 71, 74], ["IgM", "PROTEIN", 63, 66], ["IgG", "PROTEIN", 71, 74], ["studies", "TEST", 13, 20], ["IgM", "TEST", 63, 66], ["IgG", "TEST", 71, 74]]]], "PMC3557894": [["Virus and Animals ::: MethodsThe YN strain was isolated in 2005 from 30-day-old broilers that had been inoculated oculonasally with H120 vaccines of IBV on days 1, 7, and 21, respectively.", [["YN strain", "ANATOMY", 33, 42], ["Virus", "ORGANISM", 0, 5], ["YN strain", "CELL", 33, 42], ["broilers", "ORGANISM", 80, 88], ["IBV", "ORGANISM", 149, 152], ["broilers", "SPECIES", 80, 88], ["H120", "SPECIES", 132, 136], ["IBV", "SPECIES", 149, 152], ["Methods", "TREATMENT", 22, 29], ["The YN strain", "PROBLEM", 29, 42], ["H120 vaccines", "TREATMENT", 132, 145], ["IBV", "TREATMENT", 149, 152]]], ["The sick birds had respiratory signs, severe renal disease, and a death rate of 30%.", [["respiratory", "ANATOMY", 19, 30], ["renal", "ANATOMY", 45, 50], ["respiratory signs", "DISEASE", 19, 36], ["renal disease", "DISEASE", 45, 58], ["death", "DISEASE", 66, 71], ["birds", "ORGANISM", 9, 14], ["renal", "ORGAN", 45, 50], ["respiratory signs", "PROBLEM", 19, 36], ["severe renal disease", "PROBLEM", 38, 58], ["a death rate", "TEST", 64, 76], ["respiratory signs", "OBSERVATION", 19, 36], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["renal", "ANATOMY", 45, 50], ["disease", "OBSERVATION", 51, 58]]], ["The virus was propagated in 10-day-old specific-pathogen\u2013free (SPF) embryonated chicken eggs at 37\u00b0C for 40 h.", [["eggs", "ANATOMY", 88, 92], ["SPF", "ORGANISM", 63, 66], ["chicken", "ORGANISM", 80, 87], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 88, 92], ["chicken", "SPECIES", 80, 87], ["chicken", "SPECIES", 80, 87], ["The virus", "PROBLEM", 0, 9], ["pathogen\u2013free (SPF", "TREATMENT", 48, 66], ["embryonated chicken eggs", "TREATMENT", 68, 92], ["virus", "OBSERVATION", 4, 9]]], ["Allantoic fluid was recovered from infected eggs and stored at \u221280\u00b0C. All animal research was approved by the Beijing Administration Committee of Laboratory Animals under the leadership of the Beijing Association for Science and Technology (approval ID is SYXK [Beijing] 2007\u20130023).Viral RNA Extraction, Reverse Transcription PCR, and DNA Sequencing ::: MethodsOn the basis of IBV nucleotide sequences (M41, A2, BJ, ZJ971, and SC021202; GenBank accession nos.", [["Allantoic fluid", "ANATOMY", 0, 15], ["eggs", "ANATOMY", 44, 48], ["nucleotide", "CHEMICAL", 381, 391], ["nucleotide", "CHEMICAL", 381, 391], ["Allantoic fluid", "ORGANISM_SUBSTANCE", 0, 15], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 44, 48], ["DNA", "CELLULAR_COMPONENT", 335, 338], ["IBV", "ORGANISM", 377, 380], ["Viral RNA", "RNA", 282, 291], ["IBV nucleotide sequences", "DNA", 377, 401], ["A2", "DNA", 408, 410], ["IBV", "SPECIES", 377, 380], ["Allantoic fluid", "TEST", 0, 15], ["infected eggs", "PROBLEM", 35, 48], ["Viral RNA Extraction", "TREATMENT", 282, 302], ["Reverse Transcription PCR", "TEST", 304, 329], ["IBV nucleotide sequences", "TEST", 377, 401], ["A2", "TEST", 408, 410], ["BJ", "TEST", 412, 414], ["ZJ971", "TEST", 416, 421], ["fluid", "OBSERVATION", 10, 15], ["infected eggs", "OBSERVATION", 35, 48], ["BJ", "ANATOMY", 412, 414]]], ["DQ834384, AY043312, AY319651, AF352313, and AY237817, respectively), 22 pairs of specific primers (Table 1) were designed to amplify the complete genome (excluding the 5\u2032- and 3\u2032-terminal segments) of the YN strain.", [["DQ834384", "CHEMICAL", 0, 8], ["5\u2032- and 3\u2032-terminal segments", "DNA", 168, 196], ["the YN strain", "PROBLEM", 201, 214], ["terminal segments", "ANATOMY_MODIFIER", 179, 196]]], ["Viral RNA was extracted from virus-infected allantoic fluid by using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\u2019s instructions.", [["allantoic fluid", "ANATOMY", 44, 59], ["Viral", "ORGANISM", 0, 5], ["allantoic fluid", "ORGANISM_SUBSTANCE", 44, 59], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["virus", "PROBLEM", 29, 34], ["infected allantoic fluid", "TREATMENT", 35, 59], ["Trizol Reagent", "TREATMENT", 69, 83], ["Invitrogen", "TREATMENT", 85, 95], ["RNA", "OBSERVATION", 6, 9], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["allantoic fluid", "OBSERVATION", 44, 59]]], ["Reverse transcription (RT) was performed at 37\u00b0C for 1 h by using 3 \u03bcg total RNA, 1 \u03bcL random primers (500 \u03bcg/mL, random hexadeoxynucleotides; Promega, Madison, WI, USA) and 0.5 \u03bcL M-MLV RT (200 U/\u03bcL) (Promega).", [["3 \u03bcg total RNA", "TREATMENT", 66, 80], ["1 \u03bcL random primers", "TREATMENT", 82, 101], ["MLV RT", "TREATMENT", 183, 189]]], ["For PCR, 1 U Taq DNA Polymerase (Promega) and 10 pmol of each primer were added to 100 ng cDNA as template in a total of 20 \u03bcL reaction volume.", [["DNA", "CELLULAR_COMPONENT", 17, 20], ["Promega", "GENE_OR_GENE_PRODUCT", 33, 40], ["1 U Taq DNA Polymerase", "DNA", 9, 31], ["100 ng cDNA", "DNA", 83, 94], ["PCR", "TEST", 4, 7], ["1 U Taq DNA Polymerase (Promega)", "TREATMENT", 9, 41], ["10 pmol of each primer", "TREATMENT", 46, 68]]], ["PCR was performed at 95\u00b0C for 5 min, followed by 35 cycles of denaturation (95\u00b0C, 45 s), annealing (53\u00b0C or 55\u00b0C, 45 s), and polymerization (72\u00b0C, 2 min), and the postpolymerization step was performed at 72\u00b0C for 10 min.", [["PCR", "TEST", 0, 3], ["denaturation", "TEST", 62, 74], ["annealing", "TEST", 89, 98], ["polymerization", "TEST", 125, 139]]], ["Amplified sequences were analyzed by 1.2% agarose gel electrophoresis.Viral RNA Extraction, Reverse Transcription PCR, and DNA Sequencing ::: MethodsThe amplified DNA products were purified by using an AxyPrep DNA Gel Extraction Kit (AxyGEN, Union City, CA, USA), and the purified products were ligated to the pMD18-T Easy Vector system (Promega).", [["agarose", "SIMPLE_CHEMICAL", 42, 49], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["DNA", "CELLULAR_COMPONENT", 163, 166], ["Viral RNA", "RNA", 70, 79], ["pMD18", "PROTEIN", 310, 315], ["Amplified sequences", "TEST", 0, 19], ["agarose gel electrophoresis", "TEST", 42, 69], ["Viral RNA Extraction", "TREATMENT", 70, 90], ["Reverse Transcription PCR", "TEST", 92, 117], ["Methods", "TREATMENT", 142, 149], ["The amplified DNA products", "TREATMENT", 149, 175], ["an AxyPrep DNA Gel Extraction", "TREATMENT", 199, 228], ["the purified products", "TREATMENT", 268, 289]]], ["Recombinant plasmids were extracted from positive clones by using the E.Z.N.A.R. Plasmid Miniprep Kit (Omega, Norcross, GA, USA) and identified by EcoRI restriction digestion (Promega).", [["plasmids", "ANATOMY", 12, 20], ["clones", "ANATOMY", 50, 56], ["EcoRI", "GENE_OR_GENE_PRODUCT", 147, 152], ["Recombinant plasmids", "DNA", 0, 20], ["Recombinant plasmids", "TREATMENT", 0, 20], ["positive clones", "PROBLEM", 41, 56], ["the E.Z.N.A.R. Plasmid Miniprep Kit (Omega, Norcross", "TREATMENT", 66, 118], ["EcoRI restriction digestion", "TREATMENT", 147, 174], ["plasmids", "OBSERVATION", 12, 20], ["positive clones", "OBSERVATION", 41, 56]]], ["Nucleotide sequencing reactions were performed by Sunbio Biotech (Bejjing, China).Sequence and Phylogenetic Analysis ::: MethodsComplete genome or S1 gene sequences of IBV were obtained from GenBank, and these IBV sequences and the complete coding sequence of the IBV YN isolate were aligned and analyzed by using the ClustalW multiple alignment algorithm in the MegAlign program of the DNASTAR software suite (version 3.1; DNAstar, Madison, WI, USA).Sequence and Phylogenetic Analysis ::: MethodsThe phylogenetic tree of S1 gene or complete genomic sequences was constructed by using MEGA4.0 software (www.megasoftware.net) by the neighbor-joining method (1,000 bootstrap replicates).", [["S1", "GENE_OR_GENE_PRODUCT", 147, 149], ["IBV", "ORGANISM", 168, 171], ["IBV", "ORGANISM", 210, 213], ["IBV", "ORGANISM", 264, 267], ["MethodsComplete genome", "DNA", 121, 143], ["S1 gene sequences", "DNA", 147, 164], ["IBV sequences", "DNA", 210, 223], ["IBV YN isolate", "DNA", 264, 278], ["S1 gene", "DNA", 522, 529], ["genomic sequences", "DNA", 542, 559], ["MEGA4.0 software", "DNA", 585, 601], ["IBV", "SPECIES", 264, 267], ["IBV", "SPECIES", 168, 171], ["IBV", "SPECIES", 210, 213], ["IBV YN", "SPECIES", 264, 270], ["Nucleotide sequencing reactions", "TEST", 0, 31], ["S1 gene sequences", "TEST", 147, 164], ["IBV", "PROBLEM", 168, 171], ["these IBV sequences", "TEST", 204, 223], ["the IBV", "TREATMENT", 260, 267], ["version", "TEST", 411, 418], ["Methods", "TREATMENT", 490, 497], ["tree", "ANATOMY_MODIFIER", 514, 518], ["S1", "ANATOMY", 522, 524]]], ["Evolutionary distances were computed by the pairwise distance method using the maximum composite likelihood model (19).Clinicopathologic Assessment in Chickens ::: MethodsForty 30-day-old SPF white leghorn chickens were randomly divided into 2 groups of 20 birds each.", [["Chickens", "ORGANISM", 151, 159], ["chickens", "ORGANISM", 206, 214], ["birds", "ORGANISM", 257, 262], ["Chickens", "SPECIES", 151, 159], ["chickens", "SPECIES", 206, 214], ["white leghorn chickens", "SPECIES", 192, 214], ["Clinicopathologic Assessment", "TEST", 119, 147], ["MethodsForty", "TEST", 164, 176], ["SPF white leghorn chickens", "TREATMENT", 188, 214]]], ["All birds in 1 group were challenged intranasally with at least 105 50% egg infectious dose per 0.2 mL of IBV YN strain.", [["intranasally", "ANATOMY", 37, 49], ["egg", "ORGANISM", 72, 75], ["IBV", "ORGANISM", 106, 109], ["IBV", "SPECIES", 106, 109], ["IBV YN strain", "PROBLEM", 106, 119]]], ["Birds in another group were inoculated with 0.2 mL phosphate-buffered saline (PBS) as noninfected controls.", [["phosphate", "CHEMICAL", 51, 60], ["phosphate", "CHEMICAL", 51, 60], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 51, 76], ["buffered saline (PBS", "TREATMENT", 61, 81]]], ["Birds were housed in isolators and provided feed and water ad libitum.Clinicopathologic Assessment in Chickens ::: MethodsAll birds were observed daily for signs of disease (e.g., disheveled feathers, depression, respiratory signs, or diarrhea) and death for 21 days.", [["respiratory", "ANATOMY", 213, 224], ["depression", "DISEASE", 201, 211], ["respiratory signs", "DISEASE", 213, 230], ["diarrhea", "DISEASE", 235, 243], ["death", "DISEASE", 249, 254], ["birds", "ORGANISM", 126, 131], ["Chickens", "SPECIES", 102, 110], ["Clinicopathologic Assessment", "TEST", 70, 98], ["disease", "PROBLEM", 165, 172], ["disheveled feathers", "PROBLEM", 180, 199], ["depression", "PROBLEM", 201, 211], ["respiratory signs", "PROBLEM", 213, 230], ["diarrhea", "PROBLEM", 235, 243], ["death", "PROBLEM", 249, 254], ["disease", "OBSERVATION", 165, 172]]], ["Gross pathologic changes were observed, and tissues (trachea, lung, kidney, bursa, liver, and brain) were collected for RT-PCR from 10 randomly selected chickens that died within 4\u201310 days after inoculation, virus isolation, and histopathologic and IHC analyses.", [["tissues", "ANATOMY", 44, 51], ["trachea", "ANATOMY", 53, 60], ["lung", "ANATOMY", 62, 66], ["kidney", "ANATOMY", 68, 74], ["bursa", "ANATOMY", 76, 81], ["liver", "ANATOMY", 83, 88], ["brain", "ANATOMY", 94, 99], ["tissues", "TISSUE", 44, 51], ["trachea", "MULTI-TISSUE_STRUCTURE", 53, 60], ["lung", "ORGAN", 62, 66], ["kidney", "ORGAN", 68, 74], ["bursa", "ORGAN", 76, 81], ["liver", "ORGAN", 83, 88], ["brain", "ORGAN", 94, 99], ["chickens", "ORGANISM", 153, 161], ["chickens", "SPECIES", 153, 161], ["chickens", "SPECIES", 153, 161], ["Gross pathologic changes", "PROBLEM", 0, 24], ["tissues (trachea, lung, kidney, bursa, liver, and brain", "TEST", 44, 99], ["RT-PCR", "TEST", 120, 126], ["inoculation", "PROBLEM", 195, 206], ["virus isolation", "TREATMENT", 208, 223], ["histopathologic and IHC analyses", "TEST", 229, 261], ["pathologic", "OBSERVATION", 6, 16], ["trachea", "ANATOMY", 53, 60], ["lung", "ANATOMY", 62, 66], ["kidney", "ANATOMY", 68, 74], ["bursa", "ANATOMY", 76, 81], ["liver", "ANATOMY", 83, 88], ["brain", "ANATOMY", 94, 99]]], ["Serum samples collected from birds that survived were tested for IBV antibodies by a commercial ELISA kit (IDEXX Laboratories, Westbrook, ME, USA).", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["birds", "ORGANISM", 29, 34], ["IBV", "ORGANISM", 65, 68], ["IBV antibodies", "PROTEIN", 65, 79], ["IBV", "SPECIES", 65, 68], ["Serum samples", "TEST", 0, 13], ["IBV antibodies", "TEST", 65, 79]]], ["The endpoint titers were calculated according to the manufacturer\u2019s instructions, and titers >396 were considered positive for IBV antibody.RT-PCR of Tissue Samples ::: MethodsTissue samples from deceased birds were collected and used for RT-PCR to determine tissue distribution of the virus.", [["MethodsTissue samples", "ANATOMY", 169, 190], ["tissue", "ANATOMY", 259, 265], ["IBV", "ORGANISM", 127, 130], ["Tissue", "TISSUE", 150, 156], ["MethodsTissue samples", "CANCER", 169, 190], ["birds", "ORGANISM", 205, 210], ["tissue", "TISSUE", 259, 265], ["IBV antibody", "PROTEIN", 127, 139], ["IBV", "SPECIES", 127, 130], ["The endpoint titers", "TEST", 0, 19], ["titers", "TEST", 86, 92], ["IBV antibody", "PROBLEM", 127, 139], ["MethodsTissue samples", "TEST", 169, 190], ["RT-PCR", "TEST", 239, 245], ["the virus", "PROBLEM", 282, 291], ["Tissue", "ANATOMY", 150, 156], ["virus", "OBSERVATION", 286, 291]]], ["Total RNA was obtained by using Trizol Reagent (Invitrogen) as recommended for tissue samples.", [["tissue samples", "ANATOMY", 79, 93], ["tissue samples", "CANCER", 79, 93], ["Total RNA", "TEST", 0, 9], ["Trizol Reagent (Invitrogen)", "TREATMENT", 32, 59], ["tissue samples", "TEST", 79, 93]]], ["RT-PCR was performed as described above by using a pair of primers (forward: 5\u2032-TTTTGGTGATGACAAGATGAA-3\u2032; reverse: 5\u2032- CGCATTGTTCCTCTCCTC-3\u2032), which amplify and detect a 403-bp fragment of the S1 gene of IBV.", [["S1", "GENE_OR_GENE_PRODUCT", 193, 195], ["IBV", "ORGANISM", 204, 207], ["403-bp fragment", "DNA", 170, 185], ["S1 gene", "DNA", 193, 200], ["IBV", "SPECIES", 204, 207], ["RT-PCR", "TEST", 0, 6], ["TTTTGGTGATGACAAGATGAA", "TEST", 80, 101], ["IBV", "PROBLEM", 204, 207], ["S1", "ANATOMY", 193, 195], ["IBV", "OBSERVATION", 204, 207]]], ["PCR products were analyzed on 1.5% agarose gels.Virus Re-isolation from Infected Tissue Samples ::: MethodsTissue samples collected after challenge were used for virus isolation.", [["MethodsTissue samples", "ANATOMY", 100, 121], ["Virus", "ORGANISM", 48, 53], ["MethodsTissue samples", "CANCER", 100, 121], ["PCR products", "TREATMENT", 0, 12], ["1.5% agarose gels", "TREATMENT", 30, 47], ["MethodsTissue samples", "TEST", 100, 121], ["virus isolation", "TREATMENT", 162, 177], ["Infected Tissue", "OBSERVATION", 72, 87]]], ["Briefly, at least 6 SPF embryos were inoculated through the allantoic cavity, with each sample, containing 10,000 U/mL penicillin and 10,000 \u00b5g/mL streptomycin (0.2 mL/egg).", [["embryos", "ANATOMY", 24, 31], ["allantoic cavity", "ANATOMY", 60, 76], ["sample", "ANATOMY", 88, 94], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 147, 159], ["penicillin", "CHEMICAL", 119, 129], ["streptomycin", "CHEMICAL", 147, 159], ["SPF", "ORGANISM", 20, 23], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 24, 31], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 60, 76], ["penicillin", "SIMPLE_CHEMICAL", 119, 129], ["streptomycin", "SIMPLE_CHEMICAL", 147, 159], ["6 SPF embryos", "PROBLEM", 18, 31], ["penicillin", "TREATMENT", 119, 129], ["streptomycin", "TREATMENT", 147, 159], ["SPF embryos", "OBSERVATION", 20, 31], ["allantoic cavity", "ANATOMY", 60, 76]]], ["The eggs were candled daily, and allantoic fluids from 3 inoculated embryos were collected 48 h after inoculation for RT-PCR amplification.", [["eggs", "ANATOMY", 4, 8], ["allantoic fluids", "ANATOMY", 33, 49], ["embryos", "ANATOMY", 68, 75], ["eggs", "ORGANISM_SUBSTANCE", 4, 8], ["allantoic fluids", "ORGANISM_SUBSTANCE", 33, 49], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 75], ["The eggs", "TREATMENT", 0, 8], ["allantoic fluids", "TREATMENT", 33, 49], ["RT-PCR amplification", "TREATMENT", 118, 138]]], ["The remaining embryos were examined 6 days after inoculation for characteristic IBV lesions, such as dwarfing, stunting, or curling of embryos.Histopathology ::: MethodsTissues (trachea, lung, kidney, bursa, liver, and brain) were collected and fixed by immersion in 10% neutral formalin at room temperature for 48 h.", [["embryos", "ANATOMY", 14, 21], ["lesions", "ANATOMY", 84, 91], ["embryos", "ANATOMY", 135, 142], ["trachea", "ANATOMY", 178, 185], ["lung", "ANATOMY", 187, 191], ["kidney", "ANATOMY", 193, 199], ["bursa", "ANATOMY", 201, 206], ["liver", "ANATOMY", 208, 213], ["brain", "ANATOMY", 219, 224], ["IBV lesions", "DISEASE", 80, 91], ["stunting", "DISEASE", 111, 119], ["formalin", "CHEMICAL", 279, 287], ["formalin", "CHEMICAL", 279, 287], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 14, 21], ["IBV", "ORGANISM", 80, 83], ["lesions", "PATHOLOGICAL_FORMATION", 84, 91], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 135, 142], ["trachea", "MULTI-TISSUE_STRUCTURE", 178, 185], ["lung", "ORGAN", 187, 191], ["kidney", "ORGAN", 193, 199], ["bursa", "ORGAN", 201, 206], ["liver", "ORGAN", 208, 213], ["brain", "ORGAN", 219, 224], ["formalin", "SIMPLE_CHEMICAL", 279, 287], ["IBV", "SPECIES", 80, 83], ["inoculation", "TREATMENT", 49, 60], ["characteristic IBV lesions", "PROBLEM", 65, 91], ["dwarfing", "PROBLEM", 101, 109], ["stunting", "PROBLEM", 111, 119], ["curling of embryos", "PROBLEM", 124, 142], ["Histopathology", "TEST", 143, 157], ["MethodsTissues (trachea, lung, kidney, bursa, liver, and brain", "PROBLEM", 162, 224], ["embryos", "OBSERVATION", 14, 21], ["IBV", "OBSERVATION_MODIFIER", 80, 83], ["lesions", "OBSERVATION", 84, 91], ["trachea", "ANATOMY", 178, 185], ["lung", "ANATOMY", 187, 191], ["kidney", "ANATOMY", 193, 199], ["bursa", "ANATOMY", 201, 206], ["liver", "ANATOMY", 208, 213], ["brain", "ANATOMY", 219, 224]]], ["Tissue was then routinely processed, embedded in paraffin wax, and cut into 5-\u03bcm sections.", [["Tissue", "ANATOMY", 0, 6], ["sections", "ANATOMY", 81, 89], ["Tissue", "TISSUE", 0, 6]]], ["The sections were stained with hematoxylin and eosin and examined by light microscopy for lesions resulting from IBV infection.Immunohistochemistry ::: MethodsAll sampled tissues were examined by IHC analysis to detect viral antigen.", [["sections", "ANATOMY", 4, 12], ["lesions", "ANATOMY", 90, 97], ["tissues", "ANATOMY", 171, 178], ["IBV infection", "DISEASE", 113, 126], ["hematoxylin", "CHEMICAL", 31, 42], ["eosin", "CHEMICAL", 47, 52], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["hematoxylin", "SIMPLE_CHEMICAL", 31, 42], ["eosin", "SIMPLE_CHEMICAL", 47, 52], ["lesions", "PATHOLOGICAL_FORMATION", 90, 97], ["IBV", "ORGANISM", 113, 116], ["tissues", "TISSUE", 171, 178], ["viral antigen", "PROTEIN", 219, 232], ["IBV", "SPECIES", 113, 116], ["hematoxylin", "TREATMENT", 31, 42], ["eosin", "TREATMENT", 47, 52], ["light microscopy", "TEST", 69, 85], ["lesions", "PROBLEM", 90, 97], ["IBV infection", "PROBLEM", 113, 126], ["IHC analysis", "TEST", 196, 208], ["viral antigen", "PROBLEM", 219, 232], ["lesions", "OBSERVATION", 90, 97], ["IBV infection", "OBSERVATION", 113, 126]]], ["Briefly, 5-\u03bcm tissue sections were subjected to antigen retrieval (20) and were then incubated in 10% normal goat serum in PBS for 30 min to block nonspecific binding sites.", [["tissue sections", "ANATOMY", 14, 29], ["serum", "ANATOMY", 114, 119], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 14, 29], ["goat", "ORGANISM", 109, 113], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["goat", "SPECIES", 109, 113], ["goat", "SPECIES", 109, 113], ["5-\u03bcm tissue sections", "TREATMENT", 9, 29], ["antigen retrieval", "TREATMENT", 48, 65], ["block nonspecific binding sites", "PROBLEM", 141, 172], ["nonspecific", "OBSERVATION_MODIFIER", 147, 158], ["binding sites", "OBSERVATION", 159, 172]]], ["Slides were further incubated with chicken anti-IBV hyperimmune serum at 1:500 dilution in PBS for 2 h, followed by incubation with a horseradish peroxidase\u2013conjugated rabbit chicken IgG for 1 h.", [["serum", "ANATOMY", 64, 69], ["chicken", "ORGANISM", 35, 42], ["hyperimmune", "ORGANISM", 52, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["rabbit", "ORGANISM", 168, 174], ["chicken", "ORGANISM", 175, 182], ["IgG", "GENE_OR_GENE_PRODUCT", 183, 186], ["horseradish peroxidase\u2013conjugated rabbit chicken IgG", "PROTEIN", 134, 186], ["chicken", "SPECIES", 35, 42], ["hyperimmune", "SPECIES", 52, 63], ["horseradish", "SPECIES", 134, 145], ["rabbit", "SPECIES", 168, 174], ["chicken", "SPECIES", 175, 182], ["chicken", "SPECIES", 35, 42], ["anti-IBV", "SPECIES", 43, 51], ["rabbit", "SPECIES", 168, 174], ["chicken", "SPECIES", 175, 182], ["chicken anti-IBV hyperimmune serum", "TREATMENT", 35, 69], ["dilution in PBS", "TREATMENT", 79, 94], ["a horseradish peroxidase\u2013conjugated rabbit chicken IgG", "TREATMENT", 132, 186]]], ["The reaction was visualized by the addition of 3,3-diaminobenzidine (DAB; Sigma, St. Louis, MO, USA) for 15 min.", [["3,3-diaminobenzidine", "CHEMICAL", 47, 67], ["3,3-diaminobenzidine", "CHEMICAL", 47, 67], ["DAB", "CHEMICAL", 69, 72], ["3,3-diaminobenzidine", "SIMPLE_CHEMICAL", 47, 67], ["DAB", "SIMPLE_CHEMICAL", 69, 72], ["The reaction", "PROBLEM", 0, 12]]], ["After IHC staining, sections were counterstained with hematoxylin, air dried, and examined by light microscopy.Genome Sequencing ::: ResultsThe complete genome sequence (excluding the 5\u2032- and 3\u2032-terminal segments) of YN strain was obtained by assembling 22 overlapping sequences that ranged from 856 bp to 1,686 bp by the DNAstar software.", [["sections", "ANATOMY", 20, 28], ["hematoxylin", "CHEMICAL", 54, 65], ["hematoxylin", "SIMPLE_CHEMICAL", 54, 65], ["YN strain", "CELL", 217, 226], ["5\u2032- and 3\u2032-terminal segments", "DNA", 184, 212], ["22 overlapping sequences", "DNA", 254, 278], ["IHC staining", "TEST", 6, 18], ["hematoxylin", "TREATMENT", 54, 65], ["light microscopy", "TEST", 94, 110], ["The complete genome sequence", "TEST", 140, 168], ["YN strain", "PROBLEM", 217, 226], ["bp", "TEST", 300, 302], ["bp", "TEST", 312, 314]]], ["The nucleotide sequences were submitted to GenBank under accession no. JF893452.", [["JF893452", "CHEMICAL", 71, 79], ["nucleotide", "CHEMICAL", 4, 14], ["JF893452", "CHEMICAL", 71, 79], ["The nucleotide sequences", "TEST", 0, 24]]], ["The complete genomic sequences (excluding the 5\u2032- and 3\u2032-terminal segments) of YN isolate comprised 27,635 nt, which putatively contains 6 different genes, each containing single or multiple open reading frames.Phylogenetic Analysis ::: ResultsPhylogenetic trees for the genome and each gene of IBV reinforced the viral nucleotide sequencing results, suggesting that the YN isolate shares an immediate ancestor with the SC021202 strain (Figure 1).", [["nucleotide", "CHEMICAL", 320, 330], ["nucleotide", "CHEMICAL", 320, 330], ["YN", "GENE_OR_GENE_PRODUCT", 79, 81], ["IBV", "ORGANISM", 295, 298], ["YN", "GENE_OR_GENE_PRODUCT", 371, 373], ["genomic sequences", "DNA", 13, 30], ["5\u2032- and 3\u2032-terminal segments", "DNA", 46, 74], ["YN isolate", "DNA", 79, 89], ["open reading frames", "DNA", 191, 210], ["IBV", "SPECIES", 295, 298], ["The complete genomic sequences", "TEST", 0, 30], ["nt", "PROBLEM", 107, 109], ["Phylogenetic Analysis", "TEST", 211, 232], ["IBV", "TREATMENT", 295, 298], ["the viral nucleotide sequencing", "TEST", 310, 341], ["terminal", "ANATOMY_MODIFIER", 57, 65], ["segments", "ANATOMY_MODIFIER", 66, 74], ["6 different", "OBSERVATION_MODIFIER", 137, 148]]], ["To elucidate the phylogenetic relationships of China IBV strains, we further analyzed S1 genes of 70 IBVs, including 51 China isolates and 19 standard strains or vaccine strains (Figure 1, panel B).", [["IBVs", "ANATOMY", 101, 105], ["China IBV", "ORGANISM", 47, 56], ["IBVs", "CANCER", 101, 105], ["S1 genes", "DNA", 86, 94], ["China IBV", "SPECIES", 47, 56], ["China IBV strains", "PROBLEM", 47, 64], ["China isolates", "TEST", 120, 134], ["19 standard strains", "TREATMENT", 139, 158], ["vaccine strains", "TREATMENT", 162, 177]]], ["The data indicated that China isolates could be differentiated into 3 distinct genetic groups or genotypes.", [["The data", "TEST", 0, 8], ["China isolates", "PROBLEM", 24, 38]]], ["Group I included 41 of the 51 field isolates, which were tentatively named A2-like viruses.", [["A2-like viruses", "ORGANISM", 75, 90], ["A2", "PROTEIN", 75, 77], ["the 51 field isolates", "TEST", 23, 44]]], ["Four China field isolates were included in group II, which were tentatively named LSD-like viruses.", [["LSD-like viruses", "ORGANISM", 82, 98], ["Four China field isolates", "PROBLEM", 0, 25], ["viruses", "PROBLEM", 91, 98], ["viruses", "OBSERVATION", 91, 98]]], ["These results showed that at least 3 distinct groups existed in chicken flocks in China, and A2-like and M41-like viruses were mainly responsible for the IB panzootic, consistent with findngs of our previous studies (5,16).Sequence Comparisons ::: ResultsTen virus sequences were selected for pairwise comparisons with the YN strain according to the phylogenetic analysis for S1 (Figure 1, panel B), which included 2 common vaccine strains in China (M41 and H120) and 8 China isolates from 3 different gene clusters (DY07, LX4, A2, and SC021202 from cluster I; CK/CH/LSD/05I and CK/CH/LHB/100801 from cluster II; CK/CH/LHLJ/07VII and CK/CH/LDL/101212 from cluster III) (Table 2).", [["chicken", "ORGANISM", 64, 71], ["A2", "GENE_OR_GENE_PRODUCT", 93, 95], ["M41-like viruses", "ORGANISM", 105, 121], ["CK", "GENE_OR_GENE_PRODUCT", 561, 563], ["CK", "GENE_OR_GENE_PRODUCT", 613, 615], ["S1", "PROTEIN", 376, 378], ["DY07", "DNA", 517, 521], ["LX4", "DNA", 523, 526], ["A2", "DNA", 528, 530], ["SC021202", "DNA", 536, 544], ["CK", "DNA", 579, 581], ["CK", "DNA", 613, 615], ["07VII", "DNA", 624, 629], ["CK", "DNA", 634, 636], ["LDL", "DNA", 640, 643], ["chicken", "SPECIES", 64, 71], ["chicken", "SPECIES", 64, 71], ["A2", "TEST", 93, 95], ["M41-like viruses", "PROBLEM", 105, 121], ["our previous studies", "TEST", 195, 215], ["Ten virus sequences", "TEST", 255, 274], ["pairwise comparisons", "TEST", 293, 313], ["the YN strain", "PROBLEM", 319, 332], ["the phylogenetic analysis", "TEST", 346, 371], ["S1 (Figure", "TEST", 376, 386], ["CK/CH", "TEST", 561, 566], ["LSD", "TEST", 567, 570], ["CK/CH", "TEST", 579, 584], ["LHB", "TEST", 585, 588], ["II", "TEST", 609, 611], ["CK/CH", "TEST", 613, 618], ["LHLJ", "TEST", 619, 623], ["07VII", "TEST", 624, 629], ["CK/CH", "TEST", 634, 639], ["LDL", "TEST", 640, 643], ["distinct", "OBSERVATION_MODIFIER", 37, 45], ["groups", "OBSERVATION_MODIFIER", 46, 52], ["chicken flocks", "OBSERVATION", 64, 78], ["viruses", "OBSERVATION", 114, 121], ["consistent with", "UNCERTAINTY", 168, 183]]], ["Overall, the complete genomic sequences (excluding the 5\u2032- and 3\u2032-terminal segments) were 87.1%\u201398.0% identical among the isolates, and the YN strain had the highest nucleotide identity (98.0%) to the SC021202 strain isolated in southern China (GenBank accession no. EU714029).", [["nucleotide", "CHEMICAL", 166, 176], ["EU714029", "CHEMICAL", 267, 275], ["nucleotide", "CHEMICAL", 166, 176], ["EU714029", "CHEMICAL", 267, 275], ["genomic sequences", "DNA", 22, 39], ["5\u2032- and 3\u2032-terminal segments", "DNA", 55, 83], ["the complete genomic sequences", "TEST", 9, 39], ["the isolates", "TEST", 118, 130], ["the YN strain", "PROBLEM", 136, 149], ["terminal", "ANATOMY_MODIFIER", 66, 74], ["segments", "ANATOMY_MODIFIER", 75, 83]]], ["For each gene, the identity hanged from 93.7% to 100% between YN and SC021202 strains (Table 2).Sequence Comparisons ::: ResultsThe S glycoprotein is the major functional protein for IBV; thus, the putative differences between the YN strain and other IBVs were investigated.", [["S glycoprotein", "GENE_OR_GENE_PRODUCT", 132, 146], ["IBV", "ORGANISM", 183, 186], ["YN strain", "ORGANISM", 231, 240], ["IBVs", "CANCER", 251, 255], ["S glycoprotein", "PROTEIN", 132, 146], ["IBV", "SPECIES", 183, 186], ["the identity", "TEST", 15, 27], ["IBV", "PROBLEM", 183, 186], ["the YN strain", "PROBLEM", 227, 240], ["other IBVs", "TREATMENT", 245, 255]]], ["Analyses showed that a single amino acid insertion was present at position 22 (Figure 2, panel A) in addition to a 7-aa insertion at positions 74\u201381 (Figure 2, panel B) in the S1 gene of the YN isolate, in which a putative N-glycosylation site was found.", [["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["N", "CHEMICAL", 223, 224], ["amino acid", "AMINO_ACID", 30, 40], ["S1", "GENE_OR_GENE_PRODUCT", 176, 178], ["YN", "GENE_OR_GENE_PRODUCT", 191, 193], ["position 22", "PROTEIN", 66, 77], ["7-aa insertion", "DNA", 115, 129], ["positions 74\u201381", "DNA", 133, 148], ["S1 gene", "DNA", 176, 183], ["N-glycosylation site", "DNA", 223, 243], ["Analyses", "TEST", 0, 8], ["a single amino acid insertion", "TREATMENT", 21, 50], ["a 7-aa insertion at positions", "TREATMENT", 113, 142], ["Figure", "TEST", 150, 156], ["a putative N-glycosylation site", "TREATMENT", 212, 243]]], ["Among available sequences in GenBank, strains A2, BJ, CQ04\u20131, SC021202, and SAIBK had the same insertion in the S1 gene.", [["BJ", "CELL", 50, 52], ["SAIBK", "GENE_OR_GENE_PRODUCT", 76, 81], ["S1", "GENE_OR_GENE_PRODUCT", 112, 114], ["strains A2, BJ, CQ04\u20131, SC021202, and SAIBK", "DNA", 38, 81], ["S1 gene", "DNA", 112, 119], ["strains", "TEST", 38, 45], ["BJ", "TEST", 50, 52], ["CQ04\u20131", "TEST", 54, 60], ["SC021202", "TEST", 62, 70], ["SAIBK", "TEST", 76, 81], ["BJ", "ANATOMY", 50, 52], ["S1", "ANATOMY", 112, 114]]], ["Compared with other available strains, 9-aa deletions were located at the N terminal of the S2 gene (Figure 2, panel C) from a base transition (G\u2192T) at position 1,849 nt, resulting in premature stop codon in the open reading frame.Clinicopathologic Assessment in Chickens ::: ResultsClinically, some birds appeared depressed with ruffled feathers; these birds had increased water intake and huddled together in YN-inoculation group at 2 days postinfection (dpi).", [["depressed", "DISEASE", 315, 324], ["YN", "CHEMICAL", 411, 413], ["N", "CHEMICAL", 74, 75], ["S2", "GENE_OR_GENE_PRODUCT", 92, 94], ["Chickens", "ORGANISM", 263, 271], ["birds", "ORGANISM", 300, 305], ["feathers", "ORGANISM_SUBDIVISION", 338, 346], ["birds", "ORGANISM", 354, 359], ["YN", "SIMPLE_CHEMICAL", 411, 413], ["9-aa deletions", "DNA", 39, 53], ["N terminal", "DNA", 74, 84], ["S2 gene", "DNA", 92, 99], ["Figure 2", "DNA", 101, 109], ["panel C", "DNA", 111, 118], ["premature stop codon", "DNA", 184, 204], ["open reading frame", "DNA", 212, 230], ["Chickens", "SPECIES", 263, 271], ["aa deletions", "PROBLEM", 41, 53], ["a base transition", "PROBLEM", 125, 142], ["nt", "PROBLEM", 167, 169], ["premature stop codon", "PROBLEM", 184, 204], ["Clinicopathologic Assessment", "TEST", 231, 259], ["depressed", "PROBLEM", 315, 324], ["ruffled feathers", "PROBLEM", 330, 346], ["terminal", "ANATOMY_MODIFIER", 76, 84], ["S2", "ANATOMY", 92, 94], ["premature", "OBSERVATION_MODIFIER", 184, 193], ["stop codon", "OBSERVATION", 194, 204], ["depressed", "OBSERVATION", 315, 324], ["ruffled feathers", "OBSERVATION", 330, 346]]], ["At 4 dpi, IB-like signs became obvious in all infected chickens, and some birds were euthanized because of severe disease.", [["chickens", "ORGANISM", 55, 63], ["birds", "ORGANISM", 74, 79], ["chickens", "SPECIES", 55, 63], ["chickens", "SPECIES", 55, 63], ["IB-like signs", "PROBLEM", 10, 23], ["all infected chickens", "PROBLEM", 42, 63], ["severe disease", "PROBLEM", 107, 121], ["obvious", "OBSERVATION_MODIFIER", 31, 38], ["infected chickens", "OBSERVATION", 46, 63], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["disease", "OBSERVATION", 114, 121]]], ["Deaths occurred until 21 dpi; the death rate reached 65% (Figure 3, panel A).", [["death", "DISEASE", 34, 39], ["the death rate", "TEST", 30, 44]]], ["No deaths or clinical signs were observed in the control group.Clinicopathologic Assessment in Chickens ::: ResultsSlight hemorrhage with serous catarrhal exudate could be seen in the trachea of all euthanized birds.", [["serous catarrhal exudate", "ANATOMY", 138, 162], ["trachea", "ANATOMY", 184, 191], ["deaths", "DISEASE", 3, 9], ["hemorrhage", "DISEASE", 122, 132], ["Chickens", "ORGANISM", 95, 103], ["serous", "ORGANISM_SUBSTANCE", 138, 144], ["catarrhal exudate", "PATHOLOGICAL_FORMATION", 145, 162], ["trachea", "ORGAN", 184, 191], ["birds", "ORGANISM", 210, 215], ["Chickens", "SPECIES", 95, 103], ["deaths", "PROBLEM", 3, 9], ["clinical signs", "TEST", 13, 27], ["Slight hemorrhage", "PROBLEM", 115, 132], ["serous catarrhal exudate", "PROBLEM", 138, 162], ["deaths", "OBSERVATION", 3, 9], ["Slight", "OBSERVATION_MODIFIER", 115, 121], ["hemorrhage", "OBSERVATION", 122, 132], ["serous", "OBSERVATION_MODIFIER", 138, 144], ["catarrhal exudate", "OBSERVATION", 145, 162], ["could be seen", "UNCERTAINTY", 163, 176], ["trachea", "ANATOMY", 184, 191], ["all", "OBSERVATION_MODIFIER", 195, 198], ["euthanized birds", "OBSERVATION", 199, 215]]], ["Air sac lesions also were present, characterized by marked thickening of the air sac wall and a yellow caseous exudate.", [["Air sac lesions", "ANATOMY", 0, 15], ["air sac wall", "ANATOMY", 77, 89], ["caseous exudate", "ANATOMY", 103, 118], ["Air sac lesions", "PATHOLOGICAL_FORMATION", 0, 15], ["air sac wall", "TISSUE", 77, 89], ["caseous exudate", "PATHOLOGICAL_FORMATION", 103, 118], ["Air sac lesions", "PROBLEM", 0, 15], ["marked thickening of the air sac wall", "PROBLEM", 52, 89], ["a yellow caseous exudate", "PROBLEM", 94, 118], ["sac", "OBSERVATION_MODIFIER", 4, 7], ["lesions", "OBSERVATION", 8, 15], ["marked", "OBSERVATION_MODIFIER", 52, 58], ["thickening", "OBSERVATION", 59, 69], ["air sac", "ANATOMY", 77, 84], ["wall", "ANATOMY_MODIFIER", 85, 89], ["yellow", "OBSERVATION_MODIFIER", 96, 102], ["caseous", "OBSERVATION_MODIFIER", 103, 110], ["exudate", "OBSERVATION", 111, 118]]], ["All euthanized chickens showed typical kidney lesions.", [["kidney lesions", "ANATOMY", 39, 53], ["kidney lesions", "DISEASE", 39, 53], ["chickens", "ORGANISM", 15, 23], ["kidney lesions", "CANCER", 39, 53], ["chickens", "SPECIES", 15, 23], ["chickens", "SPECIES", 15, 23], ["typical kidney lesions", "PROBLEM", 31, 53], ["typical", "OBSERVATION_MODIFIER", 31, 38], ["kidney", "ANATOMY", 39, 45], ["lesions", "OBSERVATION", 46, 53]]], ["The affected kidneys were substantially enlarged, and deposits of pale urate were frequently observed in the tubules and ureters (Figure 4).", [["kidneys", "ANATOMY", 13, 20], ["tubules", "ANATOMY", 109, 116], ["ureters", "ANATOMY", 121, 128], ["urate", "CHEMICAL", 71, 76], ["urate", "CHEMICAL", 71, 76], ["kidneys", "ORGAN", 13, 20], ["urate", "SIMPLE_CHEMICAL", 71, 76], ["tubules", "TISSUE", 109, 116], ["ureters", "ORGAN", 121, 128], ["substantially enlarged", "PROBLEM", 26, 48], ["deposits of pale urate", "PROBLEM", 54, 76], ["kidneys", "ANATOMY", 13, 20], ["substantially", "OBSERVATION_MODIFIER", 26, 39], ["enlarged", "OBSERVATION", 40, 48], ["deposits", "OBSERVATION_MODIFIER", 54, 62], ["pale urate", "OBSERVATION", 66, 76], ["tubules", "ANATOMY_MODIFIER", 109, 116], ["ureters", "ANATOMY", 121, 128]]], ["No gross lesions were observed in any birds in the control group.Clinicopathologic Assessment in Chickens ::: ResultsAntibody responses in birds that survived infection were measured by a commercial ELISA kit (IDEXX Laboratories).", [["gross lesions", "ANATOMY", 3, 16], ["infection", "DISEASE", 159, 168], ["gross lesions", "PATHOLOGICAL_FORMATION", 3, 16], ["Chickens", "ORGANISM", 97, 105], ["birds", "ORGANISM", 139, 144], ["Chickens", "SPECIES", 97, 105], ["gross lesions", "PROBLEM", 3, 16], ["Clinicopathologic Assessment", "TEST", 65, 93], ["Antibody responses", "TEST", 117, 135], ["infection", "PROBLEM", 159, 168], ["gross", "OBSERVATION_MODIFIER", 3, 8], ["lesions", "OBSERVATION", 9, 16], ["infection", "OBSERVATION", 159, 168]]], ["All but 1 chicken showed a positive reaction (Figure 3, panel B) by ELISA, and the mean titer induced by the YN strain was 1,250.35 at 21 dpi.RT-PCR and Virus Isolation on Tissues ::: ResultsTo further examine the pathogenicity of IBV YN, the tissue tropism of the strain was investigated by RT-PCR and virus isolation by using tissue suspensions from dead birds.", [["Tissues", "ANATOMY", 172, 179], ["tissue", "ANATOMY", 243, 249], ["tissue suspensions", "ANATOMY", 328, 346], ["chicken", "ORGANISM", 10, 17], ["IBV", "ORGANISM", 231, 234], ["YN", "ORGANISM", 235, 237], ["tissue", "TISSUE", 243, 249], ["tissue", "TISSUE", 328, 334], ["birds", "ORGANISM", 357, 362], ["chicken", "SPECIES", 10, 17], ["chicken", "SPECIES", 10, 17], ["IBV", "SPECIES", 231, 234], ["a positive reaction", "PROBLEM", 25, 44], ["ELISA", "TEST", 68, 73], ["the mean titer", "TEST", 79, 93], ["the YN strain", "PROBLEM", 105, 118], ["RT-PCR", "TEST", 142, 148], ["IBV", "PROBLEM", 231, 234], ["the strain", "PROBLEM", 261, 271], ["PCR", "TEST", 295, 298], ["virus isolation", "TREATMENT", 303, 318], ["tissue suspensions", "TREATMENT", 328, 346], ["Virus Isolation", "OBSERVATION", 153, 168]]], ["YN strain replicated well in the various organs, including the kidneys, trachea, lungs, and bursa (Table 3; Technical Appendix).Histopathologic and IIHC Analyses ::: ResultsMicroscopic examination of the tracheal tissues revealed extensive degeneration and necrosis of the ciliated epithelial cells, sometimes with pseudoacinar structures resulting from dropout of dead cells (Figure 5, panel B).", [["organs", "ANATOMY", 41, 47], ["kidneys", "ANATOMY", 63, 70], ["trachea", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 81, 86], ["bursa", "ANATOMY", 92, 97], ["tracheal tissues", "ANATOMY", 204, 220], ["ciliated epithelial cells", "ANATOMY", 273, 298], ["pseudoacinar structures", "ANATOMY", 315, 338], ["cells", "ANATOMY", 370, 375], ["necrosis", "DISEASE", 257, 265], ["organs", "ORGAN", 41, 47], ["kidneys", "ORGAN", 63, 70], ["trachea", "MULTI-TISSUE_STRUCTURE", 72, 79], ["lungs", "ORGAN", 81, 86], ["bursa", "ORGAN", 92, 97], ["tracheal tissues", "TISSUE", 204, 220], ["ciliated epithelial cells", "CELL", 273, 298], ["pseudoacinar structures", "TISSUE", 315, 338], ["cells", "CELL", 370, 375], ["ciliated epithelial cells", "CELL_TYPE", 273, 298], ["dead cells", "CELL_TYPE", 365, 375], ["YN strain", "PROBLEM", 0, 9], ["ResultsMicroscopic examination of the tracheal tissues", "TEST", 166, 220], ["extensive degeneration", "PROBLEM", 230, 252], ["necrosis of the ciliated epithelial cells", "PROBLEM", 257, 298], ["pseudoacinar structures", "PROBLEM", 315, 338], ["dead cells", "PROBLEM", 365, 375], ["various", "ANATOMY_MODIFIER", 33, 40], ["organs", "ANATOMY", 41, 47], ["kidneys", "ANATOMY", 63, 70], ["trachea", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 81, 86], ["bursa", "ANATOMY", 92, 97], ["Appendix", "ANATOMY", 118, 126], ["tracheal tissues", "ANATOMY", 204, 220], ["extensive", "OBSERVATION_MODIFIER", 230, 239], ["degeneration", "OBSERVATION", 240, 252], ["necrosis", "OBSERVATION", 257, 265], ["ciliated", "ANATOMY_MODIFIER", 273, 281], ["epithelial cells", "ANATOMY", 282, 298], ["dead cells", "OBSERVATION", 365, 375]]], ["Viral antigen was detected at high levels in the epithelial cells of the tracheal mucosa (Figure 6, panel B).", [["epithelial cells", "ANATOMY", 49, 65], ["tracheal mucosa", "ANATOMY", 73, 88], ["Viral", "ORGANISM", 0, 5], ["epithelial cells", "CELL", 49, 65], ["tracheal mucosa", "MULTI-TISSUE_STRUCTURE", 73, 88], ["Viral antigen", "PROTEIN", 0, 13], ["epithelial cells", "CELL_TYPE", 49, 65], ["Viral antigen", "TEST", 0, 13], ["epithelial cells", "OBSERVATION", 49, 65], ["tracheal mucosa", "ANATOMY", 73, 88]]], ["Lung lesions were characterized by hemorrhage, congestion, and lymphocytic infiltration in the alveolar lumen (Figure 5, panel D), and viral antigen was detected in alveolar cells (Figure 6, panel D).", [["Lung lesions", "ANATOMY", 0, 12], ["lymphocytic", "ANATOMY", 63, 74], ["alveolar lumen", "ANATOMY", 95, 109], ["alveolar cells", "ANATOMY", 165, 179], ["Lung lesions", "DISEASE", 0, 12], ["hemorrhage", "DISEASE", 35, 45], ["congestion", "DISEASE", 47, 57], ["Lung lesions", "CANCER", 0, 12], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 95, 109], ["alveolar cells", "CELL", 165, 179], ["viral antigen", "PROTEIN", 135, 148], ["alveolar cells", "CELL_TYPE", 165, 179], ["Lung lesions", "PROBLEM", 0, 12], ["hemorrhage", "PROBLEM", 35, 45], ["congestion", "PROBLEM", 47, 57], ["lymphocytic infiltration in the alveolar lumen", "PROBLEM", 63, 109], ["panel D)", "TEST", 121, 129], ["viral antigen", "TEST", 135, 148], ["Figure", "TEST", 181, 187], ["lesions", "OBSERVATION", 5, 12], ["hemorrhage", "OBSERVATION", 35, 45], ["congestion", "OBSERVATION", 47, 57], ["lymphocytic infiltration", "OBSERVATION", 63, 87], ["alveolar", "ANATOMY_MODIFIER", 95, 103], ["lumen", "ANATOMY_MODIFIER", 104, 109], ["alveolar cells", "ANATOMY", 165, 179]]], ["Severe renal lesions, including degeneration and necrosis of renal tubular epithelial cells, lymphocytic infiltration in the interstitium, exfoliated renal tubular epithelial cells, and erythrocytes were frequently observed (Figure 5, panel F).", [["renal lesions", "ANATOMY", 7, 20], ["renal tubular epithelial cells", "ANATOMY", 61, 91], ["lymphocytic", "ANATOMY", 93, 104], ["interstitium", "ANATOMY", 125, 137], ["renal tubular epithelial cells", "ANATOMY", 150, 180], ["erythrocytes", "ANATOMY", 186, 198], ["renal lesions", "DISEASE", 7, 20], ["necrosis", "DISEASE", 49, 57], ["renal lesions", "PATHOLOGICAL_FORMATION", 7, 20], ["renal tubular epithelial cells", "CELL", 61, 91], ["interstitium", "TISSUE", 125, 137], ["renal tubular epithelial cells", "CELL", 150, 180], ["erythrocytes", "CELL", 186, 198], ["renal tubular epithelial cells", "CELL_TYPE", 61, 91], ["exfoliated renal tubular epithelial cells", "CELL_TYPE", 139, 180], ["erythrocytes", "CELL_TYPE", 186, 198], ["Severe renal lesions", "PROBLEM", 0, 20], ["degeneration", "PROBLEM", 32, 44], ["necrosis", "PROBLEM", 49, 57], ["renal tubular epithelial cells", "PROBLEM", 61, 91], ["lymphocytic infiltration in the interstitium", "PROBLEM", 93, 137], ["exfoliated renal tubular epithelial cells", "PROBLEM", 139, 180], ["erythrocytes", "PROBLEM", 186, 198], ["renal", "ANATOMY", 7, 12], ["lesions", "OBSERVATION", 13, 20], ["degeneration", "OBSERVATION", 32, 44], ["necrosis", "OBSERVATION", 49, 57], ["renal", "ANATOMY", 61, 66], ["tubular", "ANATOMY_MODIFIER", 67, 74], ["epithelial cells", "OBSERVATION", 75, 91], ["lymphocytic infiltration", "OBSERVATION", 93, 117], ["interstitium", "ANATOMY_MODIFIER", 125, 137], ["exfoliated", "ANATOMY_MODIFIER", 139, 149], ["renal", "ANATOMY", 150, 155], ["tubular", "ANATOMY_MODIFIER", 156, 163], ["epithelial cells", "OBSERVATION", 164, 180], ["erythrocytes", "ANATOMY", 186, 198]]], ["Viral antigens were detected extensively in the renal tubular epithelial cells (Figure 6, panel F).", [["renal tubular epithelial cells", "ANATOMY", 48, 78], ["Viral", "ORGANISM", 0, 5], ["renal tubular epithelial cells", "CELL", 48, 78], ["Viral antigens", "PROTEIN", 0, 14], ["renal tubular epithelial cells", "CELL_TYPE", 48, 78], ["Viral antigens", "TEST", 0, 14], ["Figure", "TEST", 80, 86], ["renal", "ANATOMY", 48, 53], ["tubular", "ANATOMY_MODIFIER", 54, 61], ["epithelial cells", "OBSERVATION", 62, 78]]], ["Serious atrophy of lymphoid follicles and widening of the interstitium were observed in the bursa of Fabricius (Figure 5, panel H), and viral antigens were detected widely in the mucosal epithelium of the bursa of Fabricius (Figure 6, panel H).", [["lymphoid follicles", "ANATOMY", 19, 37], ["interstitium", "ANATOMY", 58, 70], ["bursa", "ANATOMY", 92, 97], ["mucosal epithelium", "ANATOMY", 179, 197], ["bursa", "ANATOMY", 205, 210], ["atrophy of lymphoid follicles", "DISEASE", 8, 37], ["lymphoid follicles", "MULTI-TISSUE_STRUCTURE", 19, 37], ["interstitium", "TISSUE", 58, 70], ["bursa", "ORGANISM_SUBDIVISION", 92, 97], ["Fabricius", "TISSUE", 101, 110], ["mucosal epithelium", "TISSUE", 179, 197], ["bursa", "ORGAN", 205, 210], ["viral antigens", "PROTEIN", 136, 150], ["Serious atrophy of lymphoid follicles", "PROBLEM", 0, 37], ["widening of the interstitium", "PROBLEM", 42, 70], ["viral antigens", "TEST", 136, 150], ["atrophy", "OBSERVATION", 8, 15], ["lymphoid follicles", "OBSERVATION", 19, 37], ["widening", "OBSERVATION_MODIFIER", 42, 50], ["interstitium", "ANATOMY", 58, 70], ["bursa", "ANATOMY", 92, 97], ["Fabricius", "ANATOMY", 101, 110], ["mucosal epithelium", "ANATOMY", 179, 197], ["bursa", "ANATOMY", 205, 210], ["Fabricius", "ANATOMY", 214, 223]]], ["Sporadic congestion also was observed in the liver and cerebrum.DiscussionIBV infection leads to severe economic losses in the poultry industry because of poor weight gain and feeding efficiency in broilers or reduced egg production and egg quality in laying birds.", [["liver", "ANATOMY", 45, 50], ["cerebrum", "ANATOMY", 55, 63], ["egg", "ANATOMY", 218, 221], ["egg", "ANATOMY", 237, 240], ["infection", "DISEASE", 78, 87], ["weight gain", "DISEASE", 160, 171], ["liver", "ORGAN", 45, 50], ["cerebrum", "ORGAN", 55, 63], ["broilers", "ORGANISM_SUBDIVISION", 198, 206], ["egg", "ORGANISM_SUBDIVISION", 218, 221], ["egg", "ORGANISM_SUBDIVISION", 237, 240], ["broilers", "SPECIES", 198, 206], ["broilers", "SPECIES", 198, 206], ["Sporadic congestion", "PROBLEM", 0, 19], ["DiscussionIBV infection", "PROBLEM", 64, 87], ["severe economic losses", "PROBLEM", 97, 119], ["poor weight gain", "PROBLEM", 155, 171], ["feeding efficiency", "PROBLEM", 176, 194], ["reduced egg production", "PROBLEM", 210, 232], ["congestion", "OBSERVATION", 9, 19], ["liver", "ANATOMY", 45, 50], ["cerebrum", "ANATOMY", 55, 63], ["infection", "OBSERVATION", 78, 87], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["economic", "OBSERVATION_MODIFIER", 104, 112], ["losses", "OBSERVATION", 113, 119], ["reduced egg production", "OBSERVATION", 210, 232]]], ["Death rates are often low (<30%) unless secondary bacterial infections cause increased deaths of birds (21,22).", [["Death", "DISEASE", 0, 5], ["bacterial infections", "DISEASE", 50, 70], ["deaths", "DISEASE", 87, 93], ["Death rates", "TEST", 0, 11], ["secondary bacterial infections", "PROBLEM", 40, 70], ["increased deaths of birds", "PROBLEM", 77, 102], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["infections", "OBSERVATION", 60, 70]]], ["Evaluation of the pathogenicity of IBV was based on several criteria, including: clinical signs, gross pathologic lesions, histopathologic changes, and tissue tropism.", [["lesions", "ANATOMY", 114, 121], ["tissue", "ANATOMY", 152, 158], ["IBV", "ORGANISM", 35, 38], ["lesions", "PATHOLOGICAL_FORMATION", 114, 121], ["tissue", "TISSUE", 152, 158], ["IBV", "SPECIES", 35, 38], ["Evaluation", "TEST", 0, 10], ["the pathogenicity of IBV", "PROBLEM", 14, 38], ["several criteria", "TEST", 52, 68], ["clinical signs", "TEST", 81, 95], ["gross pathologic lesions", "PROBLEM", 97, 121], ["histopathologic changes", "PROBLEM", 123, 146], ["tissue tropism", "PROBLEM", 152, 166], ["IBV", "OBSERVATION", 35, 38], ["gross", "OBSERVATION_MODIFIER", 97, 102], ["pathologic", "OBSERVATION_MODIFIER", 103, 113], ["lesions", "OBSERVATION", 114, 121], ["tissue tropism", "OBSERVATION", 152, 166]]], ["In this study, a China IBV strain isolated from a 30-day-old vaccinated broiler flock that had a history of respiratory signs, severe renal disease, and higher than expected mortality rate was analyzed by clinical observation, histopathologic examination, RT-PCR, virus isolation, and immunohistochemistry.", [["respiratory", "ANATOMY", 108, 119], ["renal", "ANATOMY", 134, 139], ["respiratory signs", "DISEASE", 108, 125], ["renal disease", "DISEASE", 134, 147], ["IBV", "ORGANISM", 23, 26], ["broiler", "ORGANISM", 72, 79], ["renal", "ORGAN", 134, 139], ["vaccinated broiler flock", "SPECIES", 61, 85], ["China IBV strain", "SPECIES", 17, 33], ["this study", "TEST", 3, 13], ["a China IBV strain", "PROBLEM", 15, 33], ["old vaccinated broiler flock", "TREATMENT", 57, 85], ["respiratory signs", "PROBLEM", 108, 125], ["severe renal disease", "PROBLEM", 127, 147], ["clinical observation", "TEST", 205, 225], ["histopathologic examination", "TEST", 227, 254], ["RT-PCR", "TEST", 256, 262], ["virus isolation", "TREATMENT", 264, 279], ["immunohistochemistry", "TEST", 285, 305], ["30-", "OBSERVATION_MODIFIER", 50, 53], ["broiler flock", "OBSERVATION", 72, 85], ["respiratory signs", "OBSERVATION", 108, 125], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["renal", "ANATOMY", 134, 139], ["disease", "OBSERVATION", 140, 147], ["higher", "OBSERVATION_MODIFIER", 153, 159]]], ["Analyses revealed that the YN strain induced severe pathogenicity in 30-day-old SPF chickens with a 65% death rate and substantial kidney lesions.DiscussionSequence analysis of the S1 gene of YN isolate showed high nucleotide similarities to CQ04\u20131 (99.5% nt and 98.8% aa identities) and SC021202 (99.3% nt and 98.6% aa identities).", [["kidney lesions", "ANATOMY", 131, 145], ["death", "DISEASE", 104, 109], ["kidney lesions", "DISEASE", 131, 145], ["nucleotide", "CHEMICAL", 215, 225], ["nucleotide", "CHEMICAL", 215, 225], ["YN", "GENE_OR_GENE_PRODUCT", 27, 29], ["SPF", "ORGANISM", 80, 83], ["chickens", "ORGANISM", 84, 92], ["kidney lesions", "CANCER", 131, 145], ["S1", "GENE_OR_GENE_PRODUCT", 181, 183], ["YN", "GENE_OR_GENE_PRODUCT", 192, 194], ["S1 gene", "DNA", 181, 188], ["chickens", "SPECIES", 84, 92], ["chickens", "SPECIES", 84, 92], ["Analyses", "TEST", 0, 8], ["the YN strain induced severe pathogenicity", "PROBLEM", 23, 65], ["old SPF chickens", "PROBLEM", 76, 92], ["a 65% death rate", "PROBLEM", 98, 114], ["substantial kidney lesions", "PROBLEM", 119, 145], ["DiscussionSequence analysis", "TEST", 146, 173], ["the S1 gene of YN isolate", "TEST", 177, 202], ["high nucleotide similarities", "PROBLEM", 210, 238], ["CQ04\u20131", "TEST", 242, 248], ["nt", "TEST", 256, 258], ["aa identities", "TEST", 269, 282], ["SC021202", "TEST", 288, 296], ["nt", "TEST", 304, 306], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["pathogenicity", "OBSERVATION", 52, 65], ["30-", "OBSERVATION_MODIFIER", 69, 72], ["substantial", "OBSERVATION_MODIFIER", 119, 130], ["kidney", "ANATOMY", 131, 137], ["lesions", "OBSERVATION", 138, 145]]], ["Phylogenetic analysis further indicated that at least 3 distinct genetic clusters of IBV were present in chicken flocks in China, named A2-like, LSD-like, and M41-like strains.", [["IBV", "ORGANISM", 85, 88], ["chicken", "ORGANISM", 105, 112], ["A2", "GENE_OR_GENE_PRODUCT", 136, 138], ["M41-like strains", "ORGANISM", 159, 175], ["chicken", "SPECIES", 105, 112], ["IBV", "SPECIES", 85, 88], ["chicken", "SPECIES", 105, 112], ["Phylogenetic analysis", "TEST", 0, 21], ["IBV", "PROBLEM", 85, 88], ["LSD", "TEST", 145, 148], ["M41", "TEST", 159, 162], ["IBV", "OBSERVATION", 85, 88], ["chicken flocks", "OBSERVATION", 105, 119]]], ["Most China IBV field isolates belonged to the same genetic cluster (A2-like), but the serotypes of these prevalent IBV strains differed from those of the currently used vaccine strains in China (M41-like, e.g., H120, Ma5, 28/86, and W93), which are considered the main cause of disease outbreaks (5,15\u201317).", [["China IBV", "ORGANISM", 5, 14], ["IBV", "ORGANISM", 115, 118], ["Ma5", "GENE_OR_GENE_PRODUCT", 217, 220], ["W93", "GENE_OR_GENE_PRODUCT", 233, 236], ["A2", "DNA", 68, 70], ["China IBV", "SPECIES", 5, 14], ["IBV", "SPECIES", 115, 118], ["IBV strains", "PROBLEM", 115, 126], ["vaccine strains", "PROBLEM", 169, 184], ["disease outbreaks", "PROBLEM", 278, 295], ["disease", "OBSERVATION", 278, 285]]], ["An attenuated or inactivated vaccine that matches with pandemic strains is urgently needed in China to control IBV infection.DiscussionIBV has been shown to replicate in many respiratory tissues (including trachea, lungs, and air sac), causing respiratory disease; in some urogenital tissues (including kidney), causing minor or major nephritis; and in many parts of the alimentary tract (including esophagus, proventriculus, and intestine) (23\u201325).", [["respiratory tissues", "ANATOMY", 175, 194], ["trachea", "ANATOMY", 206, 213], ["lungs", "ANATOMY", 215, 220], ["air sac", "ANATOMY", 226, 233], ["respiratory", "ANATOMY", 244, 255], ["urogenital tissues", "ANATOMY", 273, 291], ["kidney", "ANATOMY", 303, 309], ["alimentary tract", "ANATOMY", 371, 387], ["esophagus", "ANATOMY", 399, 408], ["proventriculus", "ANATOMY", 410, 424], ["intestine", "ANATOMY", 430, 439], ["IBV infection", "DISEASE", 111, 124], ["DiscussionIBV", "CHEMICAL", 125, 138], ["respiratory disease", "DISEASE", 244, 263], ["nephritis", "DISEASE", 335, 344], ["IBV", "ORGANISM", 111, 114], ["respiratory tissues", "TISSUE", 175, 194], ["trachea", "MULTI-TISSUE_STRUCTURE", 206, 213], ["lungs", "ORGAN", 215, 220], ["air sac", "MULTI-TISSUE_STRUCTURE", 226, 233], ["urogenital tissues", "TISSUE", 273, 291], ["kidney", "ORGAN", 303, 309], ["alimentary tract", "ORGANISM_SUBDIVISION", 371, 387], ["esophagus", "ORGAN", 399, 408], ["proventriculus", "ORGAN", 410, 424], ["intestine", "ORGAN", 430, 439], ["IBV", "SPECIES", 111, 114], ["An attenuated or inactivated vaccine", "TREATMENT", 0, 36], ["pandemic strains", "PROBLEM", 55, 71], ["IBV infection", "PROBLEM", 111, 124], ["many respiratory tissues (including trachea, lungs, and air sac", "PROBLEM", 170, 233], ["respiratory disease", "PROBLEM", 244, 263], ["some urogenital tissues", "PROBLEM", 268, 291], ["minor or major nephritis", "PROBLEM", 320, 344], ["IBV", "OBSERVATION_MODIFIER", 111, 114], ["infection", "OBSERVATION", 115, 124], ["respiratory tissues", "ANATOMY", 175, 194], ["trachea", "ANATOMY", 206, 213], ["lungs", "ANATOMY", 215, 220], ["air sac", "ANATOMY", 226, 233], ["respiratory disease", "OBSERVATION", 244, 263], ["urogenital tissues", "ANATOMY", 273, 291], ["kidney", "ANATOMY", 303, 309], ["minor", "OBSERVATION_MODIFIER", 320, 325], ["major", "OBSERVATION_MODIFIER", 329, 334], ["nephritis", "OBSERVATION", 335, 344], ["alimentary tract", "ANATOMY", 371, 387], ["esophagus", "ANATOMY", 399, 408], ["proventriculus", "ANATOMY_MODIFIER", 410, 424], ["intestine", "ANATOMY", 430, 439]]], ["As expected, YN was most often detected in the trachea, lung, kidney, and bursa by RT-PCR, virus isolation, and IHC analysis.", [["trachea", "ANATOMY", 47, 54], ["lung", "ANATOMY", 56, 60], ["kidney", "ANATOMY", 62, 68], ["bursa", "ANATOMY", 74, 79], ["YN", "GENE_OR_GENE_PRODUCT", 13, 15], ["trachea", "MULTI-TISSUE_STRUCTURE", 47, 54], ["lung", "ORGAN", 56, 60], ["kidney", "ORGAN", 62, 68], ["bursa", "ORGAN", 74, 79], ["YN", "PROTEIN", 13, 15], ["PCR", "TEST", 86, 89], ["virus isolation", "TEST", 91, 106], ["IHC analysis", "TEST", 112, 124], ["trachea", "ANATOMY", 47, 54], ["lung", "ANATOMY", 56, 60], ["kidney", "ANATOMY", 62, 68], ["bursa", "ANATOMY", 74, 79]]], ["In addition, we found YN antigens partly from liver (1/10) and brain (1/10).DiscussionAmong 4 major structural proteins, the S glycoprotein is known to contain regions that induce neutralizing, serotype-specific, membrane fusion, attachment, and hemagglutination-inhibiting antibodies (5,26\u201328).", [["liver", "ANATOMY", 46, 51], ["brain", "ANATOMY", 63, 68], ["membrane", "ANATOMY", 213, 221], ["YN antigens", "GENE_OR_GENE_PRODUCT", 22, 33], ["liver", "ORGAN", 46, 51], ["brain", "ORGAN", 63, 68], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 125, 139], ["membrane", "CELLULAR_COMPONENT", 213, 221], ["5,26\u201328", "SIMPLE_CHEMICAL", 286, 293], ["YN antigens", "PROTEIN", 22, 33], ["DiscussionAmong 4 major structural proteins", "PROTEIN", 76, 119], ["S glycoprotein", "PROTEIN", 125, 139], ["hemagglutination-inhibiting antibodies", "PROTEIN", 246, 284], ["5,26\u201328", "PROTEIN", 286, 293], ["YN antigens", "PROBLEM", 22, 33], ["the S glycoprotein", "TREATMENT", 121, 139], ["neutralizing", "PROBLEM", 180, 192], ["membrane fusion", "TREATMENT", 213, 228], ["attachment", "PROBLEM", 230, 240], ["hemagglutination", "TEST", 246, 262], ["inhibiting antibodies", "PROBLEM", 263, 284], ["liver", "ANATOMY", 46, 51], ["brain", "ANATOMY", 63, 68], ["neutralizing", "OBSERVATION_MODIFIER", 180, 192], ["membrane fusion", "OBSERVATION", 213, 228]]], ["In addition, the S protein is a determinant of cell tropism (29,30).", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51], ["S protein", "PROTEIN", 17, 26], ["the S protein", "TEST", 13, 26], ["cell tropism", "PROBLEM", 47, 59], ["cell tropism", "OBSERVATION", 47, 59]]], ["Our data showed a 7-aa insertion between positions 72 and 78 (Figure 2, panel A) in the S1 gene of the YN strain and a 9-aa deletion in the N terminal of the S2, generating a stop codon.", [["YN strain", "ANATOMY", 103, 112], ["N", "CHEMICAL", 140, 141], ["S1", "GENE_OR_GENE_PRODUCT", 88, 90], ["YN", "GENE_OR_GENE_PRODUCT", 103, 105], ["S2", "GENE_OR_GENE_PRODUCT", 158, 160], ["7-aa insertion", "DNA", 18, 32], ["S1 gene", "DNA", 88, 95], ["9-aa deletion", "DNA", 119, 132], ["N terminal", "DNA", 140, 150], ["S2", "DNA", 158, 160], ["stop codon", "DNA", 175, 185], ["Our data", "TEST", 0, 8], ["Figure", "TEST", 62, 68], ["the YN strain", "PROBLEM", 99, 112], ["a 9-aa deletion", "PROBLEM", 117, 132], ["terminal", "ANATOMY_MODIFIER", 142, 150], ["S2", "ANATOMY", 158, 160], ["stop codon", "OBSERVATION", 175, 185]]], ["These changes are possibly related to the increased virulence observed for YN IBV, and reverse genetic analyses are needed to confirm these findings.DiscussionIn conclusion, we showed that YN-like viruses are a predominant strain in China and that YN IBV exhibits broad tissue tropism and severe pathogenicity in chickens.", [["tissue", "ANATOMY", 270, 276], ["YN IBV", "ORGANISM", 75, 81], ["YN-like viruses", "ORGANISM", 189, 204], ["YN IBV", "ORGANISM", 248, 254], ["tissue", "TISSUE", 270, 276], ["chickens", "ORGANISM", 313, 321], ["chickens", "SPECIES", 313, 321], ["YN IBV", "SPECIES", 75, 81], ["YN IBV", "SPECIES", 248, 254], ["chickens", "SPECIES", 313, 321], ["the increased virulence", "PROBLEM", 38, 61], ["YN IBV", "TREATMENT", 75, 81], ["reverse genetic analyses", "TEST", 87, 111], ["YN-like viruses", "PROBLEM", 189, 204], ["a predominant strain in China", "PROBLEM", 209, 238], ["IBV", "PROBLEM", 251, 254], ["broad tissue tropism", "PROBLEM", 264, 284], ["severe pathogenicity in chickens", "PROBLEM", 289, 321], ["possibly related to", "UNCERTAINTY", 18, 37], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["virulence", "OBSERVATION", 52, 61], ["viruses", "OBSERVATION", 197, 204], ["broad tissue tropism", "OBSERVATION", 264, 284], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["pathogenicity", "OBSERVATION", 296, 309]]], ["To better control IBV in China, more detailed analysis of the biologic and antigenic characteristics of the predominant IBV isolates is warranted, and assessments of the efficacy of current vaccines against these isolates are needed.", [["IBV", "ORGANISM", 18, 21], ["IBV", "ORGANISM", 120, 123], ["IBV", "SPECIES", 18, 21], ["IBV", "SPECIES", 120, 123], ["the predominant IBV isolates", "PROBLEM", 104, 132], ["current vaccines", "TREATMENT", 182, 198], ["these isolates", "TREATMENT", 207, 221], ["IBV", "OBSERVATION", 18, 21]]]], "9cb9167d7c58a6ee8d532caa90716a9f3db7df5f": [["INTRODUCTIONWe have built and successfully flown the Faint Intergalactic-medium Redshifted Emission Balloon (FIREBall-2), a joint mission funded by NASA and CNES.", [["the Faint Intergalactic-medium Redshifted Emission Balloon", "TREATMENT", 49, 107], ["a joint mission", "TREATMENT", 122, 137], ["Faint", "OBSERVATION_MODIFIER", 53, 58], ["Emission Balloon", "OBSERVATION", 91, 107], ["joint", "ANATOMY", 124, 129]]], ["FIREBall-2 is designed to discover and map faint emission from the circumgalactic medium of moderate redshift galaxies, in particular via Ly-\u03b1 (1216\u00c5), OVI (1033\u00c5) and CIV (1549\u00c5) redshifted into the 1950-2250\u00c5 stratospheric balloon window at redshifts of z(Ly-\u03b1) 0.7, z(OVI) 1.0, and z(CIV) 0.3.", [["map faint emission", "PROBLEM", 39, 57], ["moderate redshift galaxies", "PROBLEM", 92, 118], ["OVI", "TEST", 152, 155], ["CIV", "TEST", 168, 171], ["stratospheric balloon window", "TREATMENT", 211, 239], ["z", "TEST", 256, 257], ["z", "TEST", 269, 270], ["OVI", "TEST", 271, 274], ["z", "TEST", 285, 286], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["redshift galaxies", "OBSERVATION", 101, 118]]], ["The FIREBall-2 balloon payload is a modification of FIREBall (FB-1), a path-finding mission built by our team with two successful flights (2007 Engineering, 2009 Science Tuttle et al. 2008 Milliard et al. 2010) .", [["The FIREBall-2 balloon payload", "TREATMENT", 0, 30], ["balloon payload", "OBSERVATION", 15, 30]]], ["FB-1 provided the strongest constraints on intergalactic and circumgalactic (IGM, CGM) emission available from any instrument at the time (Milliard et al. 2010) .", [["FB-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["FB", "TEST", 0, 2], ["intergalactic", "TREATMENT", 43, 56]]], ["In contrast, FIREBall-2 was launched in a time of great strides in CGM science, with many detections of large Ly-\u03b1 emitting structures surrounding high redshift quasars (QSOs, Martin et al. 2015; Cantalupo et al. 2014; Borisova et al. 2016) .", [["large Ly-\u03b1 emitting structures", "PROBLEM", 104, 134], ["large", "OBSERVATION_MODIFIER", 104, 109], ["high redshift", "OBSERVATION", 147, 160]]], ["Despite these new, exciting discoveries, the lower redshift (z<2) CGM universe remains unexplored due to the inaccessibility of Ly-\u03b1 from the ground below a redshift of 1.9 (\u223c350 nm).", [["Ly-\u03b1", "CHEMICAL", 128, 132], ["Ly-\u03b1", "CHEMICAL", 128, 132], ["Ly-\u03b1", "GENE_OR_GENE_PRODUCT", 128, 132], ["Ly-\u03b1", "PROTEIN", 128, 132], ["the lower redshift (z", "TEST", 41, 62], ["CGM universe", "TEST", 66, 78], ["a redshift", "TEST", 155, 165], ["new", "OBSERVATION_MODIFIER", 14, 17], ["lower", "ANATOMY_MODIFIER", 45, 50]]], ["A 1-meter primary parabolic mirror 2.", [["parabolic mirror", "OBSERVATION", 18, 34]]], ["A sophisticated 6 axis attitude and pointing control system, yielding less than 1 arcsec RMS over long integration times.INTRODUCTION3.", [["A sophisticated 6 axis attitude", "TREATMENT", 0, 31], ["pointing control system", "PROBLEM", 36, 59], ["6 axis", "OBSERVATION_MODIFIER", 16, 22]]], ["A delta-doped, AR-coated UV optimized electron multiplying CCD (EMCCD), which provided >50% efficiency in the 1980-2130\u00c5 bandpass.INTRODUCTION4.", [["AR", "PROTEIN", 15, 17], ["A delta-doped, AR-coated UV", "TREATMENT", 0, 27]]], ["The first balloon flight of a multi-object spectrograph, using pre-selected targets and custom spherical slit masks.5.A flight test of an aspheric anamorphic grating developed at HORIBA Jobin Yvon.", [["a multi-object spectrograph", "TEST", 28, 55], ["custom spherical slit masks", "TREATMENT", 88, 115], ["A flight test", "TEST", 118, 131], ["an aspheric anamorphic grating", "PROBLEM", 135, 165], ["slit masks", "OBSERVATION", 105, 115]]], ["4 completed PhDs (including 3 women), with an additional 7 students receiving significant mission training as part of their thesis work.5.The 2018 flight of FIREBall-2 occurred on September 22nd from Fort Sumner, NM, with launch support provided by NASA's Columbia Scientific Ballooning Facility (CSBF).", [["women", "ORGANISM", 30, 35], ["women", "SPECIES", 30, 35], ["significant mission training", "TREATMENT", 78, 106], ["launch support", "TREATMENT", 222, 236]]], ["The balloon and payload reached an altitude of 39 km several hours after launch and then began a slow descent as a result of a hole in the 40 million cubic foot (MCF) balloon.", [["foot", "ORGANISM_SUBDIVISION", 156, 160], ["The balloon", "TREATMENT", 0, 11], ["payload", "TREATMENT", 16, 23], ["a slow descent", "PROBLEM", 95, 109], ["a hole in the 40 million cubic foot (MCF) balloon", "TREATMENT", 125, 174], ["balloon", "OBSERVATION", 4, 11], ["payload", "OBSERVATION_MODIFIER", 16, 23], ["altitude", "OBSERVATION_MODIFIER", 35, 43], ["foot", "ANATOMY", 156, 160]]], ["The balloon flight was terminated after 4 hrs of dark time, with less than one hour spent above the minimum science altitude of 32 km.", [["The balloon flight", "TREATMENT", 0, 18], ["balloon", "OBSERVATION", 4, 11]]], ["Upon landing, the payload suffered some structural damage that the team is working to repair.", [["some structural damage", "PROBLEM", 35, 57], ["repair", "TREATMENT", 86, 92], ["structural", "OBSERVATION_MODIFIER", 40, 50], ["damage", "OBSERVATION", 51, 57]]], ["We expect a second launch of the refurbished payload in 2021, due to delays from COVID-19.", [["the refurbished payload", "TREATMENT", 29, 52], ["COVID", "TEST", 81, 86]]], ["We give an overview of the analysis of the data collected during flight, which was severely limited by the low altitude and high background.5.The paper is arranged as follows.", [["the analysis", "TEST", 23, 35], ["the data", "TEST", 39, 47], ["the low altitude and high background", "PROBLEM", 103, 139], ["low altitude", "OBSERVATION_MODIFIER", 107, 119], ["high background", "OBSERVATION", 124, 139]]], ["Previous flights of the FIREBall payload are described in Section 1.2, with changes from the earlier spectrograph design detailed in Section 1.3.", [["the FIREBall payload", "TREATMENT", 20, 40]]], ["Major instrument components and their performance are described in Section 2, including the telescope (Section 2.1), spectrograph optical design (Section 2.2), delta-doped UV detector (Section 2.3), cooling and vacuum system (Section 2.4), thermal control system (Section 2.5), coarse and fine guidance systems (Sections 2.6 and 2.7), and the communications system (Section 2.8).", [["delta-doped UV detector (Section", "TREATMENT", 160, 192], ["cooling and vacuum system", "TREATMENT", 199, 224], ["thermal control system", "TREATMENT", 240, 262], ["coarse and fine guidance systems", "TEST", 278, 310], ["Sections", "TEST", 312, 320], ["vacuum system", "ANATOMY", 211, 224]]], ["Some preliminary data analysis is shown in Section 4, covering noise from smearing, cosmic rays, scattered light, and overall sensitivity.", [["Some preliminary data analysis", "TEST", 0, 30], ["cosmic rays", "TEST", 84, 95], ["scattered", "OBSERVATION_MODIFIER", 97, 106]]], ["We discuss the future of the FIREBall mission in Section 5 and the importance of continuing UV CGM science in future, more ambitious telescopes in Section 6.State of the art in CGM scienceStudies of the circumgalactic medium (CGM) are now entering their second decade.", [["continuing UV CGM science", "TREATMENT", 81, 106]]], ["Since the installation of the Cosmic Origins Spectrograph (COS) on HST (Green et al. 2012) , observations of the CGM were conducted via absorption line studies of foreground galaxies using background QSOs (Croft et al. 2002; Tumlinson et al. 2013; Lee et al. 2014; Bordoloi et al. 2014) , coincident quasars (Quasars Probing Quasars, Hennawi et al. 2006) , and blind searches for galaxies around very bright quasars (Keck Baryonic Structure Survey, Rudie et al. 2012) .", [["the CGM", "TEST", 109, 116], ["absorption line studies", "TEST", 136, 159], ["galaxies", "PROBLEM", 380, 388]]], ["These observations provided the first view of the CGM around nearby galaxies, but were limited by the method.State of the art in CGM scienceThese surveys have conclusively detected absorption from HI, MgII, CIV, OVI and other ionized metals within the projected virial radius of foreground galaxies.", [["MgII", "SIMPLE_CHEMICAL", 201, 205], ["OVI", "SIMPLE_CHEMICAL", 212, 215], ["These surveys", "TEST", 140, 153], ["HI", "PROBLEM", 197, 199], ["MgII", "TREATMENT", 201, 205], ["CIV", "TREATMENT", 207, 210], ["OVI", "TREATMENT", 212, 215], ["other ionized metals", "TREATMENT", 220, 240], ["ionized metals", "OBSERVATION", 226, 240], ["virial radius", "OBSERVATION", 262, 275], ["foreground galaxies", "OBSERVATION", 279, 298]]], ["Because these studies rely on serendipitous sightlines that typically illuminate only a single beam through the CGM of a galaxy, they are powerful but limited.", [["these studies", "TEST", 8, 21], ["serendipitous sightlines", "PROBLEM", 30, 54]]], ["There is no way to distinguish between the presence of gas in filaments, a dispersed collection of gas clumps, or a smooth distribution of gas within the CGM.", [["filaments", "ANATOMY", 62, 71], ["gas in filaments", "PROBLEM", 55, 71], ["a dispersed collection of gas clumps", "PROBLEM", 73, 109], ["a smooth distribution of gas within the CGM", "PROBLEM", 114, 157], ["no way", "UNCERTAINTY", 9, 15], ["gas", "OBSERVATION", 55, 58], ["dispersed", "OBSERVATION_MODIFIER", 75, 84], ["collection", "OBSERVATION_MODIFIER", 85, 95], ["gas clumps", "OBSERVATION", 99, 109], ["smooth", "OBSERVATION_MODIFIER", 116, 122], ["distribution", "OBSERVATION_MODIFIER", 123, 135], ["gas", "OBSERVATION_MODIFIER", 139, 142]]], ["Statistical stacking of these galaxies produces a composite picture of the CGM, but at the price of smoothing out revealing spatial/kinematic structures, including disks, bipolar outflows, warps, tidal tails, filaments, etc. Any one galaxy typically does not have multiple background QSOs and so most studies have used statistical combinations of similar type galaxies to develop an overall picture of the CGM.", [["filaments", "ANATOMY", 209, 218], ["bipolar outflows", "DISEASE", 171, 187], ["filaments", "CELLULAR_COMPONENT", 209, 218], ["Statistical stacking of these galaxies", "PROBLEM", 0, 38], ["the CGM", "TEST", 71, 78], ["spatial/kinematic structures", "PROBLEM", 124, 152], ["disks", "PROBLEM", 164, 169], ["bipolar outflows", "PROBLEM", 171, 187], ["multiple background QSOs", "PROBLEM", 264, 288], ["similar type galaxies", "PROBLEM", 347, 368], ["the CGM", "TEST", 402, 409], ["galaxies", "OBSERVATION", 30, 38], ["kinematic structures", "OBSERVATION", 132, 152], ["bipolar outflows", "OBSERVATION", 171, 187], ["tidal tails", "OBSERVATION", 196, 207], ["galaxy", "OBSERVATION", 233, 239]]], ["These studies have pointed the way forward for more targeted, but significantly more challenging, observations of direct emission from the CGM.State of the art in CGM scienceImproved detectors, higher throughput optics, and state-of-the-art instruments, like the Palomar and Keck Cosmic Web Imagers (PCWI & KCWI, Martin et al. 2014a Martin et al. ,b, 2015 Martin et al. , 2016 and Multi Unit Spectroscopic Explorer (MUSE, Borisova et al. 2016; Arrigoni Battaia et al. 2016 , 2019 , are pioneering a new field of IGM astronomy at high redshifts where Ly-\u03b1 is observable at visible wavelengths.State of the art in CGM scienceAfter the first exciting discoveries of the Slug and other similar nebulae (Cantalupo et al. 2014; Martin et al. 2015) , there has been an increasing body of work examining this new population of CGM structures.", [["Slug", "GENE_OR_GENE_PRODUCT", 667, 671], ["CGM structures", "TISSUE", 819, 833], ["Ly-\u03b1", "PROTEIN", 550, 554], ["Slug", "PROTEIN", 667, 671], ["These studies", "TEST", 0, 13], ["the CGM", "TEST", 135, 142], ["IGM astronomy", "PROBLEM", 512, 525], ["the Slug", "PROBLEM", 663, 671], ["new", "OBSERVATION_MODIFIER", 499, 502], ["IGM astronomy", "OBSERVATION", 512, 525], ["increasing", "OBSERVATION_MODIFIER", 762, 772]]], ["Borisova et al. (2016) have found a 100% incidence of large Ly-\u03b1 nebula around z>3 QSOs.", [["large Ly-\u03b1 nebula around z", "TREATMENT", 54, 80], ["large", "OBSERVATION_MODIFIER", 54, 59]]], ["Wisotzki et al. (2016) observed the Hubble Deep Field South, finding extended Ly-\u03b1 halos around 21 out of 26 galaxies with a redshift range of 3<z<6.", [["halos", "TEST", 83, 88], ["a redshift range", "TEST", 123, 139]]], ["Cai et al. (2018) found one of many extremely large Ly-\u03b1 nebula as part of a close QSO pair (around z\u223c 2.3), linking cosmic over-densities to these structures.", [["QSO pair", "DNA", 83, 91], ["many extremely large Ly-\u03b1 nebula", "PROBLEM", 31, 63], ["a close QSO pair", "PROBLEM", 75, 91], ["linking cosmic over-densities to these structures", "PROBLEM", 109, 158], ["large", "OBSERVATION_MODIFIER", 46, 51], ["nebula", "OBSERVATION", 57, 63], ["densities", "OBSERVATION", 129, 138]]], ["A follow up paper in 2019 found 16 QSOs with extended emission at lower redshifts (2.1<z<2.3) (Cai et al. 2019) .", [["extended emission at lower redshifts", "PROBLEM", 45, 81]]], ["Martin et al. (2019) has found that these nebulae have complex velocity structures that may indicate possible rotation and radial inflow.", [["nebulae", "ANATOMY", 42, 49], ["radial", "ANATOMY", 123, 129], ["nebulae", "CANCER", 42, 49], ["complex velocity structures", "PROBLEM", 55, 82], ["rotation and radial inflow", "PROBLEM", 110, 136], ["complex", "OBSERVATION_MODIFIER", 55, 62], ["velocity", "OBSERVATION", 63, 71], ["may indicate possible", "UNCERTAINTY", 88, 109], ["radial", "ANATOMY_MODIFIER", 123, 129], ["inflow", "OBSERVATION", 130, 136]]], ["This survey finds the incidence of large Ly-\u03b1 structures to be less frequent and with a lower covering fraction than those at higher redshift, likely indicating an evolutionary change between redshifts.State of the art in CGM scienceThe realm of CGM direct imaging is still in its infancy and there have been few attempts to link these individual observations to the larger surveys conducted via absorption lines.", [["large Ly-\u03b1 structures", "PROBLEM", 35, 56], ["a lower covering fraction", "PROBLEM", 86, 111], ["an evolutionary change between redshifts", "PROBLEM", 161, 201], ["CGM direct imaging", "TEST", 246, 264], ["absorption lines", "TREATMENT", 396, 412], ["large", "OBSERVATION_MODIFIER", 35, 40], ["Ly", "OBSERVATION_MODIFIER", 41, 43], ["less", "OBSERVATION_MODIFIER", 63, 67], ["frequent", "OBSERVATION_MODIFIER", 68, 76], ["lower", "OBSERVATION_MODIFIER", 88, 93], ["higher redshift", "OBSERVATION", 126, 141], ["likely indicating", "UNCERTAINTY", 143, 160], ["evolutionary change", "OBSERVATION", 164, 183], ["few", "OBSERVATION_MODIFIER", 309, 312], ["absorption lines", "OBSERVATION", 396, 412]]], ["In addition, for the lowest redshift galaxies where star formation rates are declining throughout the universe, CGM direct imaging is not possible on the ground due to the limits of atmospheric transmission.State of the art in CGM scienceThe typical blue cutoff on the ground is around 350nm, where extinction is primarily driven by Rayleigh scattering Buton et al. (2013) .", [["the lowest redshift galaxies", "PROBLEM", 17, 45], ["star formation rates", "TEST", 52, 72], ["CGM direct imaging", "TEST", 112, 130], ["not possible", "UNCERTAINTY", 134, 146], ["atmospheric transmission", "OBSERVATION", 182, 206], ["typical", "OBSERVATION_MODIFIER", 242, 249], ["blue cutoff", "OBSERVATION", 250, 261], ["350nm", "OBSERVATION_MODIFIER", 286, 291]]], ["Below 320nm, the primary absorber is Ozone, which remains significant through the ultraviolet.", [["Ozone", "CHEMICAL", 37, 42], ["Ozone", "CHEMICAL", 37, 42], ["Ozone", "SIMPLE_CHEMICAL", 37, 42], ["320nm", "OBSERVATION_MODIFIER", 6, 11], ["Ozone", "OBSERVATION", 37, 42]]], ["At sufficient altitudes (above 30 km), there is a transmission window between 195 and 220 nm where ozone and molecular oxygen both have troughs in their absorption cross sections (Matuszewski 2012; Ackerman 1971) .", [["ozone", "CHEMICAL", 99, 104], ["oxygen", "CHEMICAL", 119, 125], ["ozone", "CHEMICAL", 99, 104], ["oxygen", "CHEMICAL", 119, 125], ["ozone", "SIMPLE_CHEMICAL", 99, 104], ["oxygen", "SIMPLE_CHEMICAL", 119, 125], ["molecular oxygen", "TREATMENT", 109, 125], ["oxygen", "OBSERVATION_MODIFIER", 119, 125]]], ["The transmission increases with altitude.", [["increases", "OBSERVATION_MODIFIER", 17, 26]]], ["Figure 1 (Figure 3 .2 from (Matuszewski 2012)) shows atmospheric transmission at 34 km.State of the art in CGM scienceIn this rich landscape, FIREBall-2 provides crucial detections of the CGM around several hundred low redshift galaxies, a unique capability at a perfect time.Previous flights of FIREBallThe FIREBall telescope has flown two previous times, from Palestine, TX in 2007 (Tuttle et al. 2008 ) and from Fort Sumner, NM in 2009 (Milliard et al. 2010 .", [["FIREBall-2", "CELL", 142, 152], ["FIREBall-2", "DNA", 142, 152], ["redshift galaxies", "OBSERVATION", 219, 236]]], ["The original FIREBall instrument (FB-1) consisted of a fiber-fed integral field unit (IFU), which used an Offner spectrograph design and a GALEX NUV spare microchannel plate (MCP) as the detector.Previous flights of FIREBallThe FB-1 spectrograph had a resolution of R=5000, a plate scale of 12 \u00b5m arcsec \u22121 , an angular resolution of 10 arcsec, and a circular field of view with a diameter of 160 arcsec.", [["FIREBall", "DNA", 216, 224], ["FB-1 spectrograph", "DNA", 228, 245], ["The original FIREBall instrument (FB", "TREATMENT", 0, 36], ["a GALEX NUV spare microchannel plate (MCP)", "TREATMENT", 137, 179], ["The FB", "TEST", 224, 230], ["a plate scale", "TEST", 274, 287], ["angular", "OBSERVATION_MODIFIER", 312, 319], ["resolution", "OBSERVATION_MODIFIER", 320, 330], ["circular", "OBSERVATION_MODIFIER", 351, 359]]], ["The fiber bundle consisted of 300 fibers with a core diameter of around 8 arcsec per fiber.", [["fiber bundle", "ANATOMY", 4, 16], ["fibers", "ANATOMY", 34, 40], ["The fiber bundle", "TREATMENT", 0, 16], ["a core diameter", "TREATMENT", 46, 61], ["fiber", "OBSERVATION_MODIFIER", 4, 9], ["bundle", "OBSERVATION_MODIFIER", 10, 16], ["300 fibers", "OBSERVATION_MODIFIER", 30, 40], ["diameter", "OBSERVATION_MODIFIER", 53, 61]]], ["The telescope (1 m parabolic primary mirror and 1.2 m flat siderostat mirror) and gondola structure remained unchanged between all flights of FIREBall, including FB-1 in 2007 and 2009 and the most recent FIREBall-2 flight in 2018.", [["parabolic primary mirror", "TEST", 19, 43], ["1.2 m flat siderostat mirror) and gondola structure", "PROBLEM", 48, 99], ["FB", "TEST", 162, 164], ["unchanged", "OBSERVATION_MODIFIER", 109, 118]]], ["A computed atmospheric transmission curve for observations from an altitude of 34 km (112 kft, 7 mbar), roughly that for the second FIREBall flight in 2009.", [["A computed atmospheric transmission curve", "TEST", 0, 41], ["an altitude", "TEST", 64, 75]]], ["The calculation included absorption by O2, N2 and N2O, and Rayleigh scattering effects.", [["O2", "CHEMICAL", 39, 41], ["N2O", "CHEMICAL", 50, 53], ["O2", "CHEMICAL", 39, 41], ["N2", "CHEMICAL", 43, 45], ["N2O", "CHEMICAL", 50, 53], ["O2", "SIMPLE_CHEMICAL", 39, 41], ["N2O", "SIMPLE_CHEMICAL", 50, 53], ["O2", "TREATMENT", 39, 41], ["N2", "TREATMENT", 43, 45], ["N2O", "TREATMENT", 50, 53], ["Rayleigh scattering effects", "PROBLEM", 59, 86], ["Rayleigh", "OBSERVATION", 59, 67], ["scattering effects", "OBSERVATION", 68, 86]]], ["The solid curve shows the transmission for a target at the maximal elevation of the FIREBall telescope, 70 \u2022 , the dot-dashed curve for the minimum, 40 \u2022 .", [["The solid curve", "TEST", 0, 15], ["the FIREBall telescope", "TREATMENT", 80, 102], ["the dot-dashed curve", "TEST", 111, 131]]], ["The dashed and dotted curves show the oxygen (O2) and ozone contributions to the transmission losses.", [["oxygen", "CHEMICAL", 38, 44], ["O2", "CHEMICAL", 46, 48], ["ozone", "CHEMICAL", 54, 59], ["oxygen", "CHEMICAL", 38, 44], ["O2", "CHEMICAL", 46, 48], ["ozone", "CHEMICAL", 54, 59], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["O2", "SIMPLE_CHEMICAL", 46, 48], ["ozone", "SIMPLE_CHEMICAL", 54, 59], ["the oxygen (O2", "TREATMENT", 34, 48], ["the transmission losses", "PROBLEM", 77, 100], ["oxygen", "OBSERVATION_MODIFIER", 38, 44]]], ["The light gray areas lie outside of the FIREBall bandpass; the narrow bands near the center correspond to three nitric oxide airglow bands.", [["nitric oxide", "CHEMICAL", 112, 124], ["nitric oxide", "CHEMICAL", 112, 124], ["nitric oxide", "SIMPLE_CHEMICAL", 112, 124], ["nitric oxide airglow bands", "PROTEIN", 112, 138], ["the narrow bands", "PROBLEM", 59, 75], ["three nitric oxide airglow bands", "TREATMENT", 106, 138], ["light gray", "OBSERVATION_MODIFIER", 4, 14], ["FIREBall bandpass", "OBSERVATION", 40, 57], ["narrow bands", "OBSERVATION", 63, 75], ["nitric oxide", "OBSERVATION", 112, 124], ["airglow bands", "OBSERVATION", 125, 138]]], ["The accessible redshift ranges for the three principal FIREBall emission lines are overplotted on the axes near the top of the image.2007 FlightThe 2007 flight of FIREBall-1 was an engineering flight.", [["FIREBall emission lines", "CELL_LINE", 55, 78], ["the three principal FIREBall emission lines", "TREATMENT", 35, 78], ["accessible", "OBSERVATION_MODIFIER", 4, 14], ["redshift", "OBSERVATION_MODIFIER", 15, 23], ["ranges", "OBSERVATION_MODIFIER", 24, 30], ["three", "OBSERVATION_MODIFIER", 39, 44], ["principal", "OBSERVATION_MODIFIER", 45, 54], ["FIREBall", "OBSERVATION_MODIFIER", 55, 63], ["emission lines", "OBSERVATION", 64, 78], ["top", "OBSERVATION_MODIFIER", 116, 119]]], ["The telescope was launched on July 22nd, 2007 from the CSBF location in Palestine, TX.", [["TX", "TREATMENT", 83, 85]]], ["The instrument was only able to maintain pointing for up to 1 minute at a time due to a pivot failure that occurred during the launch and severely limited pointing control.2009 FlightThe 2009 flight was launched from Fort Sumner, NM on June 7th, 2009.", [["a pivot failure", "PROBLEM", 86, 101], ["severely limited pointing control", "PROBLEM", 138, 171], ["pivot failure", "OBSERVATION", 88, 101]]], ["This payload used the same spectrograph as the 2007 flight, with an improved fiber bundle and a reinforced pivot.", [["fiber bundle", "ANATOMY", 77, 89], ["This payload", "TREATMENT", 0, 12], ["a reinforced pivot", "TREATMENT", 94, 112], ["reinforced pivot", "OBSERVATION", 96, 112]]], ["The balloon reached an average altitude of 113 kft (yielding 25% atmospheric transmission) due to an unusual monsoon weather pattern, rather than the desired 120 kft (up to 80% transmission).", [["The balloon", "TREATMENT", 0, 11], ["an average altitude", "TEST", 20, 39], ["balloon", "OBSERVATION", 4, 11], ["average", "OBSERVATION_MODIFIER", 23, 30], ["altitude", "OBSERVATION_MODIFIER", 31, 39]]], ["The payload performed flawlessly and obtained a full night of observations on three science targets.2009 FlightThe science targets consisted of a section of the GROTH strip (Davis et al. 2007) , QSO PG1718+481 (Crighton et al. 2003) , and the DEEP2 ZLE field (Simard et al. 2002) .", [["PG", "CHEMICAL", 199, 201]]], ["Due in part to low instrument throughput, no CGM emission was detected from these targets down to a sensitivity limit of \u223c75,000 LU for a single galaxy, or 23,000 LU for a stack of 10 (1 LU = 1 photon cm \u22122 s \u22121 sr \u22121 ).", [["CGM emission", "TEST", 45, 57], ["a stack", "TEST", 170, 177], ["photon cm", "TEST", 194, 203]]], ["This lack of detection motivated the complete redesign of the FIREBall-2 spectrograph as described in Section 1.3.Changes between FIREBall-1 and FIREBall-2The spectrograph was redesigned to increase the chances of detecting emission from the CGM of z=0.7 galaxies via Ly-\u03b1.", [["Ly-\u03b1.", "CHEMICAL", 268, 273], ["Ly-\u03b1.", "CHEMICAL", 268, 273], ["FIREBall-2", "CELL", 145, 155], ["FIREBall-2 spectrograph", "DNA", 62, 85], ["FIREBall", "DNA", 130, 138], ["FIREBall", "DNA", 145, 153], ["FIREBall", "TEST", 130, 138], ["the CGM", "TEST", 238, 245], ["z", "TEST", 249, 250]]], ["The changes increased the field of view, number of targets per observation, and overall instrument throughput.", [["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["In addition, galaxies were pre-selected based in part on likelihood of expected emission.Changes between FIREBall-1 and FIREBall-2A two-mirror field corrector was designed and added to the optical path after the prime focus to increase the usable field of view to a \u223c30 arcmin diameter circle.", [["FIREBall-1 and FIREBall-2A two-mirror field corrector", "DNA", 105, 158], ["FIREBall", "TEST", 105, 113]]], ["The field of view was a 28x12 arcmin 2 rectangle set by the size of the detector.", [["a 28x12 arcmin 2 rectangle", "TREATMENT", 22, 48], ["size", "OBSERVATION_MODIFIER", 60, 64]]], ["The fiber bundle was replaced with a multi-object slit mask, which could target up to 70 galaxies per field, although this density of targets causes some spectral overlap.", [["fiber bundle", "ANATOMY", 4, 16], ["The fiber bundle", "TREATMENT", 0, 16], ["a multi-object slit mask", "TREATMENT", 35, 59], ["some spectral overlap", "PROBLEM", 149, 170], ["fiber", "OBSERVATION_MODIFIER", 4, 9], ["bundle", "OBSERVATION_MODIFIER", 10, 16], ["slit mask", "OBSERVATION", 50, 59], ["spectral overlap", "OBSERVATION", 154, 170]]], ["A rotating carousel allows for selection between nine different masks with 4 designed for particular galaxy fields.", [["A rotating carousel", "TREATMENT", 0, 19], ["selection between nine different masks", "TREATMENT", 31, 69]]], ["Four other masks are used for calibration and one slot is left empty.", [["Four other masks", "TREATMENT", 0, 16], ["masks", "OBSERVATION", 11, 16], ["left", "ANATOMY_MODIFIER", 58, 62], ["empty", "OBSERVATION", 63, 68]]], ["Using a slit mask instead of a fiber bundle increased the sensitivity by eliminating the potential for UV absorption in the fibers.", [["fibers", "ANATOMY", 124, 130], ["fibers", "CELLULAR_COMPONENT", 124, 130], ["a slit mask", "TREATMENT", 6, 17], ["a fiber bundle", "TREATMENT", 29, 43], ["UV absorption in the fibers", "TREATMENT", 103, 130]]], ["The angular resolution was also improved, from 10 arcsec to 4.5 arcsec through a new spectrograph design, in order to better separate the galaxy emission from the CGM signal.", [["angular", "OBSERVATION_MODIFIER", 4, 11], ["resolution", "OBSERVATION_MODIFIER", 12, 22], ["improved", "OBSERVATION_MODIFIER", 32, 40], ["galaxy emission", "OBSERVATION", 138, 153]]], ["The GALEX spare NUV MCP detector was replaced with a high efficiency delta-doped EMCCD, which increased throughput by a factor of 8.Changes between FIREBall-1 and FIREBall-2The change in detector from an MCP to an EMCCD drove additional technical changes from FB-1.", [["FIREBall-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["FB-1", "GENE_OR_GENE_PRODUCT", 260, 264], ["GALEX", "PROTEIN", 4, 9], ["NUV", "PROTEIN", 16, 19], ["delta-doped EMCCD", "CELL_LINE", 69, 86], ["MCP", "PROTEIN", 204, 207], ["EMCCD", "DNA", 214, 219], ["The GALEX spare NUV MCP detector", "TREATMENT", 0, 32], ["a high efficiency delta-doped EMCCD", "PROBLEM", 51, 86], ["FIREBall", "TEST", 148, 156], ["high efficiency", "OBSERVATION_MODIFIER", 53, 68], ["increased", "OBSERVATION_MODIFIER", 94, 103]]], ["This change added a requirement that the spectrograph track the sky for long (\u223c100 s) exposures.", [["the spectrograph", "TEST", 37, 53]]], ["A MCP is able to time tag photons and therefore the instrument does not need sidereal tracking ability, while an EMCCD would be read out at longer than 100 second intervals, necessitating better pointing.", [["MCP", "GENE_OR_GENE_PRODUCT", 2, 5], ["MCP", "PROTEIN", 2, 5]]], ["The use of the slit mask also demanded an improved pointing system to keep all targets in their slits without excess jitter.", [["the slit mask", "TREATMENT", 11, 24], ["excess jitter", "PROBLEM", 110, 123], ["excess jitter", "OBSERVATION", 110, 123]]], ["The gondola pointing system was improved to provide significantly finer pointing stability (requirement went from 6 to < 2 arcseconds rms error, although the in flight performance was better).", [["stability", "OBSERVATION_MODIFIER", 81, 90]]], ["The CCD detector must be operated at < -100 \u2022 C to reduce thermal noise, and so required a cryocooler and associated cold chain, charcoal getter, and vacuum system.", [["The CCD detector", "TEST", 0, 16], ["thermal noise", "PROBLEM", 58, 71], ["a cryocooler and associated cold chain", "PROBLEM", 89, 127], ["charcoal", "TREATMENT", 129, 137], ["vacuum system", "TREATMENT", 150, 163], ["cold chain", "OBSERVATION", 117, 127], ["charcoal getter", "OBSERVATION", 129, 144], ["vacuum system", "OBSERVATION", 150, 163]]], ["The CCD controller, CMOS guider, and cryocooler reject heat also required significant cooling and the addition of a thermal control system.Overall Sensitivity ImprovementsAs described in the proceeding sections, FIREBall-2 is designed to increase the sensitivity over FB-1.", [["sections", "ANATOMY", 202, 210], ["FB-1", "GENE_OR_GENE_PRODUCT", 268, 272], ["The CCD controller", "TREATMENT", 0, 18], ["CMOS guider", "TREATMENT", 20, 31], ["significant cooling", "TREATMENT", 74, 93], ["a thermal control system", "TREATMENT", 114, 138], ["Sensitivity ImprovementsAs", "OBSERVATION", 147, 173]]], ["The expected sensitivity calculation is conducted in detail in Picouet (2019) , and is briefly summarized here.", [["The expected sensitivity calculation", "TEST", 0, 36]]], ["The calculation for expected performance is based on throughput measurements of the optical system, noise performance of the detector, expected sky background, and nominal altitude transmission at 40k or 130 kft.", [["nominal altitude transmission", "TREATMENT", 164, 193]]], ["The anticipated sensitivity is 8,000 LU, an improvement of a factor of 8 over FB-1.MAJOR INSTRUMENT COMPONENTSThe major instrument components of FIREBall-2 are described below.", [["FB-1", "GENE_OR_GENE_PRODUCT", 78, 82], ["FIREBall-2", "GENE_OR_GENE_PRODUCT", 145, 155], ["FIREBall", "PROTEIN", 145, 153], ["The anticipated sensitivity", "TEST", 0, 27], ["a factor", "TEST", 59, 67], ["major", "OBSERVATION_MODIFIER", 114, 119], ["instrument", "OBSERVATION_MODIFIER", 120, 130], ["components", "OBSERVATION_MODIFIER", 131, 141]]], ["More detail is provided in additional papers that focus on the fine guidance system (Montel 2019), the overall attitude control, the calibration strategy (Picouet 2019) , and the detector performance (Kyne 2019) .", [["the detector performance", "TEST", 175, 199]]], ["The overall instrument performance is described in Section 3.3.Telescope Assembly and GondolaThe FIREBall-2 telescope and gondola are the same structures described in Tuttle et al. (2008) and Milliard et al. (2010) .", [["FIREBall-2 telescope", "DNA", 97, 117], ["The FIREBall-2 telescope and gondola", "TREATMENT", 93, 129], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["instrument", "OBSERVATION", 12, 22]]], ["The telescope assembly consists first of a flat 1.2 m siderostat mirror, which provides elevation control between 40-70 \u2022 altitude and coarse x and y pointing via a tip/tilt frame. the elevation limits are due to a mechanical hard stop at 40 \u2022 and the balloon and top of gondola at 70 \u2022 .", [["a flat 1.2 m siderostat mirror", "TREATMENT", 41, 71], ["elevation control", "TREATMENT", 88, 105], ["a tip/tilt frame", "TREATMENT", 163, 179], ["a mechanical hard stop", "PROBLEM", 213, 235], ["the balloon and top of gondola", "TREATMENT", 248, 278], ["elevation", "OBSERVATION_MODIFIER", 88, 97], ["elevation limits", "OBSERVATION", 185, 201], ["balloon", "OBSERVATION", 252, 259]]], ["The siderostat feeds the primary mirror, an f/2.5 1 m parabolic mirror.", [["siderostat", "CHEMICAL", 4, 14], ["siderostat", "CHEMICAL", 4, 14], ["siderostat", "SIMPLE_CHEMICAL", 4, 14], ["The siderostat feeds", "TREATMENT", 0, 20]]], ["The parabola debonded during the 2007 landing, but was otherwise unharmed.", [["debonded", "OBSERVATION_MODIFIER", 13, 21]]], ["The mirror coatings were stripped by Optical Mechanics, Inc., which originally fabricated them, and were then re-coated at Goddard Space Flight Center with an Al/MgF 2 coating optimized for 205 nm.Telescope Assembly and GondolaThe gondola structure consists of carbon-fiber rods with a sparse set of connecting nodes, forming a stiff (first resonance above 20 Hz), thermally-stable kinematic structure.", [["Al", "CHEMICAL", 159, 161], ["MgF 2", "CHEMICAL", 162, 167], ["carbon", "CHEMICAL", 261, 267], ["The mirror coatings", "TREATMENT", 0, 19], ["an Al/MgF 2 coating", "TREATMENT", 156, 175], ["carbon-fiber rods", "TREATMENT", 261, 278], ["connecting nodes", "PROBLEM", 300, 316], ["a stiff (first resonance", "PROBLEM", 326, 350], ["carbon-", "OBSERVATION", 261, 268], ["fiber rods", "OBSERVATION", 268, 278], ["sparse", "OBSERVATION_MODIFIER", 286, 292], ["connecting nodes", "OBSERVATION", 300, 316], ["stiff", "OBSERVATION_MODIFIER", 328, 333], ["stable", "OBSERVATION_MODIFIER", 375, 381], ["kinematic structure", "OBSERVATION", 382, 401]]], ["Optical mounts to the gondola have been athermalized to compensate for residual expansion effects in the rods and the aluminum couplings.", [["aluminum", "CHEMICAL", 118, 126], ["aluminum", "CHEMICAL", 118, 126], ["aluminum", "SIMPLE_CHEMICAL", 118, 126], ["residual expansion effects in the rods", "PROBLEM", 71, 109], ["the aluminum couplings", "TREATMENT", 114, 136], ["expansion", "OBSERVATION", 80, 89], ["aluminum couplings", "OBSERVATION", 118, 136]]], ["The gondola has also flown two previous times, sustaining damage typically only to the carbon fiber rods, which are replaced between flights.Instrument Optical DesignThe choice to increase the field of view and change from a fiber-fed IFU to a multi-object mask spectrograph necessitated a complete redesign of the spectrograph optics.", [["carbon", "CHEMICAL", 87, 93], ["sustaining damage", "PROBLEM", 47, 64], ["the carbon fiber rods", "TREATMENT", 83, 104], ["a multi-object mask spectrograph", "TREATMENT", 242, 274], ["the spectrograph optics", "TEST", 311, 334], ["damage", "OBSERVATION", 58, 64], ["carbon fiber rods", "OBSERVATION", 87, 104]]], ["Briefly, there is a two mirror field corrector to increase the quality of the field over a 30 arcmin field of view.", [["a two mirror field corrector", "TREATMENT", 18, 46]]], ["The slit mask is a spherical surface to match the focal plane from the field corrector.", [["surface", "ANATOMY", 29, 36], ["The slit mask", "TREATMENT", 0, 13], ["a spherical surface", "TREATMENT", 17, 36], ["slit mask", "OBSERVATION", 4, 13], ["focal", "OBSERVATION_MODIFIER", 50, 55]]], ["The spectrograph consists of two Schmidt mirrors (one as collimator and one as camera) with folding flats for compactness and an aspherized reflective Schmidt grating.", [["The spectrograph", "TEST", 0, 16], ["an aspherized reflective Schmidt grating", "TREATMENT", 126, 166], ["two", "OBSERVATION_MODIFIER", 29, 32], ["Schmidt mirrors", "OBSERVATION", 33, 48], ["folding flats", "OBSERVATION", 92, 105], ["reflective", "OBSERVATION_MODIFIER", 140, 150], ["Schmidt grating", "OBSERVATION", 151, 166]]], ["The grating was manufactured using a double replication process at HORIBA Jobin Yvon.", [["a double replication process", "TREATMENT", 35, 63]]], ["It is a novel high throughput cost-effective holographic grating with a groove density of 2400 l mm \u22121 over a 110x130 mm aspherized reflective surface .", [["surface", "ANATOMY", 143, 150], ["surface", "CELLULAR_COMPONENT", 143, 150], ["high", "OBSERVATION_MODIFIER", 14, 18], ["groove", "OBSERVATION_MODIFIER", 72, 78], ["density", "OBSERVATION_MODIFIER", 79, 86], ["2400 l mm", "OBSERVATION_MODIFIER", 90, 99], ["reflective", "OBSERVATION_MODIFIER", 132, 142], ["surface", "OBSERVATION_MODIFIER", 143, 150]]], ["The shape of the grating corrects for the spherical aberrations of the rest of the optical system.", [["the spherical aberrations", "PROBLEM", 38, 63], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["grating corrects", "OBSERVATION", 17, 33], ["spherical aberrations", "OBSERVATION", 42, 63], ["rest of", "ANATOMY_MODIFIER", 71, 78], ["optical system", "ANATOMY_MODIFIER", 83, 97]]], ["The grating consists of an aluminum substrate with native oxide.", [["aluminum", "CHEMICAL", 27, 35], ["oxide", "CHEMICAL", 58, 63], ["aluminum", "CHEMICAL", 27, 35], ["oxide", "CHEMICAL", 58, 63], ["oxide", "SIMPLE_CHEMICAL", 58, 63], ["an aluminum substrate", "TREATMENT", 24, 45], ["native oxide", "TREATMENT", 51, 63]]], ["Back up gratings were capped with a 70nm thick layer of MgF 2 to optimize in the FIREBall-2 band pass and a 28 \u2022 angle of incidence, but were not used in the 2018 flight.", [["Back up gratings", "TREATMENT", 0, 16], ["a 70nm thick layer of MgF", "TREATMENT", 34, 59]]], ["The flight grating reflectance exceeded 50% in the band pass, a significant improvement over the FIREBall-1 grating performance of 17% (Quiret et al. 2014) .", [["The flight grating reflectance", "TEST", 0, 30], ["the FIREBall", "TEST", 93, 105], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["improvement", "OBSERVATION_MODIFIER", 76, 87]]], ["The as built instrument performance is discussed in greater detail in Section 3.3 and in Picouet (2019).Delta-doped AR-coated EMCCDThe electron multiplying CCD used on this flight was a Teledyne-e2v CCD201-20 architecture with 13 \u00b5m square pixels.", [["Delta-doped AR", "SIMPLE_CHEMICAL", 104, 118], ["Delta-doped AR", "PROTEIN", 104, 118], ["Delta-doped AR", "TREATMENT", 104, 118], ["a Teledyne", "TEST", 184, 194]]], ["Nominally the CCD201s are frame transfer devices and have a 1k \u00d7 1k image area and storage region.", [["CCD201s", "DNA", 14, 21], ["frame transfer devices", "TREATMENT", 26, 48]]], ["However, FB-2 requires use of the entire pixel array for a larger FOV and so the detector is read out in line transfer mode as a 2k \u00d7 1k device.", [["FB-2", "CELL", 9, 13], ["FB", "TEST", 9, 11], ["the entire pixel array", "TREATMENT", 30, 52], ["a larger FOV", "TREATMENT", 57, 69], ["a 2k \u00d7 1k device", "TREATMENT", 127, 143]]], ["When these pixels are clocked with a voltage above \u223c39 V, their wells are deep enough to allow impact ionization of electrons as they are moved through the serial register.", [["a voltage", "TEST", 35, 44], ["ionization of electrons", "TREATMENT", 102, 125]]], ["The net result of this is that single electron events in the image area will be multiplied to many times above the read noise, significantly increasing the signal-to-noise ratio (SNR).", [["single electron events", "PROBLEM", 31, 53], ["the signal", "TEST", 152, 162]]], ["A more detailed description of the operation of these devices can be found in (Daigle et al. 2008 (Daigle et al. , 2010 Tulloch 2010; Tulloch & Dhillon 2011; Kyne 2019) .Delta-doped AR-coated EMCCDThe flight device was the end result of several years of technology development undertaken by JPL, Caltech, and Columbia University for use in the UV, funded by NASA.", [["Delta-doped AR", "SIMPLE_CHEMICAL", 170, 184], ["Delta", "PROTEIN", 170, 175], ["AR", "PROTEIN", 182, 184], ["the operation of these devices", "TREATMENT", 31, 61], ["Delta-doped AR", "TREATMENT", 170, 184], ["The flight device", "TREATMENT", 197, 214], ["Caltech", "TREATMENT", 296, 303]]], ["This development builds on JPL's pioneering work on delta-doping and UV detector development.", [["delta-doping", "TREATMENT", 52, 64], ["UV detector development", "TREATMENT", 69, 92]]], ["The maturation of these devices is detailed in a series of papers (Jewell et al. 2015; Hamden et al. 2016; Nikzad et al. 2017; Kyne 2019) .Delta-doped AR-coated EMCCDThe detector performance was verified via testing at JPL and Caltech, with additional validation of performance at Teledyne-e2v.", [["Delta-doped AR", "SIMPLE_CHEMICAL", 139, 153], ["Teledyne-e2v", "SIMPLE_CHEMICAL", 281, 293], ["Delta", "PROTEIN", 139, 144], ["AR", "PROTEIN", 151, 153], ["these devices", "TREATMENT", 18, 31], ["Delta", "TEST", 139, 144], ["testing", "TEST", 208, 215], ["Caltech", "TREATMENT", 227, 234]]], ["JPL testing included QE verification (measurement shown in Figure 3 ) following the method described in Jacquot et al. (2010) , while Caltech measured QE at limited wavelengths using N\u00fcv\u00fc v2 and v3 CCCP controllers and a custom flight printed circuit board (PCB).", [["CCCP", "CHEMICAL", 198, 202], ["PCB", "CHEMICAL", 258, 261], ["CCCP", "CHEMICAL", 198, 202], ["JPL testing", "TEST", 0, 11], ["QE verification", "TEST", 21, 36], ["N\u00fcv\u00fc v2", "TREATMENT", 183, 190], ["v3 CCCP controllers", "TREATMENT", 195, 214], ["a custom flight printed circuit board", "TREATMENT", 219, 256]]], ["These controllers provide 10 and 5 ns granularity, respectively, to optimize the pixel clocking strategy, readout speed, and wave form shape/height to minimize clockinduced-charge (CIC), read noise, and deferred charge Kyne et al. 2016) .", [["the pixel clocking strategy", "TREATMENT", 77, 104]]], ["The PCB was designed using the suggested configuration from N\u00fcv\u00fc to reduce additional read noise from the readout process.", [["PCB", "CHEMICAL", 4, 7], ["PCB", "CHEMICAL", 4, 7], ["PCB", "SIMPLE_CHEMICAL", 4, 7], ["N\u00fcv\u00fc", "TREATMENT", 60, 64]]], ["Total read noise in the lab camera system was 100 e \u2212 .", [["Total read noise", "TEST", 0, 16]]], ["Measured CIC from lab data was 4.2 \u00d7 10 \u22123 e-pix \u22121 frame \u22121 in the Figure 3 .", [["CIC", "PROTEIN", 9, 12], ["lab data", "TEST", 18, 26], ["e-pix", "TEST", 43, 48]]], ["Left: Model transmittance/performance for 2D-doped silicon detectors with multilayer AR coatings tailored for the FIREBall bandpass.", [["silicon", "CHEMICAL", 51, 58], ["Model transmittance/performance", "TEST", 6, 37], ["2D-doped silicon detectors", "TREATMENT", 42, 68], ["multilayer AR coatings", "TREATMENT", 74, 96], ["the FIREBall bandpass", "TREATMENT", 110, 131]]], ["Adding complexity increases peak QE, but results in a narrower peak.", [["complexity increases peak QE", "PROBLEM", 7, 35], ["a narrower peak", "PROBLEM", 52, 67], ["complexity", "OBSERVATION_MODIFIER", 7, 17], ["increases", "OBSERVATION_MODIFIER", 18, 27], ["peak QE", "OBSERVATION", 28, 35]]], ["Theoretical response for a bare 2D-doped silicon detector is also shown.", [["silicon", "CHEMICAL", 41, 48], ["a bare 2D-doped silicon detector", "TREATMENT", 25, 57]]], ["Left: Experimental results for 2D-doped silicon detector with the 3-layer FIREBall AR coating.", [["silicon", "CHEMICAL", 40, 47], ["AR", "PROTEIN", 83, 85], ["2D-doped silicon detector", "TREATMENT", 31, 56], ["the 3-layer FIREBall AR coating", "TREATMENT", 62, 93]]], ["As measured QE is shown alongside QE corrected for quantum yield Kuschnerus et al. 1998). serial register and 7 \u00d7 10 \u22124 e-pix \u22121 frame \u22121 in the parallel clocking, for a total of 4.9 \u00d7 10 \u22123 e-pix \u22121 frame \u22121 .", [["7 \u00d7 10 \u22124 e-pix \u22121 frame \u22121", "DNA", 110, 137], ["serial register", "TEST", 90, 105], ["e-pix", "TEST", 120, 125], ["e-pix", "TEST", 191, 196]]], ["The dark current level was 8 \u00d7 10 \u22122 e-pix \u22121 hr \u22121 at a temperature of -115 \u2022 C.Delta-doped AR-coated EMCCDThe detector was installed into the spectrograph in the spring of 2016, and was extensively tested in the spectrograph system.", [["C.Delta-doped AR", "SIMPLE_CHEMICAL", 79, 95], ["AR", "PROTEIN", 93, 95], ["The dark current level", "TEST", 0, 22], ["a temperature", "TEST", 55, 68], ["C.Delta-doped AR-coated EMCCDThe detector", "TREATMENT", 79, 120], ["the spectrograph", "TEST", 140, 156], ["dark", "OBSERVATION_MODIFIER", 4, 8]]], ["Both the detector and N\u00fcv\u00fc v2 controller performed reliably and with stability throughout integration and testing showing no change in behavior between installation and flight.", [["N\u00fcv\u00fc v2 controller", "TREATMENT", 22, 40], ["testing", "TEST", 106, 113], ["change in behavior", "PROBLEM", 125, 143], ["no", "UNCERTAINTY", 122, 124], ["change", "OBSERVATION_MODIFIER", 125, 131]]], ["A brief discussion of detector noise and performance is in Section 4 and is discussed in detail in Kyne (2019).Cooling and vacuum systemThe choice to change the detector from a MCP to a CCD required the addition of a cooling system to reduce the noise contribution from dark current.", [["MCP", "PROTEIN", 177, 180], ["detector noise", "TEST", 22, 36], ["Cooling and vacuum system", "TREATMENT", 111, 136], ["a cooling system", "TREATMENT", 215, 231], ["vacuum system", "OBSERVATION", 123, 136]]], ["To avoid the build up of ice or other contaminants on the detector surface, and maintain an effective vacuum during the flight, a cryopumping system was developed.", [["ice", "TREATMENT", 25, 28], ["a cryopumping system", "TREATMENT", 128, 148], ["effective", "OBSERVATION_MODIFIER", 92, 101], ["vacuum", "OBSERVATION", 102, 108]]], ["A schematic of the cooling system is shown in Figure 4 .Cooling and vacuum systemA Sunpower CryoTel CT cryocooler was used to cool both the detector and charcoal getter.", [["the cooling system", "TREATMENT", 15, 33], ["Cooling", "TREATMENT", 56, 63], ["vacuum systemA Sunpower", "TREATMENT", 68, 91], ["CryoTel CT cryocooler", "TREATMENT", 92, 113], ["charcoal", "TREATMENT", 153, 161]]], ["The CT provides up to 120 W of cooling power, providing a lift of greater than 10 watts at cryogenic temperatures.", [["The CT", "TEST", 0, 6], ["cooling power", "TREATMENT", 31, 44]]], ["This was sufficient to cool an 0.75 liter charcoal getter and maintain a pressure of less than a few 10 \u22126 Torr for the expected \u223c24 hour flight time.", [["cool an 0.75 liter charcoal", "TREATMENT", 23, 50], ["a pressure", "TEST", 71, 81], ["pressure", "OBSERVATION_MODIFIER", 73, 81]]], ["In order to achieve this vacuum, a careful strategy of tank and component bakeouts was implemented.", [["this vacuum", "TREATMENT", 20, 31], ["a careful strategy of tank and component bakeouts", "TREATMENT", 33, 82]]], ["The spectrograph tank interior (black anodized aluminum) itself was a significant source of water in the vacuum system and needed to be baked out at >50 \u2022 C for several weeks to achieve and maintain a high vacuum.Cooling and vacuum systemThe flight charcoal getter interfaces with a gold plated solid copper coldfinger, which has a one-inch diameter circular cross section and connects the cold head of the cryocooler to the rest of the system.", [["head", "ANATOMY", 395, 399], ["anodized aluminum", "CHEMICAL", 38, 55], ["copper", "CHEMICAL", 301, 307], ["aluminum", "CHEMICAL", 47, 55], ["copper", "CHEMICAL", 301, 307], ["head", "ORGANISM_SUBDIVISION", 395, 399], ["The spectrograph tank interior (black anodized aluminum", "TREATMENT", 0, 55], ["water in the vacuum system", "TREATMENT", 92, 118], ["a high vacuum", "TREATMENT", 199, 212], ["Cooling and vacuum system", "TREATMENT", 213, 238], ["a gold plated solid copper coldfinger", "PROBLEM", 281, 318], ["a one-inch diameter circular cross section", "TREATMENT", 330, 372], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["vacuum system", "ANATOMY", 105, 118], ["high vacuum", "OBSERVATION", 201, 212], ["vacuum system", "OBSERVATION", 225, 238], ["gold plated", "OBSERVATION_MODIFIER", 283, 294], ["solid copper coldfinger", "OBSERVATION", 295, 318], ["one-inch diameter", "OBSERVATION_MODIFIER", 332, 349], ["cold head", "ANATOMY_MODIFIER", 390, 399], ["rest of", "ANATOMY_MODIFIER", 425, 432], ["system", "ANATOMY", 437, 443]]], ["There is a single joint connection in the cold finger to enable installation in a tightly packed spectrograph tank.", [["a single joint connection in the cold finger", "PROBLEM", 9, 53], ["a tightly packed spectrograph tank", "TREATMENT", 80, 114], ["single", "OBSERVATION_MODIFIER", 11, 17], ["joint", "ANATOMY", 18, 23], ["connection", "OBSERVATION", 24, 34], ["cold finger", "ANATOMY", 42, 53], ["packed", "OBSERVATION_MODIFIER", 90, 96], ["spectrograph tank", "OBSERVATION", 97, 114]]], ["The EMCCD is held by a cold clamp coupled to the far end of the coldfinger via a flexible cold ribbon.", [["EMCCD", "DNA", 4, 9], ["a cold clamp", "TREATMENT", 21, 33], ["a flexible cold ribbon", "TREATMENT", 79, 101], ["flexible cold ribbon", "OBSERVATION", 81, 101]]], ["All cold surface interfaces have a layer of indium for better contact and thermal conductivity.Cooling and vacuum systemIn flight, the cryocooler was operated at 120 W to maintain the charcoal at a temperature of -180 \u2022 C and the detector at -115 \u2022 C.Thermal control systemAn additional requirement for FIREBall-2 was removing excess heat generated by a number of systems: The cryocooler, the N\u00fcv\u00fc EMCCD controller, and the pco.edge 5.5 guider camera (discussed in Section 2.7) all generated waste heat that needed to be managed in flight.", [["surface", "ANATOMY", 9, 16], ["indium", "CHEMICAL", 44, 50], ["charcoal", "CHEMICAL", 184, 192], ["indium", "CHEMICAL", 44, 50], ["FIREBall-2", "CHEMICAL", 303, 313], ["Cooling and vacuum systemIn flight", "TREATMENT", 95, 129], ["the cryocooler", "TREATMENT", 131, 145], ["the charcoal", "TREATMENT", 180, 192], ["a temperature", "TEST", 196, 209], ["the detector", "TEST", 226, 238], ["FIREBall", "TEST", 303, 311], ["the N\u00fcv\u00fc EMCCD controller", "TREATMENT", 389, 414], ["the pco.edge", "TREATMENT", 420, 432], ["layer", "OBSERVATION_MODIFIER", 35, 40], ["thermal conductivity", "OBSERVATION", 74, 94]]], ["The expected pressure at float altitude of 3 mbar presents a difficult thermal environment in which normal convective cooling is not effective.Thermal control systemThe cryocooler in particular was most sensitive to lack of convective cooling, as the temperature of the heat rejection point is directly coupled to the temperature of the cold head.", [["head", "ANATOMY", 342, 346], ["head", "ORGANISM_SUBDIVISION", 342, 346], ["a difficult thermal environment", "PROBLEM", 59, 90], ["normal convective cooling", "TREATMENT", 100, 125], ["convective cooling", "TREATMENT", 224, 242], ["the temperature", "TEST", 247, 262], ["the heat rejection", "PROBLEM", 266, 284], ["pressure", "OBSERVATION_MODIFIER", 13, 21], ["convective cooling", "OBSERVATION_MODIFIER", 107, 125], ["convective cooling", "OBSERVATION", 224, 242], ["rejection", "OBSERVATION", 275, 284], ["head", "ANATOMY", 342, 346]]], ["An inability to cool the reject point would result in inefficient cooling, a higher detector operating temperature, and higher dark current.", [["inefficient cooling", "TREATMENT", 54, 73]]], ["A thermal vacuum test conducted in the winter of 2017 at CNES in Toulouse indicated the need to actively cool the cryocooler heat rejection point.CryocoolerCold Finger To address this we used a water circulation system.", [["A thermal vacuum test", "TEST", 0, 21], ["a water circulation system", "TREATMENT", 192, 218], ["rejection", "OBSERVATION", 130, 139]]], ["It consisted of a dewar filled with 0 \u2022 C ice and water with a narrow outlet, allowing for thermal evaporation to the 3 mbar atmosphere to maintain a low temperature in the water dewar.", [["0 \u2022 C ice", "TREATMENT", 36, 45], ["a narrow outlet", "TREATMENT", 61, 76], ["thermal evaporation", "TREATMENT", 91, 110], ["the 3 mbar atmosphere", "TREATMENT", 114, 135], ["low temperature", "OBSERVATION_MODIFIER", 150, 165]]], ["A circulating water circuit passed through the dewar before reaching water blocks connected to the crycooler rejection point and body, the N\u00fcv\u00fc pressure vessel, and thermal blocks connected via copper straps to the guider camera pressure vessel inside the spectrograph tank.", [["body", "ANATOMY", 129, 133], ["vessel", "ANATOMY", 153, 159], ["copper", "CHEMICAL", 194, 200], ["copper", "CHEMICAL", 194, 200], ["body", "ORGANISM_SUBDIVISION", 129, 133], ["vessel", "MULTI-TISSUE_STRUCTURE", 153, 159], ["vessel", "MULTI-TISSUE_STRUCTURE", 238, 244], ["A circulating water circuit", "TREATMENT", 0, 27], ["water blocks", "TREATMENT", 69, 81], ["the N\u00fcv\u00fc pressure vessel", "TREATMENT", 135, 159], ["thermal blocks", "TREATMENT", 165, 179], ["copper straps", "TREATMENT", 194, 207], ["water circuit", "OBSERVATION", 14, 27], ["crycooler rejection", "OBSERVATION", 99, 118], ["body", "ANATOMY", 129, 133], ["pressure vessel", "OBSERVATION", 144, 159], ["copper straps", "OBSERVATION", 194, 207], ["vessel", "ANATOMY", 238, 244], ["spectrograph tank", "OBSERVATION", 256, 273]]], ["The dewar volume of 20 liters had sufficient cooling power for 24 hours of operation.", [["The dewar volume", "TEST", 0, 16], ["operation", "TREATMENT", 75, 84]]], ["Both the N\u00fcv\u00fc and guider camera were turned off during the ascent and daytime float phases of the flight to save cooling power for night time operations.", [["N\u00fcv\u00fc", "DNA", 9, 13], ["the N\u00fcv\u00fc and guider camera", "TREATMENT", 5, 31], ["cooling power", "TREATMENT", 113, 126], ["night time operations", "TREATMENT", 131, 152]]], ["A schematic of the cooling approach is shown in Figure 6 .", [["the cooling approach", "TREATMENT", 15, 35]]], ["We saw no evidence of any impact of the dewar system on the guidance due to, for example, sloshing of the cooling liquid.", [["the cooling liquid", "TREATMENT", 102, 120], ["no evidence of", "UNCERTAINTY", 7, 21]]], ["The mass of the cooling liquid was marginal compared to the rest of the payload (0.7% of the total mass).CryocoolerDuring the flight, the cooling system maintained a cryocooler reject temperature of 19 \u2022 C at 100 W of cooling power.", [["the cooling liquid", "TREATMENT", 12, 30], ["the payload", "TEST", 68, 79], ["the cooling system", "TREATMENT", 134, 152], ["cooling power", "TREATMENT", 218, 231], ["mass", "OBSERVATION", 4, 8], ["cooling", "OBSERVATION_MODIFIER", 16, 23], ["liquid", "OBSERVATION_MODIFIER", 24, 30], ["marginal", "OBSERVATION_MODIFIER", 35, 43], ["total", "OBSERVATION_MODIFIER", 93, 98], ["mass", "OBSERVATION", 99, 103]]], ["Because of the short duration of the flight, less than one third of the water volume was consumed.", [["the water volume", "TREATMENT", 68, 84]]], ["However, the lower altitude experienced during the flight meant the evaporative cooling scheme was less efficient than anticipated.", [["the lower altitude", "PROBLEM", 9, 27], ["the evaporative cooling scheme", "TREATMENT", 64, 94], ["lower", "OBSERVATION_MODIFIER", 13, 18]]], ["Towards the end of the flight the temperature of the cooling system, including cryocooler reject, cold head, charcoal getter, and detector, started to trend upwards, which can be seen in Figure 5 .", [["head", "ANATOMY", 103, 107], ["head", "ORGANISM_SUBDIVISION", 103, 107], ["the cooling system", "TREATMENT", 49, 67], ["cryocooler reject", "TREATMENT", 79, 96], ["charcoal", "TREATMENT", 109, 117], ["head", "ANATOMY", 103, 107]]], ["By this time, the payload altitude was so low that this did not significantly impact data collection and the flight was terminated shortly afterward.Coarse guidance systemThe attitude control system for FIREBall-2 was designed primarily by CNES.", [["the payload altitude", "PROBLEM", 14, 34], ["The attitude control system", "TEST", 171, 198]]], ["The pointing requirements are extremely constrained for a balloon payload (< 1\" pointing stability in three axes over several hours), as the system is frequently disturbed and in motion.", [["a balloon payload", "TREATMENT", 56, 73]]], ["The 3 degrees of freedom of the instrument are controlled through a 4-axis control system which uses:Coarse guidance system1.", [["3 degrees", "OBSERVATION_MODIFIER", 4, 13], ["freedom", "OBSERVATION_MODIFIER", 17, 24]]], ["Azimuth control of the gondola from the pivot connection to the balloon flight train 2.", [["the balloon flight train", "TREATMENT", 60, 84]]], ["2-axis control of the flat siderostat mirror (tip/tilt in elevation and cross elevation) 3.", [["the flat siderostat mirror", "PROBLEM", 18, 44], ["tip/tilt in elevation and cross elevation)", "TREATMENT", 46, 88], ["flat", "OBSERVATION_MODIFIER", 22, 26], ["siderostat mirror", "OBSERVATION", 27, 44], ["elevation", "OBSERVATION_MODIFIER", 58, 67]]], ["A rotation stage that also serves as the spectrograph tank mount.Coarse guidance systemThe CNES attitude control system (ACS) uses multiple sensors to determine the position and actuate each of the four axes of control.", [["A rotation stage", "PROBLEM", 0, 16], ["multiple sensors", "TEST", 131, 147], ["rotation stage", "OBSERVATION_MODIFIER", 2, 16]]], ["The azimuth fine pointing system consists of an IMU-gyrocompass and anologic gyro (IXBLUE, France) that are used to measure azimuth.", [["an IMU-gyrocompass", "TREATMENT", 45, 63]]], ["This system controls the azimuth via the pivot, which links the telescope payload to the balloon.", [["the balloon", "TREATMENT", 85, 96], ["balloon", "ANATOMY", 89, 96]]], ["This system controls elevation and cross elevation via two fine pointing actuators, encoders, and two reaction wheels.", [["This system controls elevation", "PROBLEM", 0, 30], ["cross elevation", "PROBLEM", 35, 50], ["two fine pointing actuators", "TREATMENT", 55, 82], ["elevation", "OBSERVATION_MODIFIER", 21, 30]]], ["The field rotation pointing system uses the rotation error signal from the fine guider.", [["the rotation error signal", "TEST", 40, 65]]], ["This system controls field rotation via the spectrograph tank rotation stage and encoder.", [["the spectrograph tank rotation stage", "TREATMENT", 40, 76]]], ["The three temperatures are correlated, with increases in the reject temperature resulting in increases in the cyrocooler cold head and therefore eventually EMCCD temperature.", [["head", "ORGANISM_SUBDIVISION", 126, 130], ["the reject temperature", "PROBLEM", 57, 79], ["the cyrocooler cold head", "PROBLEM", 106, 130], ["increases", "OBSERVATION_MODIFIER", 44, 53], ["increases", "OBSERVATION_MODIFIER", 93, 102], ["head", "ANATOMY", 126, 130]]], ["A heater on the EMCCD maintains a constant temperature, so the EMCCD measurement will not be immediately impacted by the reject temperature increase.", [["a constant temperature", "PROBLEM", 32, 54], ["the EMCCD measurement", "TEST", 59, 80]]], ["In the last 200 minutes of the flight, the reject temperature started to increase due to the loss of cooling capacity at lower altitudes as described in Section 2.5.Coarse guidance systemA large field of view attitude sensor (ASC from DTU, Denmark) was also on board as a back-up sensor in case of guider failure and for coarse positioning information.", [["the reject temperature", "PROBLEM", 39, 61], ["the loss of cooling capacity", "PROBLEM", 89, 117], ["guider failure", "PROBLEM", 298, 312], ["large", "OBSERVATION_MODIFIER", 189, 194], ["field", "OBSERVATION_MODIFIER", 195, 200]]], ["The DTU was mounted on the siderostat frame and observed a region of the sky adjacent, but not overlapping, with the science FOV.", [["DTU", "CANCER", 4, 7], ["DTU", "DNA", 4, 7], ["siderostat frame", "DNA", 27, 43], ["not", "UNCERTAINTY", 91, 94], ["overlapping", "OBSERVATION_MODIFIER", 95, 106]]], ["Both the DTU and IMU systems from CNES were the same as the ones used on FB-1.Coarse guidance systemThe flight train of FIREBall-2 can be modeled as a multiple torsion double pendulum.", [["FIREBall-2", "CHEMICAL", 120, 130], ["FB-1", "GENE_OR_GENE_PRODUCT", 73, 77], ["CNES", "TEST", 34, 38], ["FB", "TEST", 73, 75], ["a multiple torsion double pendulum", "PROBLEM", 149, 183], ["multiple", "OBSERVATION_MODIFIER", 151, 159], ["torsion", "OBSERVATION", 160, 167], ["double pendulum", "OBSERVATION", 168, 183]]], ["The CNES system is able to predict and account for many of the expected modes of the gondola and provide damping of the dynamic modes.", [["damping of the dynamic modes", "TREATMENT", 105, 133]]], ["There are both pendulum motion modes and wobbling modes.", [["wobbling modes", "PROBLEM", 41, 55], ["both", "OBSERVATION_MODIFIER", 10, 14], ["pendulum motion", "OBSERVATION", 15, 30]]], ["The pendulum modes are well understood, corresponding to roll and pitch, and behaved as expected during the flight.", [["pendulum modes", "OBSERVATION", 4, 18]]], ["The primary low frequency pendulum modes have periods of 23s and 9s, while the high frequency wobbling modes have periods of 1.8s and 2.2s.", [["the high frequency wobbling modes", "PROBLEM", 75, 108], ["low frequency", "OBSERVATION_MODIFIER", 12, 25]]], ["The high frequency modes are damped with an active damping system using 2 reaction wheels.", [["an active damping system", "TREATMENT", 41, 65], ["high frequency modes", "OBSERVATION_MODIFIER", 4, 24], ["damped", "OBSERVATION_MODIFIER", 29, 35], ["active", "OBSERVATION_MODIFIER", 44, 50], ["damping", "OBSERVATION", 51, 58]]], ["The wobbling frequencies in particular are sensitive to the ladder length below the parachute and the mass of the payload.", [["parachute", "OBSERVATION", 84, 93], ["mass", "OBSERVATION", 102, 106], ["payload", "ANATOMY", 114, 121]]], ["The amplitude of the wobbling modes is directly proportional to the quality of the pointing.", [["amplitude", "OBSERVATION_MODIFIER", 4, 13]]], ["Changes in balloon altitude or changes in the rotator torque excited the wobbling modes and were difficult to dampen.", [["rotator", "ANATOMY", 46, 53], ["Changes in balloon altitude", "PROBLEM", 0, 27], ["changes in the rotator torque", "PROBLEM", 31, 60], ["balloon altitude", "OBSERVATION", 11, 27], ["rotator torque", "OBSERVATION", 46, 60]]], ["This resulted in operating with reduced gains on the azimuth pointing control loop and adjustment of the roll reaction wheel filter frequency.Coarse guidance systemThis reduced pointing control was particularly an issue during the observations of Field 2 (described below in Section 3.2), where the altitude was quickly decreasing and the balloon was rotating through large angles (from 200 \u2022 to nearly 300 \u2022 , then back down to 200 \u2022 over a 1.5 hr period), requiring a lot of torque for azimuth control.", [["the azimuth pointing control loop", "TREATMENT", 49, 82], ["the roll reaction wheel filter frequency", "TREATMENT", 101, 141], ["This reduced pointing control", "PROBLEM", 164, 193], ["the balloon", "TREATMENT", 335, 346], ["a lot of torque for azimuth control", "TREATMENT", 468, 503], ["wheel filter", "OBSERVATION", 119, 131], ["decreasing", "OBSERVATION_MODIFIER", 320, 330], ["balloon", "OBSERVATION", 339, 346], ["large", "OBSERVATION_MODIFIER", 368, 373], ["angles", "OBSERVATION_MODIFIER", 374, 380]]], ["The ballast drops, which also excited a natural vertical (buoyancy) oscillation mode of the gondola, contributed to the large disturbances to position and azimuth during science operations.", [["The ballast drops", "TREATMENT", 0, 17], ["a natural vertical (buoyancy) oscillation mode", "TREATMENT", 38, 84], ["the large disturbances", "PROBLEM", 116, 138], ["azimuth during science operations", "TREATMENT", 155, 188], ["ballast drops", "OBSERVATION", 4, 17], ["large", "OBSERVATION_MODIFIER", 120, 125], ["disturbances", "OBSERVATION", 126, 138]]], ["Figure 7 , taken from Montel (2019), shows GPS measurements of the altitude, horizontal speed, and heading of the payload during the flight.", [["GPS measurements", "TEST", 43, 59]]], ["Blue arrows indicate ballast drops, and subsequent oscillations in heading can be seen.", [["Blue arrows", "PROBLEM", 0, 11], ["ballast drops", "TREATMENT", 21, 34], ["subsequent oscillations", "PROBLEM", 40, 63], ["ballast drops", "OBSERVATION", 21, 34]]], ["Block diagram of cooling scheme.", [["cooling scheme", "TREATMENT", 17, 31], ["cooling scheme", "OBSERVATION", 17, 31]]], ["Spectrograph tank and items requiring active cooling are shown as blue blocks, with blue and red lines indicating the cooling circuit.", [["blue and red lines", "CELL_LINE", 84, 102], ["Spectrograph tank", "TEST", 0, 17], ["active cooling", "TREATMENT", 38, 52], ["blue blocks", "PROBLEM", 66, 77], ["blue and red lines", "TREATMENT", 84, 102], ["the cooling circuit", "TREATMENT", 114, 133], ["red lines", "OBSERVATION", 93, 102], ["cooling circuit", "OBSERVATION", 118, 133]]], ["There are two identical cooling circuits, splitting and re-joining at the top of the tank.", [["identical cooling circuits", "TREATMENT", 14, 40], ["re-joining", "TREATMENT", 56, 66], ["two", "OBSERVATION_MODIFIER", 10, 13], ["identical", "OBSERVATION_MODIFIER", 14, 23], ["cooling circuits", "OBSERVATION", 24, 40], ["tank", "ANATOMY", 85, 89]]], ["The configuration shown is the same as during the flight, with a water ice solution in the dewar.", [["a water ice solution", "TREATMENT", 63, 83]]], ["During ground testing, a cooling circuit is used instead of water ice.Coarse guidance systemDespite these significant challenges and the extremely degraded observing conditions, the full guidance system performed within the 1\" stability requirement throughout the flight.", [["ground testing", "TEST", 7, 21], ["a cooling circuit", "TREATMENT", 23, 40], ["water ice", "TREATMENT", 60, 69], ["the full guidance system", "TEST", 178, 202], ["significant", "OBSERVATION_MODIFIER", 106, 117]]], ["A detailed description of the fine guider and input to the CNES guidance control system is described in Section 2.7.Fine guidance systemThe scientific objectives of FIREBall-2 and the multi-object nature of the spectrograph impose stringent requirements on the instrument pointing.", [["FIREBall-2", "CELL", 165, 175], ["the CNES guidance control system", "TREATMENT", 55, 87]]], ["Each science target must be centered in a 80-90 \u00b5m wide slit, corresponding to an accuracy of 6-8 arcseconds.", [["an accuracy", "TEST", 79, 90]]], ["In addition, FIREBall-2 aims to detect very faint emission, requiring long integration times (up to 100 s).", [["FIREBall", "PROTEIN", 13, 21], ["very faint emission", "PROBLEM", 39, 58]]], ["During each integration, the instrument must maintain stability to within a pixel on the detector (<1 arcsec) to avoid degrading the image.", [["stability", "OBSERVATION_MODIFIER", 54, 63]]], ["The fine guiding system corrects residual errors in the pointing by making on-sky measurements of the instrument pointing offset and providing high-cadence feedback to the attitude control system.Fine guidance systemThe entrance to the fine guidance system lies close to the focal plane of the spectrograph where a set of interchangeable masks are mounted on a rotating carousel.", [["residual errors", "PROBLEM", 33, 48], ["a rotating carousel", "TREATMENT", 359, 378], ["residual errors", "OBSERVATION", 33, 48], ["entrance", "OBSERVATION_MODIFIER", 220, 228], ["focal", "OBSERVATION_MODIFIER", 275, 280], ["masks", "OBSERVATION", 338, 343]]], ["Each mask is a duplex system with two layers; an upper mask with a reflective coating directs visible light into the fine guidance system while a lower mask with a pattern of slits transmits UV light through to the detector.", [["Each mask", "TREATMENT", 0, 9], ["a duplex system", "TREATMENT", 13, 28], ["an upper mask", "TREATMENT", 46, 59], ["a reflective coating directs", "TREATMENT", 65, 93], ["a lower mask", "TREATMENT", 144, 156], ["layers", "OBSERVATION_MODIFIER", 38, 44], ["upper mask", "OBSERVATION", 49, 59], ["lower mask", "OBSERVATION", 146, 156]]], ["Both the upper (guider) mask and lower (science) mask are curved in two dimensions to match the curvature of the focal plane created by the field corrector optics.", [["the upper (guider) mask and lower (science) mask", "TREATMENT", 5, 53], ["upper", "ANATOMY_MODIFIER", 9, 14], ["lower", "OBSERVATION_MODIFIER", 33, 38], ["curvature", "OBSERVATION_MODIFIER", 96, 105], ["focal", "OBSERVATION_MODIFIER", 113, 118]]], ["The focal plane at the mask position is spherical due to the optical design.", [["focal", "OBSERVATION_MODIFIER", 4, 9], ["plane", "OBSERVATION_MODIFIER", 10, 15]]], ["The guider mask corresponds to an 19.2 \u00d7 16.2 patch of sky adjacent to each science field.", [["The guider mask", "TREATMENT", 0, 15]]], ["Optical light reflected off the guider mask is fed through a double petzvel lens system into a dedicated guider camera (pco.edge 5.5) with a 2560 \u00d7 2160 pixel CMOS detector.", [["the guider mask", "TREATMENT", 28, 43], ["a double petzvel lens system", "TREATMENT", 59, 87]]], ["The camera itself is contained within a pressure vessel inside the spectrograph vacuum tank with a window directly above the camera detector in the optical path.", [["vessel", "ANATOMY", 49, 55], ["vessel", "MULTI-TISSUE_STRUCTURE", 49, 55], ["pressure vessel", "OBSERVATION", 40, 55], ["spectrograph", "OBSERVATION_MODIFIER", 67, 79], ["vacuum tank", "OBSERVATION", 80, 91]]], ["A PHOX CameraLink to fiber converter creates an optical fiber output which is then fed through the vacuum tank and out to the guider on board computer.", [["PHOX CameraLink", "PROTEIN", 2, 17], ["A PHOX CameraLink to fiber converter", "TREATMENT", 0, 36], ["an optical fiber output", "TEST", 45, 68], ["the vacuum tank", "TREATMENT", 95, 110]]], ["A fiber connection was necessary to maintain coherence between the two CameraLink outputs from the pco.edge without corrupting the signal given the very fast frame rate and length of transmission.", [["A fiber connection", "TREATMENT", 0, 18], ["fiber connection", "OBSERVATION", 2, 18], ["length", "OBSERVATION_MODIFIER", 173, 179]]], ["An additional PHOX converted the signal back to a CameraLink input into the frame grabber.Fine guidance systemImages of the star field viewed by the guider camera are stored and processed on board by the guider flight computer; these images are also transmitted to the ground via a video downlink.", [["PHOX", "SIMPLE_CHEMICAL", 14, 18], ["PHOX", "PROTEIN", 14, 18], ["frame grabber", "DNA", 76, 89], ["guider camera", "DNA", 149, 162], ["An additional PHOX", "TEST", 0, 18], ["these images", "TEST", 228, 240], ["PHOX", "OBSERVATION", 14, 18]]], ["Processing includes identification of stars above a certain SNR threshold and centroiding of their x and y positions in the guider image.", [["stars", "OBSERVATION", 38, 43]]], ["Corrections to the instrument pointing are calculated based on the translational and rotational offsets of these stars from their expected positions, producing attitude error signals at a rate of 20-30 Hz.", [["a rate", "TEST", 186, 192]]], ["In closed loop, these error signals are fed back into the 4-axis attitude control system, reducing residual errors in the instrument pointing and refining the pointing stability to less than 1 arcsecond.", [["these error signals", "TEST", 16, 35], ["reducing residual errors", "PROBLEM", 90, 114], ["closed loop", "OBSERVATION", 3, 14], ["residual errors", "OBSERVATION", 99, 114], ["stability", "OBSERVATION_MODIFIER", 168, 177]]], ["The real-time video feed is used for field recognition and acquisition, target alignment, spectrograph focus, and monitoring the pointing performance during flight.", [["field recognition", "TEST", 37, 54], ["acquisition", "TEST", 59, 70], ["spectrograph focus", "TEST", 90, 108]]], ["Ground control software for the fine guidance system in communication with the flight computer is capable of controlling the guider camera settings, guide star selection, guide star positioning in the guider field, guider image reduction pipeline, and spectrograph tip-tilt.", [["guide star selection", "TREATMENT", 149, 169], ["guide star positioning in the guider field", "TREATMENT", 171, 213], ["guider image reduction pipeline", "TREATMENT", 215, 246]]], ["The same error signals used to refine the guide star positions in fine pointing mode are used to set the initial positions of the guide stars on the guider image.", [["the guider image", "TEST", 145, 161]]], ["These positions are carefully calibrated pre-flight to ensure that each science target passes through its designated slit on the multi-object slit mask (this calibration is discussed in Picouet 2019).Fine guidance systemThe optical image that is re-directed to the guider camera is approximately con-focal with the UV image on the detector and the guider camera is used to perform a through focus on each science field in-flight.Fine guidance systemThe overall performance in fine guiding is shown in Figure 8 , with excellent RMS over the course of nearly two hours.", [["guider camera", "DNA", 265, 278], ["guider camera", "DNA", 348, 361], ["the multi-object slit mask", "TREATMENT", 125, 151], ["The optical image", "TEST", 220, 237], ["the guider camera", "TREATMENT", 344, 361]]], ["The balloon descended through nearly 3 vertical km during this observing period, which increases the perturbations on the guidance system.Fine guidance systemA more careful analysis of the guidance control system, the target and guide star selection, and performance can be found in Montel (2019), Montel et al. (2016) , and in a forthcoming paper, Melso et al. (in prep).Communications systemThe FIREBall-2 communications system consists of three primary transmitters/receivers, all operating via a line-ofsight link: A Consolidated Instrument Package (CIP) uplink/downlink (1200/38,400 baud respectively), a 1 Mbit s \u22121 downlink, and a video downlink.", [["The balloon", "TREATMENT", 0, 11], ["a line", "TREATMENT", 498, 504], ["A Consolidated Instrument Package (CIP", "TREATMENT", 519, 557], ["balloon", "OBSERVATION", 4, 11]]], ["A schematic of the telemetry/telecommand (TM/TC) sub-system of the FIREBall-2 communications system is shown in Figure 9 .", [["the telemetry", "TEST", 15, 28]]], ["Due to overheads on the uplink per dataword the speed was effectively 32 baud.Communications systemThe CIP uplink/downlink provided by CSBF took an input from a multiplexer (DBC, Inc., model SR-04) which slowed down and interleaved commands from the detector ground computer, fine guider ground computer, and gondola control ground computer to match the uplink speed.", [["CSBF", "PROTEIN", 135, 139], ["The CIP uplink/downlink", "TREATMENT", 99, 122], ["a multiplexer (DBC", "TREATMENT", 159, 177], ["model SR", "TEST", 185, 193]]], ["Because of the slow uplink speeds, commanding from the ground was laborious and nearly all typical flight actions were scripted ahead of time.", [["the slow uplink speeds", "PROBLEM", 11, 33]]], ["Because the downlink was significantly faster than the uplink housekeeping data for the Gondola OBC and the guider computer were sent via the CIP.", [["the Gondola OBC", "TEST", 84, 99]]], ["Intermittent housekeeping data from the detector computer was also transmitted during flight but the images generated by the detector and associated housekeeping used the faster 1 Mbit s \u22121 downlink.Communications systemThe 1 Mbit s \u22121 downlink was used to send cropped images from the science detector.", [["the images", "TEST", 97, 107], ["The 1 Mbit s \u22121 downlink", "TREATMENT", 220, 244], ["cropped images", "TEST", 262, 276]]], ["This was necessary both to verify that the targets were falling into the slits on the mask and to allow for nearly real time image processing.", [["the mask", "TREATMENT", 82, 90], ["slits", "OBSERVATION_MODIFIER", 73, 78]]], ["As images were generated by the detector, the 1 Mbit s \u22121 downlink would grab the most recent one, strip the overscan and prescan regions, compress it with the most recent housekeeping file, and relay the package to the CSBF transmitter.", [["overscan and prescan regions", "DNA", 109, 137], ["CSBF transmitter", "DNA", 220, 236]]], ["Roughly 50% percent of images were transmitted during flight, with the remaining images collected after the flight including over-scan and pre-scan regions of the downlinked images.", [["images", "TEST", 23, 29], ["the remaining images", "TEST", 67, 87], ["over-scan", "TEST", 125, 134], ["the downlinked images", "TEST", 159, 180]]], ["The downlink was stable during the flight.", [["stable", "OBSERVATION_MODIFIER", 17, 23]]], ["Only one image out of several hundred was corrupted during the downlink process.", [["one image", "TEST", 5, 14]]], ["This stability was a result of CSBF's very reliable communication equipment and significant ground testing to eliminate dropped bits as much as possible.", [["significant ground testing", "TEST", 80, 106], ["dropped bits", "PROBLEM", 120, 132]]], ["The processing power required for encoding images and sending to the 1 Mbit s \u22121 downlink while also operating the N\u00fcv\u00fc controller would freeze the flight computer and require a restart.", [["1 Mbit s \u22121 downlink", "DNA", 69, 89], ["N\u00fcv\u00fc controller", "DNA", 115, 130], ["encoding images", "TEST", 34, 49], ["a restart", "TREATMENT", 176, 185]]], ["This freezing was correlated with the rate of image acquisition.", [["image acquisition", "TEST", 46, 63]]], ["A simple re-start would correct the issue, but image acquisition was stopped while this happened.", [["A simple re-start", "TREATMENT", 0, 17], ["image acquisition", "TEST", 47, 64]]], ["For future flights, the detector computer has a faster processor which should eliminate this problem.Communications systemThe video downlink consisted of a VGA to video adapter for the guider on board computer that would process the video generated by the guider camera.", [["VGA", "PROTEIN", 156, 159], ["a faster processor", "TREATMENT", 46, 64]]], ["This was sent to a transmitter and the downlink was then relayed to a television screen on the ground and was used as described in Section 2.7.FLIGHT ON SEPTEMBER 22ND, 2018FIREBAll-2 was launched from a 40 MCF balloon from Fort Sumner, NM on the morning of September 22nd, 2018 at 10:20 AM MDT.", [["a television screen", "TEST", 68, 87], ["a 40 MCF balloon", "TREATMENT", 202, 218]]], ["At launch, all flight systems were nominal and the payload experienced minimal jerks or acceleration during the launch.", [["jerks", "DISEASE", 79, 84], ["all flight systems", "TEST", 11, 29], ["minimal jerks", "PROBLEM", 71, 84], ["minimal", "OBSERVATION_MODIFIER", 71, 78], ["jerks", "OBSERVATION", 79, 84], ["acceleration", "OBSERVATION_MODIFIER", 88, 100]]], ["Throughout the ascent phase (from the ground to float altitude of 128,000 ft) the payload systems The stratospheric winds were very low during the flight and so the balloon traveled slightly north towards Santa Rosa, NM, before eventually drifting south west and ended up over Vaughn, NM.", [["the payload systems", "PROBLEM", 78, 97], ["the balloon", "TREATMENT", 161, 172], ["stratospheric winds", "OBSERVATION", 102, 121], ["low", "OBSERVATION_MODIFIER", 132, 135], ["balloon", "OBSERVATION", 165, 172]]], ["The GPS map of the flight is shown in Figure 10 .", [["The GPS map", "TEST", 0, 11]]], ["The altitude of the payload over the course of the flight is shown in Figure 11 including ballast drops and other events.", [["the payload", "TREATMENT", 16, 27], ["ballast drops", "TREATMENT", 90, 103], ["other events", "PROBLEM", 108, 120], ["altitude", "OBSERVATION_MODIFIER", 4, 12], ["ballast drops", "OBSERVATION", 90, 103]]], ["The balloon is expected to lose altitude as the sun sets due to changing thermal conditions and then stabilize at a lower altitude after sunset.", [["The balloon", "TREATMENT", 0, 11], ["changing thermal conditions", "PROBLEM", 64, 91], ["balloon", "OBSERVATION", 4, 11]]], ["Ballast is dropped during sunset to minimize the altitude loss, and the expected nighttime altitude was 118 kft to 108 kft, depending on the particulars of the atmosphere and weather.", [["Ballast", "TREATMENT", 0, 7], ["the altitude loss", "PROBLEM", 45, 62], ["altitude loss", "OBSERVATION", 49, 62]]], ["In part due to anomalies discussed below (Section 3.1), the balloon lost altitude starting mid-afternoon and continued to descend through the night.", [["anomalies", "PROBLEM", 15, 24], ["the balloon", "TREATMENT", 56, 67], ["part due to", "UNCERTAINTY", 3, 14], ["anomalies", "OBSERVATION", 15, 24]]], ["The most likely cause of this was a hole allowing helium gas to escape.", [["helium", "CHEMICAL", 50, 56], ["most likely", "UNCERTAINTY", 4, 15]]], ["Ballast drops did not help to slow the descent and additionally created some extra pointing challenges since the timing excited a 5 minute resonant frequency in the balloon altitude.", [["Ballast drops", "TREATMENT", 0, 13], ["a 5 minute resonant frequency in the balloon altitude", "TREATMENT", 128, 181], ["balloon altitude", "OBSERVATION", 165, 181]]], ["The balloon altitude was below the required science minimum altitude of 32 km at 660 minutes after launch (roughly 9:20 PM MDT).", [["The balloon altitude", "TREATMENT", 0, 20], ["balloon altitude", "OBSERVATION", 4, 20]]], ["The balloon and payload were separated at roughly 1 AM MST, taking about an hour to land.FLIGHT ON SEPTEMBER 22ND, 2018The flight was terminated 50 miles west of Fort Sumner, near the municipality of Vaugn, NM.", [["The balloon and payload", "TREATMENT", 0, 23], ["balloon", "OBSERVATION", 4, 11], ["payload", "OBSERVATION_MODIFIER", 16, 23]]], ["The payload was recovered on September 23rd.", [["payload", "OBSERVATION", 4, 11]]], ["The landing, due in part to higher winds at night, was rough and both large optics sustained edge fractures.", [["fractures", "DISEASE", 98, 107], ["edge fractures", "PROBLEM", 93, 107], ["large", "OBSERVATION_MODIFIER", 70, 75], ["optics", "OBSERVATION_MODIFIER", 76, 82], ["sustained", "OBSERVATION_MODIFIER", 83, 92], ["edge", "OBSERVATION_MODIFIER", 93, 97], ["fractures", "OBSERVATION", 98, 107]]], ["The siderostat fracture was minimal, while the primary mirror lost roughly 5% of the area including the location of two of the six bond pads, which hold the optic to its mount.", [["optic", "ANATOMY", 157, 162], ["fracture", "DISEASE", 15, 23], ["pads", "TISSUE", 136, 140], ["The siderostat fracture", "PROBLEM", 0, 23], ["the six bond pads", "TREATMENT", 123, 140], ["siderostat", "OBSERVATION_MODIFIER", 4, 14], ["fracture", "OBSERVATION", 15, 23], ["minimal", "OBSERVATION_MODIFIER", 28, 35], ["bond pads", "OBSERVATION", 131, 140]]], ["The damage for both mirrors was on the same side so was likely a result of a hard landing.", [["The damage", "PROBLEM", 0, 10], ["damage", "OBSERVATION", 4, 10]]], ["In addition, the large mirror of the field corrector was cracked at the edge of the mirror along one of the bond locations.", [["large", "OBSERVATION_MODIFIER", 17, 22], ["mirror", "OBSERVATION_MODIFIER", 23, 29], ["field corrector", "OBSERVATION", 37, 52], ["cracked", "OBSERVATION", 57, 64], ["edge", "ANATOMY_MODIFIER", 72, 76], ["mirror", "ANATOMY_MODIFIER", 84, 90]]], ["A measurement of the surface figure of both large optics indicated that despite the damage the surface shapes were not changed significantly and there are no additional cracks or fractures that could propagate through the optic.", [["surface", "ANATOMY", 21, 28], ["surface", "ANATOMY", 95, 102], ["fractures", "DISEASE", 179, 188], ["A measurement", "TEST", 0, 13], ["the damage the surface shapes", "PROBLEM", 80, 109], ["additional cracks", "PROBLEM", 158, 175], ["fractures", "PROBLEM", 179, 188], ["surface", "OBSERVATION_MODIFIER", 21, 28], ["large", "OBSERVATION_MODIFIER", 44, 49], ["optics", "OBSERVATION", 50, 56], ["surface", "OBSERVATION_MODIFIER", 95, 102], ["not", "UNCERTAINTY", 115, 118], ["changed", "OBSERVATION_MODIFIER", 119, 126], ["no", "UNCERTAINTY", 155, 157], ["additional", "OBSERVATION_MODIFIER", 158, 168], ["cracks", "OBSERVATION", 169, 175], ["fractures", "OBSERVATION", 179, 188]]], ["Both optics have since had the broken edges sanded down and were re-aluminized at Goddard Space Flight Center in 2019.Flight anomaliesDuring the flight, there were three anomalies, two related to the balloon.", [["the broken edges", "PROBLEM", 27, 43], ["Flight anomalies", "PROBLEM", 118, 134], ["three anomalies", "PROBLEM", 164, 179], ["the balloon", "TREATMENT", 196, 207], ["broken", "OBSERVATION_MODIFIER", 31, 37], ["edges", "OBSERVATION_MODIFIER", 38, 43], ["anomalies", "OBSERVATION", 125, 134], ["anomalies", "OBSERVATION", 170, 179], ["balloon", "OBSERVATION", 200, 207]]], ["During the launch, the spool that keeps the balloon in position during inflation flew off the inflation vehicle.", [["the balloon", "TREATMENT", 40, 51], ["the inflation vehicle", "TREATMENT", 90, 111], ["balloon", "OBSERVATION", 44, 51], ["position", "OBSERVATION_MODIFIER", 55, 63], ["inflation", "OBSERVATION_MODIFIER", 71, 80], ["inflation vehicle", "OBSERVATION", 94, 111]]], ["A subsequent investigation by CSBF into the origins of this is ongoing.", [["A subsequent investigation", "TEST", 0, 26]]], ["Both CSBF and NASA believe this was unrelated to the later anomaly.", [["NASA", "TREATMENT", 14, 18], ["the later anomaly", "PROBLEM", 49, 66], ["anomaly", "OBSERVATION", 59, 66]]], ["After 3 hours at float altitude the balloon began to lose altitude, likely due to a hole that was either present from the launch or developed while at float.", [["the balloon", "TREATMENT", 32, 43], ["a hole", "PROBLEM", 82, 88], ["balloon", "OBSERVATION", 36, 43], ["likely due to", "UNCERTAINTY", 68, 81], ["hole", "OBSERVATION", 84, 88]]], ["As a result, the payload was above the science minimum altitude of 32 km for only \u223c1 hour after astronomical twilight on the balloon.", [["the payload", "PROBLEM", 13, 24], ["the balloon", "TREATMENT", 121, 132], ["balloon", "OBSERVATION", 125, 132]]], ["The atmospheric transmission in the FIREBall-2 bandpass is highly dependent on atmosphere, with a reduction of 10% for every 3 km of altitude lost.", [["The atmospheric transmission", "TEST", 0, 28], ["the FIREBall-2 bandpass", "TREATMENT", 32, 55], ["a reduction", "TREATMENT", 96, 107], ["atmospheric", "OBSERVATION_MODIFIER", 4, 15], ["highly", "OBSERVATION_MODIFIER", 59, 65], ["dependent", "OBSERVATION_MODIFIER", 66, 75], ["reduction", "OBSERVATION_MODIFIER", 98, 107]]], ["As the flight went on the UV throughput dropped precipitously, which severely impacted our ability to observe the faint targets we had selected.Flight anomaliesIn addition to degrading the overall throughput the hole in the balloon caused the balloon to deviate from the expected sphere to a more teardrop shape.", [["anomalies", "DISEASE", 151, 160], ["the UV", "TEST", 22, 28], ["the faint targets", "PROBLEM", 110, 127], ["Flight anomalies", "PROBLEM", 144, 160], ["the hole in the balloon", "TREATMENT", 208, 231], ["the balloon", "TREATMENT", 239, 250], ["a more teardrop shape", "PROBLEM", 290, 311], ["anomalies", "OBSERVATION", 151, 160], ["balloon", "OBSERVATION", 224, 231], ["balloon", "OBSERVATION", 243, 250], ["sphere", "OBSERVATION_MODIFIER", 280, 286], ["more teardrop", "OBSERVATION_MODIFIER", 292, 305], ["shape", "OBSERVATION_MODIFIER", 306, 311]]], ["The scattered light consisted primarily of visible light and was able to impinge on the detector via a small un-baffled direct path from the spectrograph tank top to the back surface of the detector PCB mount, which was then able to reflect onto the detector surface.", [["back surface", "ANATOMY", 170, 182], ["PCB", "CHEMICAL", 199, 202], ["PCB", "CHEMICAL", 199, 202], ["surface", "CELLULAR_COMPONENT", 259, 266], ["scattered", "OBSERVATION_MODIFIER", 4, 13], ["back", "ANATOMY", 170, 174], ["surface", "ANATOMY_MODIFIER", 175, 182]]], ["This possible trajectory for light was not accounted for in the optical analysis.", [["the optical analysis", "TEST", 60, 80]]], ["Since the recovery of the payload we have attempted to fully recreate the signature of the scattered light to allow us to determine both the most likely optical path of the scattered light and develop mitigation strategies for future flights.Flight anomaliesThe altitude loss had a follow-on effect of causing the balloon motion to be highly disturbed.", [["anomalies", "DISEASE", 249, 258], ["mitigation strategies", "TREATMENT", 201, 222], ["Flight anomalies", "PROBLEM", 242, 258], ["The altitude loss", "PROBLEM", 258, 275], ["the balloon motion", "TREATMENT", 310, 328], ["scattered", "OBSERVATION_MODIFIER", 173, 182], ["anomalies", "OBSERVATION", 249, 258], ["altitude loss", "OBSERVATION", 262, 275], ["balloon motion", "OBSERVATION", 314, 328]]], ["As the balloon and payload descended the wind direction shifted significantly and caused increased noise in the pointing system, degrading performance as described in Section 2.6.", [["the balloon", "TREATMENT", 3, 14], ["increased noise in the pointing system", "PROBLEM", 89, 127], ["balloon", "OBSERVATION", 7, 14], ["increased noise", "OBSERVATION", 89, 104]]], ["Additionally, the ballast drops caused the balloon to rise and fall in the atmosphere on about a 5 minute cycle.", [["the ballast drops", "TREATMENT", 14, 31], ["the balloon", "TREATMENT", 39, 50], ["ballast drops", "OBSERVATION", 18, 31], ["balloon", "OBSERVATION", 43, 50], ["rise", "OBSERVATION_MODIFIER", 54, 58]]], ["All of these motions were not expected -typical balloon motion at altitude is very stable, predictable, and tranquil.", [["typical balloon motion at altitude", "PROBLEM", 40, 74], ["balloon motion", "OBSERVATION", 48, 62], ["very", "OBSERVATION_MODIFIER", 78, 82], ["stable", "OBSERVATION_MODIFIER", 83, 89]]], ["The fact that the pointing performance was well within spec despite these significant challenges is a testament to both the quality of the pointing system design, implementation, and the team.Flight anomaliesThe third anomaly involved the Newport RV350 series rotation stage, which is used to keep the spectrograph tank tracking with the rotation of the earth.", [["anomalies", "DISEASE", 199, 208], ["Flight anomalies", "PROBLEM", 192, 208], ["The third anomaly", "PROBLEM", 208, 225], ["anomalies", "OBSERVATION", 199, 208], ["third", "OBSERVATION_MODIFIER", 212, 217], ["anomaly", "OBSERVATION", 218, 225], ["earth", "ANATOMY", 354, 359]]], ["At the time the hole in the balloon and the low altitude of the payload meant there was minimal impact to the science performance.", [["the hole in the balloon", "TREATMENT", 12, 35], ["the payload", "TREATMENT", 60, 71], ["hole", "OBSERVATION_MODIFIER", 16, 20], ["balloon", "OBSERVATION", 28, 35], ["low altitude", "OBSERVATION_MODIFIER", 44, 56], ["minimal", "OBSERVATION_MODIFIER", 88, 95]]], ["Had the balloon had a nominal flight performance, however, this failure would have been a significant problem and resulted in a loss of more than half of the observing time.", [["the balloon", "TREATMENT", 4, 15], ["this failure", "PROBLEM", 59, 71], ["a significant problem", "PROBLEM", 88, 109], ["balloon", "OBSERVATION", 8, 15], ["significant", "OBSERVATION_MODIFIER", 90, 101], ["problem", "OBSERVATION", 102, 109]]], ["Upon inspection post-flight, it was determined that an elastic ring at the end of the motor had a screw that was too short and it did not have enough thread length to hold indefinitely, and under torque.", [["elastic ring", "ANATOMY", 55, 67], ["an elastic ring", "TREATMENT", 52, 67], ["a screw", "TREATMENT", 96, 103], ["elastic ring", "OBSERVATION", 55, 67], ["screw", "OBSERVATION", 98, 103]]], ["During the flight, while attempting to rotate, the threads of the screw gave way.", [["the threads of the screw", "TREATMENT", 47, 71], ["screw", "OBSERVATION", 66, 71]]], ["The broken bolt has since been replaced by a longer one and the stage performed normally.Field Selection and ObservationFour fields were selected for the 2018 Fort Sumner campaign.", [["The broken bolt", "TREATMENT", 0, 15], ["broken bolt", "OBSERVATION", 4, 15]]], ["Observations with FIREBall-2 target dense galaxy fields at z=0.7 tracing known large scale structure.", [["FIREBall", "TEST", 18, 26], ["large scale structure", "PROBLEM", 79, 100], ["dense", "OBSERVATION_MODIFIER", 36, 41], ["galaxy", "OBSERVATION", 42, 48], ["large", "OBSERVATION_MODIFIER", 79, 84], ["scale structure", "OBSERVATION", 85, 100]]], ["Sumner NM, several survey fields were visible during the launch window and were also within the 40-60 deg elevation limitation due to balloon and gondola obstruction.", [["obstruction", "DISEASE", 154, 165], ["balloon and gondola obstruction", "PROBLEM", 134, 165], ["balloon", "OBSERVATION", 134, 141], ["obstruction", "OBSERVATION", 154, 165]]], ["Several surveys were examined in detail including BOSS, WIGGLEZ, CANDLES, UKIDSS, CFHTLS, VIPERS, and DEEP2.", [["UKIDSS", "DNA", 74, 80], ["CFHTLS", "DNA", 82, 88], ["VIPERS", "DNA", 90, 96], ["DEEP2", "DNA", 102, 107], ["CANDLES", "TEST", 65, 72], ["UKIDSS", "TEST", 74, 80], ["CFHTLS", "TEST", 82, 88], ["VIPERS", "TEST", 90, 96]]], ["DEEP2 is a galaxy redshift survey of \u223c53,000 galaxies conducted from 2002-2005 that used the DEIMOS spectrograph on Keck II (Newman et al. 2013) .", [["DEEP2", "DNA", 0, 5]]], ["DEEP2 covered four fields, each roughly 120' by 30' in area, and included the Groth survey strip, a zone of very low extinction, and two SDSS deep strips.", [["DEEP2", "DNA", 0, 5], ["very low extinction", "PROBLEM", 108, 127], ["two SDSS deep strips", "TREATMENT", 133, 153], ["four fields", "OBSERVATION_MODIFIER", 14, 25], ["very", "OBSERVATION_MODIFIER", 108, 112], ["low extinction", "OBSERVATION", 113, 127], ["deep strips", "OBSERVATION", 142, 153]]], ["The fields were sorted by redshift ranges z = 0.636 -0.751, z = 0.975 -1.025 and z = 0.275 -0.325 for Ly-\u03b1, OVI and CIV respectively.", [["Ly-\u03b1", "GENE_OR_GENE_PRODUCT", 102, 106], ["CIV", "PROTEIN", 116, 119], ["z", "TEST", 42, 43], ["z", "TEST", 60, 61], ["z", "TEST", 81, 82], ["Ly", "TEST", 102, 104], ["OVI", "TEST", 108, 111], ["CIV", "ANATOMY", 116, 119]]], ["For Ly-\u03b1 targets, redshifts z = 0.682 -0.696 were eliminated since the emission line would coincide with a bright sky line.Field Selection and ObservationAside from scientific considerations, several observational constraints needed to be considered when selecting the fields that FIREBall-2 targeted.", [["Ly-\u03b1", "GENE_OR_GENE_PRODUCT", 4, 8], ["FIREBall-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["Ly-\u03b1 targets", "DNA", 4, 16], ["z", "TEST", 28, 29], ["the emission line", "TREATMENT", 67, 84], ["a bright sky line", "TREATMENT", 105, 122], ["FIREBall", "TEST", 281, 289], ["bright", "OBSERVATION_MODIFIER", 107, 113], ["sky line", "OBSERVATION", 114, 122]]], ["The potential dates for the Fort Sumner launch window, the single night of observation, and the restriction on elevation range due to the balloon and gondola provided limits on potential fields.", [["elevation range", "TREATMENT", 111, 126], ["the balloon and gondola", "TREATMENT", 134, 157], ["balloon", "OBSERVATION", 138, 145]]], ["In addition, selected fields needed an adequate number of stars at the desired bands and magnitudes that fall in the field of view of the guidance system and act as guide stars.Targets within fieldsAfter fields were selected, the slits needed to be filled with desired targets.", [["fields", "OBSERVATION_MODIFIER", 192, 198]]], ["The criteria for selection included maximizing the number of Ly-\u03b1 galaxies at z=0.7, spectral lengths of up to a few arcmin per galaxy, providing sufficient space between spectra to avoid overlap on the detector and avoiding redshifts where important galaxy emission lines would overlap on atmospheric features (NO in the upper atmosphere in particular at 2030 and 2047\u00c5).", [["NO", "CHEMICAL", 312, 314], ["NO", "CHEMICAL", 312, 314], ["NO", "SIMPLE_CHEMICAL", 312, 314], ["Ly-\u03b1 galaxies", "PROTEIN", 61, 74], ["galaxy emission lines", "CELL_LINE", 251, 272], ["the detector", "TEST", 199, 211], ["redshifts", "TREATMENT", 225, 234], ["galaxy emission lines", "TREATMENT", 251, 272], ["atmospheric features", "TEST", 290, 310], ["galaxy", "OBSERVATION", 251, 257], ["emission lines", "OBSERVATION", 258, 272], ["upper", "ANATOMY_MODIFIER", 322, 327]]], ["When additional space was available that couldn't be filled by a Ly-\u03b1 target, OVI and CIV galaxies were also used, in that order.", [["-\u03b1", "GENE_OR_GENE_PRODUCT", 67, 69], ["Ly-\u03b1 target", "DNA", 65, 76], ["OVI and CIV galaxies", "DNA", 78, 98], ["a Ly-\u03b1 target", "TREATMENT", 63, 76], ["OVI and CIV galaxies", "TREATMENT", 78, 98]]], ["The slit length in the cut masks was slightly larger than planned due to the strength of the laser, so in practice there was some slit overlap.Targets within fieldsFor the mid-September launch from Ft.", [["slit", "MULTI-TISSUE_STRUCTURE", 4, 8], ["The slit length in the cut masks", "TREATMENT", 0, 32], ["slightly larger", "PROBLEM", 37, 52], ["some slit overlap", "PROBLEM", 125, 142], ["slit", "OBSERVATION_MODIFIER", 4, 8], ["length", "OBSERVATION_MODIFIER", 9, 15], ["slightly", "OBSERVATION_MODIFIER", 37, 45], ["larger", "OBSERVATION", 46, 52], ["laser", "OBSERVATION", 93, 98], ["slit overlap", "OBSERVATION", 130, 142], ["fields", "OBSERVATION_MODIFIER", 158, 164]]], ["Sumner, NM, the DEEP2 Fields 2, 3, and 4 were chosen and several mask alternatives were produced and reviewed.", [["the DEEP2 Fields", "TEST", 12, 28], ["several mask alternatives", "TREATMENT", 57, 82]]], ["The mask areas in Field 2 were chosen by eye to contain a maximized number of Ly-\u03b1 galaxies at z = 0.7.Targets within fieldsThe star fields were chosen from SDSS Sky Server D12 with magnitudes between 12.0 and 18.0 in the g and r bands.", [["eye", "ANATOMY", 41, 44], ["eye", "ORGAN", 41, 44], ["The mask areas", "TREATMENT", 0, 14], ["magnitudes", "TEST", 182, 192], ["the g and r bands", "TEST", 218, 235], ["eye", "ANATOMY", 41, 44], ["fields", "OBSERVATION_MODIFIER", 118, 124]]], ["The stars and exact mask coverage areas are chosen to ensure an adequate number of guide stars exist for each target field.", [["The stars", "TREATMENT", 0, 9], ["exact mask coverage areas", "TREATMENT", 14, 39]]], ["FIREBall-2 has resolution on the scale of \u00b5m; therefore, distortions from coordinate conversion and telescope properties have to be accounted for and corrected.Targets within fieldsDue to the low altitude, only FB Field 2, a sub-region from the DEEP2 survey field (Newman et al. 2013) , was observed for a significant length of time.", [["FIREBall-2", "DNA", 0, 10], ["distortions from coordinate conversion", "PROBLEM", 57, 95], ["the low altitude", "PROBLEM", 188, 204], ["resolution", "OBSERVATION_MODIFIER", 15, 25], ["fields", "OBSERVATION_MODIFIER", 175, 181], ["low altitude", "OBSERVATION_MODIFIER", 192, 204]]], ["Field 2 was acquired at 7:30 PM local time, prior to sunset on the balloon, which is 30 minutes after sunset on the ground.", [["the balloon", "TREATMENT", 63, 74], ["balloon", "ANATOMY", 67, 74]]], ["The field was lined up using a standardized acquisition procedure based on the known positions of guide stars until science operations began after the sunset ballast drops.", [["a standardized acquisition procedure", "TREATMENT", 29, 65], ["science operations", "TREATMENT", 116, 134], ["the sunset ballast drops", "TREATMENT", 147, 171]]], ["FB-2 observed Field 2 until 9:37 PM MDT for a total of about 45 minutes of exposure time post twilight.Targets within fieldsAfter leaving Field 2 we moved to the center of M31 and then a QSO field (center at RA, Dec: 17.87698, 34.563395) near QSO SDSS J011133.38+343028.5.", [["FB-2", "CELL", 0, 4], ["fields", "OBSERVATION_MODIFIER", 118, 124]]], ["While data was acquired at each of these locations the altitude was less than 32 km and atmospheric transmission in the balloon window was significantly degraded.In flight performanceThe instrument in-flight performance is described in more detail in Picouet (2019) but briefly summarized here.", [["atmospheric transmission", "TEST", 88, 112], ["the balloon window", "TREATMENT", 116, 134], ["The instrument in-flight performance", "TEST", 183, 219], ["altitude", "OBSERVATION", 55, 63], ["balloon window", "OBSERVATION", 120, 134]]], ["Post flight processing of the data from Field 2 was used to determine the in-flight performance of the spectrograph.", [["the spectrograph", "TEST", 99, 115]]], ["Due to the degraded conditions described in Sections 3.1 and 3.2 the performance of some systems were sub-optimal.In flight performanceSeveral objects are detected in the co-added data from Field 2.", [["the degraded conditions", "PROBLEM", 7, 30], ["Sections", "TEST", 44, 52], ["performanceSeveral objects", "OBSERVATION", 124, 150]]], ["The brightest was continuum emission from a UV bright horizontal branch star with M F U V =17.8, which was detected by FB-2 with SNR>15 (ID: 2MASS J16515894+3459322, known as Bright Star 1 hereafter).", [["M F U V", "TEST", 82, 89], ["FB", "TEST", 119, 121], ["SNR", "TEST", 129, 132]]], ["Two fainter UV bright stars were also detected.", [["Two fainter UV bright stars", "PROBLEM", 0, 27], ["UV", "OBSERVATION_MODIFIER", 12, 14], ["bright stars", "OBSERVATION", 15, 27]]], ["Bright Star 1 was used to measure the system efficiency, finding 30% degradation compared to the ground calibrations with atmospheric losses.", [["30% degradation", "PROBLEM", 65, 80], ["atmospheric losses", "PROBLEM", 122, 140], ["atmospheric losses", "OBSERVATION", 122, 140]]], ["This is likely due to a combination of uncertainties including target centering, true atmospheric transmission, focus, etc.In flight performanceIn flight spatial resolution is calculated as full width at half max (FWHM) 7\", 40% greater than the 5\" expected based on the optical design after convolution with the slit widths and performance on the ground.", [["true atmospheric transmission", "PROBLEM", 81, 110], ["the slit widths", "TEST", 308, 323], ["likely due to", "UNCERTAINTY", 8, 21], ["true", "OBSERVATION_MODIFIER", 81, 85], ["atmospheric transmission", "OBSERVATION", 86, 110], ["resolution", "OBSERVATION_MODIFIER", 162, 172], ["full width", "OBSERVATION_MODIFIER", 190, 200]]], ["Part of this degradation may be due to defocus -a 50 \u00b5m de-focus in flight could lead to a 1 arcsec deterioration in spatial resolution along the slit.", [["a 1 arcsec deterioration", "PROBLEM", 89, 113], ["may be due to", "UNCERTAINTY", 25, 38], ["spatial", "OBSERVATION_MODIFIER", 117, 124], ["resolution", "OBSERVATION_MODIFIER", 125, 135]]], ["Temperature variations in components of the spectrograph and tip/tilt stage can also change the focus.In flight performanceIn flight spectral resolution could not be measured because the UV bright stars that we observed have no spectral features in this narrow bandpass.", [["Temperature variations in components", "PROBLEM", 0, 36], ["the spectrograph", "TEST", 40, 56], ["tip/tilt stage", "TREATMENT", 61, 75], ["the UV bright stars", "PROBLEM", 183, 202], ["spectral features in this narrow bandpass", "PROBLEM", 228, 269], ["tip", "OBSERVATION_MODIFIER", 61, 64], ["tilt stage", "OBSERVATION", 65, 75], ["narrow bandpass", "OBSERVATION", 254, 269]]], ["There are some features from atmospheric transmission on the UV bright star that can be used, but otherwise we rely on ground calibration.", [["the UV bright star", "TREATMENT", 57, 75], ["atmospheric", "OBSERVATION_MODIFIER", 29, 40]]], ["In earlier tests we found a spectral resolution of R\u223c1600 for a diffuse object (in part due to the wide slits), R\u223c3500-4000 for a point source (Picouet 2019) .In flight performanceThe best PSF shape on the ground is 20% larger than expected (5.5\" instead of 4.5\").", [["earlier tests", "TEST", 3, 16], ["a diffuse object", "PROBLEM", 62, 78], ["the wide slits)", "PROBLEM", 95, 110], ["The best PSF shape", "TEST", 180, 198], ["diffuse", "OBSERVATION_MODIFIER", 64, 71], ["object", "OBSERVATION", 72, 78], ["PSF", "OBSERVATION_MODIFIER", 189, 192], ["shape", "OBSERVATION_MODIFIER", 193, 198], ["ground", "OBSERVATION_MODIFIER", 206, 212], ["20%", "OBSERVATION_MODIFIER", 216, 219], ["larger", "OBSERVATION_MODIFIER", 220, 226]]], ["The spectrograph was designed for 3\" PSF with an additional \u223c1\" degradation because of lowered surface quality of FC2 during polishing.", [["surface", "ANATOMY", 95, 102], ["FC2", "SIMPLE_CHEMICAL", 114, 117], ["FC2", "PROTEIN", 114, 117], ["The spectrograph", "TEST", 0, 16]]], ["The PSF degradation beyond that may be due to spherical aberrations introduced by the grating but this is pending verification.PRELIMINARY DATA ANALYSISWhile the flight provided validation of a number of technology advances, the science data was significantly degraded due to the flight anomalies.", [["The PSF degradation", "PROBLEM", 0, 19], ["spherical aberrations", "PROBLEM", 46, 67], ["the science data", "TEST", 225, 241], ["the flight anomalies", "PROBLEM", 276, 296], ["PSF degradation", "OBSERVATION", 4, 19], ["may be due to", "UNCERTAINTY", 32, 45], ["spherical aberrations", "OBSERVATION", 46, 67], ["flight anomalies", "OBSERVATION", 280, 296]]], ["Here we discuss the various noise sources and their impact on the data.", [["the data", "TEST", 62, 70]]], ["A detailed discussion of the detector performance can be found in Kyne (2019) , which also includes a significant discussion on the performance of Teledyne-e2v's CCD201-20s in a lab setting.PRELIMINARY DATA ANALYSISWe are taking steps for the next flight to reduce the effect of the noise sources described below.", [["the detector performance", "TEST", 25, 49], ["Teledyne", "TEST", 147, 155], ["the noise sources", "PROBLEM", 279, 296]]], ["This includes exploring slowing down the clocking speed to 1 MHz, making adjustments to minimize other sources of noise such as cable length, serial clocking scheme, and increasing the operating temperature of the CCD for better charge transfer efficiency (which involves a trade off with increased dark current).", [["serial clocking scheme", "TREATMENT", 142, 164], ["the CCD", "TREATMENT", 210, 217], ["slowing", "OBSERVATION_MODIFIER", 24, 31]]], ["Reducing the impact of smearing will also reduce the impact of cosmic rays on the images as their tails will inevitably be shorter.Detector in-flight performance and measured noiseIn typical visible wavelength observations the largest source of noise is sky background.", [["the images", "TEST", 78, 88], ["Detector in-flight performance", "TEST", 131, 161], ["largest", "OBSERVATION_MODIFIER", 227, 234]]], ["In the UV the sky background is orders of magnitude lower than in the visible (Leinert et al. 1998) , typically leaving detector noise as the limiting noise contribution.", [["orders of magnitude", "OBSERVATION_MODIFIER", 32, 51], ["lower", "OBSERVATION_MODIFIER", 52, 57]]], ["For an EMCCD multiple sources of detector noise need to be considered.", [["detector noise", "PROBLEM", 33, 47]]], ["These include clockinduced-charge (CIC), read noise (RN), dark current, multiplication gain noise, and any background light sources (scattered light, sky noise, etc).", [["multiplication gain noise", "PROBLEM", 72, 97], ["scattered light, sky noise", "PROBLEM", 133, 159], ["scattered", "OBSERVATION_MODIFIER", 133, 142]]], ["In this case, the primary contribution of noise in the data was the excess scattered light from the balloon onto the detector surface via a parasitic optical path that was not baffled.", [["noise in the data", "PROBLEM", 42, 59], ["the balloon", "TREATMENT", 96, 107], ["a parasitic optical path", "PROBLEM", 138, 162], ["scattered", "OBSERVATION_MODIFIER", 75, 84], ["balloon", "OBSERVATION", 100, 107], ["parasitic", "OBSERVATION", 140, 149]]], ["This contributed to a varying background on the order of 0.7 e-pix \u22121 frame \u22121 , which is well above the count rate limit of 0.1 epix \u22121 frame \u22121 for photon counting (Picouet 2019) .", [["photon counting", "TEST", 150, 165], ["varying", "OBSERVATION_MODIFIER", 22, 29]]], ["Our analysis of the resulting data is focused on understanding and reducing the effect of this scattered light as much as possible.", [["Our analysis", "TEST", 0, 12], ["this scattered light", "TREATMENT", 90, 110]]], ["Here we discuss the scattered light and additional sources of noise in the detector system.Cosmic Ray RateOne significant consideration in operating an EMCCD, especially at balloon altitudes, is the effect and impact of cosmic rays on the data.", [["noise in the detector system", "PROBLEM", 62, 90], ["cosmic rays on the data", "TEST", 220, 243], ["scattered", "OBSERVATION_MODIFIER", 20, 29], ["significant", "OBSERVATION_MODIFIER", 110, 121]]], ["Pixels with cosmic ray hits in an EMCCD will be amplified in the gain register just like any other pixel and have a tendency to then spill over into the trailing pixels (due in part to the event smearing described in Section 4.1.4).", [["cosmic ray hits", "DNA", 12, 27], ["EMCCD", "DNA", 34, 39], ["cosmic ray hits", "TREATMENT", 12, 27], ["an EMCCD", "TREATMENT", 31, 39], ["cosmic", "OBSERVATION", 12, 18], ["ray hits", "OBSERVATION", 19, 27]]], ["While this issue has been largely mitigated in more modern EMCCD architectures (those being tested for WFIRST), the FIREBall-2 devices do not have the overspill register implemented.", [["the FIREBall-2 devices", "TREATMENT", 112, 134], ["largely", "OBSERVATION_MODIFIER", 26, 33], ["mitigated", "OBSERVATION", 34, 43]]], ["Figure 12 shows example images with the full extent of cosmic ray smearing.Dark current and other noiseDetector noise performance was difficult to disentangle from the effect of excess scattered moonlight from the balloon.", [["example images", "TEST", 16, 30], ["cosmic ray smearing", "PROBLEM", 55, 74], ["Dark current and other noiseDetector noise performance", "PROBLEM", 75, 129], ["excess scattered moonlight", "PROBLEM", 178, 204], ["the balloon", "TREATMENT", 210, 221], ["cosmic ray smearing", "OBSERVATION", 55, 74], ["scattered", "OBSERVATION_MODIFIER", 185, 194], ["balloon", "OBSERVATION", 214, 221]]], ["With the doors of the gondola closed and tank shutter closed we measured a noise of 1.7\u00d710 \u22124 e-pix \u22121 s \u22121 .", [["a noise", "TEST", 73, 80], ["tank shutter", "OBSERVATION", 41, 53]]], ["This is likely a combination of dark current, light leaks due to an imperfect shutter/tank cap design, and Cherenkov radiation, and was 10 times higher in-flight than during ground testing.", [["light leaks", "PROBLEM", 46, 57], ["an imperfect shutter/tank cap design", "TREATMENT", 65, 101], ["Cherenkov radiation", "TREATMENT", 107, 126], ["ground testing", "TEST", 174, 188], ["dark", "OBSERVATION_MODIFIER", 32, 36], ["light leaks", "OBSERVATION", 46, 57], ["tank cap", "OBSERVATION", 86, 94]]], ["The read noise of the entire system was around 90ewith a pre-amp gain of 0.53 ADU e-\u22121 .", [["The read noise", "TEST", 0, 14]]], ["These gain values are typically lower than the normal high values used in photon counting mode because of the excess scattered light.Scattered light and residualsThe scattered light was primarily moonlight being scattered and re-directed from the deflated balloon.", [["These gain values", "TEST", 0, 17], ["photon counting mode", "TREATMENT", 74, 94], ["the excess scattered light", "PROBLEM", 106, 132], ["Scattered light and residuals", "PROBLEM", 133, 162], ["the deflated balloon", "TREATMENT", 243, 263], ["lower", "OBSERVATION_MODIFIER", 32, 37], ["high values", "OBSERVATION_MODIFIER", 54, 65], ["scattered", "OBSERVATION_MODIFIER", 117, 126], ["light", "OBSERVATION_MODIFIER", 127, 132], ["light", "OBSERVATION_MODIFIER", 143, 148], ["residuals", "OBSERVATION_MODIFIER", 153, 162], ["scattered", "OBSERVATION_MODIFIER", 166, 175], ["light", "OBSERVATION_MODIFIER", 176, 181], ["scattered", "OBSERVATION_MODIFIER", 212, 221], ["deflated balloon", "OBSERVATION", 247, 263]]], ["Previous tests observing Vega indicated that the expected scattered light within the optical path would be on the order of \u226410 \u22124 of the in-band signal.", [["Previous tests", "TEST", 0, 14], ["scattered", "OBSERVATION_MODIFIER", 58, 67]]], ["The deflated balloon shape, however, acted as a lens and caused illumination that bypassed the optical path entirely and instead had an un-baffled view of the detector board and nearby optics.Scattered light and residualsThe bulk pattern of scattered light (shown in the central panel of Figure 13 ) fluctuated on 5 minute intervals, in sync with the balloon vertical oscillations.", [["The deflated balloon shape", "TREATMENT", 0, 26], ["Scattered light and residuals", "PROBLEM", 192, 221], ["the balloon vertical oscillations", "TREATMENT", 347, 380], ["deflated", "OBSERVATION", 4, 12], ["balloon", "OBSERVATION_MODIFIER", 13, 20], ["shape", "OBSERVATION_MODIFIER", 21, 26], ["light", "OBSERVATION_MODIFIER", 202, 207], ["residuals", "OBSERVATION_MODIFIER", 212, 221], ["bulk", "OBSERVATION_MODIFIER", 225, 229], ["pattern", "OBSERVATION_MODIFIER", 230, 237], ["scattered", "OBSERVATION_MODIFIER", 241, 250], ["light", "OBSERVATION_MODIFIER", 251, 256], ["central", "ANATOMY_MODIFIER", 271, 278], ["balloon", "OBSERVATION", 351, 358], ["vertical oscillations", "OBSERVATION", 359, 380]]], ["We were able to re-create much of the signature of the scattered light after the fact using pseudo-dome flats and other methods to fully illuminate the entrance aperture to the spectrograph tank, beyond just the pupil.Scattered light and residualsIn addition to large scale scattered light there were occasional flashes that are visible in the flight data, shown in Figure 14 .", [["pupil", "ANATOMY", 212, 217], ["pupil", "ORGANISM_SUBDIVISION", 212, 217], ["pseudo-dome flats", "TREATMENT", 92, 109], ["Scattered light and residuals", "PROBLEM", 218, 247], ["occasional flashes", "PROBLEM", 301, 319], ["the flight data", "TEST", 340, 355], ["scattered", "OBSERVATION_MODIFIER", 55, 64], ["pupil", "ANATOMY", 212, 217], ["light", "OBSERVATION_MODIFIER", 228, 233], ["residuals", "OBSERVATION_MODIFIER", 238, 247], ["large", "OBSERVATION_MODIFIER", 262, 267], ["scale", "OBSERVATION_MODIFIER", 268, 273], ["scattered", "OBSERVATION_MODIFIER", 274, 283], ["light", "OBSERVATION_MODIFIER", 284, 289], ["occasional", "OBSERVATION_MODIFIER", 301, 311], ["flashes", "OBSERVATION", 312, 319]]], ["These flashes are typically much brighter (\u223c2.5 times) than the background level of scatter and have a characteristic spatial signature.", [["These flashes", "PROBLEM", 0, 13], ["flashes", "OBSERVATION", 6, 13], ["typically", "OBSERVATION_MODIFIER", 18, 27], ["much", "OBSERVATION_MODIFIER", 28, 32], ["brighter", "OBSERVATION_MODIFIER", 33, 41], ["scatter", "OBSERVATION_MODIFIER", 84, 91], ["spatial signature", "OBSERVATION", 118, 135]]], ["We have also been able to re-create them in the lab post-flight and believe, due in part to their transient nature, brightness, and distinctive presentation, that they are the result of light reflecting off of a metal surface on the detector PCB mount.Scattered light and residualsWe are currently running a comprehensive scattering analysis of the as-built 2018 spectrograph and gondola using the FRED software package.", [["PCB", "CHEMICAL", 242, 245], ["PCB", "CHEMICAL", 242, 245], ["a metal surface", "TREATMENT", 210, 225], ["Scattered light and residuals", "PROBLEM", 252, 281], ["a comprehensive scattering analysis", "TEST", 306, 341], ["distinctive", "OBSERVATION_MODIFIER", 132, 143], ["light", "OBSERVATION_MODIFIER", 262, 267], ["residuals", "OBSERVATION_MODIFIER", 272, 281]]], ["This analysis should identify the exact optical paths that created the both the bulk scattered light and the flashes and confirm our post-flight experiments.Scattered light and residualsFor a future flight, we will implement a multi-pronged mitigation strategy to reduce the effect of scattered light.", [["This analysis", "TEST", 0, 13], ["Scattered light and residuals", "PROBLEM", 157, 186], ["a multi-pronged mitigation strategy", "TREATMENT", 225, 260], ["bulk", "OBSERVATION_MODIFIER", 80, 84], ["scattered", "OBSERVATION_MODIFIER", 85, 94], ["light", "OBSERVATION_MODIFIER", 95, 100], ["light", "OBSERVATION_MODIFIER", 167, 172], ["residuals", "OBSERVATION_MODIFIER", 177, 186], ["scattered", "OBSERVATION_MODIFIER", 285, 294]]], ["First, we plan to reduce the field of regard of the balloon from the spectrograph tank opening by the addition of baffling that will stretch across the gondola doors when open.", [["the balloon", "TREATMENT", 48, 59], ["balloon", "OBSERVATION", 52, 59]]], ["This limits the upper altitude accessible by the siderostat and so will be carefully positioned to minimize the impact on the science target observability.", [["upper altitude", "OBSERVATION_MODIFIER", 16, 30]]], ["This includes more extensive baffling around and beyond the pupil, above the slits masks, as well as the baffling directly around the detector, to reduce reflective surfaces.Event smearingThe smearing of events in the multiplication register is a common problem in EMCCDs.", [["pupil", "ANATOMY", 60, 65], ["pupil", "MULTI-TISSUE_STRUCTURE", 60, 65], ["EMCCDs", "CANCER", 265, 271], ["more", "OBSERVATION_MODIFIER", 14, 18], ["extensive", "OBSERVATION_MODIFIER", 19, 28], ["baffling", "OBSERVATION", 29, 37], ["pupil", "ANATOMY", 60, 65], ["slits masks", "OBSERVATION", 77, 88], ["surfaces", "OBSERVATION_MODIFIER", 165, 173], ["smearing", "OBSERVATION_MODIFIER", 192, 200], ["common", "OBSERVATION_MODIFIER", 247, 253], ["problem", "OBSERVATION", 254, 261]]], ["It derives from a combination of low temperature (which can reduce CTE) and the fast pixel clocking speed (10 MHz in this case).", [["low temperature", "PROBLEM", 33, 48], ["CTE", "TEST", 67, 70], ["low temperature", "OBSERVATION_MODIFIER", 33, 48]]], ["The FIREBall-2 spectrograph set-up required the detector inside the vacuum tank pressure vessel while the N\u00fcv\u00fc controller box was Figure 13 .", [["vessel", "MULTI-TISSUE_STRUCTURE", 89, 95], ["FIREBall-2 spectrograph set", "DNA", 4, 31], ["N\u00fcv\u00fc controller box", "DNA", 106, 125], ["The FIREBall-2 spectrograph", "TEST", 0, 27], ["the vacuum tank pressure vessel", "TREATMENT", 64, 95], ["the N\u00fcv\u00fc controller box", "TREATMENT", 102, 125], ["vacuum tank", "OBSERVATION", 68, 79], ["pressure vessel", "OBSERVATION", 80, 95]]], ["Field 2 summed images.", [["Field 2 summed images", "TEST", 0, 21]]], ["Left: The summed image before cosmic ray removal.", [["cosmic ray removal", "TREATMENT", 30, 48]]], ["Center: The summed image after de-smearing and cosmic ray removal.", [["de-smearing", "TREATMENT", 31, 42], ["cosmic ray removal", "TREATMENT", 47, 65]]], ["Right: The summed image after de-smearing, cosmic ray removal, and subtracting the background scattered light.", [["de-smearing", "TREATMENT", 30, 41], ["cosmic ray removal", "TREATMENT", 43, 61], ["scattered", "OBSERVATION_MODIFIER", 94, 103], ["light", "OBSERVATION_MODIFIER", 104, 109]]], ["The sharp drop-off in scattered light on the bottom fifth of the image makes the subtraction difficult, yielding a residual along the edge of the scattered region.", [["The sharp drop", "TEST", 0, 14], ["the subtraction", "TEST", 77, 92], ["sharp", "OBSERVATION_MODIFIER", 4, 9], ["drop", "OBSERVATION_MODIFIER", 10, 14], ["scattered", "OBSERVATION_MODIFIER", 22, 31], ["light", "OBSERVATION_MODIFIER", 32, 37], ["residual", "OBSERVATION_MODIFIER", 115, 123], ["edge", "ANATOMY_MODIFIER", 134, 138], ["scattered", "OBSERVATION_MODIFIER", 146, 155]]], ["The dark region at the top of the detector was not delta-doped due to the placement of a mask during the MBE process.", [["delta-doped", "PROBLEM", 51, 62], ["a mask", "TREATMENT", 87, 93], ["the MBE process", "TREATMENT", 101, 116], ["dark", "OBSERVATION_MODIFIER", 4, 8], ["region", "OBSERVATION_MODIFIER", 9, 15], ["top", "OBSERVATION_MODIFIER", 23, 26]]], ["These pixels are not responsive to UV light.", [["UV light", "TREATMENT", 35, 43], ["not", "UNCERTAINTY", 17, 20], ["responsive", "OBSERVATION_MODIFIER", 21, 31]]], ["The bright slash of pixels in the middle right of each image is a cluster of hot pixels.", [["hot pixels", "PROBLEM", 77, 87], ["bright", "OBSERVATION_MODIFIER", 4, 10], ["slash", "OBSERVATION_MODIFIER", 11, 16], ["pixels", "OBSERVATION_MODIFIER", 20, 26], ["middle", "ANATOMY_MODIFIER", 34, 40], ["right", "ANATOMY_MODIFIER", 41, 46], ["cluster", "OBSERVATION_MODIFIER", 66, 73], ["hot pixels", "OBSERVATION", 77, 87]]], ["Additional hot pixels are clustered in the bottom right of the images.", [["Additional hot pixels", "TREATMENT", 0, 21], ["hot pixels", "OBSERVATION", 11, 21], ["bottom", "ANATOMY_MODIFIER", 43, 49], ["right", "ANATOMY_MODIFIER", 50, 55]]], ["This detector had multiple defects but the highest QE out of the available devices, which is why it was selected.", [["multiple defects", "PROBLEM", 18, 34], ["the available devices", "TREATMENT", 61, 82], ["multiple", "OBSERVATION_MODIFIER", 18, 26], ["defects", "OBSERVATION", 27, 34], ["highest", "OBSERVATION_MODIFIER", 43, 50]]], ["All images have been smoothed with a Gaussian kernel with sigma of 1.5 and a radius of 3 pixels.", [["All images", "TEST", 0, 10], ["radius", "ANATOMY", 77, 83]]], ["The emission from the brightest star, outside, connected by an 11 inch cable.", [["an 11 inch cable", "TREATMENT", 60, 76]]], ["This is at the very limit of what N\u00fcv\u00fc recommends for the 10 MHz pixel clocking speed, and was just barely manageable given the spectrograph configuration.Event smearingThe net effect of event smearing is to reduce the measured gain value (since high count pixels will be spread out over 3-4 trailing pixels, lowering the high end of the histogram and increasing the low end).", [["the 10 MHz pixel clocking speed", "TREATMENT", 54, 85], ["the measured gain value", "PROBLEM", 215, 238], ["high count pixels", "PROBLEM", 246, 263], ["the histogram", "TEST", 334, 347], ["net effect", "OBSERVATION_MODIFIER", 173, 183]]], ["In addition, it makes it difficult to distinguish between events in adjacent pixels vs. a single event that has been smeared.", [["a single event", "PROBLEM", 88, 102], ["smeared", "OBSERVATION_MODIFIER", 117, 124]]], ["The smearing signature is an exponential and is fairly easy to characterize, but like the amplification process itself, does not necessarily follow the same pattern every time.", [["smearing signature", "OBSERVATION", 4, 22], ["exponential", "OBSERVATION_MODIFIER", 29, 40], ["fairly easy to characterize", "OBSERVATION_MODIFIER", 48, 75]]], ["The impact of smearing is to reduce the number of pixels that are above the standard EMCCD 5\u03c3 threshold, and a reduction in the apparent gain.", [["smearing", "OBSERVATION", 14, 22], ["reduction", "OBSERVATION_MODIFIER", 111, 120]]], ["A de-smearing algorithm using median absolute deviation is able to reduce the impact of the smear and is detailed in Kyne (2019).Co-added data analysisHere we present the co-added data from Field 2, from the DEEP2 survey.", [["A de-smearing algorithm", "TREATMENT", 0, 23], ["median absolute deviation", "TREATMENT", 30, 55], ["the smear", "TEST", 88, 97], ["Co-added data analysis", "TEST", 129, 151], ["absolute deviation", "OBSERVATION", 37, 55], ["smear", "OBSERVATION", 92, 97]]], ["This image was made by co-adding 55 minutes worth of data, taken under sub-optimal conditions as described in Section 3.1.", [["This image", "TEST", 0, 10]]], ["The left most shows the summed image before cosmic ray removal.", [["cosmic ray removal", "TREATMENT", 44, 62], ["left", "ANATOMY_MODIFIER", 4, 8]]], ["The center image shows the summed image after de-smearing and cosmic ray removal, with individual images cosmic ray removed prior to summing.", [["The center image", "TEST", 0, 16], ["cosmic ray removal", "TREATMENT", 62, 80], ["individual images cosmic ray", "TEST", 87, 115]]], ["The pixels with cosmic rays are filled with data interpolated from the surrounding pixels.", [["cosmic rays", "TREATMENT", 16, 27], ["cosmic rays", "OBSERVATION", 16, 27]]], ["The right image shows the summed image after de-smearing, cosmic ray removal, and subtracting the background scattered light.Co-added data analysisThe process of co-adding is typical for that used for EMCCDs as described in Kyne (2019) .", [["The right image", "TEST", 0, 15], ["cosmic ray removal", "TREATMENT", 58, 76], ["data analysis", "TEST", 134, 147], ["EMCCDs", "TREATMENT", 201, 207], ["right", "ANATOMY_MODIFIER", 4, 9], ["scattered", "OBSERVATION_MODIFIER", 109, 118], ["light", "OBSERVATION_MODIFIER", 119, 124]]], ["The multiplication gain is calculated for each individual image in both the image area, pre-scan, and over-scan regions.", [["each individual image", "TEST", 42, 63], ["pre-scan", "TEST", 88, 96], ["multiplication gain", "OBSERVATION", 4, 23]]], ["Smear correction is done using the median absolute deviation (MAD) method and a 6-sigma correction.", [["Smear correction", "TEST", 0, 16], ["the median absolute deviation (MAD) method", "TREATMENT", 31, 73], ["a 6-sigma correction", "TREATMENT", 78, 98]]], ["After the smear correction, the multiplication gain is re-measured.", [["the smear correction", "TREATMENT", 6, 26], ["the multiplication gain", "TEST", 28, 51]]], ["Individual images are converted from counts to electrons using a conversion gain measured from a photon transfer curve (1.77 e-ADU \u22121 in this case).", [["Individual images", "TEST", 0, 17], ["a photon transfer curve", "TEST", 95, 118]]], ["Because of the high background, these images were not taken in a pure photon counting mode and instead the analysis uses a gain mode.", [["these images", "TEST", 32, 44], ["the analysis", "TEST", 103, 115]]], ["The EM gain calculated for each image is used to convert the image back to photons, which results is a \u221a 2 loss of overall efficiency.", [["a \u221a 2 loss of overall efficiency", "PROBLEM", 101, 133], ["overall efficiency", "OBSERVATION", 115, 133]]], ["Individual images are then summed and the total exposure time is used to convert to photons per second.Co-added data analysisAll three UV bright stars are visible in the summed image, which is significantly contaminated by stray light.", [["Individual images", "TEST", 0, 17], ["Co-added data analysis", "TEST", 103, 125], ["the summed image", "TEST", 166, 182], ["three", "OBSERVATION_MODIFIER", 129, 134], ["UV", "OBSERVATION_MODIFIER", 135, 137], ["bright stars", "OBSERVATION", 138, 150], ["visible", "OBSERVATION_MODIFIER", 155, 162], ["significantly", "OBSERVATION_MODIFIER", 193, 206], ["contaminated", "OBSERVATION_MODIFIER", 207, 219]]], ["A subsequent analysis attempted to remove the large signal from stray light, but no signal from Ly-\u03b1 was detected around individual galaxies.", [["Ly-\u03b1", "GENE_OR_GENE_PRODUCT", 96, 100], ["Ly-\u03b1", "PROTEIN", 96, 100], ["A subsequent analysis", "TEST", 0, 21], ["large", "OBSERVATION_MODIFIER", 46, 51], ["no", "UNCERTAINTY", 81, 83], ["individual galaxies", "OBSERVATION", 121, 140]]], ["Summing spectra from many galaxies also did not yield any significant detections.In-flight sensitivityDue to the low altitude, scattering from the balloon de-shape, and degraded performance, the overall sensitivity was worse than the FB-1 flight.", [["the low altitude", "PROBLEM", 109, 125], ["the overall sensitivity", "TEST", 191, 214], ["low altitude", "OBSERVATION_MODIFIER", 113, 125], ["shape", "OBSERVATION_MODIFIER", 158, 163]]], ["Picouet (2019) calculates a sensitivity of 80,000 LU (vs. 74,000 LU for FB-1) using the measured emission from the detected UV bright stars.", [["a sensitivity", "TEST", 26, 39], ["FB", "TEST", 72, 74], ["UV", "OBSERVATION", 124, 126], ["bright stars", "OBSERVATION", 127, 139]]], ["This was significantly higher than the expected sensitivity of 8,000 LU and was driven entirely by increased noise.FUTURE FLIGHT POSSIBILITIESWhile the payload sustained significant damage upon landing, the resulting analysis has shown that the major components (the two large optics, the gondola structure, the pivot, the spectrograph) can all be re-flown as they are or with limited refurbishment.", [["increased noise", "PROBLEM", 99, 114], ["the payload", "PROBLEM", 148, 159], ["significant damage", "PROBLEM", 170, 188], ["the resulting analysis", "TEST", 203, 225], ["significantly", "OBSERVATION_MODIFIER", 9, 22], ["higher", "OBSERVATION_MODIFIER", 23, 29], ["increased noise", "OBSERVATION", 99, 114], ["significant", "OBSERVATION_MODIFIER", 170, 181], ["damage", "OBSERVATION", 182, 188], ["major", "OBSERVATION_MODIFIER", 245, 250], ["components", "OBSERVATION_MODIFIER", 251, 261], ["large", "OBSERVATION_MODIFIER", 271, 276], ["optics", "OBSERVATION_MODIFIER", 277, 283]]], ["Additionally, nearly every aspect of the payload and spectrograph system performed as expected and within specifications.", [["the payload and spectrograph system", "TEST", 37, 72]]], ["We will be able to mitigate the effects of scattered light and are investigating some upgrades to the cooling/detector system to reduce the cooling power and heat load required as well as upgrade to the N\u00fcv\u00fc v3 CCCP controller to reduce the read noise in the detector.", [["CCCP", "CHEMICAL", 211, 215], ["CCCP", "CHEMICAL", 211, 215], ["the cooling/detector system", "TREATMENT", 98, 125], ["the cooling power", "TREATMENT", 136, 153], ["heat load", "TREATMENT", 158, 167], ["the N\u00fcv\u00fc v3 CCCP controller", "TREATMENT", 199, 226]]], ["We are adding an additional field with several QSOs and QSO pairs, in response to the more recent observations of QSO pairs described earlier.FUTURE FLIGHT POSSIBILITIESFuture upgrades beyond 2021 (i.e. for a FIREBall-3) may include a re-design of the spectrograph using microshutter arrays and potentially upgraded detector architecture, but are currently in a very preliminary phase.FIREBALL-2 AS A PATHFINDER FOR FUTURE UV TELESCOPESThe FIREBall sub-orbital program has always been carried out with three goals in mind.", [["QSO", "GENE_OR_GENE_PRODUCT", 114, 117], ["QSOs and QSO pairs", "DNA", 47, 65], ["QSO pairs", "DNA", 114, 123], ["QSO pairs", "PROBLEM", 114, 123], ["the spectrograph", "TEST", 248, 264], ["microshutter arrays", "TREATMENT", 271, 290], ["FUTURE UV TELESCOPESThe FIREBall sub-orbital program", "TREATMENT", 416, 468]]], ["Additionally, it provides an opportunity for postdocs to take on important, leadership roles that would otherwise not be accessible to them, giving them training as future PIs.FIREBALL-2 AS A PATHFINDER FOR FUTURE UV TELESCOPESThe second goal has been technology demonstrations.", [["FUTURE UV TELESCOPES", "TREATMENT", 207, 227]]], ["Additional technology, such as the anamorphic grating, guidance system, and use of a multi-object spectrograph on a balloon payload have also been significant improvements over the existing state of the art.FIREBALL-2 AS A PATHFINDER FOR FUTURE UV TELESCOPESFinally, FIREBall has always been a pathfinder for a larger program to observe and map the faint circumgalactic and intergalactic media.", [["a multi-object spectrograph", "TEST", 83, 110], ["a balloon payload", "TREATMENT", 114, 131], ["a larger program", "TREATMENT", 309, 325], ["the faint circumgalactic and intergalactic media", "PROBLEM", 345, 393], ["significant", "OBSERVATION_MODIFIER", 147, 158], ["improvements", "OBSERVATION", 159, 171]]], ["While the observations in the visible bandpass have vindicated the concept of directly observing the diffuse gas from the CGM, we have not yet realized the potential of doing these observations in the UV.", [["the diffuse gas from the CGM", "PROBLEM", 97, 125], ["diffuse", "OBSERVATION_MODIFIER", 101, 108], ["gas", "OBSERVATION", 109, 112]]], ["The 2021 flight of FIREBall-2 will detect this emission at a redshift of 0.7, but a future mission concept to explore the CGM in the UV from redshifts of z<2 is essential in our understanding of galaxy evolution.FIREBALL-2 AS A PATHFINDER FOR FUTURE UV TELESCOPESWhile the data gathered from the 2018 flight of FIREBall-2 may not provide a detection of the CGM at z=0.7, the flight was a success in a number of ways.", [["the CGM", "TEST", 118, 125], ["the CGM at z", "TEST", 353, 365], ["galaxy evolution", "OBSERVATION", 195, 211]]], ["Future flights of FIREBall-2 will improve on the past missions and we remain excited for the future.FIREBALL-2 AS A PATHFINDER FOR FUTURE UV TELESCOPESFor excellent advice and assistance on detector testing and optimization, we sincerely thank N\u00fcv\u00fc especially Olivier Daigle and Yoann Gosselin.", [["detector testing", "TEST", 190, 206]]], ["We also thank Teledyne-e2v, for their continued support in detector development and testing.Facilities:Software:", [["testing", "TEST", 84, 91]]]], "207c9b86b93c224ee25c03d71358c7385b4580a8": [["Correspondence laoneill@tcd.ieIn Brief Hooftman et al. reveal a role for the Krebs cycle-derived metabolite itaconate in regulating the NLRP3 inflammasome.", [["itaconate", "CHEMICAL", 108, 117], ["itaconate", "CHEMICAL", 108, 117], ["Krebs", "SIMPLE_CHEMICAL", 77, 82], ["itaconate", "SIMPLE_CHEMICAL", 108, 117], ["NLRP3", "GENE_OR_GENE_PRODUCT", 136, 141], ["NLRP3", "PROTEIN", 136, 141], ["the Krebs cycle-derived metabolite itaconate", "TREATMENT", 73, 117], ["NLRP3 inflammasome", "OBSERVATION", 136, 154]]], ["Itaconate specifically blocks NLRP3 inflammasome activation by reducing the NLRP3-NEK7 interaction, likely due to modification of C548 on NLRP3.", [["Itaconate", "CHEMICAL", 0, 9], ["Itaconate", "CHEMICAL", 0, 9], ["Itaconate", "SIMPLE_CHEMICAL", 0, 9], ["NLRP3", "GENE_OR_GENE_PRODUCT", 30, 35], ["NLRP3", "GENE_OR_GENE_PRODUCT", 76, 81], ["NEK7", "GENE_OR_GENE_PRODUCT", 82, 86], ["C548", "GENE_OR_GENE_PRODUCT", 130, 134], ["NLRP3", "GENE_OR_GENE_PRODUCT", 138, 143], ["NLRP3", "PROTEIN", 30, 35], ["NLRP3", "PROTEIN", 76, 81], ["NEK7", "PROTEIN", 82, 86], ["C548", "PROTEIN", 130, 134], ["NLRP3", "PROTEIN", 138, 143], ["Itaconate", "TREATMENT", 0, 9], ["NLRP3 inflammasome activation", "TREATMENT", 30, 59], ["NLRP3", "TREATMENT", 138, 143]]], ["Furthermore, itaconate inhibits IL-1b release from cells isolated from patients with the NLRP3-mediated disease CAPS.INTRODUCTIONInflammasomes are intracellular multi-protein complexes that respond to a wide range of stimuli, including invading pathogens, host cell-derived danger signals, and environmental irritants (Lamkanfi and Dixit, 2014; Swanson et al., 2019) .", [["cells", "ANATOMY", 51, 56], ["intracellular", "ANATOMY", 147, 160], ["cell", "ANATOMY", 261, 265], ["itaconate", "CHEMICAL", 13, 22], ["itaconate", "CHEMICAL", 13, 22], ["itaconate", "SIMPLE_CHEMICAL", 13, 22], ["IL-1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["cells", "CELL", 51, 56], ["patients", "ORGANISM", 71, 79], ["NLRP3", "GENE_OR_GENE_PRODUCT", 89, 94], ["CAPS.INTRODUCTIONInflammasomes", "GENE_OR_GENE_PRODUCT", 112, 142], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["host cell", "CELL", 256, 265], ["IL-1b", "PROTEIN", 32, 37], ["NLRP3", "PROTEIN", 89, 94], ["intracellular multi-protein complexes", "PROTEIN", 147, 184], ["patients", "SPECIES", 71, 79], ["itaconate inhibits IL", "TREATMENT", 13, 34], ["the NLRP3-mediated disease CAPS.INTRODUCTIONInflammasomes", "PROBLEM", 85, 142], ["intracellular multi-protein complexes", "PROBLEM", 147, 184], ["a wide range of stimuli", "TREATMENT", 201, 224], ["invading pathogens", "PROBLEM", 236, 254], ["multi-protein complexes", "OBSERVATION", 161, 184]]], ["Numerous different inflammasomes exist, each responding to its own activating stimuli.", [["inflammasomes", "PROTEIN", 19, 32], ["Numerous different inflammasomes", "PROBLEM", 0, 32], ["different", "OBSERVATION_MODIFIER", 9, 18], ["inflammasomes", "OBSERVATION", 19, 32]]], ["The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome is one of the best characterized inflammasomes, consisting of its central protein NLRP3, the adaptor protein ASC (also known as PYCARD), the mitotic kinase NIMA-related kinase 7 (NEK7) (He et al., 2016; Schmid-Burgk et al., 2016; Shi et al., 2016b) , and the effector protein caspase-1.", [["NOD", "GENE_OR_GENE_PRODUCT", 4, 7], ["LRR", "GENE_OR_GENE_PRODUCT", 10, 13], ["pyrin domain-containing protein 3", "GENE_OR_GENE_PRODUCT", 20, 53], ["NLRP3", "GENE_OR_GENE_PRODUCT", 55, 60], ["NLRP3", "GENE_OR_GENE_PRODUCT", 157, 162], ["ASC", "GENE_OR_GENE_PRODUCT", 184, 187], ["PYCARD", "GENE_OR_GENE_PRODUCT", 203, 209], ["NIMA-related kinase 7", "GENE_OR_GENE_PRODUCT", 231, 252], ["NEK7", "GENE_OR_GENE_PRODUCT", 254, 258], ["caspase-1", "GENE_OR_GENE_PRODUCT", 351, 360], ["NOD", "PROTEIN", 4, 7], ["LRR", "PROTEIN", 10, 13], ["pyrin domain-containing protein 3 (NLRP3) inflammasome", "PROTEIN", 20, 74], ["inflammasomes", "PROTEIN", 108, 121], ["NLRP3", "PROTEIN", 157, 162], ["adaptor protein", "PROTEIN", 168, 183], ["ASC", "PROTEIN", 184, 187], ["PYCARD", "PROTEIN", 203, 209], ["mitotic kinase", "PROTEIN", 216, 230], ["NIMA-related kinase 7", "PROTEIN", 231, 252], ["NEK7", "PROTEIN", 254, 258], ["effector protein caspase-1", "PROTEIN", 334, 360], ["The NOD", "TEST", 0, 7], ["LRR", "TEST", 10, 13], ["pyrin domain", "TEST", 20, 32], ["protein", "TEST", 44, 51], ["inflammasome", "PROBLEM", 62, 74], ["the mitotic kinase NIMA", "TEST", 212, 235], ["kinase", "TEST", 244, 250], ["the effector protein caspase", "TEST", 330, 358], ["central", "ANATOMY_MODIFIER", 141, 148]]], ["NLRP3 consists of three domains: an amino-terminal pyrin domain (PYD), a carboxy-terminal leucine-rich repeat (LRR) domain, and a central NACHT domain (Hu et al., 2013) .", [["carboxy", "CHEMICAL", 73, 80], ["leucine", "CHEMICAL", 90, 97], ["NLRP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["pyrin", "GENE_OR_GENE_PRODUCT", 51, 56], ["PYD", "GENE_OR_GENE_PRODUCT", 65, 68], ["NLRP3", "PROTEIN", 0, 5], ["amino-terminal pyrin domain", "PROTEIN", 36, 63], ["PYD", "PROTEIN", 65, 68], ["carboxy-terminal leucine-rich repeat (LRR) domain", "PROTEIN", 73, 122], ["NACHT domain", "PROTEIN", 138, 150], ["NLRP3", "TREATMENT", 0, 5], ["an amino-terminal pyrin domain", "TREATMENT", 33, 63], ["a carboxy-terminal leucine", "TREATMENT", 71, 97], ["a central NACHT domain", "TREATMENT", 128, 150]]], ["Interactions between NLRP3 and NEK7 are essential for NLRP3 oligomerization and associated inflammasome activation, and these occur at multiple surfaces in the LRR and NACHT domains of NLRP3 (Sharif et al., 2019).", [["NLRP3", "GENE_OR_GENE_PRODUCT", 21, 26], ["NEK7", "GENE_OR_GENE_PRODUCT", 31, 35], ["NLRP3", "GENE_OR_GENE_PRODUCT", 54, 59], ["NLRP3", "GENE_OR_GENE_PRODUCT", 185, 190], ["NLRP3", "PROTEIN", 21, 26], ["NEK7", "PROTEIN", 31, 35], ["NLRP3", "PROTEIN", 54, 59], ["LRR", "PROTEIN", 160, 163], ["NACHT domains", "PROTEIN", 168, 181], ["NLRP3", "PROTEIN", 185, 190], ["NEK7", "TREATMENT", 31, 35], ["NLRP3 oligomerization", "TREATMENT", 54, 75], ["associated inflammasome activation", "PROBLEM", 80, 114], ["inflammasome activation", "OBSERVATION", 91, 114]]], ["Activation of the NLRP3 inflamma-some results in caspase-1-mediated cleavage of pro-IL-1b, pro-IL-18, and gasdermin D into their active subunits.", [["gasdermin D", "CHEMICAL", 106, 117], ["NLRP3", "GENE_OR_GENE_PRODUCT", 18, 23], ["caspase-1", "GENE_OR_GENE_PRODUCT", 49, 58], ["pro-IL-1b", "GENE_OR_GENE_PRODUCT", 80, 89], ["pro-IL-18", "GENE_OR_GENE_PRODUCT", 91, 100], ["gasdermin D", "GENE_OR_GENE_PRODUCT", 106, 117], ["NLRP3", "PROTEIN", 18, 23], ["caspase-1", "PROTEIN", 49, 58], ["pro-IL-1b", "PROTEIN", 80, 89], ["pro-IL-18", "PROTEIN", 91, 100], ["gasdermin D", "PROTEIN", 106, 117], ["the NLRP3 inflamma", "TREATMENT", 14, 32], ["caspase", "TEST", 49, 56], ["pro-IL", "TEST", 80, 86], ["pro-IL", "TEST", 91, 97]]], ["Despite advances in our understanding of the interactions that facilitate NLRP3 activation, a unifying molecular pathway from stimulus to NLRP3 activation remains to be elucidated.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 74, 79], ["NLRP3", "GENE_OR_GENE_PRODUCT", 138, 143], ["NLRP3", "PROTEIN", 74, 79], ["NLRP3", "PROTEIN", 138, 143], ["NLRP3 activation", "TREATMENT", 74, 90]]], ["This is further complicated by the fact that the stimuli that trigger NLRP3 activation are so wide-ranging: potassium efflux (Mu\u00f1 oz- Planillo et al., 2013) , chloride efflux (Domingo-Fern\u00e1 ndez et al., 2017; Tang et al., 2017) , lysosomal disruption (Hornung et al., 2008) , trans-Golgi network disassembly (Chen and Chen, 2018) , and mitochondrial dysfunction (Gro\u00df et al., 2016; Shimada et al., 2012) are notable NLRP3-activating stimuli.", [["lysosomal", "ANATOMY", 230, 239], ["mitochondrial", "ANATOMY", 336, 349], ["potassium", "CHEMICAL", 108, 117], ["chloride", "CHEMICAL", 159, 167], ["mitochondrial dysfunction", "DISEASE", 336, 361], ["potassium", "CHEMICAL", 108, 117], ["chloride", "CHEMICAL", 159, 167], ["NLRP3", "GENE_OR_GENE_PRODUCT", 70, 75], ["potassium", "SIMPLE_CHEMICAL", 108, 117], ["chloride", "SIMPLE_CHEMICAL", 159, 167], ["lysosomal", "CELLULAR_COMPONENT", 230, 239], ["mitochondrial", "CELLULAR_COMPONENT", 336, 349], ["NLRP3", "GENE_OR_GENE_PRODUCT", 416, 421], ["NLRP3", "PROTEIN", 70, 75], ["NLRP3", "PROTEIN", 416, 421], ["the stimuli", "TEST", 45, 56], ["potassium efflux", "TEST", 108, 124], ["chloride efflux", "TEST", 159, 174], ["Domingo", "TEST", 176, 183], ["lysosomal disruption", "PROBLEM", 230, 250], ["mitochondrial dysfunction", "PROBLEM", 336, 361], ["lysosomal disruption", "OBSERVATION", 230, 250], ["mitochondrial dysfunction", "OBSERVATION", 336, 361]]], ["The NLRP3 inflammasome may also be regulated metabolically.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 4, 9], ["NLRP3", "PROTEIN", 4, 9], ["The NLRP3 inflammasome", "TREATMENT", 0, 22], ["NLRP3 inflammasome", "OBSERVATION", 4, 22], ["may also be", "UNCERTAINTY", 23, 34]]], ["Mitochondrial localization of NLRP3 is thought to precede inflammasome activation (Iyer et al., 2013) , and mitochondrial reactive oxygen species (ROS) have been implicated in NLRP3 activation (Gro\u00df et al., NLRP3 has been implicated in several diseases.", [["Mitochondrial", "ANATOMY", 0, 13], ["mitochondrial", "ANATOMY", 108, 121], ["oxygen", "CHEMICAL", 131, 137], ["ROS", "CHEMICAL", 147, 150], ["oxygen", "CHEMICAL", 131, 137], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["NLRP3", "GENE_OR_GENE_PRODUCT", 30, 35], ["mitochondrial", "CELLULAR_COMPONENT", 108, 121], ["reactive oxygen species", "SIMPLE_CHEMICAL", 122, 145], ["ROS", "SIMPLE_CHEMICAL", 147, 150], ["NLRP3", "GENE_OR_GENE_PRODUCT", 176, 181], ["NLRP3", "GENE_OR_GENE_PRODUCT", 207, 212], ["NLRP3", "PROTEIN", 30, 35], ["NLRP3", "PROTEIN", 176, 181], ["NLRP3", "PROTEIN", 207, 212], ["Mitochondrial localization of NLRP3", "TEST", 0, 35], ["mitochondrial reactive oxygen species", "PROBLEM", 108, 145], ["NLRP3", "OBSERVATION", 30, 35], ["thought to precede", "UNCERTAINTY", 39, 57], ["reactive", "OBSERVATION_MODIFIER", 122, 130], ["oxygen species", "OBSERVATION", 131, 145], ["several", "OBSERVATION_MODIFIER", 236, 243], ["diseases", "OBSERVATION", 244, 252]]], ["Cryopyrinassociated periodic syndrome (CAPS) refers to a group of autoinflammatory disorders characterized by autosomal dominant mutations in Nlrp3, resulting in dysregulated release of IL-1b (Hoffman et al., 2001) and the development of multi-organ systemic inflammation.", [["multi-organ", "ANATOMY", 238, 249], ["Cryopyrinassociated periodic syndrome", "DISEASE", 0, 37], ["CAPS", "DISEASE", 39, 43], ["autoinflammatory disorders", "DISEASE", 66, 92], ["autosomal dominant mutations", "DISEASE", 110, 138], ["multi-organ systemic inflammation", "DISEASE", 238, 271], ["Nlrp3", "GENE_OR_GENE_PRODUCT", 142, 147], ["IL-1b", "GENE_OR_GENE_PRODUCT", 186, 191], ["Nlrp3", "PROTEIN", 142, 147], ["IL", "PROTEIN", 186, 188], ["Cryopyrinassociated periodic syndrome (CAPS)", "PROBLEM", 0, 44], ["autoinflammatory disorders", "PROBLEM", 66, 92], ["autosomal dominant mutations in Nlrp3", "PROBLEM", 110, 147], ["multi-organ systemic inflammation", "PROBLEM", 238, 271], ["periodic syndrome", "OBSERVATION", 20, 37], ["dominant mutations", "OBSERVATION", 120, 138], ["multi-organ", "ANATOMY", 238, 249], ["systemic", "OBSERVATION_MODIFIER", 250, 258], ["inflammation", "OBSERVATION", 259, 271]]], ["The role of NLRP3 in disease is not restricted to monogenic NLRP3-driven diseases, however, as NLRP3 has been implicated in a wide range of different autoinflammatory diseases including Alzheimer disease and rheumatoid arthritis (Mangan et al., 2018) .", [["autoinflammatory diseases", "DISEASE", 150, 175], ["Alzheimer disease", "DISEASE", 186, 203], ["rheumatoid arthritis", "DISEASE", 208, 228], ["NLRP3", "GENE_OR_GENE_PRODUCT", 12, 17], ["NLRP3", "GENE_OR_GENE_PRODUCT", 60, 65], ["NLRP3", "GENE_OR_GENE_PRODUCT", 95, 100], ["NLRP3", "PROTEIN", 12, 17], ["NLRP3", "PROTEIN", 60, 65], ["NLRP3", "PROTEIN", 95, 100], ["NLRP3 in disease", "PROBLEM", 12, 28], ["monogenic NLRP3", "PROBLEM", 50, 65], ["different autoinflammatory diseases", "PROBLEM", 140, 175], ["Alzheimer disease", "PROBLEM", 186, 203], ["rheumatoid arthritis", "PROBLEM", 208, 228], ["NLRP3", "OBSERVATION", 12, 17], ["wide range", "OBSERVATION_MODIFIER", 126, 136], ["autoinflammatory diseases", "OBSERVATION", 150, 175], ["Alzheimer disease", "OBSERVATION", 186, 203], ["rheumatoid arthritis", "OBSERVATION", 208, 228]]], ["The pathological involvement of NLRP3 therefore necessitates that its activation is tightly regulated.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 32, 37], ["NLRP3", "PROTEIN", 32, 37], ["NLRP3", "TREATMENT", 32, 37]]], ["A major mechanism involves post-translational modifications.", [["post-translational modifications", "OBSERVATION", 27, 59]]], ["NLRP3 is ubiquitylated under resting conditions (Juliana et al., 2012) , whereas its phosphorylation and acetylation promote activation (He et al., 2020; Stutz et al., 2017) .", [["NLRP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["NLRP3", "PROTEIN", 0, 5], ["NLRP3", "TREATMENT", 0, 5]]], ["Covalent inhibitors of NLRP3, which include parthenolide (Juliana et al., 2010) and oridonin (He et al., 2018) , have revealed that NLRP3 is also susceptible to electrophilic modification of reactive cysteines, thus opening up another potential route through which NLRP3 inflammasome activation may be controlled.INTRODUCTIONItaconate is an unsaturated dicarboxylic acid that is synthesized from the decarboxylation of the Krebs cycle intermediate cis-aconitate by the enzyme immune-responsive gene 1 (IRG1), also termed ACOD1 (Hooftman and O'Neill, 2019; Michelucci et al., 2013; O'Neill and Artyomov, 2019) .", [["parthenolide", "CHEMICAL", 44, 56], ["INTRODUCTIONItaconate", "CHEMICAL", 313, 334], ["unsaturated dicarboxylic acid", "CHEMICAL", 341, 370], ["cis-aconitate", "CHEMICAL", 448, 461], ["parthenolide", "CHEMICAL", 44, 56], ["oridonin", "CHEMICAL", 84, 92], ["cysteines", "CHEMICAL", 200, 209], ["INTRODUCTIONItaconate", "CHEMICAL", 313, 334], ["unsaturated dicarboxylic acid", "CHEMICAL", 341, 370], ["Krebs", "CHEMICAL", 423, 428], ["cis-aconitate", "CHEMICAL", 448, 461], ["NLRP3", "GENE_OR_GENE_PRODUCT", 23, 28], ["parthenolide", "SIMPLE_CHEMICAL", 44, 56], ["oridonin", "SIMPLE_CHEMICAL", 84, 92], ["NLRP3", "GENE_OR_GENE_PRODUCT", 132, 137], ["reactive cysteines", "SIMPLE_CHEMICAL", 191, 209], ["NLRP3", "GENE_OR_GENE_PRODUCT", 265, 270], ["INTRODUCTIONItaconate", "SIMPLE_CHEMICAL", 313, 334], ["unsaturated dicarboxylic acid", "SIMPLE_CHEMICAL", 341, 370], ["cis-aconitate", "SIMPLE_CHEMICAL", 448, 461], ["immune-responsive gene 1", "GENE_OR_GENE_PRODUCT", 476, 500], ["IRG1", "GENE_OR_GENE_PRODUCT", 502, 506], ["ACOD1", "GENE_OR_GENE_PRODUCT", 521, 526], ["NLRP3", "PROTEIN", 23, 28], ["NLRP3", "PROTEIN", 132, 137], ["NLRP3", "PROTEIN", 265, 270], ["enzyme immune-responsive gene 1", "DNA", 469, 500], ["IRG1", "DNA", 502, 506], ["Covalent inhibitors of NLRP3", "TREATMENT", 0, 28], ["parthenolide", "TREATMENT", 44, 56], ["oridonin", "TREATMENT", 84, 92], ["NLRP3", "TREATMENT", 132, 137], ["reactive cysteines", "PROBLEM", 191, 209], ["NLRP3 inflammasome activation", "TREATMENT", 265, 294], ["an unsaturated dicarboxylic acid", "TREATMENT", 338, 370], ["the Krebs cycle", "TREATMENT", 419, 434], ["the enzyme immune", "TEST", 465, 482], ["reactive cysteines", "OBSERVATION", 191, 209], ["may be", "UNCERTAINTY", 295, 301]]], ["Itaconate is a prime example of metabolic reprogramming in macrophages.", [["macrophages", "ANATOMY", 59, 70], ["Itaconate", "CHEMICAL", 0, 9], ["Itaconate", "CHEMICAL", 0, 9], ["Itaconate", "SIMPLE_CHEMICAL", 0, 9], ["macrophages", "CELL", 59, 70], ["macrophages", "CELL_TYPE", 59, 70], ["metabolic reprogramming", "OBSERVATION", 32, 55]]], ["Although synthesized as a by-product of the Krebs cycle, its production is scaled up upon LPS treatment (Lee et al., 1995) seemingly with the purpose of restraining macrophage immune responses to TLR stimulation.", [["macrophage", "ANATOMY", 165, 175], ["LPS", "CHEMICAL", 90, 93], ["LPS", "SIMPLE_CHEMICAL", 90, 93], ["macrophage", "CELL", 165, 175], ["TLR", "GENE_OR_GENE_PRODUCT", 196, 199], ["TLR", "PROTEIN", 196, 199], ["the Krebs cycle", "TREATMENT", 40, 55], ["LPS treatment", "TREATMENT", 90, 103], ["restraining macrophage", "TREATMENT", 153, 175], ["TLR stimulation", "TREATMENT", 196, 211]]], ["Endogenous itaconate and/or its cell-permeable derivative 4-octyl itaconate (4-OI) have been shown to alkylate cysteine residues on multiple proteins, including kelch-like ECH-associated protein 1 (KEAP1) (Mills et al., 2018) , glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Liao et al., 2019) , aldolase A (ALDOA) (Qin et al., 2019) , and receptor-interacting serine/threonine-protein kinase 3 (RIPK3) (Qin et al., 2020) .", [["cell", "ANATOMY", 32, 36], ["itaconate", "CHEMICAL", 11, 20], ["4-octyl itaconate", "CHEMICAL", 58, 75], ["4-OI", "CHEMICAL", 77, 81], ["glyceraldehyde 3-phosphate", "CHEMICAL", 228, 254], ["itaconate", "CHEMICAL", 11, 20], ["4-octyl itaconate", "CHEMICAL", 58, 75], ["4-OI", "CHEMICAL", 77, 81], ["cysteine", "CHEMICAL", 111, 119], ["glyceraldehyde 3-phosphate", "CHEMICAL", 228, 254], ["serine", "CHEMICAL", 364, 370], ["threonine", "CHEMICAL", 371, 380], ["itaconate", "SIMPLE_CHEMICAL", 11, 20], ["cell", "CELL", 32, 36], ["4-octyl itaconate", "SIMPLE_CHEMICAL", 58, 75], ["4-OI", "SIMPLE_CHEMICAL", 77, 81], ["kelch-like ECH-associated protein 1", "GENE_OR_GENE_PRODUCT", 161, 196], ["KEAP1", "GENE_OR_GENE_PRODUCT", 198, 203], ["glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 228, 268], ["GAPDH", "GENE_OR_GENE_PRODUCT", 270, 275], ["aldolase A", "GENE_OR_GENE_PRODUCT", 299, 309], ["ALDOA", "GENE_OR_GENE_PRODUCT", 311, 316], ["receptor-interacting serine/threonine-protein kinase 3", "GENE_OR_GENE_PRODUCT", 343, 397], ["RIPK3", "GENE_OR_GENE_PRODUCT", 399, 404], ["kelch-like ECH-associated protein 1", "PROTEIN", 161, 196], ["KEAP1", "PROTEIN", 198, 203], ["glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 228, 268], ["GAPDH", "PROTEIN", 270, 275], ["aldolase A", "PROTEIN", 299, 309], ["receptor-interacting serine/threonine-protein kinase 3", "PROTEIN", 343, 397], ["RIPK3", "PROTEIN", 399, 404], ["Endogenous itaconate", "TREATMENT", 0, 20], ["its cell-permeable derivative", "TREATMENT", 28, 57], ["octyl itaconate", "TREATMENT", 60, 75], ["alkylate cysteine residues", "PROBLEM", 102, 128], ["multiple proteins", "TEST", 132, 149], ["kelch", "TEST", 161, 166], ["protein", "TEST", 187, 194], ["glyceraldehyde", "TEST", 228, 242], ["aldolase A (ALDOA)", "TREATMENT", 299, 317], ["threonine-protein kinase", "TREATMENT", 371, 395]]], ["This form of cysteine alkylation, termed 2,3-dicarboxypropylation or itaconation, has been shown to be an important part of the anti-inflammatory properties of itaconate.", [["cysteine", "CHEMICAL", 13, 21], ["2,3-dicarboxypropylation", "CHEMICAL", 41, 65], ["itaconation", "CHEMICAL", 69, 80], ["itaconate", "CHEMICAL", 160, 169], ["cysteine", "CHEMICAL", 13, 21], ["itaconate", "CHEMICAL", 160, 169], ["cysteine", "AMINO_ACID", 13, 21], ["2,3-dicarboxypropylation", "SIMPLE_CHEMICAL", 41, 65], ["itaconation", "SIMPLE_CHEMICAL", 69, 80], ["itaconate", "SIMPLE_CHEMICAL", 160, 169], ["cysteine alkylation", "TREATMENT", 13, 32], ["dicarboxypropylation", "TREATMENT", 45, 65], ["itaconation", "TREATMENT", 69, 80], ["the anti-inflammatory properties of itaconate", "TREATMENT", 124, 169], ["cysteine alkylation", "OBSERVATION", 13, 32]]], ["As an example, the modification of KEAP1 activates the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), thereby blocking macrophage IL-1b transcription following LPS stimulation, which requires ROS (Mills et al., 2018) .", [["LPS", "CHEMICAL", 198, 201], ["ROS", "CHEMICAL", 230, 233], ["KEAP1", "GENE_OR_GENE_PRODUCT", 35, 40], ["nuclear factor erythroid 2-related factor 2", "GENE_OR_GENE_PRODUCT", 88, 131], ["NRF2", "GENE_OR_GENE_PRODUCT", 133, 137], ["macrophage", "CELL", 157, 167], ["IL-1b", "GENE_OR_GENE_PRODUCT", 168, 173], ["LPS", "SIMPLE_CHEMICAL", 198, 201], ["ROS", "SIMPLE_CHEMICAL", 230, 233], ["KEAP1", "PROTEIN", 35, 40], ["antioxidant transcription factor nuclear factor erythroid 2-related factor 2", "PROTEIN", 55, 131], ["NRF2", "PROTEIN", 133, 137], ["macrophage IL-1b", "PROTEIN", 157, 173], ["erythroid", "TEST", 103, 112], ["thereby blocking macrophage IL", "TREATMENT", 140, 170], ["LPS stimulation", "TREATMENT", 198, 213]]], ["However, the effect of itaconate on inflammasome-dependent IL-1b cleavage and release has not been fully explored.", [["itaconate", "CHEMICAL", 23, 32], ["itaconate", "CHEMICAL", 23, 32], ["itaconate", "SIMPLE_CHEMICAL", 23, 32], ["IL-1b", "GENE_OR_GENE_PRODUCT", 59, 64], ["itaconate", "TREATMENT", 23, 32], ["inflammasome-dependent IL", "TREATMENT", 36, 61]]], ["Here we provide evidence that itaconate modifies a specific cysteine (C548) on NLRP3 and inhibits NLRP3 activation by interfering with the interaction between NLRP3 and NEK7.", [["itaconate", "CHEMICAL", 30, 39], ["cysteine", "CHEMICAL", 60, 68], ["itaconate", "CHEMICAL", 30, 39], ["cysteine", "CHEMICAL", 60, 68], ["C548", "CHEMICAL", 70, 74], ["itaconate", "SIMPLE_CHEMICAL", 30, 39], ["cysteine", "AMINO_ACID", 60, 68], ["C548", "AMINO_ACID", 70, 74], ["NLRP3", "GENE_OR_GENE_PRODUCT", 79, 84], ["NLRP3", "GENE_OR_GENE_PRODUCT", 98, 103], ["NLRP3", "GENE_OR_GENE_PRODUCT", 159, 164], ["NEK7", "GENE_OR_GENE_PRODUCT", 169, 173], ["NLRP3", "PROTEIN", 79, 84], ["NLRP3", "PROTEIN", 98, 103], ["NLRP3", "PROTEIN", 159, 164], ["NEK7", "PROTEIN", 169, 173], ["a specific cysteine", "TREATMENT", 49, 68], ["NLRP3", "TREATMENT", 79, 84], ["NLRP3 activation", "TREATMENT", 98, 114], ["NEK7", "TREATMENT", 169, 173]]], ["Itaconate may therefore be an important negative regulator of NLRP3, which could have utility as a therapy in NLRP3-mediated diseases.4-OI Specifically Blocks NLRP3 Inflammasome ActivationTreatment of LPS-primed bone marrow-derived macrophages (BMDMs) with 4-OI prior to activation of NLRP3 with ATP or nigericin ( Figure 1A ) resulted in a concentration-dependent reduction in IL-1b release ( Figures 1B and 1D ) as well as a reduction in LDH release ( Figures 1C and 1E ), which is used as a measure of pyroptosis.", [["bone marrow-derived macrophages", "ANATOMY", 212, 243], ["BMDMs", "ANATOMY", 245, 250], ["Itaconate", "CHEMICAL", 0, 9], ["LPS", "CHEMICAL", 201, 204], ["ATP", "CHEMICAL", 296, 299], ["nigericin", "CHEMICAL", 303, 312], ["pyroptosis", "DISEASE", 505, 515], ["Itaconate", "CHEMICAL", 0, 9], ["4-OI", "CHEMICAL", 134, 138], ["ATP", "CHEMICAL", 296, 299], ["nigericin", "CHEMICAL", 303, 312], ["Itaconate", "SIMPLE_CHEMICAL", 0, 9], ["NLRP3", "GENE_OR_GENE_PRODUCT", 62, 67], ["NLRP3", "GENE_OR_GENE_PRODUCT", 110, 115], ["NLRP3", "GENE_OR_GENE_PRODUCT", 159, 164], ["LPS", "SIMPLE_CHEMICAL", 201, 204], ["bone marrow-derived macrophages", "CELL", 212, 243], ["BMDMs", "CELL", 245, 250], ["NLRP3", "GENE_OR_GENE_PRODUCT", 285, 290], ["ATP", "SIMPLE_CHEMICAL", 296, 299], ["nigericin", "SIMPLE_CHEMICAL", 303, 312], ["IL-1b", "GENE_OR_GENE_PRODUCT", 378, 383], ["LDH", "SIMPLE_CHEMICAL", 440, 443], ["NLRP3", "PROTEIN", 62, 67], ["NLRP3", "PROTEIN", 110, 115], ["NLRP3", "PROTEIN", 159, 164], ["LPS-primed bone marrow-derived macrophages", "CELL_LINE", 201, 243], ["BMDMs", "CELL_TYPE", 245, 250], ["NLRP3", "PROTEIN", 285, 290], ["IL", "PROTEIN", 378, 380], ["LDH", "PROTEIN", 440, 443], ["Itaconate", "TREATMENT", 0, 9], ["NLRP3", "TREATMENT", 62, 67], ["a therapy", "TREATMENT", 97, 106], ["mediated diseases", "PROBLEM", 116, 133], ["LPS", "TEST", 201, 204], ["bone marrow", "TEST", 212, 223], ["OI", "PROBLEM", 259, 261], ["NLRP3", "TREATMENT", 285, 290], ["ATP", "TREATMENT", 296, 299], ["nigericin", "TREATMENT", 303, 312], ["a concentration-dependent reduction in IL", "TREATMENT", 339, 380], ["a reduction in LDH release", "TREATMENT", 425, 451], ["pyroptosis", "PROBLEM", 505, 515], ["diseases", "OBSERVATION", 125, 133], ["bone", "ANATOMY", 212, 216], ["dependent", "OBSERVATION_MODIFIER", 355, 364], ["reduction", "OBSERVATION_MODIFIER", 365, 374], ["pyroptosis", "OBSERVATION", 505, 515]]], ["Cleavage and release of IL-1b in this assay were NLRP3-dependent (Figures S1A and S1B).", [["IL-1b", "GENE_OR_GENE_PRODUCT", 24, 29], ["NLRP3", "GENE_OR_GENE_PRODUCT", 49, 54], ["S1B", "GENE_OR_GENE_PRODUCT", 82, 85], ["IL-1b", "PROTEIN", 24, 29], ["NLRP3", "PROTEIN", 49, 54], ["S1B", "PROTEIN", 82, 85], ["Cleavage and release of IL", "TREATMENT", 0, 26]]], ["The effect of 4-OI was confirmed by western blot as it blocked the cleavage of IL-1b and caspase-1 to their mature p17 and p20 forms, respectively ( Figures 1F and 1G , compare lanes 5-7 to lane 4).", [["4-OI", "CHEMICAL", 14, 18], ["4-OI", "SIMPLE_CHEMICAL", 14, 18], ["IL-1b", "GENE_OR_GENE_PRODUCT", 79, 84], ["caspase-1", "GENE_OR_GENE_PRODUCT", 89, 98], ["p17", "GENE_OR_GENE_PRODUCT", 115, 118], ["p20", "GENE_OR_GENE_PRODUCT", 123, 126], ["IL-1b", "PROTEIN", 79, 84], ["caspase-1", "PROTEIN", 89, 98], ["p17", "PROTEIN", 115, 118], ["p20 forms", "PROTEIN", 123, 132], ["OI", "PROBLEM", 16, 18], ["the cleavage of IL", "TREATMENT", 63, 81], ["caspase", "TREATMENT", 89, 96], ["Figures", "TEST", 149, 156]]], ["4-OI also blocked the cleavage of gasdermin D, the pyroptosis executioner (Shi et al., 2015) , to its active N-terminal fragment (Figure S1C, compare lanes 5-7 to lane 4).", [["4-OI", "CHEMICAL", 0, 4], ["gasdermin D", "CHEMICAL", 34, 45], ["4-OI", "CHEMICAL", 0, 4], ["gasdermin D", "CHEMICAL", 34, 45], ["N", "CHEMICAL", 109, 110], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["gasdermin D", "SIMPLE_CHEMICAL", 34, 45], ["gasdermin D", "PROTEIN", 34, 45], ["N-terminal fragment", "PROTEIN", 109, 128], ["gasdermin D", "PROBLEM", 34, 45], ["the pyroptosis executioner", "PROBLEM", 47, 73], ["terminal fragment", "PROBLEM", 111, 128], ["pyroptosis", "OBSERVATION", 51, 61], ["active", "OBSERVATION_MODIFIER", 102, 108], ["terminal", "OBSERVATION_MODIFIER", 111, 119], ["fragment", "OBSERVATION", 120, 128]]], ["Dimethyl itaconate (DMI), a different itaconate derivative, similarly blocked IL-1b release and cleavage (Figures S1D and S1E).", [["Dimethyl itaconate", "CHEMICAL", 0, 18], ["DMI", "CHEMICAL", 20, 23], ["itaconate", "CHEMICAL", 38, 47], ["Dimethyl itaconate", "CHEMICAL", 0, 18], ["DMI", "CHEMICAL", 20, 23], ["itaconate", "CHEMICAL", 38, 47], ["Dimethyl itaconate", "SIMPLE_CHEMICAL", 0, 18], ["DMI", "SIMPLE_CHEMICAL", 20, 23], ["itaconate", "SIMPLE_CHEMICAL", 38, 47], ["IL-1b", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL", "PROTEIN", 78, 80], ["Dimethyl itaconate (DMI", "TREATMENT", 0, 23], ["a different itaconate derivative", "TREATMENT", 26, 58], ["similarly blocked IL", "TREATMENT", 60, 80]]], ["However, the octyl control compounds 4-octyl succinate (4-OS) and 4-octyl-2methyl succinate (4-O-2-MS), designed to control for the potentially reactive octyl tail on 4-OI, did not block IL-1b cleavage and release to the same extent (Figures S1F-S1H).", [["octyl", "CHEMICAL", 13, 18], ["4-octyl succinate", "CHEMICAL", 37, 54], ["4-OS", "CHEMICAL", 56, 60], ["4-octyl-2methyl succinate", "CHEMICAL", 66, 91], ["4-O-2-MS", "CHEMICAL", 93, 101], ["octyl", "CHEMICAL", 153, 158], ["4-OI", "CHEMICAL", 167, 171], ["octyl", "CHEMICAL", 13, 18], ["4-octyl succinate", "CHEMICAL", 37, 54], ["4-OS", "CHEMICAL", 56, 60], ["4-octyl-2methyl succinate", "CHEMICAL", 66, 91], ["4-O-2-MS", "CHEMICAL", 93, 101], ["octyl", "CHEMICAL", 153, 158], ["4-OI", "CHEMICAL", 167, 171], ["octyl", "SIMPLE_CHEMICAL", 13, 18], ["4-octyl succinate", "SIMPLE_CHEMICAL", 37, 54], ["4-OS", "SIMPLE_CHEMICAL", 56, 60], ["4-octyl-2methyl succinate", "SIMPLE_CHEMICAL", 66, 91], ["4-O-2-MS", "SIMPLE_CHEMICAL", 93, 101], ["octyl tail", "SIMPLE_CHEMICAL", 153, 163], ["4-OI", "SIMPLE_CHEMICAL", 167, 171], ["IL-1b", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL", "PROTEIN", 187, 189], ["S1H", "PROTEIN", 246, 249], ["the octyl control compounds", "TREATMENT", 9, 36], ["octyl succinate", "TREATMENT", 39, 54], ["octyl-2methyl succinate", "TREATMENT", 68, 91], ["reactive", "OBSERVATION_MODIFIER", 144, 152], ["octyl tail", "OBSERVATION", 153, 163]]], ["The specific NLRP3 inhibitor MCC950 (Coll et al., 2015) was also used as a control in these experiments (Figures S1I and S1J).", [["MCC950", "CHEMICAL", 29, 35], ["NLRP3", "GENE_OR_GENE_PRODUCT", 13, 18], ["NLRP3", "PROTEIN", 13, 18], ["The specific NLRP3 inhibitor", "TREATMENT", 0, 28]]], ["The cytokine IL-18 is co-secreted with IL-1b in an NLRP3-dependent manner (Ghayur et al., 1997) , and its release was completely inhibited by 4-OI ( Figure 1H ).", [["4-OI", "CHEMICAL", 142, 146], ["1H", "CHEMICAL", 156, 158], ["IL-18", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-1b", "GENE_OR_GENE_PRODUCT", 39, 44], ["NLRP3", "GENE_OR_GENE_PRODUCT", 51, 56], ["4-OI", "SIMPLE_CHEMICAL", 142, 146], ["cytokine", "PROTEIN", 4, 12], ["IL-18", "PROTEIN", 13, 18], ["IL-1b", "PROTEIN", 39, 44], ["NLRP3", "PROTEIN", 51, 56], ["The cytokine IL", "TEST", 0, 15]]], ["Upon NLRP3 inflammasome activation, the adaptor protein ASC is recruited by NLRP3 and forms large multimeric complexes (Lu et al., 2014) , termed ASC specks.", [["ASC specks", "ANATOMY", 146, 156], ["NLRP3", "GENE_OR_GENE_PRODUCT", 5, 10], ["ASC", "GENE_OR_GENE_PRODUCT", 56, 59], ["NLRP3", "GENE_OR_GENE_PRODUCT", 76, 81], ["ASC", "GENE_OR_GENE_PRODUCT", 146, 149], ["NLRP3", "PROTEIN", 5, 10], ["adaptor protein", "PROTEIN", 40, 55], ["ASC", "PROTEIN", 56, 59], ["NLRP3", "PROTEIN", 76, 81], ["multimeric complexes", "PROTEIN", 98, 118], ["ASC specks", "PROTEIN", 146, 156], ["NLRP3 inflammasome activation", "TREATMENT", 5, 34], ["the adaptor protein ASC", "TREATMENT", 36, 59], ["inflammasome activation", "OBSERVATION", 11, 34], ["large", "OBSERVATION_MODIFIER", 92, 97], ["multimeric complexes", "OBSERVATION", 98, 118], ["ASC specks", "OBSERVATION", 146, 156]]], ["We found that 4-OI inhibited ASC speck formation, as detected by flow cytometry (Figure 1I ), and reduced the appearance of large multimeric ASC complexes, as detected by western blot (Figure 1J , compare lane 4 to lane 3).4-OI Specifically Blocks NLRP3 Inflammasome ActivationIt was important to ensure that any effect was specific to NLRP3 activation rather than priming.", [["ASC speck", "ANATOMY", 29, 38], ["4-OI", "CHEMICAL", 14, 18], ["4-OI", "CHEMICAL", 223, 227], ["4-OI", "SIMPLE_CHEMICAL", 14, 18], ["ASC speck", "PATHOLOGICAL_FORMATION", 29, 38], ["ASC", "GENE_OR_GENE_PRODUCT", 141, 144], ["NLRP3", "GENE_OR_GENE_PRODUCT", 248, 253], ["NLRP3", "GENE_OR_GENE_PRODUCT", 336, 341], ["multimeric ASC complexes", "PROTEIN", 130, 154], ["NLRP3", "PROTEIN", 248, 253], ["NLRP3", "PROTEIN", 336, 341], ["OI", "PROBLEM", 16, 18], ["ASC speck formation", "PROBLEM", 29, 48], ["flow cytometry", "TEST", 65, 79], ["large multimeric ASC complexes", "PROBLEM", 124, 154], ["flow cytometry", "OBSERVATION", 65, 79], ["reduced", "OBSERVATION_MODIFIER", 98, 105], ["large", "OBSERVATION_MODIFIER", 124, 129], ["multimeric ASC complexes", "OBSERVATION", 130, 154], ["Inflammasome Activation", "OBSERVATION", 254, 277]]], ["We found that 4-OI did not affect tumor necrosis factor a (TNFa) release ( Figure S2A ) and only inhibited pro-IL-1b expression when added before LPS priming and not after LPS priming ( Figure S2B , compare lanes 3-5 to lane 2 and lanes 7-9 to lane 6), in accordance with previous findings (Mills et al., 2018) .", [["tumor", "DISEASE", 34, 39], ["necrosis", "DISEASE", 40, 48], ["LPS", "CHEMICAL", 146, 149], ["LPS", "CHEMICAL", 172, 175], ["4-OI", "CHEMICAL", 14, 18], ["4-OI", "SIMPLE_CHEMICAL", 14, 18], ["tumor necrosis factor a", "GENE_OR_GENE_PRODUCT", 34, 57], ["TNFa", "GENE_OR_GENE_PRODUCT", 59, 63], ["-IL-1b", "GENE_OR_GENE_PRODUCT", 110, 116], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["LPS", "SIMPLE_CHEMICAL", 172, 175], ["tumor necrosis factor", "PROTEIN", 34, 55], ["TNFa", "PROTEIN", 59, 63], ["-IL", "PROTEIN", 110, 113], ["OI", "PROBLEM", 16, 18], ["tumor necrosis factor", "PROBLEM", 34, 55], ["a (TNFa)", "TREATMENT", 56, 64], ["LPS priming", "TREATMENT", 146, 157], ["LPS", "TEST", 172, 175], ["tumor", "OBSERVATION_MODIFIER", 34, 39], ["necrosis", "OBSERVATION", 40, 48]]], ["In order to elucidate whether the effect was specific to the NLRP3 inflammasome, we also tested 4-OI in AIM2, NLRC4, and non-canonical inflammasome assays.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 61, 66], ["AIM2", "GENE_OR_GENE_PRODUCT", 104, 108], ["NLRC4", "GENE_OR_GENE_PRODUCT", 110, 115], ["NLRP3", "PROTEIN", 61, 66], ["AIM2", "PROTEIN", 104, 108], ["NLRC4", "PROTEIN", 110, 115], ["the NLRP3 inflammasome", "TEST", 57, 79], ["NLRC4", "TEST", 110, 115], ["non-canonical inflammasome assays", "TEST", 121, 154]]], ["4-OI, when added between LPS and (B and C) LPS (3 h) and ATP (45 min) induced IL-1b release (B, n = 10) and LDH release (C, n = 4 for ATP alone, n = 7 for others, measured as % LDH release of total lysis control) \u00b1 4-OI.", [["LPS", "CHEMICAL", 25, 28], ["LPS", "CHEMICAL", 43, 46], ["ATP", "CHEMICAL", 57, 60], ["ATP", "CHEMICAL", 134, 137], ["4-OI", "CHEMICAL", 0, 4], ["ATP", "CHEMICAL", 57, 60], ["ATP", "CHEMICAL", 134, 137], ["4-OI", "CHEMICAL", 215, 219], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["ATP", "SIMPLE_CHEMICAL", 57, 60], ["IL-1b", "GENE_OR_GENE_PRODUCT", 78, 83], ["LDH", "SIMPLE_CHEMICAL", 108, 111], ["ATP", "SIMPLE_CHEMICAL", 134, 137], ["LDH", "SIMPLE_CHEMICAL", 177, 180], ["IL", "PROTEIN", 78, 80], ["LDH", "PROTEIN", 108, 111], ["LPS and (B and C) LPS", "TREATMENT", 25, 46], ["ATP", "TEST", 57, 60], ["IL", "TEST", 78, 80], ["LDH release", "TEST", 108, 119], ["C", "TEST", 121, 122], ["ATP alone", "TEST", 134, 143], ["LDH release", "TEST", 177, 188], ["total lysis control", "TREATMENT", 192, 211], ["OI", "PROBLEM", 217, 219]]], ["(D and E) LPS (3 h) and nigericin (45 min) induced IL-1b release (D, n = 7) and LDH release (E, n = 5 for NS alone, n = 6 for others) \u00b1 4-OI.", [["LPS", "CHEMICAL", 10, 13], ["nigericin", "CHEMICAL", 24, 33], ["nigericin", "CHEMICAL", 24, 33], ["4-OI", "CHEMICAL", 136, 140], ["LPS", "SIMPLE_CHEMICAL", 10, 13], ["nigericin", "SIMPLE_CHEMICAL", 24, 33], ["IL-1b", "GENE_OR_GENE_PRODUCT", 51, 56], ["LDH", "SIMPLE_CHEMICAL", 80, 83], ["LDH", "PROTEIN", 80, 83], ["LPS", "TEST", 10, 13], ["nigericin", "TREATMENT", 24, 33], ["IL", "TEST", 51, 53], ["LDH release", "TEST", 80, 91], ["NS alone", "TREATMENT", 106, 114], ["OI", "PROBLEM", 138, 140]]], ["(F and G) Immunoblot analysis (F) and quantification by densitometry (G, n = 4) of pro-and mature caspase-1 and IL-1b protein in lysates and supernatants of BMDMs treated with LPS (3 h) and nigericin (45 min) \u00b1 4-OI. ll Short Article poly(dA:dT) transfection, did not reduce IL-1b release or pyroptosis associated with AIM2 inflammasome activation (Figures 2A and 2B ).", [["lysates", "ANATOMY", 129, 136], ["supernatants", "ANATOMY", 141, 153], ["BMDMs", "ANATOMY", 157, 162], ["LPS", "CHEMICAL", 176, 179], ["nigericin", "CHEMICAL", 190, 199], ["dA", "CHEMICAL", 239, 241], ["nigericin", "CHEMICAL", 190, 199], ["caspase-1", "GENE_OR_GENE_PRODUCT", 98, 107], ["IL-1b", "GENE_OR_GENE_PRODUCT", 112, 117], ["lysates", "ORGANISM_SUBSTANCE", 129, 136], ["BMDMs", "CELL", 157, 162], ["LPS", "SIMPLE_CHEMICAL", 176, 179], ["nigericin", "SIMPLE_CHEMICAL", 190, 199], ["IL-1b", "GENE_OR_GENE_PRODUCT", 275, 280], ["AIM2", "GENE_OR_GENE_PRODUCT", 319, 323], ["pro-and mature caspase-1 and IL-1b protein", "PROTEIN", 83, 125], ["BMDMs", "CELL_TYPE", 157, 162], ["IL", "PROTEIN", 275, 277], ["AIM2", "PROTEIN", 319, 323], ["Immunoblot analysis", "TEST", 10, 29], ["quantification", "TEST", 38, 52], ["densitometry", "TEST", 56, 68], ["G", "TEST", 70, 71], ["caspase", "TEST", 98, 105], ["IL", "TEST", 112, 114], ["lysates", "TEST", 129, 136], ["BMDMs", "PROBLEM", 157, 162], ["LPS", "TREATMENT", 176, 179], ["nigericin", "TREATMENT", 190, 199], ["IL", "TEST", 275, 277], ["pyroptosis", "PROBLEM", 292, 302], ["AIM2 inflammasome activation", "PROBLEM", 319, 347], ["pyroptosis", "OBSERVATION", 292, 302]]], ["Furthermore, it had no effect on IL-1b or caspase-1 cleavage ( Figures 2C and 2D , compare lanes 5 and 6 to lane 4).", [["IL-1b", "GENE_OR_GENE_PRODUCT", 33, 38], ["caspase-1", "GENE_OR_GENE_PRODUCT", 42, 51], ["IL", "PROTEIN", 33, 35], ["caspase-1", "PROTEIN", 42, 51], ["IL", "TREATMENT", 33, 35], ["caspase", "TREATMENT", 42, 49]]], ["We made similar observations when 4-OI was added to cells between LPS and transfection of purified flagellin to activate the NLRC4 inflammasome.", [["cells", "ANATOMY", 52, 57], ["LPS", "CHEMICAL", 66, 69], ["4-OI", "CHEMICAL", 34, 38], ["4-OI", "SIMPLE_CHEMICAL", 34, 38], ["cells", "CELL", 52, 57], ["LPS", "SIMPLE_CHEMICAL", 66, 69], ["flagellin", "GENE_OR_GENE_PRODUCT", 99, 108], ["NLRC4", "GENE_OR_GENE_PRODUCT", 125, 130], ["flagellin", "PROTEIN", 99, 108], ["NLRC4", "PROTEIN", 125, 130], ["OI", "PROBLEM", 36, 38], ["LPS", "TREATMENT", 66, 69], ["transfection", "TREATMENT", 74, 86], ["purified flagellin", "TREATMENT", 90, 108], ["NLRC4 inflammasome", "OBSERVATION", 125, 143]]], ["IL-1b release, pyroptosis, and cleavage of IL-1b and caspase-1 were unaffected by addition of 4-OI .", [["4-OI", "CHEMICAL", 94, 98], ["IL-1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1b", "GENE_OR_GENE_PRODUCT", 43, 48], ["caspase-1", "GENE_OR_GENE_PRODUCT", 53, 62], ["4-OI", "SIMPLE_CHEMICAL", 94, 98], ["IL", "PROTEIN", 0, 2], ["IL-1b", "PROTEIN", 43, 48], ["caspase-1", "PROTEIN", 53, 62], ["IL", "TREATMENT", 0, 2], ["pyroptosis", "PROBLEM", 15, 25], ["IL", "TREATMENT", 43, 45], ["caspase", "TREATMENT", 53, 60], ["pyroptosis", "OBSERVATION", 15, 25]]], ["The non-canonical inflammasome differs from canonical inflammasome signaling in that it senses cytosolic LPS using the effector protein caspase-11 (caspase-4 and -5 in humans) (Kayagaki et al., 2011; Shi et al., 2014) .", [["cytosolic", "ANATOMY", 95, 104], ["LPS", "CHEMICAL", 105, 108], ["LPS", "SIMPLE_CHEMICAL", 105, 108], ["caspase-11", "GENE_OR_GENE_PRODUCT", 136, 146], ["caspase-4", "GENE_OR_GENE_PRODUCT", 148, 157], ["-5", "GENE_OR_GENE_PRODUCT", 162, 164], ["humans", "ORGANISM", 168, 174], ["non-canonical inflammasome", "PROTEIN", 4, 30], ["effector protein caspase-11", "PROTEIN", 119, 146], ["caspase-4 and -5", "PROTEIN", 148, 164], ["humans", "SPECIES", 168, 174], ["humans", "SPECIES", 168, 174], ["The non-canonical inflammasome", "PROBLEM", 0, 30], ["canonical inflammasome signaling", "PROBLEM", 44, 76], ["cytosolic LPS", "TEST", 95, 108], ["the effector protein caspase", "TEST", 115, 143], ["caspase", "TEST", 148, 155], ["non-canonical inflammasome", "OBSERVATION", 4, 30], ["canonical inflammasome", "OBSERVATION", 44, 66]]], ["Although pyroptosis in this model is caspase-11 dependent, IL-1b release remains dependent on canonical NLRP3 activation, as this occurs secondary to K + efflux resulting from pyroptosis (Rathinam et al., 2019) .", [["pyroptosis", "DISEASE", 9, 19], ["K", "CHEMICAL", 150, 151], ["pyroptosis", "DISEASE", 176, 186], ["K +", "CHEMICAL", 150, 153], ["caspase-11", "GENE_OR_GENE_PRODUCT", 37, 47], ["IL-1b", "GENE_OR_GENE_PRODUCT", 59, 64], ["NLRP3", "GENE_OR_GENE_PRODUCT", 104, 109], ["K +", "SIMPLE_CHEMICAL", 150, 153], ["IL", "PROTEIN", 59, 61], ["NLRP3", "PROTEIN", 104, 109], ["pyroptosis", "PROBLEM", 9, 19], ["caspase", "TEST", 37, 44], ["IL", "TREATMENT", 59, 61], ["canonical NLRP3 activation", "TREATMENT", 94, 120], ["K + efflux", "PROBLEM", 150, 160], ["pyroptosis", "PROBLEM", 176, 186], ["pyroptosis", "OBSERVATION", 9, 19], ["pyroptosis", "OBSERVATION", 176, 186]]], ["We added 4-OI in between LPS priming and LPS transfection in a non-canonical inflammasome assay and found that it blocked IL-1b release, but not pyroptosis, in this assay, further indicating the specific targeting of NLRP3 ( Figures 2I and 2J ).Endogenous Itaconate Regulates NLRP3 Inflammasome ActivationAlthough 4-OI treatment boosts levels of unmodified itaconate in activated macrophages (Mills et al., 2018) , it is unclear whether LPS stimulation is required for this increase and whether the intracellular itaconate arises from de-esterification of 4-OI or from increased production of endogenous itaconate (Swain et al., 2020) .", [["macrophages", "ANATOMY", 380, 391], ["intracellular", "ANATOMY", 499, 512], ["LPS", "CHEMICAL", 25, 28], ["LPS", "CHEMICAL", 41, 44], ["Itaconate", "CHEMICAL", 256, 265], ["itaconate", "CHEMICAL", 357, 366], ["LPS", "CHEMICAL", 437, 440], ["itaconate", "CHEMICAL", 513, 522], ["4-OI", "CHEMICAL", 556, 560], ["itaconate", "CHEMICAL", 604, 613], ["4-OI", "CHEMICAL", 9, 13], ["Itaconate", "CHEMICAL", 256, 265], ["4-OI", "CHEMICAL", 314, 318], ["itaconate", "CHEMICAL", 357, 366], ["itaconate", "CHEMICAL", 513, 522], ["4-OI", "CHEMICAL", 556, 560], ["itaconate", "CHEMICAL", 604, 613], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["LPS", "SIMPLE_CHEMICAL", 41, 44], ["IL-1b", "GENE_OR_GENE_PRODUCT", 122, 127], ["NLRP3", "GENE_OR_GENE_PRODUCT", 217, 222], ["Figures 2I and 2J", "GENE_OR_GENE_PRODUCT", 225, 242], ["Itaconate", "SIMPLE_CHEMICAL", 256, 265], ["NLRP3", "GENE_OR_GENE_PRODUCT", 276, 281], ["4-OI", "SIMPLE_CHEMICAL", 314, 318], ["itaconate", "SIMPLE_CHEMICAL", 357, 366], ["macrophages", "CELL", 380, 391], ["LPS", "SIMPLE_CHEMICAL", 437, 440], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 499, 512], ["itaconate", "SIMPLE_CHEMICAL", 513, 522], ["4-OI", "SIMPLE_CHEMICAL", 556, 560], ["itaconate", "SIMPLE_CHEMICAL", 604, 613], ["NLRP3", "PROTEIN", 217, 222], ["Figures 2I and 2J", "PROTEIN", 225, 242], ["NLRP3", "PROTEIN", 276, 281], ["activated macrophages", "CELL_TYPE", 370, 391], ["LPS priming", "TREATMENT", 25, 36], ["LPS transfection", "TREATMENT", 41, 57], ["a non-canonical inflammasome assay", "TEST", 61, 95], ["pyroptosis", "PROBLEM", 145, 155], ["Endogenous Itaconate Regulates NLRP3 Inflammasome ActivationAlthough", "TREATMENT", 245, 313], ["OI treatment", "TREATMENT", 316, 328], ["unmodified itaconate", "TREATMENT", 346, 366], ["LPS stimulation", "PROBLEM", 437, 452], ["the intracellular itaconate", "TEST", 495, 522], ["OI", "PROBLEM", 558, 560], ["not", "UNCERTAINTY", 141, 144], ["pyroptosis", "OBSERVATION", 145, 155]]], ["We therefore examined whether 4-OI could directly generate itaconate.", [["itaconate", "CHEMICAL", 59, 68], ["4-OI", "CHEMICAL", 30, 34], ["itaconate", "CHEMICAL", 59, 68], ["4-OI", "SIMPLE_CHEMICAL", 30, 34], ["itaconate", "SIMPLE_CHEMICAL", 59, 68]]], ["As shown in Figure S2C , 13 C 5 -labeled itaconate was detected in human macrophages treated with 13 C 5 octyl itaconate both in the presence and absence of LPS.", [["macrophages", "ANATOMY", 73, 84], ["C 5 -labeled itaconate", "CHEMICAL", 28, 50], ["13 C 5 octyl itaconate", "CHEMICAL", 98, 120], ["LPS", "CHEMICAL", 157, 160], ["itaconate", "CHEMICAL", 41, 50], ["13 C 5 octyl itaconate", "CHEMICAL", 98, 120], ["13 C 5 -labeled itaconate", "SIMPLE_CHEMICAL", 25, 50], ["human", "ORGANISM", 67, 72], ["macrophages", "CELL", 73, 84], ["C 5 octyl itaconate", "SIMPLE_CHEMICAL", 101, 120], ["LPS", "SIMPLE_CHEMICAL", 157, 160], ["human macrophages", "CELL_TYPE", 67, 84], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Figure S2C", "TEST", 12, 22], ["13 C 5 octyl itaconate", "TREATMENT", 98, 120], ["LPS", "PROBLEM", 157, 160], ["human macrophages", "ANATOMY", 67, 84]]], ["13 C 5 itaconate was detectable as soon as 30 min after treatment with 13 C 5 octyl itaconate.", [["C 5 itaconate", "CHEMICAL", 3, 16], ["13 C 5 octyl itaconate", "CHEMICAL", 71, 93], ["itaconate", "CHEMICAL", 7, 16], ["13 C 5 octyl itaconate", "CHEMICAL", 71, 93], ["C 5 itaconate", "SIMPLE_CHEMICAL", 3, 16], ["5 octyl itaconate", "SIMPLE_CHEMICAL", 76, 93], ["treatment", "TREATMENT", 56, 65], ["5 octyl itaconate", "TREATMENT", 76, 93]]], ["This confirmed that 4-OI can indeed generate itaconate directly.", [["itaconate", "CHEMICAL", 45, 54], ["4-OI", "CHEMICAL", 20, 24], ["itaconate", "CHEMICAL", 45, 54], ["4-OI", "SIMPLE_CHEMICAL", 20, 24], ["itaconate", "SIMPLE_CHEMICAL", 45, 54]]], ["It is also unclear as to whether a transporter or cell-surface receptor exists for exogenous itaconate, hence the widespread use of itaconate derivatives in the field of itaconate biology.", [["cell", "ANATOMY", 50, 54], ["surface", "ANATOMY", 55, 62], ["itaconate", "CHEMICAL", 93, 102], ["itaconate", "CHEMICAL", 132, 141], ["itaconate", "CHEMICAL", 170, 179], ["itaconate", "CHEMICAL", 93, 102], ["itaconate", "CHEMICAL", 132, 141], ["itaconate", "CHEMICAL", 170, 179], ["cell", "CELL", 50, 54], ["itaconate", "SIMPLE_CHEMICAL", 93, 102], ["itaconate derivatives", "SIMPLE_CHEMICAL", 132, 153], ["itaconate", "SIMPLE_CHEMICAL", 170, 179], ["transporter or cell-surface receptor", "PROTEIN", 35, 71], ["exogenous itaconate", "TREATMENT", 83, 102], ["itaconate derivatives", "TREATMENT", 132, 153]]], ["However, isotope tracing studies have shown that itaconate does accumulate in macrophages exposed to high concentrations of itaconic acid in culture media (Puchalska et al., 2018; Swain et al., 2020) .", [["macrophages", "ANATOMY", 78, 89], ["itaconate", "CHEMICAL", 49, 58], ["itaconic acid", "CHEMICAL", 124, 137], ["itaconate", "CHEMICAL", 49, 58], ["itaconic acid", "CHEMICAL", 124, 137], ["itaconate", "SIMPLE_CHEMICAL", 49, 58], ["macrophages", "CELL", 78, 89], ["itaconic acid", "SIMPLE_CHEMICAL", 124, 137], ["macrophages", "CELL_TYPE", 78, 89], ["isotope tracing studies", "TEST", 9, 32], ["itaconic acid in culture media", "TREATMENT", 124, 154], ["macrophages", "OBSERVATION", 78, 89], ["high concentrations", "OBSERVATION_MODIFIER", 101, 120], ["itaconic acid", "OBSERVATION", 124, 137]]], ["Pre-treatment of BMDMs with itaconic acid (pH 7) prior to LPS and nigericin stimulation resulted in a significant and concentration-dependent reduction in IL-1b release ( Figure S2E ) and a non-significant reduction in pyroptosis (Figure S2F) .", [["BMDMs", "ANATOMY", 17, 22], ["itaconic acid", "CHEMICAL", 28, 41], ["LPS", "CHEMICAL", 58, 61], ["nigericin", "CHEMICAL", 66, 75], ["pyroptosis", "DISEASE", 219, 229], ["itaconic acid", "CHEMICAL", 28, 41], ["nigericin", "CHEMICAL", 66, 75], ["BMDMs", "CELL", 17, 22], ["itaconic acid", "SIMPLE_CHEMICAL", 28, 41], ["LPS", "SIMPLE_CHEMICAL", 58, 61], ["nigericin", "SIMPLE_CHEMICAL", 66, 75], ["IL-1b", "GENE_OR_GENE_PRODUCT", 155, 160], ["BMDMs", "CELL_TYPE", 17, 22], ["IL", "PROTEIN", 155, 157], ["BMDMs", "PROBLEM", 17, 22], ["itaconic acid (pH", "TEST", 28, 45], ["LPS", "TREATMENT", 58, 61], ["nigericin stimulation", "TREATMENT", 66, 87], ["a significant and concentration", "PROBLEM", 100, 131], ["dependent reduction in IL", "TREATMENT", 132, 157], ["a non-significant reduction in pyroptosis", "PROBLEM", 188, 229], ["BMDMs", "OBSERVATION", 17, 22], ["significant", "OBSERVATION_MODIFIER", 102, 113], ["dependent", "OBSERVATION_MODIFIER", 132, 141], ["reduction", "OBSERVATION_MODIFIER", 142, 151], ["non-significant", "OBSERVATION_MODIFIER", 190, 205], ["reduction", "OBSERVATION_MODIFIER", 206, 215], ["pyroptosis", "OBSERVATION", 219, 229]]], ["Thus, unmodified itaconate, as well as derivatized itaconate, is capable of regulating NLRP3 activation.Endogenous Itaconate Regulates NLRP3 Inflammasome ActivationThe enzyme IRG1 is responsible for the production of itaconate in macrophages, which reaches a concentration of 5 mM in LPS-stimulated BMDMs (Mills et al., 2018) .", [["macrophages", "ANATOMY", 230, 241], ["BMDMs", "ANATOMY", 299, 304], ["itaconate", "CHEMICAL", 17, 26], ["itaconate", "CHEMICAL", 51, 60], ["Itaconate", "CHEMICAL", 115, 124], ["itaconate", "CHEMICAL", 217, 226], ["LPS", "CHEMICAL", 284, 287], ["itaconate", "CHEMICAL", 17, 26], ["itaconate", "CHEMICAL", 51, 60], ["Itaconate", "CHEMICAL", 115, 124], ["itaconate", "CHEMICAL", 217, 226], ["itaconate", "SIMPLE_CHEMICAL", 17, 26], ["itaconate", "SIMPLE_CHEMICAL", 51, 60], ["NLRP3", "GENE_OR_GENE_PRODUCT", 87, 92], ["Itaconate", "SIMPLE_CHEMICAL", 115, 124], ["NLRP3", "GENE_OR_GENE_PRODUCT", 135, 140], ["IRG1", "GENE_OR_GENE_PRODUCT", 175, 179], ["itaconate", "SIMPLE_CHEMICAL", 217, 226], ["macrophages", "CELL", 230, 241], ["LPS", "SIMPLE_CHEMICAL", 284, 287], ["BMDMs", "CELL", 299, 304], ["NLRP3", "PROTEIN", 87, 92], ["NLRP3", "PROTEIN", 135, 140], ["IRG1", "PROTEIN", 175, 179], ["macrophages", "CELL_TYPE", 230, 241], ["BMDMs", "CELL_TYPE", 299, 304], ["unmodified itaconate", "TREATMENT", 6, 26], ["derivatized itaconate", "TREATMENT", 39, 60], ["Endogenous Itaconate Regulates", "TREATMENT", 104, 134], ["The enzyme IRG1", "TEST", 164, 179], ["itaconate in macrophages", "PROBLEM", 217, 241], ["NLRP3 Inflammasome", "OBSERVATION", 135, 153], ["macrophages", "OBSERVATION", 230, 241]]], ["It is therefore possible to deplete or induce the production of endogenous itaconate through manipulation of IRG1.", [["itaconate", "CHEMICAL", 75, 84], ["itaconate", "CHEMICAL", 75, 84], ["itaconate", "SIMPLE_CHEMICAL", 75, 84], ["IRG1", "GENE_OR_GENE_PRODUCT", 109, 113], ["IRG1", "PROTEIN", 109, 113], ["endogenous itaconate", "TREATMENT", 64, 84], ["manipulation of IRG1", "TREATMENT", 93, 113], ["therefore possible", "UNCERTAINTY", 6, 24]]], ["We performed NLRP3 inflammasome assays in Irg1 \u00c0/\u00c0 BMDMs and found that IL-1b release was significantly increased relative to wild-type (WT) BMDMs ( Figure 3A ).", [["BMDMs", "ANATOMY", 51, 56], ["NLRP3", "GENE_OR_GENE_PRODUCT", 13, 18], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL", 42, 56], ["IL-1b", "GENE_OR_GENE_PRODUCT", 72, 77], ["BMDMs", "CELL", 141, 146], ["NLRP3", "PROTEIN", 13, 18], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 42, 56], ["BMDMs", "CELL_TYPE", 141, 146], ["NLRP3 inflammasome assays", "TEST", 13, 38], ["BMDMs", "PROBLEM", 51, 56], ["IL", "TEST", 72, 74]]], ["There was also a non-significant increase in pyroptosis in Irg1 \u00c0/\u00c0 BMDMs ( Figure 3B ).", [["pyroptosis", "DISEASE", 45, 55], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 59, 73], ["a non-significant increase", "PROBLEM", 15, 41], ["pyroptosis", "PROBLEM", 45, 55], ["non-significant", "OBSERVATION_MODIFIER", 17, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["pyroptosis", "OBSERVATION", 45, 55]]], ["IL-1b and caspase-1 processing into their mature forms, as detected by western blot, was increased in Irg1 \u00c0/\u00c0 BMDMs ( Figures 3C and 3D , compare lane 8 to lane 4).", [["BMDMs", "ANATOMY", 111, 116], ["IL-1b", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase-1", "GENE_OR_GENE_PRODUCT", 10, 19], ["caspase-1", "PROTEIN", 10, 19], ["Irg1", "PROTEIN", 102, 106], ["IL", "TREATMENT", 0, 2], ["caspase", "TREATMENT", 10, 17], ["BMDMs", "PROBLEM", 111, 116], ["increased", "OBSERVATION_MODIFIER", 89, 98]]], ["These effects were specific for NLRP3 inflammasome activation, as IL-1b release resulting from AIM2 inflammasome activation was not increased in Irg1 \u00c0/\u00c0 BMDMs ( Figure S2G ).", [["BMDMs", "ANATOMY", 154, 159], ["NLRP3", "GENE_OR_GENE_PRODUCT", 32, 37], ["IL-1b", "GENE_OR_GENE_PRODUCT", 66, 71], ["AIM2", "GENE_OR_GENE_PRODUCT", 95, 99], ["NLRP3", "PROTEIN", 32, 37], ["IL-1b", "PROTEIN", 66, 71], ["AIM2", "PROTEIN", 95, 99], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 145, 159], ["NLRP3 inflammasome activation", "TREATMENT", 32, 61], ["AIM2 inflammasome activation", "PROBLEM", 95, 123], ["BMDMs", "PROBLEM", 154, 159], ["increased", "OBSERVATION_MODIFIER", 132, 141]]], ["As NLRP3 expression is LPS-inducible as part of priming, we verified that increased NLRP3 inflammasome activation in Irg1 \u00c0/\u00c0 BMDMs was not due to increased NLRP3 expression ( Figure S2H , compare lane 4 to lane 2).Endogenous Itaconate Regulates NLRP3 Inflammasome ActivationIt is possible to reconstitute the murine NLRP3 inflammasome in HEK293T cells, as previously described (Shi et al., 2016a) .", [["Irg1 \u00c0/\u00c0 BMDMs", "ANATOMY", 117, 131], ["HEK293T cells", "ANATOMY", 339, 352], ["LPS", "CHEMICAL", 23, 26], ["Itaconate", "CHEMICAL", 226, 235], ["Itaconate", "CHEMICAL", 226, 235], ["NLRP3", "GENE_OR_GENE_PRODUCT", 3, 8], ["LPS", "GENE_OR_GENE_PRODUCT", 23, 26], ["NLRP3", "GENE_OR_GENE_PRODUCT", 84, 89], ["Irg1", "GENE_OR_GENE_PRODUCT", 117, 121], ["NLRP3", "GENE_OR_GENE_PRODUCT", 157, 162], ["Itaconate", "SIMPLE_CHEMICAL", 226, 235], ["NLRP3", "GENE_OR_GENE_PRODUCT", 246, 251], ["murine", "ORGANISM", 310, 316], ["NLRP3", "GENE_OR_GENE_PRODUCT", 317, 322], ["HEK293T cells", "CELL", 339, 352], ["NLRP3", "PROTEIN", 3, 8], ["NLRP3", "PROTEIN", 84, 89], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 117, 131], ["NLRP3", "PROTEIN", 157, 162], ["NLRP3", "PROTEIN", 246, 251], ["NLRP3", "PROTEIN", 317, 322], ["HEK293T cells", "CELL_LINE", 339, 352], ["murine", "SPECIES", 310, 316], ["LPS", "TEST", 23, 26], ["increased NLRP3 inflammasome activation", "PROBLEM", 74, 113], ["BMDMs", "PROBLEM", 126, 131], ["increased NLRP3 expression", "PROBLEM", 147, 173], ["Endogenous Itaconate Regulates NLRP3 Inflammasome Activation", "TREATMENT", 215, 275], ["the murine NLRP3 inflammasome in HEK293T cells", "TREATMENT", 306, 352], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["NLRP3 inflammasome", "OBSERVATION", 84, 102], ["NLRP3 Inflammasome", "OBSERVATION", 246, 264], ["HEK293T cells", "OBSERVATION", 339, 352]]], ["Transfection of the various NLRP3 inflammasome components followed by stimulation with nigericin results in IL-1b cleavage and release from the cell ( Figure 3E ).", [["cell", "ANATOMY", 144, 148], ["nigericin", "CHEMICAL", 87, 96], ["nigericin", "CHEMICAL", 87, 96], ["NLRP3", "GENE_OR_GENE_PRODUCT", 28, 33], ["nigericin", "SIMPLE_CHEMICAL", 87, 96], ["IL-1b", "GENE_OR_GENE_PRODUCT", 108, 113], ["cell", "CELL", 144, 148], ["NLRP3 inflammasome components", "PROTEIN", 28, 57], ["the various NLRP3 inflammasome components", "TREATMENT", 16, 57], ["nigericin", "TREATMENT", 87, 96], ["IL", "TREATMENT", 108, 110]]], ["We found that overexpression of a plasmid encoding IRG1 in this system resulted in reduced IL-1b cleavage and release relative to transfection of an empty vector plasmid ( Figure 3E , compare lane 4 to lane 3).", [["plasmid", "ANATOMY", 34, 41], ["IRG1", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL-1b", "GENE_OR_GENE_PRODUCT", 91, 96], ["plasmid", "DNA", 34, 41], ["IRG1", "PROTEIN", 51, 55], ["IL", "PROTEIN", 91, 93], ["empty vector plasmid", "DNA", 149, 169], ["a plasmid encoding IRG1", "TREATMENT", 32, 55], ["reduced IL-1b cleavage", "TREATMENT", 83, 105], ["an empty vector plasmid", "TREATMENT", 146, 169], ["reduced", "OBSERVATION_MODIFIER", 83, 90], ["IL", "OBSERVATION", 91, 93]]], ["Thus, while the absence of endogenous itaconate boosts NLRP3 inflammasome activation, increased IRG1 expression has the opposite effect, indicating that endogenous itaconate regulates NLRP3.4-OI Blocks the NLRP3-NEK7 Interaction and Dicarboxypropylates C548 on NLRP3Itaconate alkylates C151 on KEAP1, in a modification termed 2,3-dicarboxypropylation (Mills et al., 2018) , leading to activation of NRF2, a protein that is thought to regulate NLRP3 inflammasome activation (Garstkiewicz et al., 2017; Zhao et al., 2014) .", [["itaconate", "CHEMICAL", 38, 47], ["itaconate", "CHEMICAL", 164, 173], ["NLRP3Itaconate", "CHEMICAL", 261, 275], ["2,3-dicarboxypropylation", "CHEMICAL", 326, 350], ["itaconate", "CHEMICAL", 38, 47], ["itaconate", "CHEMICAL", 164, 173], ["4-OI", "CHEMICAL", 190, 194], ["Dicarboxypropylates C548", "CHEMICAL", 233, 257], ["NLRP3Itaconate", "CHEMICAL", 261, 275], ["C151", "CHEMICAL", 286, 290], ["itaconate", "SIMPLE_CHEMICAL", 38, 47], ["NLRP3", "GENE_OR_GENE_PRODUCT", 55, 60], ["IRG1", "GENE_OR_GENE_PRODUCT", 96, 100], ["itaconate", "SIMPLE_CHEMICAL", 164, 173], ["NLRP3", "GENE_OR_GENE_PRODUCT", 184, 189], ["4-OI", "SIMPLE_CHEMICAL", 190, 194], ["NLRP3", "GENE_OR_GENE_PRODUCT", 206, 211], ["NEK7", "GENE_OR_GENE_PRODUCT", 212, 216], ["Dicarboxypropylates C548", "SIMPLE_CHEMICAL", 233, 257], ["NLRP3Itaconate alkylates C151", "SIMPLE_CHEMICAL", 261, 290], ["KEAP1", "SIMPLE_CHEMICAL", 294, 299], ["2,3-dicarboxypropylation", "SIMPLE_CHEMICAL", 326, 350], ["NRF2", "GENE_OR_GENE_PRODUCT", 399, 403], ["NLRP3", "GENE_OR_GENE_PRODUCT", 443, 448], ["NLRP3", "PROTEIN", 55, 60], ["IRG1", "PROTEIN", 96, 100], ["NLRP3", "PROTEIN", 184, 189], ["NLRP3", "PROTEIN", 206, 211], ["NEK7", "PROTEIN", 212, 216], ["KEAP1", "PROTEIN", 294, 299], ["NRF2", "PROTEIN", 399, 403], ["NLRP3", "PROTEIN", 443, 448], ["NLRP3 inflammasome activation", "TREATMENT", 55, 84], ["increased IRG1 expression", "PROBLEM", 86, 111], ["endogenous itaconate regulates NLRP3", "TREATMENT", 153, 189], ["Dicarboxypropylates", "TREATMENT", 233, 252], ["NLRP3Itaconate alkylates", "TREATMENT", 261, 285], ["a protein", "TEST", 405, 414]]], ["However, we found that 4-OI still inhibited NLRP3-dependent caspase-1 and IL-1b processing, as well as IL-1b release in Nfe2l2 \u00c0/\u00c0 (gene encoding NRF2) BMDMs (Figures S3A-S3D), ruling out NRF2 in the inhibitory process.", [["4-OI", "CHEMICAL", 23, 27], ["4-OI", "SIMPLE_CHEMICAL", 23, 27], ["NLRP3", "GENE_OR_GENE_PRODUCT", 44, 49], ["caspase-1", "GENE_OR_GENE_PRODUCT", 60, 69], ["IL-1b", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-1b", "GENE_OR_GENE_PRODUCT", 103, 108], ["Nfe2l2 \u00c0", "GENE_OR_GENE_PRODUCT", 120, 128], ["\u00c0", "GENE_OR_GENE_PRODUCT", 129, 130], ["NRF2", "GENE_OR_GENE_PRODUCT", 146, 150], ["NRF2", "GENE_OR_GENE_PRODUCT", 188, 192], ["NLRP3", "PROTEIN", 44, 49], ["Nfe2l2", "PROTEIN", 120, 126], ["NRF2", "PROTEIN", 146, 150], ["BMDMs", "PROTEIN", 152, 157], ["S3A", "PROTEIN", 167, 170], ["S3D", "PROTEIN", 171, 174], ["NRF2", "PROTEIN", 188, 192], ["NLRP3", "TEST", 44, 49], ["caspase", "TEST", 60, 67], ["IL", "TEST", 74, 76], ["BMDMs", "TEST", 152, 157], ["Figures", "TEST", 159, 166], ["NRF2", "PROBLEM", 188, 192]]], ["Itaconate also limits inflammation through inhibition of succinate dehydrogenase (SDH) (Cordes et al., 2016; Lampropoulou et al., 2016) .", [["Itaconate", "CHEMICAL", 0, 9], ["inflammation", "DISEASE", 22, 34], ["succinate", "CHEMICAL", 57, 66], ["Itaconate", "CHEMICAL", 0, 9], ["succinate", "CHEMICAL", 57, 66], ["Itaconate", "SIMPLE_CHEMICAL", 0, 9], ["succinate dehydrogenase", "GENE_OR_GENE_PRODUCT", 57, 80], ["SDH", "GENE_OR_GENE_PRODUCT", 82, 85], ["succinate dehydrogenase", "PROTEIN", 57, 80], ["SDH", "PROTEIN", 82, 85], ["Itaconate", "TREATMENT", 0, 9], ["succinate dehydrogenase (SDH", "PROBLEM", 57, 85], ["inflammation", "OBSERVATION", 22, 34]]], ["The SDH inhibitor dimethyl malonate (DMM), however, did not inhibit IL-1b release in an NLRP3 inflammasome assay ( Figure S3E ), indicating that SDH inhibition was unlikely to be important here.", [["dimethyl malonate", "CHEMICAL", 18, 35], ["DMM", "CHEMICAL", 37, 40], ["dimethyl malonate", "CHEMICAL", 18, 35], ["DMM", "CHEMICAL", 37, 40], ["SDH", "SIMPLE_CHEMICAL", 4, 7], ["dimethyl malonate", "SIMPLE_CHEMICAL", 18, 35], ["DMM", "SIMPLE_CHEMICAL", 37, 40], ["IL-1b", "GENE_OR_GENE_PRODUCT", 68, 73], ["NLRP3", "GENE_OR_GENE_PRODUCT", 88, 93], ["SDH", "GENE_OR_GENE_PRODUCT", 145, 148], ["IL", "PROTEIN", 68, 70], ["NLRP3", "PROTEIN", 88, 93], ["SDH", "PROTEIN", 145, 148], ["The SDH inhibitor dimethyl malonate (DMM", "PROBLEM", 0, 40], ["an NLRP3 inflammasome assay", "TEST", 85, 112], ["SDH inhibition", "PROBLEM", 145, 159]]], ["We also explored whether 4-OI may be interacting with the deglutathionylating enzyme glutathione transferase omega 1 (GSTO1-1), recently described as a regulator of NLRP3 inflammasome activation (Hughes et al., 2019).", [["glutathione", "CHEMICAL", 85, 96], ["4-OI", "CHEMICAL", 25, 29], ["glutathione", "CHEMICAL", 85, 96], ["4-OI", "SIMPLE_CHEMICAL", 25, 29], ["glutathione transferase omega 1", "GENE_OR_GENE_PRODUCT", 85, 116], ["GSTO1-1", "GENE_OR_GENE_PRODUCT", 118, 125], ["NLRP3", "GENE_OR_GENE_PRODUCT", 165, 170], ["deglutathionylating enzyme", "PROTEIN", 58, 84], ["glutathione transferase omega 1 (GSTO1-1", "PROTEIN", 85, 125], ["NLRP3", "PROTEIN", 165, 170], ["the deglutathionylating enzyme glutathione transferase omega", "TEST", 54, 114]]], ["However, 4-OI still inhibited IL-1b release in an NLRP3 inflammasome assay in Gsto1 \u00c0/\u00c0 BMDMs ( Figures S3F and S3G ).Short ArticleWe subsequently hypothesized that the acute and specific effect of 4-OI on NLRP3 activation may be the result of targeting NLRP3 and/or NEK7 directly, but not ASC or caspase-1 as these components are shared by other inflammasomes.", [["BMDMs", "ANATOMY", 88, 93], ["4-OI", "CHEMICAL", 9, 13], ["4-OI", "CHEMICAL", 198, 202], ["4-OI", "SIMPLE_CHEMICAL", 9, 13], ["IL-1b", "GENE_OR_GENE_PRODUCT", 30, 35], ["NLRP3", "GENE_OR_GENE_PRODUCT", 50, 55], ["Gsto1", "GENE_OR_GENE_PRODUCT", 78, 83], ["4-OI", "SIMPLE_CHEMICAL", 198, 202], ["NLRP3", "GENE_OR_GENE_PRODUCT", 206, 211], ["NLRP3", "GENE_OR_GENE_PRODUCT", 254, 259], ["NEK7", "GENE_OR_GENE_PRODUCT", 267, 271], ["ASC", "GENE_OR_GENE_PRODUCT", 290, 293], ["caspase-1", "GENE_OR_GENE_PRODUCT", 297, 306], ["IL", "PROTEIN", 30, 32], ["NLRP3", "PROTEIN", 50, 55], ["Gsto1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 78, 93], ["NLRP3", "PROTEIN", 206, 211], ["NLRP3", "PROTEIN", 254, 259], ["NEK7", "PROTEIN", 267, 271], ["ASC", "PROTEIN", 290, 293], ["caspase-1", "PROTEIN", 297, 306], ["inflammasomes", "PROTEIN", 347, 360], ["an NLRP3 inflammasome assay", "TEST", 47, 74], ["Gsto1", "TEST", 78, 83], ["BMDMs", "PROBLEM", 88, 93], ["NLRP3 activation", "TREATMENT", 206, 222], ["NEK7", "TREATMENT", 267, 271], ["caspase", "TREATMENT", 297, 304], ["acute", "OBSERVATION_MODIFIER", 169, 174]]], ["Upon NLRP3 inflammasome stimulation, NLRP3 and NEK7 interact with each other to promote activation (Sharif et al., 2019) .", [["NLRP3", "GENE_OR_GENE_PRODUCT", 5, 10], ["NLRP3", "GENE_OR_GENE_PRODUCT", 37, 42], ["NEK7", "GENE_OR_GENE_PRODUCT", 47, 51], ["NLRP3", "PROTEIN", 5, 10], ["NLRP3", "PROTEIN", 37, 42], ["NEK7", "PROTEIN", 47, 51], ["NLRP3 inflammasome stimulation", "TREATMENT", 5, 35], ["NLRP3", "TREATMENT", 37, 42], ["NEK7", "TREATMENT", 47, 51], ["inflammasome stimulation", "OBSERVATION", 11, 35]]], ["This interaction was blocked by treatment with 4-OI ( Figure 3F , compare lane 3 to lane 2).", [["4-OI", "CHEMICAL", 47, 51]]], ["Subsequent tandem mass spectrometry of murine NLRP3, immunoprecipitated from 4-OI-treated NLRP3-overexpressing HEK293T cells, showed that 4-OI dicarboxypropylated (+242.15 Da) C548 on NLRP3 ( Figure 3G ).", [["HEK293T cells", "ANATOMY", 111, 124], ["4-OI", "CHEMICAL", 77, 81], ["4-OI dicarboxypropylated", "CHEMICAL", 138, 162], ["murine", "ORGANISM", 39, 45], ["NLRP3", "GENE_OR_GENE_PRODUCT", 46, 51], ["4-OI", "SIMPLE_CHEMICAL", 77, 81], ["NLRP3", "GENE_OR_GENE_PRODUCT", 90, 95], ["HEK293T cells", "CELL", 111, 124], ["4-OI dicarboxypropylated", "SIMPLE_CHEMICAL", 138, 162], ["NLRP3", "GENE_OR_GENE_PRODUCT", 184, 189], ["murine NLRP3", "PROTEIN", 39, 51], ["4-OI-treated NLRP3-overexpressing HEK293T cells", "CELL_LINE", 77, 124], ["NLRP3", "PROTEIN", 184, 189], ["Figure 3G", "PROTEIN", 192, 201], ["murine", "SPECIES", 39, 45], ["Subsequent tandem mass spectrometry of murine NLRP3", "PROBLEM", 0, 51], ["OI", "TEST", 79, 81], ["NLRP3", "TREATMENT", 90, 95], ["overexpressing HEK293T cells", "PROBLEM", 96, 124], ["OI dicarboxypropylated", "TEST", 140, 162]]], ["C548 is present in the helical domain 2 (HD2) of NLRP3, which is one of the surfaces at which NLRP3 interacts with NEK7 (Sharif et al., 2019).", [["NLRP3", "GENE_OR_GENE_PRODUCT", 49, 54], ["NLRP3", "GENE_OR_GENE_PRODUCT", 94, 99], ["NEK7", "GENE_OR_GENE_PRODUCT", 115, 119], ["C548", "PROTEIN", 0, 4], ["helical domain 2", "PROTEIN", 23, 39], ["HD2", "PROTEIN", 41, 44], ["NLRP3", "PROTEIN", 49, 54], ["NLRP3", "PROTEIN", 94, 99], ["NEK7", "PROTEIN", 115, 119], ["NLRP3", "TREATMENT", 49, 54]]], ["This points to a possible mechanism for inhibition of NLRP3, involving modification of NLRP3 on C548.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 54, 59], ["NLRP3", "GENE_OR_GENE_PRODUCT", 87, 92], ["NLRP3", "PROTEIN", 54, 59], ["NLRP3", "PROTEIN", 87, 92], ["C548", "PROTEIN", 96, 100], ["inhibition of NLRP3", "TREATMENT", 40, 59], ["modification of NLRP3", "TREATMENT", 71, 92]]], ["This might interfere with the interaction between NLRP3 and NEK7, thereby blocking NLRP3 inflammasome activation.4-OI Reduces NLRP3-Driven Peritonitis In Vivo and Blocks IL-1b Release from Human CAPS PBMCsMonosodium urate (MSU) crystals, the causative agent of gout, are activators of the NLRP3 inflammasome and cause caspase-1-and ASC-dependent inflammation when injected into mice intraperitoneally (Martinon et al., 2006) .", [["Peritonitis", "DISEASE", 139, 150], ["PBMCsMonosodium urate", "CHEMICAL", 200, 221], ["MSU", "CHEMICAL", 223, 226], ["gout", "DISEASE", 261, 265], ["inflammation", "DISEASE", 346, 358], ["4-OI", "CHEMICAL", 113, 117], ["PBMCsMonosodium urate", "CHEMICAL", 200, 221], ["NLRP3", "GENE_OR_GENE_PRODUCT", 50, 55], ["NEK7", "GENE_OR_GENE_PRODUCT", 60, 64], ["NLRP3", "GENE_OR_GENE_PRODUCT", 83, 88], ["4-OI", "SIMPLE_CHEMICAL", 113, 117], ["NLRP3", "GENE_OR_GENE_PRODUCT", 126, 131], ["IL-1b", "GENE_OR_GENE_PRODUCT", 170, 175], ["Human", "ORGANISM", 189, 194], ["CAPS PBMCsMonosodium urate", "SIMPLE_CHEMICAL", 195, 221], ["MSU", "SIMPLE_CHEMICAL", 223, 226], ["NLRP3", "GENE_OR_GENE_PRODUCT", 289, 294], ["caspase-1", "GENE_OR_GENE_PRODUCT", 318, 327], ["ASC", "GENE_OR_GENE_PRODUCT", 332, 335], ["mice", "ORGANISM", 378, 382], ["NLRP3", "PROTEIN", 50, 55], ["NEK7", "PROTEIN", 60, 64], ["NLRP3", "PROTEIN", 83, 88], ["NLRP3", "PROTEIN", 126, 131], ["NLRP3", "PROTEIN", 289, 294], ["Human", "SPECIES", 189, 194], ["mice", "SPECIES", 378, 382], ["mice", "SPECIES", 378, 382], ["NLRP3 and NEK7", "TREATMENT", 50, 64], ["blocking NLRP3 inflammasome activation", "TREATMENT", 74, 112], ["NLRP3", "PROBLEM", 126, 131], ["Peritonitis", "PROBLEM", 139, 150], ["Vivo and Blocks IL", "TREATMENT", 154, 172], ["Human CAPS PBMCsMonosodium urate (MSU) crystals", "TREATMENT", 189, 236], ["gout", "PROBLEM", 261, 265], ["the NLRP3 inflammasome", "TREATMENT", 285, 307], ["caspase", "TEST", 318, 325], ["ASC", "PROBLEM", 332, 335], ["dependent inflammation", "PROBLEM", 336, 358], ["Peritonitis", "OBSERVATION", 139, 150], ["gout", "OBSERVATION", 261, 265], ["dependent", "OBSERVATION_MODIFIER", 336, 345], ["inflammation", "OBSERVATION", 346, 358]]], ["Co-injection of 4-OI with MSU crystals reduced IL-1b and IL-6 (which is downstream of IL-1b) concentrations, as well as neutrophil numbers, in the peritoneal lavage fluid ( Figures 4A-4C ).4-OI Reduces NLRP3-Driven Peritonitis In Vivo and Blocks IL-1b Release from Human CAPS PBMCsFinally, we tested 4-OI on peripheral blood mononuclear cells (PBMCs) from CAPS patients.", [["neutrophil", "ANATOMY", 120, 130], ["peritoneal lavage fluid", "ANATOMY", 147, 170], ["peripheral blood mononuclear cells", "ANATOMY", 308, 342], ["PBMCs", "ANATOMY", 344, 349], ["MSU", "CHEMICAL", 26, 29], ["Peritonitis", "DISEASE", 215, 226], ["4-OI", "CHEMICAL", 16, 20], ["4-OI", "SIMPLE_CHEMICAL", 16, 20], ["MSU crystals", "SIMPLE_CHEMICAL", 26, 38], ["IL-1b", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-1b", "GENE_OR_GENE_PRODUCT", 86, 91], ["neutrophil", "CELL", 120, 130], ["peritoneal lavage fluid", "ORGANISM_SUBSTANCE", 147, 170], ["NLRP3", "GENE_OR_GENE_PRODUCT", 202, 207], ["IL-1b", "GENE_OR_GENE_PRODUCT", 246, 251], ["Human", "ORGANISM", 265, 270], ["4-OI", "SIMPLE_CHEMICAL", 300, 304], ["peripheral blood mononuclear cells", "CELL", 308, 342], ["PBMCs", "CELL", 344, 349], ["patients", "ORGANISM", 361, 369], ["IL-1b and IL-6", "PROTEIN", 47, 61], ["NLRP3", "PROTEIN", 202, 207], ["peripheral blood mononuclear cells", "CELL_TYPE", 308, 342], ["PBMCs", "CELL_TYPE", 344, 349], ["Human", "SPECIES", 265, 270], ["patients", "SPECIES", 361, 369], ["Co-injection", "TEST", 0, 12], ["MSU crystals reduced IL", "TREATMENT", 26, 49], ["IL", "TEST", 57, 59], ["IL", "TEST", 86, 88], ["neutrophil numbers", "TEST", 120, 138], ["the peritoneal lavage fluid", "TEST", 143, 170], ["Figures", "TEST", 173, 180], ["4A", "TEST", 181, 183], ["OI", "PROBLEM", 191, 193], ["NLRP3", "PROBLEM", 202, 207], ["Peritonitis", "PROBLEM", 215, 226], ["Vivo and Blocks IL", "TREATMENT", 230, 248], ["Human CAPS PBMCsFinally", "TEST", 265, 288], ["peripheral blood mononuclear cells", "TREATMENT", 308, 342], ["peritoneal", "ANATOMY", 147, 157], ["lavage", "OBSERVATION", 158, 164], ["Peritonitis", "OBSERVATION", 215, 226], ["peripheral", "ANATOMY_MODIFIER", 308, 318], ["blood", "ANATOMY", 319, 324], ["mononuclear cells", "OBSERVATION", 325, 342]]], ["We first confirmed that 4-OI would block NLRP3 activation in human PBMCs isolated from healthy donors.", [["PBMCs", "ANATOMY", 67, 72], ["4-OI", "CHEMICAL", 24, 28], ["4-OI", "SIMPLE_CHEMICAL", 24, 28], ["NLRP3", "GENE_OR_GENE_PRODUCT", 41, 46], ["human", "ORGANISM", 61, 66], ["PBMCs", "CELL", 67, 72], ["donors", "ORGANISM", 95, 101], ["NLRP3", "PROTEIN", 41, 46], ["human PBMCs", "CELL_TYPE", 61, 72], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["NLRP3 activation in human PBMCs", "TREATMENT", 41, 72]]], ["4-OI, but not 4-O-2-MS, blocked IL-1b release when added between Pam3CSK4 or LPS and nigericin in human PBMCs ( Figure 4D ).", [["PBMCs", "ANATOMY", 104, 109], ["4-OI", "CHEMICAL", 0, 4], ["4-O-2-MS", "CHEMICAL", 14, 22], ["Pam3CSK4", "CHEMICAL", 65, 73], ["LPS", "CHEMICAL", 77, 80], ["nigericin", "CHEMICAL", 85, 94], ["4-OI", "CHEMICAL", 0, 4], ["4-O-2-MS", "CHEMICAL", 14, 22], ["nigericin", "CHEMICAL", 85, 94], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["4-O-2-MS", "SIMPLE_CHEMICAL", 14, 22], ["IL-1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["Pam3CSK4", "SIMPLE_CHEMICAL", 65, 73], ["LPS", "SIMPLE_CHEMICAL", 77, 80], ["nigericin", "SIMPLE_CHEMICAL", 85, 94], ["human", "ORGANISM", 98, 103], ["PBMCs", "CELL", 104, 109], ["human PBMCs", "CELL_TYPE", 98, 109], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["MS", "PROBLEM", 20, 22], ["blocked IL", "TREATMENT", 24, 34], ["Pam3CSK4", "TREATMENT", 65, 73], ["LPS", "TREATMENT", 77, 80], ["nigericin", "TREATMENT", 85, 94]]], ["4-OI also blocked IL-1b cleavage into its mature form ( Figures 4E and 4F , compare lane 5 to lane 4).", [["4-OI", "CHEMICAL", 0, 4], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["IL-1b", "GENE_OR_GENE_PRODUCT", 18, 23], ["IL", "PROTEIN", 18, 20], ["4F", "PROTEIN", 71, 73], ["blocked IL", "TREATMENT", 10, 20]]], ["The efficacy of 4-OI was similar to that of MCC950 and glyburide, albeit at a higher concentration ( Figure S4A ).", [["MCC950", "CHEMICAL", 44, 50], ["glyburide", "CHEMICAL", 55, 64], ["4-OI", "CHEMICAL", 16, 20], ["MCC950", "CHEMICAL", 44, 50], ["glyburide", "CHEMICAL", 55, 64], ["4-OI", "SIMPLE_CHEMICAL", 16, 20], ["MCC950", "SIMPLE_CHEMICAL", 44, 50], ["glyburide", "SIMPLE_CHEMICAL", 55, 64], ["MCC950", "TREATMENT", 44, 50], ["glyburide", "TREATMENT", 55, 64]]], ["PBMCs can also engage an ''alternative'' inflammasome pathway, which involves caspase-8 and NLRP3, and can be activated by LPS alone (Gaidt et al., 2016) .", [["PBMCs", "ANATOMY", 0, 5], ["LPS", "CHEMICAL", 123, 126], ["PBMCs", "CELL", 0, 5], ["caspase-8", "GENE_OR_GENE_PRODUCT", 78, 87], ["NLRP3", "GENE_OR_GENE_PRODUCT", 92, 97], ["LPS", "SIMPLE_CHEMICAL", 123, 126], ["PBMCs", "CELL_TYPE", 0, 5], ["caspase-8", "PROTEIN", 78, 87], ["NLRP3", "PROTEIN", 92, 97], ["an ''alternative'' inflammasome pathway", "TREATMENT", 22, 61], ["caspase", "TEST", 78, 85], ["NLRP3", "TREATMENT", 92, 97]]], ["4-OI blocked IL-1b release from human PBMCs in this assay ( Figure S4B ).", [["PBMCs", "ANATOMY", 38, 43], ["4-OI", "CHEMICAL", 0, 4], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["IL-1b", "GENE_OR_GENE_PRODUCT", 13, 18], ["human", "ORGANISM", 32, 37], ["PBMCs", "CELL", 38, 43], ["IL-1b", "PROTEIN", 13, 18], ["human PBMCs", "CELL_TYPE", 32, 43], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["OI blocked IL", "TREATMENT", 2, 15]]], ["We then tested PBMCs isolated from the whole blood of CAPS patients who have hyperactive NLRP3, which can be stimulated with LPS to release large amounts of IL-1b.", [["PBMCs", "ANATOMY", 15, 20], ["whole blood", "ANATOMY", 39, 50], ["CAPS", "DISEASE", 54, 58], ["LPS", "CHEMICAL", 125, 128], ["PBMCs", "CELL", 15, 20], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["patients", "ORGANISM", 59, 67], ["NLRP3", "GENE_OR_GENE_PRODUCT", 89, 94], ["LPS", "SIMPLE_CHEMICAL", 125, 128], ["IL-1b", "GENE_OR_GENE_PRODUCT", 157, 162], ["PBMCs", "CELL_TYPE", 15, 20], ["NLRP3", "PROTEIN", 89, 94], ["IL", "PROTEIN", 157, 159], ["patients", "SPECIES", 59, 67], ["PBMCs", "TEST", 15, 20], ["hyperactive NLRP3", "TREATMENT", 77, 94], ["LPS", "TREATMENT", 125, 128], ["hyperactive NLRP3", "OBSERVATION", 77, 94]]], ["We treated CAPS PBMCs with 4-OI after 1 h stimulation with LPS and found that both 4-OI and MCC950 blocked IL-1b release from these cells ( Figure 4G ).DISCUSSIONIt is now generally accepted that NLRP3 inflammasome signaling plays a critical role in the pathogenesis of several autoimmune disorders, including Alzheimer disease (Heneka et al., 2013) , rheumatoid arthritis (Vande Walle et al., 2014) , and type 2 diabetes (Masters et al., 2010; Vandanmagsar et al., 2011) .", [["PBMCs", "ANATOMY", 16, 21], ["cells", "ANATOMY", 132, 137], ["CAPS", "DISEASE", 11, 15], ["LPS", "CHEMICAL", 59, 62], ["MCC950", "CHEMICAL", 92, 98], ["autoimmune disorders", "DISEASE", 278, 298], ["Alzheimer disease", "DISEASE", 310, 327], ["rheumatoid arthritis", "DISEASE", 352, 372], ["type 2 diabetes", "DISEASE", 406, 421], ["MCC950", "CHEMICAL", 92, 98], ["PBMCs", "CELL", 16, 21], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["4-OI", "SIMPLE_CHEMICAL", 83, 87], ["MCC950", "SIMPLE_CHEMICAL", 92, 98], ["IL-1b", "GENE_OR_GENE_PRODUCT", 107, 112], ["cells", "CELL", 132, 137], ["NLRP3", "GENE_OR_GENE_PRODUCT", 196, 201], ["CAPS PBMCs", "CELL_LINE", 11, 21], ["NLRP3", "PROTEIN", 196, 201], ["CAPS PBMCs", "TREATMENT", 11, 21], ["LPS", "TREATMENT", 59, 62], ["MCC950 blocked IL", "TREATMENT", 92, 109], ["NLRP3 inflammasome signaling", "PROBLEM", 196, 224], ["several autoimmune disorders", "PROBLEM", 270, 298], ["Alzheimer disease", "PROBLEM", 310, 327], ["rheumatoid arthritis", "PROBLEM", 352, 372], ["type 2 diabetes", "PROBLEM", 406, 421], ["several", "OBSERVATION_MODIFIER", 270, 277], ["autoimmune", "OBSERVATION", 278, 288], ["rheumatoid arthritis", "OBSERVATION", 352, 372]]], ["This has heightened the need for a greater understanding of how inflammasome activation is regulated endogenously and how it may be inhibited.DISCUSSIONWe hereby provide evidence of itaconate being a specific endogenous inhibitor of NLRP3 inflammasome activation.", [["itaconate", "CHEMICAL", 182, 191], ["itaconate", "CHEMICAL", 182, 191], ["itaconate", "SIMPLE_CHEMICAL", 182, 191], ["NLRP3", "GENE_OR_GENE_PRODUCT", 233, 238], ["NLRP3", "PROTEIN", 233, 238], ["itaconate", "TREATMENT", 182, 191], ["a specific endogenous inhibitor", "TREATMENT", 198, 229], ["NLRP3 inflammasome activation", "TREATMENT", 233, 262]]], ["Previous studies have pointed toward a role for itaconate in regulating IL-1b cleavage (Lampropoulou et al., 2016; Swain et al., 2020) , but by pre-treating cells with itaconate prior to LPS stimulation they were unable to rule out an effect on signal 1.", [["cells", "ANATOMY", 157, 162], ["itaconate", "CHEMICAL", 48, 57], ["itaconate", "CHEMICAL", 168, 177], ["LPS", "CHEMICAL", 187, 190], ["itaconate", "CHEMICAL", 48, 57], ["itaconate", "CHEMICAL", 168, 177], ["itaconate", "SIMPLE_CHEMICAL", 48, 57], ["IL-1b", "GENE_OR_GENE_PRODUCT", 72, 77], ["cells", "CELL", 157, 162], ["itaconate", "SIMPLE_CHEMICAL", 168, 177], ["LPS", "SIMPLE_CHEMICAL", 187, 190], ["IL", "PROTEIN", 72, 74], ["Previous studies", "TEST", 0, 16], ["itaconate in regulating IL", "TREATMENT", 48, 74], ["itaconate", "TREATMENT", 168, 177], ["LPS stimulation", "TREATMENT", 187, 202], ["an effect on signal 1", "PROBLEM", 232, 253]]], ["Nor did these studies demonstrate itaconate's specificity for NLRP3, which we have shown through our AIM2 and NLRC4 experiments.DISCUSSIONThe mechanism that we propose for this inhibition is itaconatemediated dicarboxypropylation of C548.", [["itaconate", "CHEMICAL", 34, 43], ["C548", "CHEMICAL", 233, 237], ["itaconate", "CHEMICAL", 34, 43], ["C548", "CHEMICAL", 233, 237], ["itaconate", "SIMPLE_CHEMICAL", 34, 43], ["NLRP3", "GENE_OR_GENE_PRODUCT", 62, 67], ["AIM2", "GENE_OR_GENE_PRODUCT", 101, 105], ["NLRC4", "GENE_OR_GENE_PRODUCT", 110, 115], ["C548", "SIMPLE_CHEMICAL", 233, 237], ["NLRP3", "PROTEIN", 62, 67], ["AIM2", "PROTEIN", 101, 105], ["NLRC4", "PROTEIN", 110, 115], ["these studies", "TEST", 8, 21], ["NLRP3", "PROBLEM", 62, 67]]], ["This particular modification was also detected by Qin et al. using an itaconate-alkyne (iTALK) probe in Raw264.7 macrophages (Qin et al., 2020) .", [["Raw264.7 macrophages", "ANATOMY", 104, 124], ["itaconate-alkyne", "CHEMICAL", 70, 86], ["itaconate", "CHEMICAL", 70, 79], ["alkyne", "CHEMICAL", 80, 86], ["iTALK", "CHEMICAL", 88, 93], ["itaconate-alkyne", "SIMPLE_CHEMICAL", 70, 86], ["iTALK", "SIMPLE_CHEMICAL", 88, 93], ["Raw264.7 macrophages", "CELL", 104, 124], ["itaconate-alkyne (iTALK) probe", "DNA", 70, 100], ["Raw264.7 macrophages", "CELL_LINE", 104, 124], ["an itaconate-alkyne (iTALK) probe", "TREATMENT", 67, 100]]], ["It is possible that modification of NLRP3 at this surface would abolish its ability to interact with NEK7, a process that is necessary for inflammasome activation to take place (Sharif et al., 2019) .", [["surface", "ANATOMY", 50, 57], ["NLRP3", "GENE_OR_GENE_PRODUCT", 36, 41], ["surface", "CELLULAR_COMPONENT", 50, 57], ["NEK7", "GENE_OR_GENE_PRODUCT", 101, 105], ["NLRP3", "PROTEIN", 36, 41], ["NEK7", "PROTEIN", 101, 105], ["NLRP3", "TREATMENT", 36, 41], ["inflammasome activation", "PROBLEM", 139, 162]]], ["However, further studies are required to establish (1) whether endogenous itaconate, as well as 4-OI, can cause the same modification-the study by Qin et al. indicates that this might be the case (Qin et al., 2020); (2) whether modification at this surface is functionally relevant with regard to inflammasome activation; and (3) whether there may be other targets for dicarboxypropylation along this pathway.", [["surface", "ANATOMY", 249, 256], ["itaconate", "CHEMICAL", 74, 83], ["itaconate", "CHEMICAL", 74, 83], ["4-OI", "CHEMICAL", 96, 100], ["itaconate", "SIMPLE_CHEMICAL", 74, 83], ["surface", "CELLULAR_COMPONENT", 249, 256], ["further studies", "TEST", 9, 24], ["the study", "TEST", 134, 143], ["inflammasome activation", "PROBLEM", 297, 320], ["dicarboxypropylation", "TREATMENT", 369, 389], ["this pathway", "TREATMENT", 396, 408]]], ["Qin et al. also detected ''itaconation sites'' on gasdermin D, the pyroptosis executioner (Qin et al., 2020), further emphasizing the inhibitory effect of itaconate on pyroptosis.", [["pyroptosis", "DISEASE", 67, 77], ["itaconate", "CHEMICAL", 155, 164], ["pyroptosis", "DISEASE", 168, 178], ["gasdermin D", "CHEMICAL", 50, 61], ["itaconate", "CHEMICAL", 155, 164], ["gasdermin D", "SIMPLE_CHEMICAL", 50, 61], ["itaconate", "SIMPLE_CHEMICAL", 155, 164], ["''itaconation sites", "PROBLEM", 25, 44], ["the pyroptosis executioner", "PROBLEM", 63, 89], ["itaconate", "TREATMENT", 155, 164], ["pyroptosis", "PROBLEM", 168, 178], ["pyroptosis", "OBSERVATION", 67, 77], ["pyroptosis", "OBSERVATION", 168, 178]]], ["In addition, the recent observation that NEK7 deglutathionylation of C253 promotes NLRP3 inflammasome activation (Hughes et al., 2019) demonstrates that post-transcriptional modifications of NEK7 are also important in regulating inflammasome function.DISCUSSIONOur observation that unmodified itaconic acid can limit NLRP3 activation is important when comparing the compounds widely used to deliver itaconate intracellularly.", [["C253", "CHEMICAL", 69, 73], ["itaconic acid", "CHEMICAL", 293, 306], ["itaconate", "CHEMICAL", 399, 408], ["itaconic acid", "CHEMICAL", 293, 306], ["itaconate", "CHEMICAL", 399, 408], ["NEK7", "GENE_OR_GENE_PRODUCT", 41, 45], ["C253", "GENE_OR_GENE_PRODUCT", 69, 73], ["NLRP3", "GENE_OR_GENE_PRODUCT", 83, 88], ["NEK7", "GENE_OR_GENE_PRODUCT", 191, 195], ["itaconic acid", "SIMPLE_CHEMICAL", 293, 306], ["NLRP3", "GENE_OR_GENE_PRODUCT", 317, 322], ["itaconate", "SIMPLE_CHEMICAL", 399, 408], ["NLRP3", "PROTEIN", 83, 88], ["NEK7", "PROTEIN", 191, 195], ["NLRP3", "PROTEIN", 317, 322], ["post-transcriptional modifications of NEK7", "PROBLEM", 153, 195], ["unmodified itaconic acid", "TREATMENT", 282, 306], ["NLRP3 activation", "TREATMENT", 317, 333], ["itaconate intracellularly", "TREATMENT", 399, 424], ["post-transcriptional modifications", "OBSERVATION", 153, 187]]], ["There has been a focus on how unmodified and derivatized itaconate diverge in their ability to accumulate inside the cell and exert immunomodulatory functions (Swain et al., 2020) .", [["cell", "ANATOMY", 117, 121], ["itaconate", "CHEMICAL", 57, 66], ["itaconate", "CHEMICAL", 57, 66], ["itaconate", "SIMPLE_CHEMICAL", 57, 66], ["cell", "CELL", 117, 121], ["cell", "ANATOMY", 117, 121]]], ["However, we demonstrated that 13 C 5 -labeled octyl itaconate was converted into 13 C 5 itaconate intracellularly and also found consistency in the way 4-OI and itaconic acid inhibited NLRP3 inflammasome activation.", [["C 5 -labeled octyl itaconate", "CHEMICAL", 33, 61], ["C 5 itaconate", "CHEMICAL", 84, 97], ["itaconic acid", "CHEMICAL", 161, 174], ["13 C", "CHEMICAL", 30, 34], ["octyl itaconate", "CHEMICAL", 46, 61], ["4-OI", "CHEMICAL", 152, 156], ["itaconic acid", "CHEMICAL", 161, 174], ["13 C 5 -labeled octyl itaconate", "SIMPLE_CHEMICAL", 30, 61], ["13 C 5 itaconate", "SIMPLE_CHEMICAL", 81, 97], ["4-OI", "SIMPLE_CHEMICAL", 152, 156], ["itaconic acid", "SIMPLE_CHEMICAL", 161, 174], ["NLRP3", "GENE_OR_GENE_PRODUCT", 185, 190], ["NLRP3", "PROTEIN", 185, 190], ["labeled octyl itaconate", "TREATMENT", 38, 61], ["OI", "PROBLEM", 154, 156], ["itaconic acid", "PROBLEM", 161, 174], ["NLRP3 inflammasome activation", "TREATMENT", 185, 214], ["inflammasome activation", "OBSERVATION", 191, 214]]], ["In contrast to the view of Swain et al. (2020) , we feel that 4-OI can be used as a tool compound in the study of itaconate, since we have shown that it can be taken up and converted to intracellular itaconate by macrophages.", [["intracellular", "ANATOMY", 186, 199], ["macrophages", "ANATOMY", 213, 224], ["itaconate", "CHEMICAL", 114, 123], ["4-OI", "CHEMICAL", 62, 66], ["itaconate", "CHEMICAL", 114, 123], ["itaconate", "CHEMICAL", 200, 209], ["4-OI", "SIMPLE_CHEMICAL", 62, 66], ["itaconate", "SIMPLE_CHEMICAL", 114, 123], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 186, 199], ["itaconate", "SIMPLE_CHEMICAL", 200, 209], ["macrophages", "CELL", 213, 224], ["macrophages", "CELL_TYPE", 213, 224], ["OI", "PROBLEM", 64, 66], ["the study", "TEST", 101, 110], ["itaconate", "TREATMENT", 114, 123]]], ["We have previously also demonstrated that there is significant overlap in the cysteine (45 min) induced IL-1b release (A, n = 6) and LDH release (B) in wild-type (WT, n = 7) and Irg1 \u00c0/\u00c0 (n = 8) BMDMs.", [["BMDMs", "ANATOMY", 195, 200], ["cysteine", "CHEMICAL", 78, 86], ["cysteine", "CHEMICAL", 78, 86], ["cysteine", "SIMPLE_CHEMICAL", 78, 86], ["IL-1b", "GENE_OR_GENE_PRODUCT", 104, 109], ["LDH", "GENE_OR_GENE_PRODUCT", 133, 136], ["BMDMs", "CELL", 195, 200], ["IL", "PROTEIN", 104, 106], ["LDH", "PROTEIN", 133, 136], ["BMDMs", "CELL_TYPE", 195, 200], ["significant overlap in the cysteine", "PROBLEM", 51, 86], ["LDH release", "TEST", 133, 144], ["WT", "TEST", 163, 165], ["Irg1", "TEST", 178, 182], ["BMDMs", "PROBLEM", 195, 200], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["overlap", "OBSERVATION", 63, 70]]], ["(C and D) Immunoblot analysis (C) and quantification by densitometry (D, n = 4) of pro-and mature caspase-1 and IL-1b protein in lysates and supernatants of wild-type (WT) and Irg1 \u00c0/\u00c0 BMDMs treated with LPS (3 h) and nigericin (45 min).", [["lysates", "ANATOMY", 129, 136], ["supernatants", "ANATOMY", 141, 153], ["BMDMs", "ANATOMY", 185, 190], ["LPS", "CHEMICAL", 204, 207], ["nigericin", "CHEMICAL", 218, 227], ["nigericin", "CHEMICAL", 218, 227], ["caspase-1", "GENE_OR_GENE_PRODUCT", 98, 107], ["IL-1b", "GENE_OR_GENE_PRODUCT", 112, 117], ["lysates", "ORGANISM_SUBSTANCE", 129, 136], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL", 176, 190], ["LPS", "SIMPLE_CHEMICAL", 204, 207], ["nigericin", "SIMPLE_CHEMICAL", 218, 227], ["pro-and mature caspase-1 and IL-1b protein", "PROTEIN", 83, 125], ["Irg1 \u00c0/\u00c0 BMDMs", "CELL_LINE", 176, 190], ["Immunoblot analysis", "TEST", 10, 29], ["quantification", "TEST", 38, 52], ["densitometry", "TEST", 56, 68], ["D", "TEST", 70, 71], ["caspase", "TEST", 98, 105], ["IL", "TEST", 112, 114], ["lysates", "TEST", 129, 136], ["supernatants", "TEST", 141, 153], ["WT", "TEST", 168, 170], ["Irg1", "TEST", 176, 180], ["BMDMs", "PROBLEM", 185, 190], ["LPS", "TREATMENT", 204, 207], ["nigericin", "TREATMENT", 218, 227]]], ["(E) IL-1b release from NLRP3 inflammasome-reconstituted HEK293T cells treated with nigericin (45 min) (n = 3).", [["HEK293T cells", "ANATOMY", 56, 69], ["nigericin", "CHEMICAL", 83, 92], ["nigericin", "CHEMICAL", 83, 92], ["IL-1b", "GENE_OR_GENE_PRODUCT", 4, 9], ["NLRP3", "GENE_OR_GENE_PRODUCT", 23, 28], ["HEK293T cells", "CELL", 56, 69], ["nigericin", "SIMPLE_CHEMICAL", 83, 92], ["NLRP3 inflammasome", "PROTEIN", 23, 41], ["HEK293T cells", "CELL_LINE", 56, 69], ["NLRP3 inflammasome", "TREATMENT", 23, 41], ["nigericin", "TREATMENT", 83, 92]]], ["Immunoblot analysis of pro-and mature IL-1b and IRG1 protein in supernatants and lysates of these cells.", [["supernatants", "ANATOMY", 64, 76], ["lysates", "ANATOMY", 81, 88], ["cells", "ANATOMY", 98, 103], ["IL-1b", "GENE_OR_GENE_PRODUCT", 38, 43], ["IRG1", "GENE_OR_GENE_PRODUCT", 48, 52], ["lysates", "ORGANISM_SUBSTANCE", 81, 88], ["cells", "CELL", 98, 103], ["pro-and mature IL-1b", "PROTEIN", 23, 43], ["IRG1 protein", "PROTEIN", 48, 60], ["Immunoblot analysis", "TEST", 0, 19], ["pro-and mature IL", "TEST", 23, 40], ["IRG1 protein in supernatants", "TREATMENT", 48, 76]]], ["(F) Endogenous co-immunoprecipitation of NLRP3 and NEK7 in BMDMs treated with LPS (3 h) and nigericin (45 min) \u00b1 4-OI (250 mM).", [["BMDMs", "ANATOMY", 59, 64], ["LPS", "CHEMICAL", 78, 81], ["nigericin", "CHEMICAL", 92, 101], ["nigericin", "CHEMICAL", 92, 101], ["4-OI", "CHEMICAL", 113, 117], ["NLRP3", "GENE_OR_GENE_PRODUCT", 41, 46], ["NEK7", "GENE_OR_GENE_PRODUCT", 51, 55], ["BMDMs", "CELL", 59, 64], ["LPS", "SIMPLE_CHEMICAL", 78, 81], ["nigericin", "SIMPLE_CHEMICAL", 92, 101], ["4-OI", "SIMPLE_CHEMICAL", 113, 117], ["NLRP3", "PROTEIN", 41, 46], ["NEK7", "PROTEIN", 51, 55], ["BMDMs", "CELL_TYPE", 59, 64], ["NLRP3", "PROBLEM", 41, 46], ["LPS", "TREATMENT", 78, 81], ["nigericin", "TREATMENT", 92, 101]]], ["(G) Tandem mass spectrometry spectrum of C548-containing NLRP3 peptide following 4-OI treatment (250 mM, 24 h). p < 0.001.", [["4-OI", "CHEMICAL", 81, 85], ["C548", "CHEMICAL", 41, 45], ["4-OI", "CHEMICAL", 81, 85], ["C548", "SIMPLE_CHEMICAL", 41, 45], ["NLRP3", "GENE_OR_GENE_PRODUCT", 57, 62], ["4-OI", "SIMPLE_CHEMICAL", 81, 85], ["NLRP3", "PROTEIN", 57, 62], ["Tandem mass spectrometry spectrum", "TEST", 4, 37], ["C548", "TEST", 41, 45], ["NLRP3 peptide", "TREATMENT", 57, 70], ["4-OI treatment", "TREATMENT", 81, 95]]], ["Blots are representative of a minimum of 3 independent experiments. residues alkylated by 4-OI and endogenous itaconate (Mills et al., 2018) .", [["4-OI", "CHEMICAL", 90, 94], ["itaconate", "CHEMICAL", 110, 119], ["4-OI", "CHEMICAL", 90, 94], ["itaconate", "CHEMICAL", 110, 119], ["4-OI", "SIMPLE_CHEMICAL", 90, 94], ["itaconate", "SIMPLE_CHEMICAL", 110, 119]]], ["In spite of this, it must be acknowledged that the relative electrophilicity of 4-OI/DMI, and therefore its ability to impact certain pathways (such as the ATF3-IKBz axis), is higher than that of unmodified itaconate (Swain et al., 2020) .", [["4-OI", "CHEMICAL", 80, 84], ["DMI", "CHEMICAL", 85, 88], ["itaconate", "CHEMICAL", 207, 216], ["4-OI", "CHEMICAL", 80, 84], ["DMI", "CHEMICAL", 85, 88], ["itaconate", "CHEMICAL", 207, 216], ["4-OI", "SIMPLE_CHEMICAL", 80, 84], ["DMI", "SIMPLE_CHEMICAL", 85, 88], ["ATF3", "GENE_OR_GENE_PRODUCT", 156, 160], ["itaconate", "SIMPLE_CHEMICAL", 207, 216], ["ATF3", "PROTEIN", 156, 160], ["IKBz", "PROTEIN", 161, 165], ["DMI", "PROBLEM", 85, 88], ["the ATF3", "TEST", 152, 160], ["higher", "OBSERVATION_MODIFIER", 176, 182]]], ["As such, any results obtained with these derivatives must be verified in Irg1 \u00c0/\u00c0 experiments in order to be considered attributable to itaconate.DISCUSSIONOur studies performed in Irg1 \u00c0/\u00c0 macrophages have shown that an absence of endogenous itaconate results in dysregulated IL-1b release and increased pyroptosis, establishing the importance of the itaconate-NLRP3 axis in restraining macrophage inflammation.", [["Irg1 \u00c0/\u00c0 macrophages", "ANATOMY", 181, 201], ["macrophage", "ANATOMY", 388, 398], ["itaconate", "CHEMICAL", 136, 145], ["itaconate", "CHEMICAL", 243, 252], ["pyroptosis", "DISEASE", 305, 315], ["inflammation", "DISEASE", 399, 411], ["itaconate", "CHEMICAL", 136, 145], ["itaconate", "CHEMICAL", 243, 252], ["itaconate", "CHEMICAL", 352, 361], ["itaconate", "SIMPLE_CHEMICAL", 136, 145], ["Irg1 \u00c0/\u00c0 macrophages", "CELL", 181, 201], ["itaconate", "SIMPLE_CHEMICAL", 243, 252], ["IL-1b", "GENE_OR_GENE_PRODUCT", 277, 282], ["itaconate", "SIMPLE_CHEMICAL", 352, 361], ["NLRP3", "GENE_OR_GENE_PRODUCT", 362, 367], ["macrophage", "CELL", 388, 398], ["Irg1 \u00c0/\u00c0 macrophages", "CELL_LINE", 181, 201], ["IL-1b", "PROTEIN", 277, 282], ["NLRP3", "PROTEIN", 362, 367], ["these derivatives", "TEST", 35, 52], ["itaconate", "TREATMENT", 136, 145], ["DISCUSSIONOur studies", "TEST", 146, 167], ["dysregulated IL", "PROBLEM", 264, 279], ["increased pyroptosis", "PROBLEM", 295, 315], ["the itaconate-NLRP3 axis", "TREATMENT", 348, 372], ["restraining macrophage inflammation", "PROBLEM", 376, 411], ["increased", "OBSERVATION_MODIFIER", 295, 304], ["pyroptosis", "OBSERVATION", 305, 315], ["macrophage inflammation", "OBSERVATION", 388, 411]]], ["Evidence suggests that, at least in the context of NLRP3 inflammasome activation, the presence of itaconate would limit pathogenic inflammation and resulting damage to the host.", [["itaconate", "CHEMICAL", 98, 107], ["inflammation", "DISEASE", 131, 143], ["itaconate", "CHEMICAL", 98, 107], ["NLRP3", "GENE_OR_GENE_PRODUCT", 51, 56], ["itaconate", "SIMPLE_CHEMICAL", 98, 107], ["NLRP3", "PROTEIN", 51, 56], ["NLRP3 inflammasome activation", "PROBLEM", 51, 80], ["itaconate", "TREATMENT", 98, 107], ["pathogenic inflammation", "PROBLEM", 120, 143], ["resulting damage to the host", "PROBLEM", 148, 176], ["NLRP3", "OBSERVATION", 51, 56], ["inflammasome activation", "OBSERVATION", 57, 80]]], ["Recent studies showed that plasma itaconate levels correlated with improved disease score and reduced severity in patients with rheumatoid arthritis (Daly et al., 2020) and COVID-19 (Song et al., 2020) , respectively.", [["plasma", "ANATOMY", 27, 33], ["itaconate", "CHEMICAL", 34, 43], ["rheumatoid arthritis", "DISEASE", 128, 148], ["itaconate", "CHEMICAL", 34, 43], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["itaconate", "SIMPLE_CHEMICAL", 34, 43], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["Recent studies", "TEST", 0, 14], ["plasma itaconate levels", "TEST", 27, 50], ["improved disease score", "PROBLEM", 67, 89], ["reduced severity", "PROBLEM", 94, 110], ["rheumatoid arthritis", "PROBLEM", 128, 148], ["COVID", "TEST", 173, 178], ["improved", "OBSERVATION_MODIFIER", 67, 75], ["disease", "OBSERVATION", 76, 83], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["severity", "OBSERVATION_MODIFIER", 102, 110], ["rheumatoid arthritis", "OBSERVATION", 128, 148]]], ["These studies add further weight to the concept that itaconate is a critical determinant of innate immune responses, with profound anti-inflammatory effects.DISCUSSIONIn conclusion, our work provides evidence for the regulation of NLRP3 by itaconate.", [["itaconate", "CHEMICAL", 53, 62], ["itaconate", "CHEMICAL", 240, 249], ["itaconate", "CHEMICAL", 53, 62], ["itaconate", "CHEMICAL", 240, 249], ["itaconate", "SIMPLE_CHEMICAL", 53, 62], ["NLRP3", "GENE_OR_GENE_PRODUCT", 231, 236], ["itaconate", "SIMPLE_CHEMICAL", 240, 249], ["NLRP3", "PROTEIN", 231, 236], ["These studies", "TEST", 0, 13], ["profound anti-inflammatory effects", "TREATMENT", 122, 156], ["NLRP3", "TREATMENT", 231, 236], ["anti-inflammatory effects", "OBSERVATION", 131, 156]]], ["Furthermore, in 4-OI we present a ll Short Article compound that may be developed further for the treatment of NLRP3-driven disorders, as evidenced by its effect on IL-1b release from CAPS PBMCs.", [["PBMCs", "ANATOMY", 189, 194], ["NLRP3", "GENE_OR_GENE_PRODUCT", 111, 116], ["IL-1b", "GENE_OR_GENE_PRODUCT", 165, 170], ["CAPS PBMCs", "CELL", 184, 194], ["NLRP3", "PROTEIN", 111, 116], ["CAPS PBMCs", "CELL_TYPE", 184, 194], ["a ll Short Article compound", "PROBLEM", 32, 59], ["NLRP3", "TREATMENT", 111, 116], ["driven disorders", "PROBLEM", 117, 133], ["IL", "TREATMENT", 165, 167], ["CAPS PBMCs", "TREATMENT", 184, 194]]], ["The targeting of NLRP3 by itaconate therefore holds tremendous therapeutic potential and expands the role of itaconate as a key immunometabolite that regulates innate immunity and inflammation.Limitations of StudyOur study has demonstrated that 4-OI modifies C548 of NLRP3, a mechanism that is likely to be responsible for itaconate-mediated inhibition of inflammasome activation.", [["itaconate", "CHEMICAL", 26, 35], ["itaconate", "CHEMICAL", 109, 118], ["inflammation", "DISEASE", 180, 192], ["itaconate", "CHEMICAL", 323, 332], ["itaconate", "CHEMICAL", 26, 35], ["itaconate", "CHEMICAL", 109, 118], ["4-OI", "CHEMICAL", 245, 249], ["itaconate", "CHEMICAL", 323, 332], ["NLRP3", "GENE_OR_GENE_PRODUCT", 17, 22], ["itaconate", "SIMPLE_CHEMICAL", 26, 35], ["itaconate", "SIMPLE_CHEMICAL", 109, 118], ["4-OI", "SIMPLE_CHEMICAL", 245, 249], ["NLRP3", "GENE_OR_GENE_PRODUCT", 267, 272], ["itaconate", "SIMPLE_CHEMICAL", 323, 332], ["NLRP3", "PROTEIN", 17, 22], ["NLRP3", "PROTEIN", 267, 272], ["NLRP3", "TREATMENT", 17, 22], ["itaconate", "TREATMENT", 26, 35], ["itaconate", "TREATMENT", 109, 118], ["inflammation", "PROBLEM", 180, 192], ["StudyOur study", "TEST", 208, 222], ["NLRP3", "TREATMENT", 267, 272], ["inflammasome activation", "PROBLEM", 356, 379], ["inflammation", "OBSERVATION", 180, 192], ["is likely to be responsible", "UNCERTAINTY", 291, 318], ["inflammasome activation", "OBSERVATION", 356, 379]]], ["However, further studies are required to demonstrate the functional effects of this modification, perhaps through site-directed mutagenesis of C548.STAR+METHODSDetailed methods are provided in the online version of this paper and include the following: Ghayur, T., Banerjee, S., Hugunin, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., Talanian, R., Paskind, M., et al. (1997) .", [["C548", "CHEMICAL", 143, 147], ["further studies", "TEST", 9, 24], ["this modification", "TREATMENT", 79, 96], ["Herzog", "ANATOMY", 304, 310], ["L.", "ANATOMY", 312, 314], ["R.", "ANATOMY", 362, 364]]], ["Caspase-1 processes IFNgamma-inducing factor and regulates LPS-induced IFN-gamma production.", [["LPS", "CHEMICAL", 59, 62], ["Caspase-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["IFNgamma-inducing factor", "GENE_OR_GENE_PRODUCT", 20, 44], ["LPS", "SIMPLE_CHEMICAL", 59, 62], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 71, 80], ["IFNgamma", "PROTEIN", 20, 28], ["inducing factor", "PROTEIN", 29, 44], ["IFN", "PROTEIN", 71, 74], ["Caspase", "TEST", 0, 7], ["IFNgamma", "TEST", 20, 28], ["LPS", "TEST", 59, 62], ["gamma production", "PROBLEM", 75, 91]]], ["Nature 386, 619-623.STAR+METHODSGro\u00df, C.J., Mishra, R., Schneider, K.S., M\u00e9 dard, G., Wettmarshausen, J., Dittlein, D.C., Shi, H., Gorka, O., Koenig, P.A., Fromm, S., et al. (2016) .", [["R.", "ANATOMY", 52, 54], ["Schneider", "ANATOMY", 56, 65]]], ["K + efflux-independent NLRP3 inflammasome activation by small molecules targeting mitochondria.", [["mitochondria", "ANATOMY", 82, 94], ["K", "CHEMICAL", 0, 1], ["K +", "CHEMICAL", 0, 3], ["K +", "SIMPLE_CHEMICAL", 0, 3], ["NLRP3", "GENE_OR_GENE_PRODUCT", 23, 28], ["mitochondria", "CELLULAR_COMPONENT", 82, 94], ["NLRP3", "PROTEIN", 23, 28], ["K", "TEST", 0, 1], ["efflux", "TEST", 4, 10], ["NLRP3 inflammasome activation", "TREATMENT", 23, 52], ["small molecules targeting mitochondria", "PROBLEM", 56, 94], ["efflux", "OBSERVATION_MODIFIER", 4, 10], ["NLRP3 inflammasome", "OBSERVATION", 23, 41], ["small molecules", "OBSERVATION", 56, 71]]], ["Goutassociated uric acid crystals activate the NALP3 inflammasome.", [["uric acid", "CHEMICAL", 15, 24], ["uric acid", "CHEMICAL", 15, 24], ["uric acid", "SIMPLE_CHEMICAL", 15, 24], ["NALP3", "GENE_OR_GENE_PRODUCT", 47, 52], ["NALP3 inflammasome", "PROTEIN", 47, 65], ["Goutassociated uric acid crystals", "PROBLEM", 0, 33], ["the NALP3 inflammasome", "PROBLEM", 43, 65], ["uric acid", "OBSERVATION", 15, 24], ["NALP3 inflammasome", "OBSERVATION", 47, 65]]], ["Nature 440, 237-241.STAR+METHODSMasters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) .", [["Franchi", "ANATOMY", 131, 138]]], ["Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes.", [["type 2 diabetes", "DISEASE", 109, 124], ["NLRP3", "GENE_OR_GENE_PRODUCT", 18, 23], ["islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 40, 65], ["IL-1b", "GENE_OR_GENE_PRODUCT", 100, 105], ["NLRP3 inflammasome", "PROTEIN", 18, 36], ["IL-1b", "PROTEIN", 100, 105], ["the NLRP3 inflammasome", "TREATMENT", 14, 36], ["islet amyloid polypeptide", "TREATMENT", 40, 65], ["type 2 diabetes", "PROBLEM", 109, 124], ["diabetes", "OBSERVATION", 116, 124]]], ["Immunol.", [["Immunol", "CHEMICAL", 0, 7], ["Immunol", "SIMPLE_CHEMICAL", 0, 7], ["Immunol", "TREATMENT", 0, 7]]], ["Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production.", [["itaconic acid", "CHEMICAL", 76, 89], ["itaconic acid", "CHEMICAL", 76, 89], ["Immune-responsive gene 1", "GENE_OR_GENE_PRODUCT", 0, 24], ["itaconic acid", "SIMPLE_CHEMICAL", 76, 89], ["Immune-responsive gene 1 protein", "PROTEIN", 0, 32], ["Immune", "TEST", 0, 6], ["itaconic acid production", "PROBLEM", 76, 100], ["itaconic acid", "OBSERVATION", 76, 89]]], ["Natl.", [["Natl", "CHEMICAL", 0, 4]]], ["Puchalska, P., Huang, X., Martin, S.E., Han, X., Patti, G.J., and Crawford, P.A. (2018) .", [["Huang", "ANATOMY", 15, 20]]], ["Isotope tracing untargeted metabolomics reveals macrophage polarization-state-specific metabolic coordination across intracellular compartments. iScience 9, 298-313.STAR+METHODSQin, W., Qin, K., Zhang, Y., Jia, W., Chen, Y., Cheng, B., Peng, L., Chen, N., Liu, Y., Zhou, W., et al. (2019) .", [["macrophage", "ANATOMY", 48, 58], ["intracellular compartments", "ANATOMY", 117, 143], ["iScience 9, 298-313", "CHEMICAL", 145, 164], ["macrophage", "CELL", 48, 58], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["Isotope tracing untargeted metabolomics", "TEST", 0, 39], ["macrophage polarization", "TEST", 48, 71], ["macrophage polarization", "OBSERVATION", 48, 71], ["metabolic coordination", "OBSERVATION", 87, 109], ["intracellular compartments", "OBSERVATION", 117, 143], ["L.", "OBSERVATION_MODIFIER", 242, 244]]], ["S-glycosylation-based cysteine profiling reveals regulation of glycolysis by itaconate.", [["cysteine", "CHEMICAL", 22, 30], ["itaconate", "CHEMICAL", 77, 86], ["cysteine", "CHEMICAL", 22, 30], ["itaconate", "CHEMICAL", 77, 86], ["cysteine", "AMINO_ACID", 22, 30], ["itaconate", "SIMPLE_CHEMICAL", 77, 86], ["glycosylation", "TREATMENT", 2, 15], ["based cysteine profiling", "TEST", 16, 40]]], ["Chem.", [["Chem", "TEST", 0, 4]]], ["15, 983-991.STAR+METHODSQin, W., Zhang, Y., Tang, H., Liu, D., Chen, Y., Liu, Y., and Wang, C. (2020) . mice and their wild-type counterparts were kindly provided by Professor Ed Lavelle (Trinity College Dublin).", [["mice", "ORGANISM", 104, 108], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108]]], ["In vivo models were performed with 6-week old female C57BL/6J mice and littermates were randomly assigned to experimental groups.", [["C57BL/6J mice", "ORGANISM", 53, 66], ["littermates", "ORGANISM", 71, 82], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66]]], ["Animals were maintained under specific pathogen-free conditions in line with Irish and European Union regulations.", [["Animals", "ORGANISM", 0, 7]]], ["All animal procedures were ethically approved by the Trinity College Dublin Animal Research Ethics Committee prior to experimentation, and conformed with the Directive 2010/63/EU of the European Parliament.STAR+METHODSGeneration of Murine BMDMs 6-12-week old mice were euthanised in a CO 2 chamber, and death was confirmed by cervical dislocation.", [["cervical", "ANATOMY", 326, 334], ["death", "DISEASE", 303, 308], ["cervical dislocation", "DISEASE", 326, 346], ["STAR", "GENE_OR_GENE_PRODUCT", 206, 210], ["Murine", "ORGANISM", 232, 238], ["mice", "ORGANISM", 259, 263], ["cervical", "ORGAN", 326, 334], ["Murine", "SPECIES", 232, 238], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["Murine BMDMs", "TEST", 232, 244], ["death", "PROBLEM", 303, 308], ["cervical dislocation", "PROBLEM", 326, 346], ["cervical", "ANATOMY", 326, 334], ["dislocation", "OBSERVATION", 335, 346]]], ["Bone marrow was subsequently harvested from the tibia and fibula and cells were differentiated in DMEM containing L929 supernatant (10%), fetal calf serum (FCS) (10%), and penicillin/streptomycin (1%) for 6 days, after which cells were counted and plated at 0.5 3 10 6 cells/mL unless otherwise stated.CAPS Patient RecruitmentRecruitment was carried out by members of the patient's own clinical team.", [["Bone marrow", "ANATOMY", 0, 11], ["tibia", "ANATOMY", 48, 53], ["fibula", "ANATOMY", 58, 64], ["cells", "ANATOMY", 69, 74], ["L929 supernatant", "ANATOMY", 114, 130], ["fetal calf serum", "ANATOMY", 138, 154], ["cells", "ANATOMY", 225, 230], ["cells", "ANATOMY", 269, 274], ["penicillin", "CHEMICAL", 172, 182], ["streptomycin", "CHEMICAL", 183, 195], ["penicillin", "CHEMICAL", 172, 182], ["streptomycin", "CHEMICAL", 183, 195], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 0, 11], ["tibia", "ORGAN", 48, 53], ["fibula", "ORGAN", 58, 64], ["cells", "CELL", 69, 74], ["L929 supernatant", "CELL", 114, 130], ["fetal calf", "ORGANISM_SUBSTANCE", 138, 148], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["FCS", "ORGANISM_SUBSTANCE", 156, 159], ["penicillin", "SIMPLE_CHEMICAL", 172, 182], ["streptomycin", "SIMPLE_CHEMICAL", 183, 195], ["cells", "CELL", 225, 230], ["cells", "CELL", 269, 274], ["patient", "ORGANISM", 372, 379], ["calf", "SPECIES", 144, 148], ["Patient", "SPECIES", 307, 314], ["patient", "SPECIES", 372, 379], ["DMEM", "TEST", 98, 102], ["L929 supernatant", "TEST", 114, 130], ["fetal calf serum", "TEST", 138, 154], ["FCS", "TEST", 156, 159], ["penicillin/streptomycin", "TREATMENT", 172, 195], ["marrow", "ANATOMY", 5, 11], ["harvested", "OBSERVATION", 29, 38], ["tibia", "ANATOMY", 48, 53], ["fibula", "ANATOMY", 58, 64], ["calf", "ANATOMY", 144, 148]]], ["Patients were approached to provide a voluntary blood sample for the study.", [["blood sample", "ANATOMY", 48, 60], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["Patients", "SPECIES", 0, 8], ["a voluntary blood sample", "TEST", 36, 60], ["the study", "TEST", 65, 74]]], ["Patients were provided with an information leaflet 24 h in advance of sample donation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["sample donation", "TREATMENT", 70, 85]]], ["All patients or their parents/legal guardians gave informed written consent.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["Direct travel costs were covered but no incentive or compensation was offered.", [["Direct travel costs", "TREATMENT", 0, 19]]], ["Patient demographics were not recorded.", [["Patient", "SPECIES", 0, 7]]], ["Patients were receiving standard anti-IL-1 therapy (Anakinra).", [["Patients", "ORGANISM", 0, 8], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 33, 42], ["Anakinra", "SIMPLE_CHEMICAL", 52, 60], ["Patients", "SPECIES", 0, 8], ["standard anti-IL-1 therapy", "TREATMENT", 24, 50], ["Anakinra", "TREATMENT", 52, 60]]], ["This treatment was not discontinued prior to blood sampling.Isolation of Human PBMCsHuman blood samples from healthy donors were collected and processed at the School of Biochemistry and Immunology in TBSI (TCD).", [["blood", "ANATOMY", 45, 50], ["PBMCsHuman blood samples", "ANATOMY", 79, 103], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["Human", "ORGANISM", 73, 78], ["PBMCsHuman blood samples", "ORGANISM_SUBSTANCE", 79, 103], ["donors", "ORGANISM", 117, 123], ["Human", "SPECIES", 73, 78], ["Human", "SPECIES", 73, 78], ["This treatment", "TREATMENT", 0, 14], ["blood sampling", "TEST", 45, 59], ["Human PBMCsHuman blood samples", "TREATMENT", 73, 103]]], ["Blood samples were obtained anonymously and written informed consent for the use of blood for research purposes has been obtained from the donors.", [["Blood samples", "ANATOMY", 0, 13], ["blood", "ANATOMY", 84, 89], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["donors", "ORGANISM", 139, 145], ["Blood samples", "TEST", 0, 13], ["research purposes", "TEST", 94, 111]]], ["All the procedures involving experiments on human samples have been approved by the School of Biochemistry and Immunology Research Ethics Committee (TCD).", [["samples", "ANATOMY", 50, 57], ["human", "ORGANISM", 44, 49], ["samples", "CANCER", 50, 57], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49]]], ["30 mL whole blood was layered on 20 mL Lymphoprep (Axis-Shield), followed by centrifugation for 20 min at 400 x g with the brake off, after which the upper plasma layer was removed and discarded.", [["whole blood", "ANATOMY", 6, 17], ["plasma layer", "ANATOMY", 156, 168], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["Lymphoprep", "SIMPLE_CHEMICAL", 39, 49], ["upper", "ORGANISM_SUBSTANCE", 150, 155], ["plasma layer", "ORGANISM_SUBSTANCE", 156, 168], ["20 mL Lymphoprep (Axis-Shield)", "TREATMENT", 33, 63], ["the upper plasma layer", "TREATMENT", 146, 168], ["upper", "ANATOMY_MODIFIER", 150, 155]]], ["The layer of mononuclear cells at the plasma-density gradient medium interface was retained, and 20 mL PBS was added.", [["mononuclear cells", "ANATOMY", 13, 30], ["plasma", "ANATOMY", 38, 44], ["mononuclear cells", "CELL", 13, 30], ["plasma", "ORGANISM_SUBSTANCE", 38, 44], ["mononuclear cells", "CELL_TYPE", 13, 30], ["the plasma-density gradient medium interface", "TREATMENT", 34, 78], ["20 mL PBS", "TREATMENT", 97, 106], ["layer", "OBSERVATION_MODIFIER", 4, 9], ["mononuclear cells", "OBSERVATION", 13, 30], ["plasma", "OBSERVATION_MODIFIER", 38, 44], ["density", "OBSERVATION_MODIFIER", 45, 52], ["gradient", "OBSERVATION_MODIFIER", 53, 61], ["medium interface", "OBSERVATION", 62, 78], ["retained", "OBSERVATION_MODIFIER", 83, 91]]], ["Cells were centrifuged for 8 min at 300 x g and the resulting supernatant was removed and discarded.", [["Cells", "ANATOMY", 0, 5], ["supernatant", "ANATOMY", 62, 73], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["The remaining pellet of mononuclear cells was resuspended, counted and plated at 1 3 10 6 cells/mL in RPMI supplemented with FCS (10%) and penicillin-streptomycin (1%).Human Monocyte DifferentiationFrozen human monocytes (Biological Specialty Labs) were thawed and seeded in 10 cm dishes at 1 3 10 6 cells/mL in macrophage media (RPMI media supplemented with 10% fetal calf serum and penicillin/streptomycin) and 0.1 mg/mL recombinant human M-CSF (Peprotech) and incubated at 37 C and 5% CO2.", [["mononuclear cells", "ANATOMY", 24, 41], ["cells", "ANATOMY", 90, 95], ["monocytes", "ANATOMY", 211, 220], ["cells", "ANATOMY", 300, 305], ["macrophage", "ANATOMY", 312, 322], ["fetal calf serum", "ANATOMY", 363, 379], ["FCS", "CHEMICAL", 125, 128], ["penicillin", "CHEMICAL", 139, 149], ["streptomycin", "CHEMICAL", 150, 162], ["penicillin", "CHEMICAL", 384, 394], ["streptomycin", "CHEMICAL", 395, 407], ["CO2", "CHEMICAL", 488, 491], ["penicillin", "CHEMICAL", 139, 149], ["streptomycin", "CHEMICAL", 150, 162], ["penicillin", "CHEMICAL", 384, 394], ["streptomycin", "CHEMICAL", 395, 407], ["CO2", "CHEMICAL", 488, 491], ["mononuclear cells", "CELL", 24, 41], ["cells", "CELL", 90, 95], ["FCS", "ORGANISM_SUBSTANCE", 125, 128], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 139, 162], ["Human", "ORGANISM", 168, 173], ["Monocyte", "CELL", 174, 182], ["human", "ORGANISM", 205, 210], ["monocytes", "CELL", 211, 220], ["macrophage", "CELL", 312, 322], ["calf", "ORGANISM", 369, 373], ["serum", "ORGANISM_SUBSTANCE", 374, 379], ["penicillin", "SIMPLE_CHEMICAL", 384, 394], ["streptomycin", "SIMPLE_CHEMICAL", 395, 407], ["human", "ORGANISM", 435, 440], ["M-CSF", "GENE_OR_GENE_PRODUCT", 441, 446], ["Peprotech", "GENE_OR_GENE_PRODUCT", 448, 457], ["CO2", "SIMPLE_CHEMICAL", 488, 491], ["mononuclear cells", "CELL_TYPE", 24, 41], ["Human Monocyte DifferentiationFrozen human monocytes", "CELL_LINE", 168, 220], ["CSF", "PROTEIN", 443, 446], ["Peprotech", "PROTEIN", 448, 457], ["Human", "SPECIES", 168, 173], ["human", "SPECIES", 205, 210], ["calf", "SPECIES", 369, 373], ["human", "SPECIES", 435, 440], ["Human", "SPECIES", 168, 173], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 435, 440], ["The remaining pellet of mononuclear cells", "TREATMENT", 0, 41], ["RPMI", "TEST", 102, 106], ["FCS", "TREATMENT", 125, 128], ["penicillin", "TREATMENT", 139, 149], ["streptomycin", "TREATMENT", 150, 162], ["Human Monocyte", "TEST", 168, 182], ["macrophage media", "TREATMENT", 312, 328], ["RPMI media", "TREATMENT", 330, 340], ["10% fetal calf serum", "TREATMENT", 359, 379], ["penicillin", "TREATMENT", 384, 394], ["streptomycin", "TREATMENT", 395, 407], ["pellet", "OBSERVATION_MODIFIER", 14, 20], ["mononuclear cells", "OBSERVATION", 24, 41], ["10 cm", "OBSERVATION_MODIFIER", 275, 280], ["calf", "ANATOMY", 369, 373]]], ["Cells were cultured for 6 days total to differentiate the monocytes to macrophages, with removal and replacement of media and M-CSF at three days of culture.Culture of HEK293T CellsHEK293T cells were obtained from the Centre for Applied Microbiology and Research (Wiltshire, UK) and cultured in DMEM containing FCS (10%) and penicillin-streptomycin (1%).METHOD DETAILSCanonical Inflammasome Assays BMDMs were plated in 12-well cell culture plates and left overnight to adhere.", [["Cells", "ANATOMY", 0, 5], ["monocytes", "ANATOMY", 58, 67], ["macrophages", "ANATOMY", 71, 82], ["HEK293T CellsHEK293T cells", "ANATOMY", 168, 194], ["BMDMs", "ANATOMY", 398, 403], ["cell", "ANATOMY", 427, 431], ["FCS", "CHEMICAL", 311, 314], ["penicillin", "CHEMICAL", 325, 335], ["streptomycin", "CHEMICAL", 336, 348], ["penicillin", "CHEMICAL", 325, 335], ["streptomycin", "CHEMICAL", 336, 348], ["Cells", "CELL", 0, 5], ["monocytes", "CELL", 58, 67], ["macrophages", "CELL", 71, 82], ["M-CSF", "GENE_OR_GENE_PRODUCT", 126, 131], ["HEK293T CellsHEK293T cells", "CELL", 168, 194], ["FCS", "ORGANISM_SUBSTANCE", 311, 314], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 325, 348], ["BMDMs", "CELL", 398, 403], ["cell", "CELL", 427, 431], ["monocytes", "CELL_TYPE", 58, 67], ["macrophages", "CELL_TYPE", 71, 82], ["HEK293T CellsHEK293T cells", "CELL_LINE", 168, 194], ["BMDMs", "CELL_TYPE", 398, 403], ["Cells", "TEST", 0, 5], ["removal", "TREATMENT", 89, 96], ["replacement of media", "TREATMENT", 101, 121], ["culture", "TEST", 149, 156], ["Culture", "TEST", 157, 164], ["HEK293T CellsHEK293T cells", "TEST", 168, 194], ["FCS", "TEST", 311, 314], ["penicillin", "TREATMENT", 325, 335], ["streptomycin", "TREATMENT", 336, 348], ["METHOD DETAILSCanonical Inflammasome Assays BMDMs", "TEST", 354, 403], ["monocytes", "ANATOMY", 58, 67], ["left", "ANATOMY_MODIFIER", 451, 455]]], ["Cells were treated the following day with LPS from Escherichia coli, serotype EH100 (Enzo Life Sciences, 100 ng/mL) for 3 h.", [["Cells", "ANATOMY", 0, 5], ["LPS", "CHEMICAL", 42, 45], ["Cells", "CELL", 0, 5], ["LPS", "SIMPLE_CHEMICAL", 42, 45], ["Escherichia coli", "ORGANISM", 51, 67], ["Escherichia coli", "SPECIES", 51, 67], ["Escherichia coli", "SPECIES", 51, 67], ["LPS", "TREATMENT", 42, 45], ["Escherichia coli", "PROBLEM", 51, 67], ["serotype EH100 (Enzo Life Sciences", "TREATMENT", 69, 103]]], ["Medium was removed and replaced with serum-and antibiotic-free medium and treated with compounds as required for 45 min.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["antibiotic", "SIMPLE_CHEMICAL", 47, 57], ["serum", "TEST", 37, 42], ["antibiotic-free medium", "TREATMENT", 47, 69]]], ["4-OI, 4-O-2-MS and 4-OS were kindly supplied by Professor Richard Hartley and dissolved in DMSO.", [["4-O-2-MS", "CHEMICAL", 6, 14], ["4-OS", "CHEMICAL", 19, 23], ["DMSO", "CHEMICAL", 91, 95], ["4-OI", "CHEMICAL", 0, 4], ["4-O-2-MS", "CHEMICAL", 6, 14], ["4-OS", "CHEMICAL", 19, 23], ["DMSO", "CHEMICAL", 91, 95], ["4-OI", "SIMPLE_CHEMICAL", 0, 4], ["4-O-2-MS", "SIMPLE_CHEMICAL", 6, 14], ["4-OS", "SIMPLE_CHEMICAL", 19, 23], ["DMSO", "SIMPLE_CHEMICAL", 91, 95]]], ["Itaconic acid (Sigma Aldrich) was dissolved at 500 mM in PBS and the required volume of NaOH was added in order to achieve a pH of 7.", [["Itaconic acid", "CHEMICAL", 0, 13], ["NaOH", "CHEMICAL", 88, 92], ["Itaconic acid", "CHEMICAL", 0, 13], ["NaOH", "CHEMICAL", 88, 92], ["Itaconic acid", "SIMPLE_CHEMICAL", 0, 13], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 15, 28], ["NaOH", "SIMPLE_CHEMICAL", 88, 92], ["Itaconic acid (Sigma Aldrich)", "TREATMENT", 0, 29], ["PBS", "TREATMENT", 57, 60], ["volume of NaOH", "TREATMENT", 78, 92], ["a pH", "TEST", 123, 127]]], ["Cells were treated with nigericin (10 mM, Invivogen) or ATP (5 mM, Sigma Aldrich) for 45 min to activate the NLRP3 inflammasome.", [["Cells", "ANATOMY", 0, 5], ["nigericin", "CHEMICAL", 24, 33], ["ATP", "CHEMICAL", 56, 59], ["nigericin", "CHEMICAL", 24, 33], ["Invivogen", "CHEMICAL", 42, 51], ["ATP", "CHEMICAL", 56, 59], ["Cells", "CELL", 0, 5], ["nigericin", "SIMPLE_CHEMICAL", 24, 33], ["Invivogen", "SIMPLE_CHEMICAL", 42, 51], ["ATP", "SIMPLE_CHEMICAL", 56, 59], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 67, 80], ["NLRP3", "GENE_OR_GENE_PRODUCT", 109, 114], ["NLRP3", "PROTEIN", 109, 114], ["nigericin", "TREATMENT", 24, 33], ["Invivogen", "TREATMENT", 42, 51], ["ATP", "TREATMENT", 56, 59], ["Sigma Aldrich)", "TREATMENT", 67, 81]]], ["In order to activate the AIM2 inflammasome, LPS-primed cells were transfected with 1.5 mg poly(dA:dT) (Invivogen) using lipofectamine 2000 (Thermo Fisher Scientific) for 6 h.", [["cells", "ANATOMY", 55, 60], ["LPS", "CHEMICAL", 44, 47], ["poly(dA:dT", "CHEMICAL", 90, 100], ["lipofectamine", "CHEMICAL", 120, 133], ["AIM2", "GENE_OR_GENE_PRODUCT", 25, 29], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["cells", "CELL", 55, 60], ["dA:dT", "SIMPLE_CHEMICAL", 95, 100], ["Invivogen", "SIMPLE_CHEMICAL", 103, 112], ["AIM2", "PROTEIN", 25, 29], ["LPS-primed cells", "CELL_LINE", 44, 60], ["the AIM2 inflammasome", "TREATMENT", 21, 42], ["LPS", "TEST", 44, 47], ["lipofectamine", "TREATMENT", 120, 133]]], ["In order to activate the NLRC4 inflammasome, LPS-primed cells were transfected with 1.6 mg purified flagellin from Pseudomonas aeruginosa (Invivogen) for 2.5 h.METHOD DETAILSTo activate the NLRP3 inflammasome in healthy human PBMCs, cells were treated for 14 h with LPS (200 ng/mL) or Pam3CSK4 (2 mg/mL, Invivogen).", [["cells", "ANATOMY", 56, 61], ["PBMCs", "ANATOMY", 226, 231], ["cells", "ANATOMY", 233, 238], ["LPS", "CHEMICAL", 45, 48], ["LPS", "CHEMICAL", 266, 269], ["Pam3CSK4", "CHEMICAL", 285, 293], ["NLRC4", "GENE_OR_GENE_PRODUCT", 25, 30], ["LPS", "SIMPLE_CHEMICAL", 45, 48], ["cells", "CELL", 56, 61], ["flagellin", "GENE_OR_GENE_PRODUCT", 100, 109], ["Pseudomonas aeruginosa", "ORGANISM", 115, 137], ["Invivogen", "SIMPLE_CHEMICAL", 139, 148], ["NLRP3", "GENE_OR_GENE_PRODUCT", 190, 195], ["human", "ORGANISM", 220, 225], ["PBMCs", "CELL", 226, 231], ["cells", "CELL", 233, 238], ["LPS", "SIMPLE_CHEMICAL", 266, 269], ["Pam3CSK4", "SIMPLE_CHEMICAL", 285, 293], ["NLRC4", "PROTEIN", 25, 30], ["LPS-primed cells", "CELL_LINE", 45, 61], ["flagellin", "PROTEIN", 100, 109], ["NLRP3 inflammasome", "PROTEIN", 190, 208], ["healthy human PBMCs", "CELL_TYPE", 212, 231], ["Pseudomonas aeruginosa", "SPECIES", 115, 137], ["human", "SPECIES", 220, 225], ["Pseudomonas aeruginosa", "SPECIES", 115, 137], ["human", "SPECIES", 220, 225], ["the NLRC4 inflammasome", "TREATMENT", 21, 43], ["LPS", "TEST", 45, 48], ["primed cells", "PROBLEM", 49, 61], ["flagellin from Pseudomonas aeruginosa (Invivogen)", "TREATMENT", 100, 149], ["the NLRP3 inflammasome in healthy human PBMCs, cells", "TREATMENT", 186, 238], ["LPS", "TREATMENT", 266, 269], ["Pam3CSK4", "TREATMENT", 285, 293], ["Invivogen", "TREATMENT", 304, 313]]], ["Medium was removed and replaced with serum-and antibiotic-free medium and treated with compounds as required for 45 min.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["antibiotic", "SIMPLE_CHEMICAL", 47, 57], ["serum", "TEST", 37, 42], ["antibiotic-free medium", "TREATMENT", 47, 69]]], ["Cells were subsequently treated with nigericin (6.5 mM) for 2 h.", [["Cells", "ANATOMY", 0, 5], ["nigericin", "CHEMICAL", 37, 46], ["nigericin", "CHEMICAL", 37, 46], ["Cells", "CELL", 0, 5], ["nigericin", "SIMPLE_CHEMICAL", 37, 46], ["nigericin", "TREATMENT", 37, 46]]], ["For alternative inflammasome activation in healthy human PBMCs, cells were pre-treated with compounds for 1 h, after which they were treated with LPS (200 ng/mL) for 14 h, as described previously (Gaidt et al., 2016) .", [["PBMCs", "ANATOMY", 57, 62], ["cells", "ANATOMY", 64, 69], ["LPS", "CHEMICAL", 146, 149], ["human", "ORGANISM", 51, 56], ["PBMCs", "CELL", 57, 62], ["cells", "CELL", 64, 69], ["LPS", "SIMPLE_CHEMICAL", 146, 149], ["healthy human PBMCs", "CELL_TYPE", 43, 62], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["alternative inflammasome activation", "PROBLEM", 4, 39], ["LPS", "TREATMENT", 146, 149], ["inflammasome", "OBSERVATION", 16, 28]]], ["Human CAPS PBMCs were treated for 1 h with LPS (100 ng/mL), after which medium was removed and replaced with serum-and antibiotic-free medium and treated with compounds as required for 4 h.Non-Canonical Inflammasome AssayCells were treated with LPS (100 ng/mL) for 3 h, after which the medium was replaced and cells were treated with compounds as required for 45 min.", [["PBMCs", "ANATOMY", 11, 16], ["serum", "ANATOMY", 109, 114], ["cells", "ANATOMY", 310, 315], ["LPS", "CHEMICAL", 43, 46], ["LPS", "CHEMICAL", 245, 248], ["Human", "ORGANISM", 0, 5], ["CAPS PBMCs", "CELL", 6, 16], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["antibiotic", "SIMPLE_CHEMICAL", 119, 129], ["LPS", "SIMPLE_CHEMICAL", 245, 248], ["cells", "CELL", 310, 315], ["Human CAPS PBMCs", "CELL_LINE", 0, 16], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human CAPS PBMCs", "TREATMENT", 0, 16], ["LPS", "TREATMENT", 43, 46], ["serum", "TEST", 109, 114], ["antibiotic-free medium", "TREATMENT", 119, 141], ["compounds", "TREATMENT", 159, 168], ["Canonical Inflammasome AssayCells", "TREATMENT", 193, 226], ["LPS", "TREATMENT", 245, 248]]], ["2 mg LPS was transfected using FuGENE HD (Promega) overnight (18 h) in order to activate the inflammasome.ASC Speck AssayFlow cytometry was used to analyze ASC speck formation following inflammasome activation.", [["ASC speck", "ANATOMY", 156, 165], ["LPS", "CHEMICAL", 5, 8], ["LPS", "SIMPLE_CHEMICAL", 5, 8], ["FuGENE", "ORGANISM", 31, 37], ["2 mg LPS", "TREATMENT", 0, 8], ["FuGENE HD (Promega)", "TREATMENT", 31, 50], ["ASC Speck AssayFlow cytometry", "TEST", 106, 135], ["inflammasome activation", "PROBLEM", 186, 209], ["inflammasome", "OBSERVATION", 93, 105], ["inflammasome activation", "OBSERVATION", 186, 209]]], ["BMDMs were treated as desired, after which the supernatant was removed and 1 mL of cold PBS was added to the wells.", [["BMDMs", "ANATOMY", 0, 5], ["supernatant", "ANATOMY", 47, 58], ["BMDMs", "CELL", 0, 5], ["BMDMs", "CELL_TYPE", 0, 5], ["BMDMs", "PROBLEM", 0, 5], ["cold PBS", "TREATMENT", 83, 91]]], ["Cells were then detached from the plates using a cell scraper and transferred to round-bottom tubes.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 49, 53], ["Cells", "CELL", 0, 5], ["cell", "CELL", 49, 53], ["a cell scraper", "TREATMENT", 47, 61], ["bottom tubes", "OBSERVATION", 87, 99]]], ["4 mL ethanol (100%) was added to the cells while simultaneously vortexing the tubes, in order to fix the cells and prevent clumping.", [["cells", "ANATOMY", 37, 42], ["tubes", "ANATOMY", 78, 83], ["cells", "ANATOMY", 105, 110], ["ethanol", "CHEMICAL", 5, 12], ["ethanol", "CHEMICAL", 5, 12], ["ethanol", "SIMPLE_CHEMICAL", 5, 12], ["cells", "CELL", 37, 42], ["cells", "CELL", 105, 110], ["4 mL ethanol", "TREATMENT", 0, 12], ["simultaneously vortexing the tubes", "TREATMENT", 49, 83], ["clumping", "PROBLEM", 123, 131], ["tubes", "OBSERVATION", 78, 83], ["clumping", "OBSERVATION", 123, 131]]], ["Cells were incubated at room temperature for 15 min, before being centrifuged at 600 x g for 10 min.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Supernatant was removed, and cells were resuspended in FACS buffer (0.1% Sodium azide, 0.1% BSA, 1.5% FCS in PBS) containing FC block (0.4%).", [["Supernatant", "ANATOMY", 0, 11], ["cells", "ANATOMY", 29, 34], ["Sodium azide", "CHEMICAL", 73, 85], ["BSA", "CHEMICAL", 92, 95], ["Sodium azide", "CHEMICAL", 73, 85], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["cells", "CELL", 29, 34], ["Sodium azide", "SIMPLE_CHEMICAL", 73, 85], ["BSA", "SIMPLE_CHEMICAL", 92, 95], ["cells", "TREATMENT", 29, 34], ["Sodium azide", "TREATMENT", 73, 85], ["1.5% FCS in PBS", "TREATMENT", 97, 112], ["FC block", "TREATMENT", 125, 133]]], ["Cells were incubated for 20 min at room temperature after which anti-mouse ASC antibody (Santa Cruz, sc-22514-R) was added to a final dilution of 1/1500.", [["Cells", "ANATOMY", 0, 5], ["sc-22514-R", "CHEMICAL", 101, 111], ["Cells", "CELL", 0, 5], ["anti-mouse ASC antibody", "PROTEIN", 64, 87], ["anti-mouse ASC antibody", "TEST", 64, 87], ["Santa Cruz", "TEST", 89, 99], ["sc", "TEST", 101, 103]]], ["Cells were incubated for 90 min at room temperature.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["1 mL of FACS buffer was added to the cells and they were centrifuged at 600 x g for 10 min.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["FACS buffer", "TREATMENT", 8, 19]]], ["Supernatant was removed, and the cells were resuspended in Alexa Fluor 488 anti-rabbit IgG antibody (Invitrogen, A27304 1/1500 in FACS buffer), before being incubated in the dark for 45 min at room temperature.", [["Supernatant", "ANATOMY", 0, 11], ["cells", "ANATOMY", 33, 38], ["Alexa Fluor 488", "CHEMICAL", 59, 74], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["cells", "CELL", 33, 38], ["Alexa Fluor", "SIMPLE_CHEMICAL", 59, 70], ["Alexa Fluor 488 anti-rabbit IgG antibody", "PROTEIN", 59, 99], ["anti-rabbit", "SPECIES", 75, 86], ["Alexa Fluor 488", "SPECIES", 59, 74], ["anti-rabbit", "SPECIES", 75, 86], ["Alexa Fluor", "TEST", 59, 70], ["anti-rabbit IgG antibody", "TEST", 75, 99], ["Invitrogen", "TEST", 101, 111]]], ["Cells were pelleted and resuspended in 200 mL FACS buffer.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["Samples were acquired on a FACSCanto (BD Biosciences).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a FACSCanto (BD Biosciences", "TREATMENT", 25, 52]]], ["Samples were gated based on forward light scatter (FSC) versus side scatter (SSC) in order to exclude cell debris.", [["Samples", "ANATOMY", 0, 7], ["cell", "ANATOMY", 102, 106], ["cell", "CELL", 102, 106], ["Samples", "TEST", 0, 7], ["side scatter (SSC)", "TEST", 63, 81], ["cell debris", "PROBLEM", 102, 113], ["cell debris", "OBSERVATION", 102, 113]]], ["Doublets were also excluded from analysis using FSC-area versus FSC-width analysis.", [["Doublets", "TREATMENT", 0, 8], ["analysis", "TEST", 33, 41], ["FSC", "TEST", 48, 51], ["FSC-width analysis", "TEST", 64, 82]]], ["Sorting was conducted by analyzing the pulse height, width and area of the 488nm laser and 530/30nm laser channel.", [["530/30nm laser channel", "PROTEIN", 91, 113], ["the pulse height", "TEST", 35, 51], ["width", "TEST", 53, 58], ["width", "OBSERVATION_MODIFIER", 53, 58]]], ["ASC speck positive cells were detected by a decreased width or increased height in the pulse of emitted fluorescence when compared with unstimulated cells.ASC OligomerisationBMDMs were treated as desired.", [["ASC speck positive cells", "ANATOMY", 0, 24], ["cells", "ANATOMY", 149, 154], ["cells", "CELL", 149, 154], ["ASC speck positive cells", "CELL_LINE", 0, 24], ["unstimulated cells", "CELL_TYPE", 136, 154], ["ASC speck positive cells", "PROBLEM", 0, 24], ["a decreased width", "PROBLEM", 42, 59], ["increased height", "PROBLEM", 63, 79], ["ASC OligomerisationBMDMs", "TREATMENT", 155, 179], ["positive cells", "OBSERVATION", 10, 24], ["decreased", "OBSERVATION_MODIFIER", 44, 53], ["width", "OBSERVATION_MODIFIER", 54, 59], ["increased", "OBSERVATION_MODIFIER", 63, 72], ["height", "OBSERVATION_MODIFIER", 73, 79], ["OligomerisationBMDMs", "OBSERVATION", 159, 179]]], ["After treatment, cells were washed twice with 200 mL cold PBS before being lysed in crosslinking lysis buffer (50 mM HEPES, 0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 11.5 mg/mL aprotinin, 1 mg/mL leupeptin and 1 mM sodium orthovanadate).", [["cells", "ANATOMY", 17, 22], ["Triton X-100", "CHEMICAL", 129, 141], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 148, 177], ["PMSF", "CHEMICAL", 179, 183], ["sodium orthovanadate", "CHEMICAL", 235, 255], ["HEPES", "CHEMICAL", 117, 122], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 148, 177], ["PMSF", "CHEMICAL", 179, 183], ["aprotinin", "CHEMICAL", 197, 206], ["leupeptin", "CHEMICAL", 216, 225], ["sodium orthovanadate", "CHEMICAL", 235, 255], ["cells", "CELL", 17, 22], ["Triton X-100", "SIMPLE_CHEMICAL", 129, 141], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 148, 177], ["PMSF", "SIMPLE_CHEMICAL", 179, 183], ["aprotinin", "SIMPLE_CHEMICAL", 197, 206], ["leupeptin", "SIMPLE_CHEMICAL", 216, 225], ["sodium orthovanadate", "SIMPLE_CHEMICAL", 235, 255], ["treatment", "TREATMENT", 6, 15], ["cells", "TREATMENT", 17, 22], ["200 mL cold PBS", "TREATMENT", 46, 61], ["crosslinking lysis buffer", "TREATMENT", 84, 109], ["50 mM HEPES", "TREATMENT", 111, 122], ["1 mM phenylmethylsulfonyl fluoride (PMSF", "TREATMENT", 143, 183], ["aprotinin", "TREATMENT", 197, 206], ["leupeptin", "TREATMENT", 216, 225], ["1 mM sodium orthovanadate", "TREATMENT", 230, 255]]], ["Samples were placed on ice for 15 min and benzonase nuclease was added in order to break down DNA in the lysates.", [["Samples", "ANATOMY", 0, 7], ["lysates", "ANATOMY", 105, 112], ["benzonase", "CHEMICAL", 42, 51], ["benzonase nuclease", "GENE_OR_GENE_PRODUCT", 42, 60], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["lysates", "ORGANISM_SUBSTANCE", 105, 112], ["benzonase nuclease", "PROTEIN", 42, 60], ["Samples", "TEST", 0, 7], ["ice", "TREATMENT", 23, 26], ["benzonase nuclease", "TREATMENT", 42, 60]]], ["Lysates were centrifuged for 15 min at 6000 x g at 4 C and the supernatant was removed and frozen down as the 'soluble fraction.' 20 mL of the soluble fraction was mixed with 5 mL of sample lysis buffer (0.125M Tris pH 6.8, 10% glycerol, 0.02% SDS, 5% DTT) and run on a 12% gel.", [["Lysates", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 63, 74], ["sample", "ANATOMY", 183, 189], ["glycerol", "CHEMICAL", 228, 236], ["glycerol", "CHEMICAL", 228, 236], ["DTT", "CHEMICAL", 252, 255], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["glycerol", "SIMPLE_CHEMICAL", 228, 236], ["DTT", "SIMPLE_CHEMICAL", 252, 255], ["Lysates", "TEST", 0, 7], ["the 'soluble fraction", "TREATMENT", 106, 127], ["the soluble fraction", "TREATMENT", 139, 159], ["sample lysis buffer", "TREATMENT", 183, 202], ["Tris pH", "TEST", 211, 218], ["10% glycerol", "TREATMENT", 224, 236], ["a 12% gel", "TREATMENT", 268, 277]]], ["The insoluble pellet was resuspended in HEPES (50 mM) and washed 3 times by centrifuging at 6000 x g at 4 C and removing the supernatant each time.", [["pellet", "ANATOMY", 14, 20], ["supernatant", "ANATOMY", 125, 136], ["HEPES", "CHEMICAL", 40, 45], ["The insoluble pellet", "TREATMENT", 0, 20], ["insoluble", "OBSERVATION_MODIFIER", 4, 13], ["pellet", "OBSERVATION", 14, 20]]], ["After the final wash, the pellet was resuspended in 500 mL crosslinking buffer (50 mM HEPES, 150 mM NaCl) and disuccinimidyl suberate (DSS, Thermo Fisher, made up in anhydrous DMSO) was added to the final concentration of 2 mM.", [["pellet", "ANATOMY", 26, 32], ["NaCl", "CHEMICAL", 100, 104], ["disuccinimidyl suberate", "CHEMICAL", 110, 133], ["DSS", "CHEMICAL", 135, 138], ["DMSO", "CHEMICAL", 176, 180], ["HEPES", "CHEMICAL", 86, 91], ["NaCl", "CHEMICAL", 100, 104], ["disuccinimidyl suberate", "CHEMICAL", 110, 133], ["DMSO", "CHEMICAL", 176, 180], ["disuccinimidyl suberate", "SIMPLE_CHEMICAL", 110, 133], ["DSS", "SIMPLE_CHEMICAL", 135, 138], ["anhydrous DMSO", "SIMPLE_CHEMICAL", 166, 180], ["the pellet", "TREATMENT", 22, 32], ["HEPES", "TREATMENT", 86, 91], ["disuccinimidyl suberate", "TREATMENT", 110, 133], ["anhydrous DMSO", "TREATMENT", 166, 180]]], ["Immediately following the addition of DSS, the sample was inverted several times and incubated for 45 min at 37 C. The sample was then centrifuged for 15 min at 6000 x g at 4 C, before the supernatant was removed and the pellet was resuspended in 30 mL sample lysis buffer.", [["sample", "ANATOMY", 47, 53], ["sample", "ANATOMY", 119, 125], ["supernatant", "ANATOMY", 189, 200], ["sample", "ANATOMY", 253, 259], ["DSS", "CHEMICAL", 38, 41], ["DSS", "TREATMENT", 38, 41], ["the supernatant", "TREATMENT", 185, 200], ["the pellet", "TREATMENT", 217, 227], ["sample lysis buffer", "TREATMENT", 253, 272]]], ["The resuspended 'insoluble fraction' was subsequently boiled for 5 min at 95 C before being run on a gel.HEK293T Inflammasome ReconstitutionHEK293T cells were plated at a density of 2 3 10 5 cells/mL in 24-well plates in DMEM containing FCS (10%).", [["HEK293T Inflammasome ReconstitutionHEK293T cells", "ANATOMY", 105, 153], ["cells", "ANATOMY", 191, 196], ["HEK293T Inflammasome ReconstitutionHEK293T cells", "CELL", 105, 153], ["cells", "CELL", 191, 196], ["ReconstitutionHEK293T cells", "CELL_LINE", 126, 153], ["The resuspended 'insoluble fraction", "TREATMENT", 0, 35], ["a gel", "TREATMENT", 99, 104], ["ReconstitutionHEK293T cells", "TEST", 126, 153], ["a density", "TEST", 169, 178], ["FCS", "TEST", 237, 240]]], ["The following morning, cells were transfected with plasmids encoding murine GFP-IRG1 (280 ng, Origene, MG217265) and murine NLRP3 inflammasome components: HA-ASC (20 ng, Addgene, 41553), HA-NEK7 (200 ng, Addgene, 75142), FLAG-pro-caspase 1 (100 ng, Addgene, 75128), FLAG-NLRP3 (200 ng, Addgene, 75127), FLAG-Pro-IL-1b (200 ng, Addgene, 75131).", [["cells", "ANATOMY", 23, 28], ["plasmids", "ANATOMY", 51, 59], ["cells", "CELL", 23, 28], ["murine", "ORGANISM", 69, 75], ["GFP", "GENE_OR_GENE_PRODUCT", 76, 79], ["IRG1", "GENE_OR_GENE_PRODUCT", 80, 84], ["murine", "ORGANISM", 117, 123], ["NLRP3", "GENE_OR_GENE_PRODUCT", 124, 129], ["Addgene", "GENE_OR_GENE_PRODUCT", 170, 177], ["HA-NEK7", "GENE_OR_GENE_PRODUCT", 187, 194], ["FLAG-pro-caspase 1", "GENE_OR_GENE_PRODUCT", 221, 239], ["Addgene", "GENE_OR_GENE_PRODUCT", 249, 256], ["FLAG", "GENE_OR_GENE_PRODUCT", 266, 270], ["NLRP3", "GENE_OR_GENE_PRODUCT", 271, 276], ["FLAG-Pro-IL-1b", "GENE_OR_GENE_PRODUCT", 303, 317], ["plasmids", "DNA", 51, 59], ["murine GFP", "PROTEIN", 69, 79], ["IRG1", "PROTEIN", 80, 84], ["murine NLRP3 inflammasome components", "PROTEIN", 117, 153], ["ASC", "PROTEIN", 158, 161], ["FLAG", "PROTEIN", 221, 225], ["caspase 1", "PROTEIN", 230, 239], ["FLAG", "PROTEIN", 266, 270], ["NLRP3", "PROTEIN", 271, 276], ["IL", "PROTEIN", 312, 314], ["murine", "SPECIES", 69, 75], ["murine", "SPECIES", 117, 123], ["murine GFP", "TEST", 69, 79], ["IRG1", "TEST", 80, 84], ["Origene", "TEST", 94, 101], ["HA", "PROBLEM", 155, 157], ["ASC", "PROBLEM", 158, 161], ["HA", "TEST", 187, 189], ["Addgene", "TEST", 204, 211], ["FLAG-pro-caspase", "TREATMENT", 221, 237], ["FLAG-NLRP3", "TREATMENT", 266, 276], ["FLAG-Pro-IL", "TREATMENT", 303, 314]]], ["Plasmids were transfected using lipofectamine 2000 for 24 h.", [["lipofectamine", "CHEMICAL", 32, 45], ["Plasmids", "TREATMENT", 0, 8], ["lipofectamine", "TREATMENT", 32, 45]]], ["Following the 24 h transfection, medium was replaced with DMEM containing FCS (10%) and penicillin-streptomycin (1%).", [["FCS", "CHEMICAL", 74, 77], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 99, 111], ["penicillin", "CHEMICAL", 88, 98], ["streptomycin", "CHEMICAL", 99, 111], ["FCS", "ORGANISM_SUBSTANCE", 74, 77], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 88, 111], ["the 24 h transfection", "TREATMENT", 10, 31], ["DMEM containing FCS", "TREATMENT", 58, 77], ["penicillin", "TREATMENT", 88, 98], ["streptomycin", "TREATMENT", 99, 111]]], ["4 h later, nigericin (10 mM) was added to cells in order to activate the inflammasome.", [["cells", "ANATOMY", 42, 47], ["nigericin", "CHEMICAL", 11, 20], ["nigericin", "CHEMICAL", 11, 20], ["nigericin", "SIMPLE_CHEMICAL", 11, 20], ["cells", "CELL", 42, 47], ["nigericin", "TREATMENT", 11, 20]]], ["Supernatants and cell lysates were harvested 45 min later.", [["Supernatants", "ANATOMY", 0, 12], ["cell lysates", "ANATOMY", 17, 29], ["Supernatants", "CELL", 0, 12], ["cell lysates", "CELL", 17, 29], ["Supernatants and cell lysates", "TREATMENT", 0, 29], ["cell lysates", "OBSERVATION", 17, 29]]], ["This protocol was described previously (Shi et al., 2016a) .Western BlottingSupernatant was removed from cells following stimulation and lysates were harvested in 30-50 mL lysis buffer (0.125 M Tris pH 6.8, 10% glycerol, 0.02% SDS, 5% DTT) Lysates were subsequently heated to 95 C for 5 min to denature proteins.", [["cells", "ANATOMY", 105, 110], ["lysates", "ANATOMY", 137, 144], ["Lysates", "ANATOMY", 240, 247], ["glycerol", "CHEMICAL", 211, 219], ["glycerol", "CHEMICAL", 211, 219], ["DTT", "CHEMICAL", 235, 238], ["cells", "CELL", 105, 110], ["lysates", "ORGANISM_SUBSTANCE", 137, 144], ["glycerol", "SIMPLE_CHEMICAL", 211, 219], ["Lysates", "ORGANISM_SUBSTANCE", 240, 247], ["This protocol", "TREATMENT", 0, 13], ["stimulation and lysates", "TREATMENT", 121, 144], ["Tris pH", "TEST", 194, 201], ["10% glycerol", "TREATMENT", 207, 219], ["5% DTT", "TREATMENT", 232, 238], ["Lysates", "TREATMENT", 240, 247]]], ["In order to concentrate supernatants for western blot, 5 mL Strataclean Resin (Agilent) was added to 500 mL of supernatant and vortexed for 1 min.", [["supernatants", "ANATOMY", 24, 36], ["supernatant", "ANATOMY", 111, 122], ["western blot", "TREATMENT", 41, 53], ["5 mL Strataclean Resin (Agilent)", "TREATMENT", 55, 87]]], ["Supernatants were then centrifuged at 210 x g for 2 min at 4 C. Supernatants were removed and discarded, and the remaining pellet was resuspended in 30 mL lysis buffer.", [["Supernatants", "ANATOMY", 0, 12], ["Supernatants", "ANATOMY", 64, 76], ["pellet", "ANATOMY", 123, 129], ["Supernatants", "CELL", 0, 12]]], ["Samples were boiled at 95 C for 5 min prior to loading into a 5% stacking gel.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a 5% stacking gel", "TREATMENT", 60, 77]]], ["The percentage resolving gel depended on the molecular weight of the given protein.Western BlottingThe Bio-Rad gel running system was used to resolve proteins and the Bio-Rad wet transfer system was used for the electrophoretic transfer of proteins onto PVDF membrane.", [["PVDF membrane", "ANATOMY", 254, 267], ["PVDF", "CHEMICAL", 254, 258], ["membrane", "CELLULAR_COMPONENT", 259, 267], ["The percentage resolving gel", "PROBLEM", 0, 28], ["The Bio-Rad gel running system", "TREATMENT", 99, 129], ["the Bio-Rad wet transfer system", "TREATMENT", 163, 194], ["the electrophoretic transfer of proteins onto PVDF membrane", "TREATMENT", 208, 267], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["resolving", "OBSERVATION_MODIFIER", 15, 24], ["gel depended", "OBSERVATION_MODIFIER", 25, 37]]], ["Following transfer, the membrane was incubated in milk powder (5% in TBST) for 1 h and subsequently incubated in primary antibody rolling overnight at 4 C. The membrane was incubated for 1 h with secondary antibody (diluted in 5% milk powder) at room temperature.", [["membrane", "ANATOMY", 24, 32], ["milk", "ANATOMY", 50, 54], ["membrane", "ANATOMY", 160, 168], ["membrane", "CELLULAR_COMPONENT", 24, 32], ["milk", "ORGANISM_SUBSTANCE", 50, 54], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["milk", "ORGANISM", 230, 234], ["secondary antibody", "PROTEIN", 196, 214], ["milk powder", "TREATMENT", 50, 61], ["primary antibody rolling", "TREATMENT", 113, 137], ["secondary antibody (diluted in 5% milk powder", "TREATMENT", 196, 241]]], ["Prior to visualization, the membrane was immersed in WesternBright ECL Spray (Advansta).", [["membrane", "ANATOMY", 28, 36], ["membrane", "CELLULAR_COMPONENT", 28, 36], ["visualization", "TEST", 9, 22], ["the membrane", "TREATMENT", 24, 36]]], ["Protein visualization took place on a ChemiDoc MPTM Imaging System (Bio-Rad), and both chemiluminescent and white light images were taken.", [["Protein visualization", "TEST", 0, 21], ["both chemiluminescent", "TEST", 82, 103], ["white light images", "TEST", 108, 126]]], ["Quantification of western blot images was performed using Image Lab Software (Bio-Rad).", [["western blot images", "TEST", 18, 37], ["Image Lab Software", "TEST", 58, 76]]], ["Adjusted band volume was calculated for each band and for each experimental condition this was presented as target protein/housekeeping protein.Co-ImmunoprecipitationBMDMs were seeded at 1x10 6 cells/mL in 10 cm dishes the day prior to treatment.", [["cells", "ANATOMY", 194, 199], ["housekeeping protein", "PROTEIN", 123, 143], ["Adjusted band volume", "TREATMENT", 0, 20], ["each band", "TREATMENT", 40, 49], ["each experimental condition", "PROBLEM", 58, 85], ["ImmunoprecipitationBMDMs", "TEST", 147, 171], ["treatment", "TREATMENT", 236, 245], ["band volume", "OBSERVATION", 9, 20], ["10 cm", "OBSERVATION_MODIFIER", 206, 211]]], ["The following day, cells were treated as required.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["cells", "PROBLEM", 19, 24]]], ["Following treatment, cells were washed with 3 mL PBS before lysis in 500 mL low stringency lysis buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Nonident P40 (NP-40), 1 mM phenylmethylsulfonyl fluoride (PMSF), 11.5 mg/mL aprotinin, 1 mg/mL leupeptin and 1 mM sodium orthovanadate) on ice.", [["cells", "ANATOMY", 21, 26], ["NaCl", "CHEMICAL", 132, 136], ["glycerol", "CHEMICAL", 153, 161], ["NP-40", "CHEMICAL", 182, 187], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 195, 224], ["PMSF", "CHEMICAL", 226, 230], ["sodium orthovanadate", "CHEMICAL", 282, 302], ["NaCl", "CHEMICAL", 132, 136], ["EDTA", "CHEMICAL", 143, 147], ["glycerol", "CHEMICAL", 153, 161], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 195, 224], ["PMSF", "CHEMICAL", 226, 230], ["aprotinin", "CHEMICAL", 244, 253], ["leupeptin", "CHEMICAL", 263, 272], ["sodium orthovanadate", "CHEMICAL", 282, 302], ["cells", "CELL", 21, 26], ["EDTA", "SIMPLE_CHEMICAL", 143, 147], ["glycerol", "SIMPLE_CHEMICAL", 153, 161], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 195, 224], ["PMSF", "SIMPLE_CHEMICAL", 226, 230], ["aprotinin", "SIMPLE_CHEMICAL", 244, 253], ["leupeptin", "SIMPLE_CHEMICAL", 263, 272], ["sodium orthovanadate", "SIMPLE_CHEMICAL", 282, 302], ["treatment", "TREATMENT", 10, 19], ["cells", "TREATMENT", 21, 26], ["lysis", "TREATMENT", 60, 65], ["low stringency lysis buffer", "TREATMENT", 76, 103], ["HEPES", "TEST", 111, 116], ["pH", "TEST", 117, 119], ["NaCl", "TEST", 132, 136], ["EDTA", "TEST", 143, 147], ["glycerol", "TEST", 153, 161], ["NP", "TEST", 182, 184], ["1 mM phenylmethylsulfonyl fluoride", "TREATMENT", 190, 224], ["aprotinin", "TREATMENT", 244, 253], ["leupeptin", "TREATMENT", 263, 272], ["1 mM sodium orthovanadate", "TREATMENT", 277, 302], ["ice", "TREATMENT", 307, 310]]], ["Plates were scraped with a cell scraper and lysate transferred into microcentrifuge tubes.", [["cell", "ANATOMY", 27, 31], ["lysate", "ANATOMY", 44, 50], ["cell", "CELL", 27, 31], ["a cell scraper", "TREATMENT", 25, 39], ["lysate", "TREATMENT", 44, 50], ["microcentrifuge tubes", "TREATMENT", 68, 89]]], ["Tubes were agitated at 1100 rpm at 4 C for 15 min before being centrifuged at 21380 x g for 10 min at 4 C. 25 mL of resulting supernatant was mixed with 25 mL sample lysis buffer and treated as the whole cell lysate (WCL) sample.", [["supernatant", "ANATOMY", 126, 137], ["whole cell lysate", "ANATOMY", 198, 215], ["WCL", "ANATOMY", 217, 220], ["sample", "ANATOMY", 222, 228], ["Tubes", "ORGANISM_SUBSTANCE", 0, 5], ["cell", "CELL", 204, 208], ["WCL", "CELL", 217, 220], ["Tubes", "TREATMENT", 0, 5], ["agitated", "PROBLEM", 11, 19], ["25 mL sample lysis buffer", "TREATMENT", 153, 178], ["the whole cell lysate", "TREATMENT", 194, 215]]], ["0.0153 mg/mL anti-NEK7 antibody (Abcam, ab133514) or the equivalent concentration of rabbit IgG antibody (Millipore, pp64), and 40 mL A/G PLUS agarose beads (Santa Cruz) was added to the remaining supernatant, which was subsequently incubated at 4 C in a ferris wheel mixer for 3 h.", [["supernatant", "ANATOMY", 197, 208], ["Abcam", "GENE_OR_GENE_PRODUCT", 33, 38], ["rabbit", "ORGANISM", 85, 91], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 92, 104], ["agarose beads", "SIMPLE_CHEMICAL", 143, 156], ["Santa Cruz", "SIMPLE_CHEMICAL", 158, 168], ["anti-NEK7 antibody", "PROTEIN", 13, 31], ["Abcam", "PROTEIN", 33, 38], ["ab133514", "PROTEIN", 40, 48], ["rabbit IgG antibody", "PROTEIN", 85, 104], ["pp64", "PROTEIN", 117, 121], ["Santa Cruz", "PROTEIN", 158, 168], ["rabbit", "SPECIES", 85, 91], ["rabbit", "SPECIES", 85, 91], ["anti-NEK7 antibody", "TEST", 13, 31], ["Abcam", "TEST", 33, 38], ["rabbit IgG antibody", "TEST", 85, 104], ["Millipore", "TEST", 106, 115], ["A/G PLUS agarose beads", "TREATMENT", 134, 156]]], ["IP samples were subsequently centrifuged at 400 x g for 2 min at 4 C, supernatant removed, and beads washed three times with 1 mL low stringency lysis buffer.", [["samples", "ANATOMY", 3, 10], ["supernatant", "ANATOMY", 70, 81], ["IP samples", "ORGANISM_SUBSTANCE", 0, 10], ["IP samples", "TEST", 0, 10], ["1 mL low stringency lysis buffer", "TREATMENT", 125, 157]]], ["The immune complexes were eluted by addition of 40 mL sample lysis buffer, boiled for 5 min and analyzed by SDS-PAGE.ELISADuoSet ELISA kits for IL-1b, TNFa and IL-6 were purchased from R&D Systems and were carried out according to the manufacturer's instructions with appropriately diluted cell supernatants added to each plate in duplicate or triplicate.", [["sample", "ANATOMY", 54, 60], ["cell supernatants", "ANATOMY", 290, 307], ["IL-1b", "GENE_OR_GENE_PRODUCT", 144, 149], ["TNFa", "GENE_OR_GENE_PRODUCT", 151, 155], ["IL-6", "GENE_OR_GENE_PRODUCT", 160, 164], ["cell", "CELL", 290, 294], ["immune complexes", "PROTEIN", 4, 20], ["IL-1b, TNFa and IL-6", "PROTEIN", 144, 164], ["40 mL sample lysis buffer", "TREATMENT", 48, 73], ["IL", "TEST", 144, 146], ["TNFa and IL", "TREATMENT", 151, 162], ["appropriately diluted cell supernatants", "TREATMENT", 268, 307]]], ["Quantikine ELISA kits for IL-1b (R&D Systems) and IL-18 (Invitrogen) were similarly carried out according to the manufacturer's instructions.", [["IL-1b", "GENE_OR_GENE_PRODUCT", 26, 31], ["R&D", "GENE_OR_GENE_PRODUCT", 33, 36], ["IL-18", "GENE_OR_GENE_PRODUCT", 50, 55], ["Invitrogen", "ORGANISM", 57, 67], ["IL-1b", "PROTEIN", 26, 31], ["IL-18", "PROTEIN", 50, 55], ["Quantikine ELISA kits", "TEST", 0, 21], ["IL", "TEST", 26, 28], ["IL", "TEST", 50, 52]]], ["Absorbance at 450 nm was then quantified using a FLUOstar Optima plate reader.", [["a FLUOstar Optima plate reader", "TREATMENT", 47, 77]]], ["Corrected absorbance values were calculated by subtracting the background absorbance, and cytokine concentrations were subsequently obtained by extrapolation from a standard curve plotted on GraphPad Prism 8.0.LDH AssayThe CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega) was used to quantify lactate dehydrogenase (LDH) release from cells as a measure of cell death in BMDMs following inflammasome stimulation.", [["cells", "ANATOMY", 341, 346], ["cell", "ANATOMY", 363, 367], ["BMDMs", "ANATOMY", 377, 382], ["lactate", "CHEMICAL", 300, 307], ["death", "DISEASE", 368, 373], ["lactate", "CHEMICAL", 300, 307], ["LDH", "SIMPLE_CHEMICAL", 210, 213], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 300, 321], ["LDH", "GENE_OR_GENE_PRODUCT", 323, 326], ["cells", "CELL", 341, 346], ["cell", "CELL", 363, 367], ["BMDMs", "CELL", 377, 382], ["cytokine", "PROTEIN", 90, 98], ["lactate dehydrogenase", "PROTEIN", 300, 321], ["LDH", "PROTEIN", 323, 326], ["BMDMs", "CELL_TYPE", 377, 382], ["Corrected absorbance values", "TEST", 0, 27], ["cytokine concentrations", "TEST", 90, 113], ["a standard curve", "TEST", 163, 179], ["GraphPad Prism", "TEST", 191, 205], ["LDH Assay", "TEST", 210, 219], ["The CytoTox", "TEST", 219, 230], ["Non-Radioactive Cytotoxicity Assay", "TEST", 234, 268], ["lactate dehydrogenase (LDH) release from cells", "PROBLEM", 300, 346], ["cell death", "PROBLEM", 363, 373], ["inflammasome stimulation", "TREATMENT", 393, 417], ["Non-Radioactive Cytotoxicity", "OBSERVATION", 234, 262], ["cell death", "OBSERVATION", 363, 373], ["inflammasome stimulation", "OBSERVATION", 393, 417]]], ["Freshly harvested supernatants were used in this assay.", [["supernatants", "ANATOMY", 18, 30], ["Freshly harvested supernatants", "TREATMENT", 0, 30], ["harvested supernatants", "OBSERVATION", 8, 30]]], ["50 mL of each supernatant was added to 50 mL Cytotox 96 Reagent and incubated in the dark at room temperature for 30 min.", [["supernatant", "ANATOMY", 14, 25]]], ["50 mL acetic acid was added to stop the reaction, and the absorbance at 492 nm was measured using a FLUOstar optima.", [["acetic acid", "CHEMICAL", 6, 17], ["acetic acid", "CHEMICAL", 6, 17], ["acetic acid", "SIMPLE_CHEMICAL", 6, 17], ["50 mL acetic acid", "TREATMENT", 0, 17], ["the reaction", "PROBLEM", 36, 48], ["the absorbance", "TEST", 54, 68], ["a FLUOstar optima", "TREATMENT", 98, 115]]], ["100 mL total lysis solution was added to untreated cells 30 min before harvesting and served as a maximum LDH release control.", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["LDH", "SIMPLE_CHEMICAL", 106, 109], ["total lysis solution", "TREATMENT", 7, 27], ["harvesting", "TREATMENT", 71, 81], ["a maximum LDH release control", "TREATMENT", 96, 125]]], ["Medium alone was also used to correct for background absorbance.LDH AssayGeneration of 13 C 5 Octyl Itaconate All NMR spectra were collected using a Varian 400 MHz NMR.", [["Octyl", "CHEMICAL", 94, 99], ["LDH", "SIMPLE_CHEMICAL", 64, 67], ["C 5 Octyl Itaconate", "SIMPLE_CHEMICAL", 90, 109], ["background absorbance", "PROBLEM", 42, 63], ["LDH AssayGeneration", "TEST", 64, 83], ["Octyl Itaconate", "TREATMENT", 94, 109], ["All NMR spectra", "TEST", 110, 125], ["a Varian 400 MHz NMR", "TREATMENT", 147, 167]]], ["Synthesis was performed by WuXi AppTec.", [["WuXi AppTec", "SIMPLE_CHEMICAL", 27, 38], ["Synthesis", "TREATMENT", 0, 9]]], ["Synthesis of 13 C 5 octyl itaconate was performed as previously described (Richard et al., 2016) with minor modifications.", [["13 C 5 octyl itaconate", "CHEMICAL", 13, 35], ["13 C 5 octyl itaconate", "CHEMICAL", 13, 35], ["13 C 5 octyl itaconate", "SIMPLE_CHEMICAL", 13, 35], ["Synthesis", "TEST", 0, 9], ["5 octyl itaconate", "TREATMENT", 18, 35]]], ["Uniformly labeled 13 C 6 -citric acid (0.32 mmol) was placed into a distillation apparatus and subjected to pyrolysis by heating to 175 C for 30 min with constant stirring.", [["13 C 6 -citric acid", "CHEMICAL", 18, 37], ["13 C 6 -citric acid", "CHEMICAL", 18, 37], ["13 C 6 -citric acid", "SIMPLE_CHEMICAL", 18, 37], ["citric acid", "TREATMENT", 26, 37], ["a distillation apparatus", "TREATMENT", 66, 90]]], ["The reaction was then heated up to 200 C at a pressure of 2 Torr.", [["The reaction", "PROBLEM", 0, 12]]], ["The cyclised product was collected as a white solid in the distillation bulb at a temperature of \u00c020 C (3.9% yield).", [["distillation bulb", "ANATOMY", 59, 76], ["bulb", "ORGAN", 72, 76], ["a temperature", "TEST", 80, 93], ["distillation bulb", "OBSERVATION", 59, 76]]], ["Equimolar quantities of the product and octanol (20 mM final concentration) were mixed in toluene, heated to 100 C and stirred for 12 h.", [["octanol", "CHEMICAL", 40, 47], ["toluene", "CHEMICAL", 90, 97], ["octanol", "CHEMICAL", 40, 47], ["toluene", "CHEMICAL", 90, 97], ["octanol", "SIMPLE_CHEMICAL", 40, 47], ["toluene", "SIMPLE_CHEMICAL", 90, 97], ["octanol (20 mM final concentration)", "TREATMENT", 40, 75]]], ["The mixture was concentrated and subjected to preparative HPLC using a Shimadzu LC-8A preparative HPLC with a Waters Xbridge column (150 mm x 25 mm, 5 mM).", [["preparative HPLC", "TEST", 46, 62], ["a Shimadzu LC", "TREATMENT", 69, 82], ["8A preparative HPLC", "TREATMENT", 83, 102], ["a Waters Xbridge column", "TREATMENT", 108, 131]]], ["Mobile phase consisted of 10 mM ammonium bicarbonate in water with a gradient of acetonitrile from 15% to 45% over 20 min with a flow rate of 30 mL/min.", [["ammonium bicarbonate", "CHEMICAL", 32, 52], ["acetonitrile", "CHEMICAL", 81, 93], ["ammonium bicarbonate", "CHEMICAL", 32, 52], ["acetonitrile", "CHEMICAL", 81, 93], ["ammonium bicarbonate", "SIMPLE_CHEMICAL", 32, 52], ["10 mM ammonium bicarbonate", "TREATMENT", 26, 52], ["a gradient of acetonitrile", "TREATMENT", 67, 93], ["a flow rate", "TEST", 127, 138]]], ["Purified yield of 13 C 5 -octylitaconate was 20%.", [["13 C 5 -octylitaconate", "CHEMICAL", 18, 40], ["13 C 5 -octylitaconate", "CHEMICAL", 18, 40], ["C 5 -octylitaconate", "SIMPLE_CHEMICAL", 21, 40], ["-octylitaconate", "TREATMENT", 25, 40]]], ["Synthesis of 13 C 5 -octylitaconate was confirmed by 1 H NMR and LC/MS (ESI+).Treatment of Human Macrophages with 13 C 5 Octyl ItaconateAt the end of the macrophage differentiation, medium was removed and replaced with macrophage medium with or without 100 ng/ mL of LPS, from Escherichia coli serotype O127:B8 (Sigma) and 125 mM 13 C 5 octyl itaconate dissolved in DMSO and incubated for various times at 37 C and 5% CO2.", [["Macrophages", "ANATOMY", 97, 108], ["macrophage", "ANATOMY", 154, 164], ["macrophage", "ANATOMY", 219, 229], ["13 C 5 -octylitaconate", "CHEMICAL", 13, 35], ["LPS", "CHEMICAL", 267, 270], ["13 C 5 octyl itaconate", "CHEMICAL", 330, 352], ["DMSO", "CHEMICAL", 366, 370], ["CO2", "CHEMICAL", 418, 421], ["13 C 5 -octylitaconate", "CHEMICAL", 13, 35], ["1 H", "CHEMICAL", 53, 56], ["13 C 5 octyl itaconate", "CHEMICAL", 330, 352], ["DMSO", "CHEMICAL", 366, 370], ["CO2", "CHEMICAL", 418, 421], ["13 C 5 -octylitaconate", "SIMPLE_CHEMICAL", 13, 35], ["Human", "ORGANISM", 91, 96], ["Macrophages", "CELL", 97, 108], ["macrophage", "CELL", 154, 164], ["macrophage", "CELL", 219, 229], ["LPS", "SIMPLE_CHEMICAL", 267, 270], ["Escherichia coli", "ORGANISM", 277, 293], ["serotype O127:B8", "ORGANISM", 294, 310], ["Sigma", "SIMPLE_CHEMICAL", 312, 317], ["5 octyl itaconate", "SIMPLE_CHEMICAL", 335, 352], ["DMSO", "SIMPLE_CHEMICAL", 366, 370], ["CO2", "SIMPLE_CHEMICAL", 418, 421], ["Human Macrophages", "CELL_TYPE", 91, 108], ["Human", "SPECIES", 91, 96], ["Escherichia coli serotype", "SPECIES", 277, 302], ["Human", "SPECIES", 91, 96], ["Escherichia coli", "SPECIES", 277, 293], ["Synthesis", "TEST", 0, 9], ["ESI", "TEST", 72, 75], ["Treatment of Human Macrophages", "TREATMENT", 78, 108], ["5 Octyl ItaconateAt", "TREATMENT", 119, 138], ["the macrophage differentiation", "TREATMENT", 150, 180], ["macrophage medium", "TREATMENT", 219, 236], ["LPS", "TREATMENT", 267, 270], ["Escherichia coli serotype", "TEST", 277, 302], ["5 octyl itaconate", "TREATMENT", 335, 352], ["DMSO", "TREATMENT", 366, 370], ["LC", "ANATOMY", 65, 67], ["Escherichia coli", "OBSERVATION", 277, 293]]], ["In cultures with 13 C 5 octyl itaconate alone, supernatants and cells were harvested 0.5, 3, 6, 9 and 27 h after addition of 13 C 5 octyl itaconate.", [["supernatants", "ANATOMY", 47, 59], ["cells", "ANATOMY", 64, 69], ["C 5 octyl itaconate", "CHEMICAL", 20, 39], ["13 C 5 octyl itaconate", "CHEMICAL", 125, 147], ["13 C 5 octyl itaconate", "CHEMICAL", 17, 39], ["13 C 5 octyl itaconate", "CHEMICAL", 125, 147], ["C 5 octyl itaconate", "SIMPLE_CHEMICAL", 20, 39], ["cells", "CELL", 64, 69], ["C 5 octyl itaconate", "SIMPLE_CHEMICAL", 128, 147], ["cultures", "TEST", 3, 11], ["C 5 octyl itaconate", "TREATMENT", 20, 39], ["supernatants and cells", "TREATMENT", 47, 69], ["5 octyl itaconate", "TREATMENT", 130, 147]]], ["Cultures with LPS were treated with 13 C 5 octyl itaconate three h prior or three h following LPS addition.", [["LPS", "CHEMICAL", 14, 17], ["C 5 octyl itaconate", "CHEMICAL", 39, 58], ["LPS", "CHEMICAL", 94, 97], ["13 C 5 octyl itaconate", "CHEMICAL", 36, 58], ["LPS", "SIMPLE_CHEMICAL", 14, 17], ["5 octyl itaconate", "SIMPLE_CHEMICAL", 41, 58], ["LPS", "SIMPLE_CHEMICAL", 94, 97], ["Cultures", "TEST", 0, 8], ["LPS", "TEST", 14, 17], ["13 C 5 octyl itaconate", "TREATMENT", 36, 58]]], ["Supernatants and cells were harvested 3, 6 and 24 h post LPS if added after 13 C 5 octyl itaconate and 6, 9 and 24 h post LPS if added before 13 C 5 octyl itaconate.", [["Supernatants", "ANATOMY", 0, 12], ["cells", "ANATOMY", 17, 22], ["LPS", "CHEMICAL", 57, 60], ["5 octyl itaconate", "CHEMICAL", 81, 98], ["LPS", "CHEMICAL", 122, 125], ["C 5 octyl itaconate", "CHEMICAL", 145, 164], ["octyl itaconate", "CHEMICAL", 83, 98], ["octyl itaconate", "CHEMICAL", 149, 164], ["Supernatants", "CELL", 0, 12], ["cells", "CELL", 17, 22], ["LPS", "SIMPLE_CHEMICAL", 57, 60], ["octyl itaconate", "SIMPLE_CHEMICAL", 83, 98], ["LPS", "SIMPLE_CHEMICAL", 122, 125], ["5 octyl itaconate", "SIMPLE_CHEMICAL", 147, 164], ["LPS", "TREATMENT", 57, 60], ["5 octyl itaconate", "TREATMENT", 81, 98], ["LPS", "TREATMENT", 122, 125], ["5 octyl itaconate", "TREATMENT", 147, 164]]], ["Control cultures without 13 C 5 octyl itaconate included cells alone and 24 h treatment with LPS.", [["cells", "ANATOMY", 57, 62], ["C 5 octyl itaconate", "CHEMICAL", 28, 47], ["LPS", "CHEMICAL", 93, 96], ["13 C 5 octyl itaconate", "CHEMICAL", 25, 47], ["C 5 octyl itaconate", "SIMPLE_CHEMICAL", 28, 47], ["cells", "CELL", 57, 62], ["LPS", "SIMPLE_CHEMICAL", 93, 96], ["Control cultures", "TEST", 0, 16], ["5 octyl itaconate", "TREATMENT", 30, 47], ["cells", "TREATMENT", 57, 62], ["LPS", "TREATMENT", 93, 96]]], ["Supernatants were transferred to Eppendorf tubes and stored at \u00c080 C until analysis.", [["Supernatants", "ANATOMY", 0, 12], ["Eppendorf tubes", "TREATMENT", 33, 48], ["analysis", "TEST", 75, 83]]], ["Cells were washed with D-PBS (GIBCO), trypsinized (GIBCO), scraped with a cell scraper and transferred to conical tubes.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 74, 78], ["Cells", "CELL", 0, 5], ["D-PBS", "SIMPLE_CHEMICAL", 23, 28], ["GIBCO", "CELL", 51, 56], ["cell", "CELL", 74, 78], ["D-PBS", "TREATMENT", 23, 28], ["a cell scraper", "TREATMENT", 72, 86], ["conical tubes", "TREATMENT", 106, 119], ["conical tubes", "OBSERVATION", 106, 119]]], ["Cells were washed three times with 40 mM ammonium formate (Sigma) and transferred to Eppendorf tubes prior to snap freezing on dry ice and stored at \u00c080 C until analysis.Treatment of Human Macrophages with 13 C 5 Octyl ItaconateMeasurement of 13 C 5 Itaconate and 13 C 5 Octyl Itaconate in Human Macrophages by LC-HRMS Cell pellet samples were thawed on wet ice immediately prior to analysis.", [["Cells", "ANATOMY", 0, 5], ["Macrophages", "ANATOMY", 189, 200], ["Macrophages", "ANATOMY", 296, 307], ["Cell pellet samples", "ANATOMY", 319, 338], ["ammonium formate", "CHEMICAL", 41, 57], ["13 C 5 Itaconate", "CHEMICAL", 243, 259], ["C 5 Octyl Itaconate", "CHEMICAL", 267, 286], ["ammonium formate", "CHEMICAL", 41, 57], ["Itaconate", "CHEMICAL", 250, 259], ["13 C 5 Octyl Itaconate", "CHEMICAL", 264, 286], ["Cells", "CELL", 0, 5], ["ammonium formate", "SIMPLE_CHEMICAL", 41, 57], ["Sigma", "SIMPLE_CHEMICAL", 59, 64], ["Human", "ORGANISM", 183, 188], ["Macrophages", "CELL", 189, 200], ["C 5 Itaconate", "SIMPLE_CHEMICAL", 246, 259], ["C 5 Octyl Itaconate", "SIMPLE_CHEMICAL", 267, 286], ["Human", "ORGANISM", 290, 295], ["Macrophages", "CELL", 296, 307], ["LC-HRMS Cell", "CELL", 311, 323], ["Human Macrophages", "CELL_TYPE", 183, 200], ["Human Macrophages", "CELL_TYPE", 290, 307], ["Human", "SPECIES", 183, 188], ["Human", "SPECIES", 290, 295], ["Human", "SPECIES", 183, 188], ["Human", "SPECIES", 290, 295], ["40 mM ammonium formate", "TREATMENT", 35, 57], ["Eppendorf tubes", "TREATMENT", 85, 100], ["dry ice", "TREATMENT", 127, 134], ["analysis", "TEST", 161, 169], ["Treatment of Human Macrophages", "TREATMENT", 170, 200], ["C 5 Octyl ItaconateMeasurement", "TREATMENT", 209, 239], ["Itaconate", "TREATMENT", 250, 259], ["Octyl Itaconate in Human Macrophages", "TREATMENT", 271, 307], ["Cell pellet samples", "TREATMENT", 319, 338], ["analysis", "TEST", 383, 391]]], ["1 mL of ice cold 8:2 methanol-water (Sigma; Milli-Q water) was added to each sample.", [["8:2 methanol", "CHEMICAL", 17, 29], ["methanol", "CHEMICAL", 21, 29], ["Milli-Q water", "SIMPLE_CHEMICAL", 44, 57], ["ice cold 8:2 methanol-water (Sigma; Milli-Q water)", "TREATMENT", 8, 58]]], ["The tubes were briefly vortexed, sonicated (10 min/ice bath), and briefly vortexed again to lyse cells and extract analytes.", [["tubes", "ANATOMY", 4, 9], ["cells", "ANATOMY", 97, 102], ["tubes", "ORGANISM_SUBSTANCE", 4, 9], ["cells", "CELL", 97, 102], ["lyse cells", "CELL_TYPE", 92, 102], ["The tubes", "TREATMENT", 0, 9], ["extract analytes", "TEST", 107, 123], ["tubes", "OBSERVATION", 4, 9]]], ["Each sample was centrifuged at 6 C for 15 min at 15,000 x g.", [["sample", "ANATOMY", 5, 11]]], ["450 mL of supernatant was transferred to a 1.5 mL were determined on the basis of previous experiments using similar methodologies.", [["supernatant", "ANATOMY", 10, 21]]], ["All depicted data points are biological replicates taken from distinct samples.", [["samples", "ANATOMY", 71, 78]]], ["Each figure consists of a minimum of 3 independent experiments from multiple biological replicates. n = the number of animals or the number of independent experiments with cell lines.", [["cell lines", "ANATOMY", 172, 182], ["cell lines", "CELL", 172, 182], ["cell lines", "CELL_LINE", 172, 182], ["cell lines", "TREATMENT", 172, 182], ["cell lines", "OBSERVATION", 172, 182]]], ["For in vivo studies, mice were randomly assigned to treatment groups.", [["mice", "ORGANISM", 21, 25], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["vivo studies", "TEST", 7, 19], ["treatment groups", "TREATMENT", 52, 68]]], ["For mass spectrometry analyses, samples were processed in random order and experimenters were blinded to experimental conditions. ll Short Article e7 Cell Metabolism 32, 1-11.e1-e7, October 6, 2020", [["samples", "ANATOMY", 32, 39], ["mass spectrometry analyses", "TEST", 4, 30], ["samples", "TEST", 32, 39], ["e7 Cell Metabolism", "OBSERVATION", 147, 165]]]]}